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ABSTRACT 
Development of the human heart is a complex process controlled by multiple 
genes (in interacting pathways), many of which are still to be determined. 
Abnormal heart development results in a spectrum of congenital heart disease 
(CHD), occurring in isolation or part of a syndrome, and with or without a family 
history, implying a genetic basis in some individuals. In this project I 
investigated the molecular genetic basis of CHD, in 23 families with non-
syndromic CHD. Using autozygosity mapping, I initially investigated the 
molecular basis of CHD in a single large consanguineous family (CHD1), and 
identified a region of interest containing a candidate gene (GDF1). I proceeded 
to sequence GDF1 (and genes in the same developmental pathway - NODAL, 
CFC1, TDGF1, and FOXH1) in 9 kindreds, but did not identify any pathogenic 
mutations. I then utilised whole exome sequencing (WES) to identify candidate 
mutations in potential CHD genes (GMFG, WNT11 and DVL2), and investigated 
these further by conventional sequencing. A novel GMFG nonsense variant was 
validated in family CHD1 and was absent from ethnically matched controls. 
Bioinformatics analysis of WES data from 19 affected individuals from 9 
kindreds did not identify a frequently mutated candidate gene (or further GMFG 
candidate mutations), though candidate variants in individual kindreds were 
identified. Further functional analysis using animal models is required to 
determine the pathophysiological effect of the GMFG truncating mutation in 
cardiac development.  
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GENERAL INTRODUCTION 
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1.1 Introduction and overview  
‘With the advent of modern genetic analysis techniques, congenital heart 
disease research will no longer be limited by sequencing or genotyping 
capacity’                         (Andelfinger and Khairy, 2011) 
 
The formation of the heart involves a precisely orchestrated series of molecular 
and morphogenetic events and subtle changes of this process can have serious 
consequences in the form of congenital heart disease (CHD). This is a major 
cause of childhood morbidity and mortality worldwide, and despite advances in 
clinical and surgical management, understanding the aetiology of CHD remains 
incomplete. Advances have been made in understanding the molecular aspects 
of normal heart development, including the identification of transcriptional 
regulators, signalling molecules, and structural genes. Animal models have 
significantly aided in identifying the molecular mechanisms of abnormal heart 
development, however more research needs to be directed in investigating 
these in humans to better understand the pathogenesis of human CHD. The 
improved resolution of cytogenetic analysis, common use of fluorescent in situ 
hybridisation (FISH) analysis, and addition of molecular techniques 
(Comparative Genomic Hybridisation arrays, linkage analysis, whole exome 
sequencing), have allowed advancements in localising and detecting loci critical 
for heart development in humans. Identifying and understanding the molecular 
functions, interactions and pathways involved in heart development, will 
ultimately benefit families and clinicians to improve clinical diagnosis with 
diagnostic tests, provide accurate genetic counselling on recurrence risks, and 
pave the way for potential therapeutic interventions. 
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1.2 Normal heart development  
The cardiovascular system (heart and blood vessels) is the first major organ 
system to function in the developing embryo. The heart begins to beat at day 
22-23 and blood flow begins during the fourth week (Moore and Persaud, 
1998). Establishment of left-right asymmetry is also very important for normal 
heart development. 
 
1.2.1  Primordial heart tube  
The primitive streak develops at day 13, and the primordium of the heart is 
mainly derived from the splanchnic mesoderm which appears around day 18 of 
embryonic development.  Cells from the anterior lateral plate mesoderm (which 
contributes to most of the visceral organs) fuse at the primitive streak to form a 
cardiac crescent. As the embryo folds laterally, the cells of the crescent 
coalesce along the ventral midline to form a single primitive heart tube. The 
inner cells of the heart tube become the endothelial lining of the heart 
(endocardium), and an external layer of cells become the muscular wall of the 
heart (myocardium). As the embryo continues to fold the heart tube comes to lie 
ventrally to the foregut. The linear heart tube is segmentally patterned into 
precursors of the atria, ventricles and outflow tracts. It continues to elongate 
and develop dilatations and constrictions (i.e. truncus arteriosus, bulbous 
cordis, ventricle, atrium, and sinus venosus). The arterial and venous ends of 
the heart are fixed by other embryonic structures, and the bulbous cordis and 
ventricle grow faster than the other nearby regions, resulting in the heart tube 
bending upon itself (rightward looping) to form a U-shaped bulboventricular 
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loop. The atrium and sinus venosus end up lying dorsal to the truncus 
arteriosus, bulbous cordis, and ventricle. This heart looping process is complete 
by day 28 (Figures 1 & 2) (Moore and Persaud, 1998; Srivastava, 2006). 
 
1.2.2  Partitioning of the primordial heart and chamber development 
Partitioning of the atrioventricular (AV) canal, atrium and ventricle all occur 
concurrently from the middle of the fourth week and are completed by the end 
of the fifth week. The endocardial cushions form from the dorsal and ventral 
walls of the AV canal and fuse dividing the AV canal into the right and left AV 
canals. These AV canals partially separate the primordial atrium from the 
ventricle. 
 
The primordial atrium is divided into right and left atria by the formation, 
modification and fusion of two septa (septum primum and septum secundum). 
The septum primum grows towards the fusing endocardial cushions from the 
roof of the primordial atrium, thereby partially dividing it into right and left atria. 
The area between the endocardial cushion and the free edge of the septum 
primum is called the foramen primum, which eventually closes as the septum 
primum fuses with the endocardial cushion. Just before the foramen primum 
closes, perforations in the septum primum appear creating another opening 
(foramen secundum). The septum secundum then grows from the roof of the 
atria (to the right of the septum primum) towards the endocardial cushion, 
gradually overlapping the foramen secundum and the septum primum, resulting 
in the formation of the foramen ovale which allows blood entering the right 
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atrium to pass to the left atrium in one direction only (before birth). After birth 
the foramen ovale closes resulting in a complete partition between the atria. 
 
Division of the primordial ventricle begins with the formation of the muscular 
primordial interventricular (IV) septum in the floor of the ventricle near its apex. 
Initially the growth in the IV septum is due to the dilatation of the ventricles on 
either side of the IV septum, and then active proliferation of myoblasts in the 
septum results in the final increase in size. The gap between the growing IV 
septum and endocardial cushion is called the IV foramen, which allows blood to 
flow between the two ventricles. Proliferation of the mesenchymal cells in the 
walls of the bulbous cordis results in the formation of the right and left bulbar 
ridges. Fusion of the right and left bulbar ridges and the endocardial cushion 
results in the closure of the IV foramen (usually by the end of the seventh week) 
and the formation of the membranous part of the IV septum. This membranous 
IV septum develops as an extension of tissue from the endocardial cushion to 
the muscular IV septum and also merges with the aorticopulmonary septum 
(see later). This is completed by end of week 7 (Figures 3 & 4) (Moore and 
Persaud, 1998). 
 
1.2.3  Partitioning of the bulbous cordis and truncus arteriosus 
In the fifth week of development, ridges (similar to the bulbar ridges) develop in 
the truncus arteriosus and are continuous with the bulbar ridges. Both the 
bulbar and truncal ridges undergo a 180 degree spiralling motion resulting in the 
formation of a spiral aorticopulmonary septum when the ridges fuse. This 
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septum creates two arterial channels – the aorta and the pulmonary trunk. This 
spiralling also twists the pulmonary trunk around the ascending aorta. Therefore 
once the IV foramen has closed and the membranous IV septum fully formed 
(see before), the pulmonary trunk communicates with the right ventricle and the 
aorta communicates with the left ventricle. This is completed by end of week 7 
(Figure 5) (Moore and Persaud, 1998). 
 
1.2.4  Valve development  
Once partitioning of the truncus arteriosus is almost complete, the semilunar 
valves begin to develop from three swellings of subendocardial tissue located 
around the openings of the aorta and pulmonary trunk. These swellings reshape 
to form three thin-walled cusps. The atrioventricular valves develop in a very 
similar manner from swellings of the tissue around the AV canals (Moore and 
Persaud, 1998). 
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Figure 1: Drawings of views of the developing heart (20-28 days).  
Taken from Moore & Persaud (1998) 
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Figure 2: Drawings of ventral views of the developing heart (22-35 days).  
Taken from Moore & Persaud (1998) 
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Figure 3: Drawings the heart during the fourth and fifth weeks.  
Taken from Moore & Persaud (1998) 
Figure 4: Drawings illustrating partitioning of the primordial atrium, 
ventricle and atrioventricular canal.  
Taken from Moore & Persaud (1998) 
 11 
Figure 5: Drawings illustrating partitioning of the bulbous cordis and 
truncus arteriosus.  
Taken from Moore & Persaud (1998) 
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1.2.5  Normal heart circulation 
Deoxygenated blood returns from the body via the superior and inferior vena 
cavae, which connect to the right atrium. Blood flows from the right atrium 
through the tricuspid valve into the right ventricle. From the right ventricle, it 
flows through the pulmonary valve in the right ventricular outflow tract into the 
main pulmonary artery, which then branches into the left and right pulmonary 
arteries, taking blood to the respective lungs. Four pulmonary veins (two from 
each side) return oxygenated blood from the lungs to the left atrium. It then 
flows to the left ventricle via the mitral valve, and then through the aortic valve in 
the left ventricular outflow tract into the aorta and to the rest of the body (Figure 
9).  
 
1.2.6  Heart fields, Networks and Pathways  
1.2.6.1 Heart fields 
The complex process of heart development described above requires the 
contribution of numerous cell types in a precise and coordinated manner. The 
current model of heart development suggests several distinct groups of 
myocardial progenitor cells (the First Heart Field and Second Heart Field) which 
contribute spatially to the development of the mature heart in a highly regulated 
fashion (Figure 6) (Srivastava and Olson, 2000). The First Heart Field (FHF) 
consists of splanchnic mesoderm cells in the anterior lateral plate mesoderm, 
which form the linear heart tube and the left ventricle, via the formation of the 
cardiac crescent. The Second Heart Field (SHF) consists of undifferentiated 
myocardial progenitor cells of the pharyngeal mesoderm (medial and caudal to 
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the FHF), which migrate into the arterial and venous parts of the primitive heart 
tube and contribute to the development of the outflow tracts, right ventricle, and 
the inflow region (i.e. the atria). A third heart field has been identified consisting 
of cells located ventral to the heart tube, which will give rise to the venous pole 
(i.e. the periphery of inflow tracts) (Andelfinger, 2008). The cardiac neural crest 
cells represent a subdivision of the cranial neural crest cells (from the dorsal 
neural tube). They migrate from the neural tube and form the smooth muscle of 
the great arteries and have a role in the remodelling of the six pairs of 
pharyngeal arch arteries that later become the ascending aorta, proximal 
subclavian, carotid, pulmonary arteries, and ductus arteriousus. They also 
migrate to the outflow tract and contribute to the spiral aortopulmonary septum, 
separating the truncus into the aorta and pulmonary artery (Jiang et al., 2000; 
Clark et al., 2006). The final lineage of cardiac precursor cells are derived from 
the proepicardium (which develops from the mesothelium overlaying the liver 
bud). They extend towards the primitive heart, attach, and spread over the 
myocardial surface to form the epicardium and the coronary vessels (Yamagishi 
et al., 2009).  
 
1.2.6.2 Heart networks and pathways  
Experiments in animal models (mice, zebrafish, and frogs) have led to the 
identification of numerous genes involved in normal heart development. Cells 
derived from the FHF and SHF appear to be regulated by complex signalling 
pathways involving members of the bone morphogenetic protein (BMP), sonic 
hedgehog (SHH), fibroblast growth factor (FGF), Wnt, and Notch proteins, and 
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a highly conserved network of transcription factors. The core regulators appear 
to be the transcription factors: NKX2, GATA, TBX, and MEF2, but numerous 
other transcription factors contribute to heart development by acting as 
accessory factors to these core regulators (Figure 7) (Srivastava, 2006; Jing-Bin 
et al., 2009). 
 
The right ventricle is enriched in a transcription factor called Hand2 (or dHAND) 
which is required for its expansion, and disruption of this factor leads to right 
ventricular hypoplasia in mice. Right ventricular hypoplasia is also observed in 
mice lacking Mef2c which is a target of Isl1, Gata4, Foxh1, and Tbx20 in the 
SHF. This suggests these factors are important for SHF cells to expand into the 
right ventricle. Sonic hedgehog (Shh) regulates the expression of Tbx1, through 
forkhead-containing transcription factors (like Foxc1/Foxc2). Tbx1 is known to 
be a central SHF transcriptional regulator which is necessary for the 
development of the outflow tracts. Mice lacking Tbx1, Foxc1, Foxc2, or Shh 
show similar outflow tract anomalies. Tbx1 also regulates the production of 
fibroblast growth factors (like Fgf8), which activate receptors on adjacent neural 
crest-derived cells affecting their differentiation, which as described previously  
are also important in outflow tract development (Srivastava, 2006). Hand1 (or 
eHAND) which is closely related to Hand2, is expressed in the FHF and mostly 
in the left ventricle. Its expression depends on Nkx2.5 in the left ventricle 
suggesting Nkx2.5 is critical for FHF development. Many of the transcription 
factors found in the FHF are also present in the SHF (Nkx2.5 and Gata4) 
implying they also contribute to SHF development (Srivastava, 2006).  
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The Notch intracellular signalling pathway plays an important role in the 
development of the endocardial cushions that contribute to valve formation. In 
humans there are four Notch family receptors (NOTCH1-4) with their ligands 
encoded by the Jagged (JAG1 and JAG2) and Delta-like (DLL1, DLL3, and 
DLL4) gene families. (Jing-Bin et al., 2009); The BMP signalling pathway (via 
BMP, ALK3, BMPR4, and SMAD6) is involved in valve and outflow tract 
development (Tan et al., 2012). Details regarding the NODAL and WNT 
pathways are described later. Disruption of all of these signalling pathways can 
lead to a variety of genetic causes of CHD (see later).  
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Figure 6: Frontal views of cardiac precursors of heart development.  
Taken from Srivastava (2006)  
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Figure 7: Pathways regulating cardiac morphogenesis.  
Taken from Srivastava (2006)  
 18 
1.2.7  Left-Right patterning  
The embryonic body plan is initially symmetric and the first indication of 
patterning the left-right axis in humans is the rightward looping of the midline 
heart tube. The proper folding of the straight heart tube aligns the atria with their 
appropriate ventricles, and the right and left ventricles with the pulmonary trunk 
and aorta respectively. The normal positioning of the organs on the left or right 
side of the chest and abdomen relies on normal left-right axis patterning. This 
intricate change on body plan must rely on highly conserved genetic pathways 
that control determination of the left-right axis. There are three major steps 
involved in establishing the left-right axis: (a) node-dependent symmetry 
breaking, (b) establishment of embryonic midline, and (c) node-dependent 
signalling in the left lateral plate mesoderm (Clark et al., 2006). 
 
Several signalling molecules have been found to regulate the left-right 
asymmetry of the embryo. Hensen’s node controls the establishment of 
asymmetric gene expression throughout the lateral plate mesoderm (LPM) 
(Figure 8). Asymmetric expression of Shh at the left nodal region leads to 
perinodal expression of Nodal and Lefty in the left lateral plate mesoderm, and 
of Caronte (Car). As Car expression extends to the left lateral plate mesoderm, 
it inhibits Bone Morphogenetic Proteins (BMPs), which normally inhibit Nodal 
and Lefty activity. Nodal induces the expression of Nkx3.2 and Pitx2 
(transcription factors) in the left lateral plate mesoderm. On the right side, an 
Activin receptor mediated pathway inhibits Shh expression and thereby it 
inhibits expression of Nodal and Lefty on the right side. This is done by a 
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pathway that upregulates Fibroblast growth factor 8 (Fgf8) which in turn inhibits 
Car expression. The block of Car activity in the LPM allows BMP to further block 
any Nodal activity on the right side, and reduces levels of Nkx3.2 and Pitx2. 
Nodal establishes expression of Lefty1 in the midline and Lefty2 in the LPM, 
which both act as barriers of Nodal to maintain its expression on the left side 
and prevent spread to the right side. The two pathways on the left and right 
(Nodal and Activin) ultimately result in a net expression of Pitx2 on the left side 
of the embryo and this induces rightward looping of the primitive heart tube, and 
is also sufficient to establish the left-right asymmetry in the developing heart, 
lungs, and gut (Kathiriya and Srivastava, 2000; Garg, 2006). 
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Figure 8: Diagram illustrating components of left-right patterning.  
Adapted from (Kathiriya and Srivastava, 2000; Brand, 2003; Shiratori and 
Hamada, 2006) 
 
Active parts of the pathway are marked in full black lines & arrows, and inactive 
parts are marked in dotted black lines & arrows. Components with increased 
expression have full back borders, and those with decreased expression have 
dotted black borders. LPM: lateral plate mesoderm; Shh: sonic hedgehog; Fgf8: 
fibroblast growth factor 8; Car: caronte; BMP: bone morphogenetic protein.   
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1.2.8  Epigenetic factors and heart development   
The regulation of cardiac development through complex signalling pathways is 
well studied and defined (as described above), but a more in depth 
understanding of the regulatory mechanisms of gene expression is still required. 
Epigenetics refers to functionally relevant modifications to the genome caused 
by mechanisms other than changes in the underlying DNA sequence. The most 
well described epigenetic factors are those affecting gene regulation at the 
chromatin level. Chromatin is a dynamic structure composed of nucleosomes 
(147 base pairs wrapped around an octameric core of histone proteins), and the 
compact organisation requires regulatory mechanisms to alter its structure and 
prepare genomic loci for recombination, repair, replication, and transcription. 
Three mechanisms controlling chromatin structure are: (a) nucleosome 
positioning (by chromatin remodelers), (b) histone modification (by histone 
modifiers), and (c) DNA methylation (by DNA modifiers) (van Weerd et al., 
2011). 
 
Numerous factors in these mechanisms have been described in cardiac 
development, including evidence based on animal models with CHD, and some 
have also been identified in human diseases associated with syndromic CHD 
(Chang and Bruneau, 2012; Vallaster et al., 2012). Chromatin remodelers 
(containing an ATPase subunit) can restructure nucleosomes (move, eject, 
destabilise, or alter the composition) via the energy from ATP hydrolysis. 
Mutations in a chromatin remodeler (CHD7) are associated with CHARGE 
syndrome, an autosomal dominant condition characterised by Coloboma of the 
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eye, Heart defects, Atresia of the choanae, Retardation of growth and/or 
development, Genitourinary abnormalities, and Ear abnormalities and deafness 
(MIM 214800). CHD7 is essential for orchestrating neural crest cell gene 
expression programs, the cells which migrate to regulate cardiac outflow tract 
development (malformations of which are seen in this syndrome) (Bajpai et al., 
2010). Histone modifiers (by altering the histone-DNA contacts via covalent 
modification of histone proteins) loosen or tighten the chromatin to regulate the 
availability of genes to transcription factors. This can occur via many chemical 
processes such as methylation, phosphorylation, ubiquitination, and acetylation. 
Kabuki syndrome (MIM 147920) and Kleefstra syndrome (MIM 610253) are 
autosomal dominant conditions characterised by a number of congenital 
defects, including cardiac defects, and mental retardation. They are caused by 
mutations in histone methyltransferases (MLL2 – Kabuki syndrome, EHMT1 – 
Kleefstra syndrome) which impair histone methylation and effect the expression 
of target genes (Ogawa et al., 2002; Ng et al., 2010b). It is therefore evident 
that chromatin regulators (of structure and function) exert their effects in a 
tissue-specific and time-specific manner, and can control cardiac development.  
 
More recently microRNAs (miRNAs), which are small non-coding RNAs have 
been shown to have a role in cardiovascular development and function. They 
are suspected to control cardiac gene expression, due to their expression in 
specific cardiac cell types and the effects on known cardiac transcription factors 
with over expression of micro-RNAs in animal models. They are evolutionarily 
conserved, act at the post-transcriptional level, and can be categorised into 
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intergenic, intronic and exonic miRNAs. Studies indicate that individual miRNAs 
may not function as essential on-off switches, but may act as fine tuners of 
gene expression in cardiac development (Cordes et al., 2010; Chen and Wang, 
2012).  
 
1.2.9  Haemodynamic factors and heart development   
The pattern of blood flow in the developing heart has been proposed to play a 
role in heart development, and been termed the ‘no flow-no grow’ hypothesis, 
suggesting that the amount of flow through a structure can determine the extent 
of its development (Andelfinger, 2008). Normal blood flow is needed for 
remodelling and growth of the myocardium and heart valves, as well as the 
vascular structures. Vascular remodelling during cardiovascular development is 
an adaptation of the vascular network (through feedback mechanisms in the 
vascular endothelial cells) to a wide range of both chemical (hypoxia and 
nutritional requirements) and mechanical cues from blood flow (shear stress 
and circumferential stretch), resulting in differential expression of vascular 
developmental genes (Jones, 2011). It has been shown that decreased shear 
forces during blood flow of a developing zebrafish embryo can result in a 
number of cardiac phenotypes. Disrupting either the inflow or outflow (altering 
the shear stress) led to either: (a) collapse and fusion of the walls of the inflow 
and outflow tracts impairing valve formation, (b) lack of bulbous cordis 
formation, or (c) lack of heart looping (Hove et al., 2003). Therefore 
haemodynamic factors appear to be important ‘epigenetic’ modulators of 
cardiovascular development.  
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1.3 Congenital heart disease  
1.3.1  Definitions 
Congenital Anomaly: A structural abnormality of any type, present from birth. 
Congenital Malformation: A morphological defect of an organ, part of an 
organ, or larger region of the body that results from an intrinsically abnormal 
developmental process (e.g. genetic factors) 
Congenital Disruption: A morphological defect of an organ, part of an organ, 
or larger region of the body that results from an extrinsic breakdown of, or an 
interference with, an originally normal developmental process (e.g. 
environmental factors).  
Syndrome: A pattern of multiple anomalies thought to be pathogenetically 
related (e.g. Down syndrome). 
Congenital heart disease: A gross structural abnormality of the heart or 
intrathoracic great vessels that is actually or potentially of functional significance 
(Mitchell et al., 1971). 
 
1.3.2  Epidemiology  
Congenital heart disease or defect (CHD) is the most common birth defect 
affecting 8 in 1000 live births. It is the leading non-infectious cause of neonatal 
and infant mortality worldwide. Around 40% are diagnosed within the first year 
of life, and fifty years ago only ~25% of infants would survive beyond the first 
year of life, but with early diagnosis and advances in medical and surgical 
management, the prognosis for many of the different CHDs has improved with 
time, and now more than 85% will survive to adulthood (Moller et al., 1994). 
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There are now over 250,000 adults with CHD in the UK, and this number is 
estimated to be growing by 5% each year (Brickner et al., 2000). When 
assessing a patient with CHD it is important to determine if there is a family 
history of CHD (familial CHD) or no family history (sporadic CHD). Then one 
should identify if it occurs as an isolated finding (non-syndromic) or in 
association with other congenital anomalies (syndromic).  
 
1.3.3  Classification of congenital heart disease  
There are many ways to classify CHD, and traditionally it has been either the 
physiological or anatomical method. The physiological approach is to divide 
them into either cyanotic or acyanotic lesions. Cyanotic lesions have the 
presence of deoxygenated blood in the systemic circulation due to either (a) 
reduced blood flow to the pulmonary circulation with obligatory right to left 
shunting, or (b) increased blood flow to the pulmonary circulation leading to 
increased pulmonary vascular resistance and a late onset right to left shunt. 
Acyanotic lesions include those with (a) simple left to right shunts, or (b) 
obstructive outflow or regurgitant valves. The anatomical approach is to divide 
them into simple or complex lesions. Nowadays clinicians will combine both the 
physiological and anatomical methods (Table 1). 
 26 
Table 1: Classification of types of CHD. 
Adapted from (Wu and Child, 2004) 
 
Left to Right shunt 
Atrial septal defect 
Ventricular septal defect 
Atrioventricular septal defect 
Patent ductus arteriosus 
Partial anomalous pulmonary venous drainage 
 
Outflow obstruction 
Bicuspid aortic valve 
Coarctation of the aorta 
Pulmonary stenosis 
Hypoplastic left heart syndrome 
 
Cyanosis and decreased pulmonary blood flow 
Tetralogy of Fallot  
Tricuspid atresia 
Pulmonary atresia 
Hypoplasia of right ventricle 
Ebstein’s anomaly 
 
Cyanosis and increased pulmonary blood flow 
Transposition of the great arteries 
Double outlet ventricle 
Double inlet ventricle 
Truncus arteriosus 
Total anomalous pulmonary venous drainage 
 
Cyanosis and increased pulmonary vascular resistance 
VSD with Eisenmenger syndrome 
ASD with Eisenmenger syndrome 
PDA with Eisenmenger syndrome 
 
Anomalies of major blood vessels 
Congenitally corrected transposition of the great arteries 
Coronary artery anomalies 
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1.3.4  Description of congenital heart disease  
I will now describe some of the common types of CHD, incidences, their clinical 
presentations and management options (Figure 9) (Hoffman and Kaplan, 2002; 
Everett and Lim, 2004).  
 
Figure 9: Normal heart and common types of CHD types 
All diagrams of the CHD lesions are taken from Everett and Lim (2004). 
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Atrial Septal Defect (ASD) – 1 in 1000 
This refers to a communication between the right and left atria and can clinically 
result in a shunting of blood. Early in life there is little shunting but with time 
there can be significant left to right shunting leading to enlargement of the right 
atrium and ventricle, atrial arrhythmias, ventricular dysfunction and increased 
pulmonary blood flow. If left untreated, with time this can result in increased 
pulmonary vascular resistance and irreversible pulmonary vascular obstructive 
disease. These defects are usually closed surgically or by catheter based 
procedures by the age of 3-4 years. 
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Ventricular Septal Defect (VSD) – 1 in 300 
This refers to a communication between the right and left ventricles. They may 
be single or multiple and can occur anywhere along the ventricular septum, so 
are usually classified according to their location. Small defects usually close 
spontaneously in the first few years of life. Moderate to large VSDs become 
haemodynamically significant in the first few weeks of life as they can result in 
shunting of blood from the left ventricle to the right ventricle, leading to 
excessive pulmonary blood flow and irreversible pulmonary vascular obstructive 
disease. The vast majority are closed surgically, but some can be closed by 
catheter based procedures. 
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Atrioventricular Septal Defect (AVSD) – 1 in 2800 
This refers to an abnormality of the endocardial cushions. Therefore in this 
defect one has malformed mitral and tricuspid valves resulting in a common 
atrioventricular valve that straddles the ventricular septum. There can be 
significant left to right shunting of blood at the atrial and ventricular levels 
leading to excessive pulmonary blood flow and irreversible pulmonary vascular 
obstructive disease. This requires surgical correction with the optimum time 
being between 4-6 months of life.  
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Patent Ductus Arteriosus (PDA) – 1 in 1250 
The ductus arteriosus connects the main pulmonary artery to the descending 
aorta and acts as a shunt in the fetal circulation to bypass the non-aerated 
lungs, and after birth this duct closes. Persistence of this duct after birth is 
termed PDA and results in a left to right shunt from the aorta into the pulmonary 
artery. If this PDA is small the shunt will be insignificant, however if large there 
will be increased pulmonary artery blood flow and the risks associated with that. 
In many CHDs (e.g. hypoplastic left heart syndrome, coarctation of the aorta, 
pulmonary atresia) a PDA is essential to provide pulmonary or systemic blood 
flow. A PDA may be closed pharmaceutically with indomethacin, but if it does 
not close may need catheter closure or surgical ligation.  
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Tetralogy of Fallot (TOF) – 1 in 2400 
This is the most common cyanotic heart defect beyond infancy. It refers to a 
combination of four cardiac lesions: VSD, stenosis of right ventricular outflow 
tract with associated pulmonary atresia/stenosis, right ventricular hypertrophy, 
and an enlarged aorta that overrides the VSD. The degree of cyanosis depends 
on the degree of pulmonary stenosis. These patients experience intermittent 
spells of extreme cyanosis caused by increased pulmonary stenosis with stress 
(crying, fever, dehydration) leading to an increased right to left shunt across the 
VSD. Surgery may involve a palliative procedure at the start with a systemic-
pulmonary artery shunt to allow adequate pulmonary blood flow. Complete 
surgical repair is commonly performed between 4-6 months of age.  
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Transposition of the Great Arteries (TGA) – 1 in 3200 
This is the most common cyanotic CHD presenting in the first week of life. This 
refers to when the aorta arises from the right ventricle (returning deoxygenated 
blood to the systemic circulation) and the pulmonary artery arises from the left 
ventricle (returning oxygenated blood to the pulmonary circulation), resulting in 
nearly separate, parallel circulations. The existence of a communication 
between these two circuits (via an ASD, VSD, or PDA) to allow adequate mixing 
of blood is required for survival. The coronary arteries may also be 
malpositioned with this defect. Emergency palliative procedures to allow 
adequate mixing (maintaining patency of ductus arteriosus or patency of 
foramen ovale) are needed very soon after birth. Surgical correction by an 
arterial switch procedure is usually performed within the first week of life.  
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Truncus Arteriosus (TrA) – 1 in 9300 
This refers to when the aorta and pulmonary artery leave the heart as a single 
common trunk. There is usually an anatomically abnormal truncal valve and a 
co-existing VSD. It can be associated with other cardiac anomalies like right 
sided aortic arch, aortic arch hypoplasia, coarctation of the aorta, or interrupted 
aortic arch. There is complete mixing of the systemic and pulmonary 
circulations with resulting systemic desaturation. Most infants present with 
congestive heart failure in the first few weeks of life, and may be cyanotic. 
Prompt surgical repair is the treatment of choice due to the haemodynamic 
instability and the possibility of irreversible pulmonary vascular disease. This 
would involve detachment of the pulmonary arteries from the common trunk, 
closure of the VSD, and an artificial conduit from the right ventricle to the main 
pulmonary artery.   
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Double Outlet Right Ventricle (DORV) – 1 in 6400 
This refers to when both the aorta and the pulmonary artery arise predominantly 
from the right ventricle, and is usually associated with a VSD. These children 
present depending on the exact relationship of the great vessels to the VSD. 
Definitive therapy is surgical, but in some cases palliative procedures are 
performed to allow temporary improvement in the medical condition of the child.  
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Pulmonary Stenosis (PS) – 1 in 1400 
This describes a narrowing around the pulmonary valve. In valvular PS the 
valve leaflets may be thickened and fused at their edges. There is usually post-
stenotic dilatation of the pulmonary artery and the valve may be bicuspid. If the 
narrowing occurs in the pulmonary artery above the valve it is termed 
supravalvular PS, and this obstruction can be in the main or branch pulmonary 
arteries (branch pulmonary artery stenosis (PPAS). If the narrowing occurs 
below the level of the pulmonary valve in the right ventricular outflow tract it is 
termed subvalvular PS or infundibular stenosis. If less severe these lesions are 
well tolerated by children and often asymptomatic. Severe stenosis results in 
increased afterload on the right ventricle and right sided heart failure. Balloon 
valvuloplasty can be performed in mild cases, stenotic resection for branch 
pulmonary artery stenosis, or surgical repair in severe cases.    
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Aortic Stenosis (AS) – 1 in 2500 
This describes a narrowing around the aortic valve. In valvular AS the valve 
leaflets may be thickened or bicuspid. If the narrowing occurs in the proximal 
aorta above the valve it is termed supravalvular AS. If it occurs at the level of 
the left ventricular outflow tract it is termed subvalvular AS. These lesions can 
cause increased afterload on the left ventricle and left ventricular hypertrophy, 
and subendocardial ischemia (due to increased oxygen demand of the 
myocardium). Ventricular arrhythmias and sudden death can occur in severe 
cases. Balloon valvuloplasty is a palliative procedure, but most patients will 
require a valve transplant.    
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Coarctation of the Aorta (CoA) – 1 in 2400 
This is characterised by a narrowing of the lumen of the aorta, and is frequently 
associated with a bicuspid aortic valve. The obstruction to aortic blood flow 
leads to increased afterload of the left side of the heart, and in severe cases 
can compromise perfusion of organs distal to the point of obstruction. Surgical 
resection with end-to-end anastamosis is the preferred treatment of choice in 
the neonatal or infant period.  
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Interrupted Aortic Arch (IAA) 
This refers to obstruction/narrowing along the aortic arch between the 
ascending and descending aorta, and is usually associated with a narrowed left 
ventricular outflow tract and left ventricular hypoplasia. It presents with shock or 
congestive heart failure in the first 2 weeks of life (and is similar to CoA). 
Surgical reconstruction is the only therapeutic option and is performed as soon 
as the patient is haemodynamically stable.  
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Hypoplastic Left Heart Syndrome (HLHS) – 1 in 3800 
This refers to a small or absent left ventricle with hypoplastic or atretic mitral 
and aortic valves. It is usually associated with hypoplasia of the ascending aorta 
and coarctation of the aorta, and an ASD. A PDA is essential for systemic blood 
flow and coronary perfusion. There is mixing of blood in the right atrium with 
oxygenated/deoxygenated blood flowing to the rest of the body. Surgical 
therapy is necessary for the survival of these individuals, even though medical 
stabilisation is an important part of treatment as well. Surgery would involve 
staged reconstruction or rarely a heart transplant. 
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Ebstein’s Anomaly – 1 in 8800 
This is an abnormality of the tricuspid valve where it is abnormally formed and 
displaced lower than it should be normally. This displacement causes 
atrialisation of a portion of the right ventricle, and can lead to a regurgitant 
tricuspid valve and dilatation of the right atrium if significant. If there is an atrial 
communication (e.g. ASD) then there is right to left shunting with resulting 
cyanosis. In most severe cases the infants present at birth with cyanosis and an 
enlarged heart. Surgical intervention usually requires a palliative shunt to allow 
adequate pulmonary blood flow, with possible surgical repair of the tricuspid 
valve at an older age.   
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Anomalous Pulmonary Venous Drainage (APVD) – 1 in 10600 
In this defect at least one (partial - PAPVD) or all (total - TAPVD) pulmonary 
veins connect anomalously to the right heart. Therefore oxygenated blood from 
the lungs returns to the right side of the heart rather than to the left side. This 
oxygenated blood mixes with the deoxygenated blood in the right atrium. There 
are various forms of this defect. The most common one in PAPVD is when the 
right upper pulmonary vein drains into the superior vena cava and this is 
identical in physiology to that of an ASD (left to right shunting), so the greater 
the number of veins draining anomalously, the larger the shunt. Most patients 
with PAPVD are usually asymptomatic and identified by chance. Those with 
TAPVD present with varying degrees of cyanosis. The surgical repair involves 
replumbing the pulmonary veins to the left atrium,  
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Laterality Defects  
These defects can range from dextrocardia to complex CHDs. Dextrocardia is a 
term used for when the heart is positioned on the right side of the chest with its 
apex pointing to the right. It can be associated with a number of CHD and 
abnormalities of lungs and abdominal organs (e.g. alobar/multilobar lungs, 
malrotated intestines, asplenia/polysplenia, midline liver). Isolated dextrocardia 
has no haemodynamic implications and requires no therapy. However if other 
anomalies are present then surgical treatment may be required.  
 
1.3.5  Management of congenital heart disease 
Advances in echocardiography have allowed CHDs to be detected as early as 
17-18 weeks gestation, and most are well tolerated during fetal life due the 
connection with the maternal circulation. It is only after birth when that 
connection is lost, do many of the CHDs manifest clinically, some will be 
incompatible with extra uterine life, some clinically apparent within the first few 
days/weeks of life, and others may remain undetected into adult life. Advances 
in cardiovascular surgery and intensive care have meant many of the CHDs can 
be corrected surgically, and in the future fetal cardiac surgery may be a 
possibility. During adulthood, some patients can develop further complications 
(e.g. endocarditis, stroke, systemic or pulmonary hypertension, aortic aneurysm 
or dissection and arrhythmias), and the main causes of death are heart failure 
and sudden cardiac death. Current guidelines focus on the surveillance and 
treatment of adults with CHD, aiming to reduce symptoms, and the risk and 
severity of late complications (Warnes et al., 2008; Marelli et al., 2010). 
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1.3.6  Aetiology of congenital heart disease 
Studies of recurrence and transmission have for a long time provided the 
hypothesis that CHD is caused by ‘multifactorial inheritance’ – i.e. due to a 
combination of both ‘genetic’ and ‘environmental’ factors, where the 
environmental factor interacts with a genetic predisposition in an individual to 
cause CHD (Nora, 1968). In recent years, however, separate genetic and 
environmental factors have been identified, but there still remains a large 
proportion of CHD which has an unknown cause. Understanding the 
embryology and molecular events (‘molecular embryology’) allows us to focus 
on individual modular steps in cardiac development, to determine the aetiology 
of CHD, as many defects are due to abnormal morphogenesis in specific 
components of the heart and vessels (Figure 10). A malformation may originate 
from different embryological mechanisms, and this is known as the ‘One heart 
disease—several mechanisms—several genes’ concept (Bajolle et al., 2009). In 
addition, impairment of these different mechanisms may generate a broad 
spectrum of heart diseases. These concepts explain the genetic heterogeneity 
of a single type of CHD and the phenotypic heterogeneity of mutations in a 
single gene (Figure 11).  
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Figure 10: Diagram illustrating cardiovascular development with specific 
structural components.  
Taken from Yamagashi et al. (2009) 
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Figure 11: Diagram illustrating the concept of ‘One heart disease—several mechanisms—several genes’. 
Taken from Bajolle et al. (2009) 
 
A common arterial trunk may result from a participation defect of progenitors from the second cardiac field and/or a migration defect of the 
neural crest cells and/or a rotation defect of the myocardium and/or a formation abnormality of the endocardial cushions. In addition, 
impairment of these different mechanisms may generate a broad spectrum of heart diseases affecting the conotruncal region.CAT: 
common arterial trunk; DORV: double outlet right ventricle; EM: epithelio-mesenchymal; IAA: interrupted aortic arch; TGA: transposition of 
the great arteries; TOF: tetralogy of Fallot; TOF&PA: tetralogy of Fallot with pulmonary atresia; VSD: sub-arterial ventricular septal defect. 
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1.3.6.1 Environmental factors 
Many environmental agents (termed-teratogens) have been shown to cause 
developmental disruptions following maternal exposure to them (e.g. drugs, 
chemicals, radiation, and infections). During development biochemical 
differentiation usually precedes morphological differentiation, so the period at 
which structures are sensitive to teratogens is usually a few days before the 
stage at which they visibly develop. The exact mechanisms by which teratogens 
disrupt embryogenesis and cause anomalies still remain to be elucidated. A 
number of environmental factors have been reported to be associated with CHD 
(Table 2), and the ability to reduce the risk of CHD by modifying environmental 
interactions is a favourable preventative strategy. 
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Table 2: Environmental factors and associated CHD (humans). 
Adapted from LMD;(Firth et al., 2005; Mahler and Butcher, 2011) 
 
Drugs 
Antifungals 
Bifonazole / Fluconazole ASD, CHD 
 
Anticonvulsants 
Carbamazepine CHD 
Hydantoin CHD 
Primidone TOF, PS 
Trimethadione CHD 
Valproic acid VSD, TOF 
 
Immunosuppressants  
Aminopterin / Methotrexate Laterality defects  
Cytarabine / Thioguanine ASD 
Mycophenolate mofetil PS, TrA, TGA 
 
Recreational  
Alcohol  ASD, VSD, TOF 
Cocaine ASD, VSD, PS, laterality defects 
Marijuana VSD, Ebstein’s anomaly 
 
Other  
Carbimazole CoA 
Lithium Ebstein’s anomaly, tricuspid atresia,  
ASD, CoA, laterality defects 
Misoprostol Laterality defects 
Retinoic acid ASD, VSD, TOF, TGA, TrA, CoA, HLHS  
Thalidomide ASD, VSD, PDA, TOF, TrA, PS 
Warfarin  TrA, laterality defects  
  
Organic solvents 
 VSD, PS, HLHS, CoA, TGA, TOF,  
TAPVD, AVSD, Ebstein’s anomaly 
  
Infections 
Cytomegalovirus VSD, PS 
Herpes simplex virus CHD 
Rubella virus PDA, PPAS, ASD, VSD, PS 
  
Maternal Illness 
Diabetes Mellitus ASD, VSD, CoA, PDA, HLHS, AVSD, TOF,  
TGA, TrA, tricuspid atresia, laterality defects   
Phenylketonuria TOF, CoA 
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1.3.6.2 Genetic factors 
The known genetic causes of CHD (syndromic or non-syndromic) can be 
classified according to underlying genetic mechanism. Syndromic CHD can be 
caused by chromosomal, single gene, or unknown causes. At the date of 
submission, CHD had been recorded as a clinical feature in at least one case in 
957 syndromes (London Medical Databases). Non-syndromic CHD is more 
likely to be caused by single gene or unknown causes. These syndromic or 
non-syndromic cases can be familial or sporadic (i.e. first case in family). 
Approximately 20% of CHD is associated with a chromosomal abnormality, a 
congenital syndrome, or a single gene mutation with Mendelian inheritance 
pattern (Pierpont et al., 2007; Warnes et al., 2008). For the remaining 80% of 
non-syndromic/non-Mendelian CHD (sporadic) cases the underlying genetic 
mechanisms are still poorly understood. Table 3 summarises some of the 
common known chromosomal abnormalities, syndromes (with associated genes 
if known), and single genes (non-syndromic) associated with each type of CHD 
in humans. 
 
1.3.6.2.1 Chromosomal   
A recent population study identified a chromosomal abnormality in 12.3% of 
infants with CHD, with some defects more likely to be associated with a 
chromosome abnormality (e.g. IAA – 69.2%, AVSD – 67.2%, and DORV – 
33.3%) (Hartman et al., 2011). Of all children with a chromosomal abnormality 
around 30% have CHD (Pierpont et al., 2007). The type of CHD can sometimes 
guide clinicians to test for particular chromosomal abnormalities (even in the 
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absence of other clinical features). The most common chromosomal 
abnormalities are trisomies 21, 18, 13, and 22q11.2 deletion. Down syndrome 
(Trisomy 21) accounts for ~80% of children with CHDs and a chromosomal 
abnormality (Warnes et al., 2008), and around 40% of children with Down 
syndrome have CHD, with the most common type being an AVSD. Turner 
syndrome (45,X) can cause left sided obstructive defects with CoA being the 
most common (10% of patients) (Mazzanti and Cacciari, 1998). Approximately 
15% of patients with TOF or a conotruncal anomaly have a chromosome 
22q11.2 deletion. CHD occurs in around 75% of patients with chromosome 
22q11.2 deletion (Ryan et al., 1997). Supravalvular AS is seen in up to 75% of 
patients with Williams syndrome (due to a chromosome 7q11.23 deletion) 
(Eronen et al., 2002).  Screening for chromosomal abnormalities in patients with 
CHD may lead to an early diagnosis and treatment of extracardiac 
manifestations, as CHD is often the presenting symptom for these patients. 
CHD patients with other organ system anomalies and/or mental retardation 
should raise the suspicion of an underlying chromosomal abnormality. 
 
Cytogenetic deletion/duplication syndromes are rare, and the introduction of 
microarray analysis to detect small deletions/duplications (copy number 
variation - CNV) has increased the identification of chromosomal abnormalities 
associated with CHD. One study identified significant CNVs in 17% of patients 
with CHD and other birth defects, who had normal standard cytogenetic 
analysis (Thienpont et al., 2007). Another looked at isolated cases of CHD and 
suggested CNVs can increase the susceptibility to CHD (as 44% of the CNVs 
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were also identified in parents with no CHD), and that other modifying factors 
are needed to manifest the phenotype (Erdogan et al., 2008). Smaller CNVs 
can provide clues to the localisation of loci critical for heart development and 
developmental genes. This is best illustrated by the association of CHD and 
chromosome 8p23.1 deletions, with the subsequent identification of the GATA4 
gene and its role in cardiac development (Pehlivan et al., 1999).  
 
Appendix B: summarises cases of syndomic CHD present on DECIPHER 
(DatabasE of Chromosomal Imbalance and Phenotype in Humans using 
Ensembl Resources) database, with a chromosomal abnormality detected by 
comparative genomic hybridisation array technique.  
 
1.3.6.2.2 Single Gene   
Many genes have been identified to be involved in the complex process of heart 
development in animal models, however few have been shown to be associated 
with CHD in humans (isolated cases or familial cases). Of the known genes 
associated with CHD, some cause non-syndromic CHD, and others cause 
syndromic CHD (Wessels and Willems, 2010). A number of types of CHDs can 
occur due to mutations in more than one gene (genetic heterogeneity), and 
mutations in one gene can cause variable CHDs (phenotypic heterogeneity). 
Many of these CHD genes encode members of the heart developmental 
programme involving numerous pathways (as described before) with cross 
communication, ligand-receptor interactions, complex signal transduction 
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pathways, and a network of transcription factors affecting the expression of 
cardiac specific genes of heart (Figure 12).  
 
Non-syndromic CHD genes have been identified via genetic studies of familial 
CHD. One of the first non-syndromic CHD genes identified was NKX2.5 giving 
rise to inherited ASD, VSD, TOF, Ebstein's anomaly and cardiac conduction 
defects (Schott et al., 1998; Benson et al., 1999). Inherited septal defects were 
then shown to be caused my mutations in GATA4, which interacts with NKX2.5 
(Garg et al., 2003). Subsequently interactions between GATA4 and TBX5 have 
also been identified. Therefore it is apparent that a complex interaction between 
NKX2.5, GATA4, and TBX5 is needed for proper heart septation. TBX20 gene 
mutations (another transcription factor within these 3 super-families) have been 
shown to cause familial ASD, VSD, valve defects and cardiomyopathies (Kirk et 
al., 2007). NOTCH1 mutations have been associated with bicuspid aortic valve 
and AS (Garg et al., 2005).  
 
The more common syndromic CHD genes include: TBX5, PTPN11, and JAG1. 
CHD and cardiac conduction defects occur in up to 75% of patients with Holt-
Oram syndrome (due to mutations in TBX5), and the most common defects 
include ASDs and VSDs (Basson et al., 1994). The majority (80%) of patients 
with Noonan syndrome (due to mutations in a number of genes – PTPN11, 
KRAS, RAF1, SOS1) have some form of CHD, typically PS or hypertrophic 
cardiomyopathy (Burch et al., 1993). More than 90% of patients with Alagille 
syndrome (due to a chromosome 20p12 deletion or mutations in JAG1 located 
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within this chromosome region) have CHDs, typically peripheral pulmonary 
artery stenosis (PPAS), TOF and/or PS (McElhinney et al., 2002). Detailed 
genetic studies of chromosome 22q11.2 deletion syndrome have tried to identify 
candidate genes within the deleted region. TBX1 has been proposed as a good 
candidate gene, and the identification of missense mutations in this gene in 
cases with features of chromosome 22q11.2 deletion syndrome (but normal 
cytogenetic studies), has further supported this theory (Yagi et al., 2003).    
 
Further support for an underlying genetic mechanism for CHD is seen in studies 
showing mutations in genes controlling heart development in sporadic cases of 
CHD, however the frequency of the gene mutations is in <2% of cases. These 
genes include: CFC1, CITED2, CRELD1, FOG2, GATA4, GDF1, LEFTYA, 
NKX2.5, NOTCH1, PROSIT240, TBX1, TBX20, and ZIC3 (Kosaki et al., 1999; 
Bamford et al., 2000; Goldmuntz et al., 2002; McElhinney et al., 2002; Muncke 
et al., 2003; Pizzuti et al., 2003; Robinson et al., 2003; Ware et al., 2004; 
Sarkozy et al., 2005; Sperling et al., 2005; Mohamed et al., 2006; Karkera et al., 
2007; Kirk et al., 2007). Most of the mutations in these cases are heterozygous 
mutations and are transmitted from unaffected parents, implying these 
mutations are partially penetrant. A possible mechanism for CHD in these 
sporadic cases is the accumulation of rare mutations in a number of the heart 
development genes (mutational load). 
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Figure 12: Diagram illustrating the signalling pathways involved in cardiac development in non-syndromic CHD.  
Taken from Wessels and Willems (2010) 
 
Disease genes encode proteins in all compartments of the pathways, including ligands (LEFTY2, NODAL, VEGF, GDF1, JAGGED1), 
receptors (CFC1, TDGF1, ACVR2B, NOTCH1), transcription factors (CITED2, TFAP2B, ZIC3, FOXH1, FOG2, MYOCD, NKX2.5, NKX2.6, 
GATA4, TBX5), and downstream targets (ACTC1, Myosins, ANF, NOS3). 
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Table 3: Genetics factors and associated CHD (humans).  
Adapted from (Johnson et al., 1997; Wimalasundera and Gardiner, 2004; 
Pierpont et al., 2007; Weismann and Gelb, 2007; Bentham and Bhattacharya, 
2008; Bruneau, 2008; Joziasse et al., 2008; Jing-Bin et al., 2009; Barriot et al., 
2010; Wessels and Willems, 2010; Ware and Jefferies, 2012).   
Type of CHD Genetic Aetiology with Examples 
  
Septal Anomalies 
Atrial septal defect (secundum) 
 Chromosomal 
 Deletions of 1, 4, 4p, 5p, 6, 10p, 11, 13, 17, 18, 22 
 Trisomies 13, 18, 21 
 Klinefelter (XXY) 
 Thrombocytopenia-absent radius (1q21.1 deletion) 
 Williams (7q11.23 deletion) 
 Syndromic (single gene or unknown) 
 Axenfeld Rieger (FOXC1) 
 Cardiofaciocutaneous (BRAF, KRAS, MEK1, MEK2) 
 CHARGE (CHD7) 
 Ellis-van Creveld (EVC, EVC2) 
 Goldenhar  
 Holt-Oram (TBX5) 
 Kabuki (MLL2, KDM6A) 
 Noonan (PTPN11, KRAS, SOS1, BRAF) 
 Oculofaciocardiodental (BCOR) 
 Okihiro (SALL4) 
 Rubinstein-Taybi (EP300, CREBBP) 
 Smith-Magenis (RAI1) 
 Sotos (NSD1) 
 Townes-Brocks (SALL1) 
 Non-syndromic (single gene) 
 ACTC1 
 ALK2 
 BMPR2  
 CFC1 
 CITED2  
 GATA4  
 GATA6 
 MYH6  
 MYH7 
 MYHBPC3 
 NKX2.5  
 TBX20  
 TLL1 
 ZIC3 
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Atrial septal defect primum) See AVSD 
 
Ventricular septal defect  
 Chromosomal 
 Deletions of many (incl. 4p, 5p, 8p, 10p, 11q, 22q) 
 Duplications of many 
 Trisomies 8, 9, 13, 18, 21 
 Williams (7q11.23 deletion) 
 Syndromic (single gene or unknown) 
 Carpenter (RAB23) 
 CHARGE (CHD7) 
 Frank-Ter-Haar (SH3PXD2B) 
 Goldenhar  
 Holt-Oram (TBX5) 
 Kabuki (MLL2, KDM6A) 
 Noonan (PTPN11) 
 Oculofaciocardiodental (BCOR) 
 Okihiro (SALL4) 
 Opitz G (MID1) 
 Rubinstein-Taybi (EP300, CREBBP) 
 Townes-Brocks (SALL1) 
 Ulnar mammary (TBX3) 
 VACTERL association 
 Non-syndromic (single gene) 
 ACTC1 
 CFC1 
 CITED2  
 GATA4  
 MYHBPC3 
 NKX2.5 
 NOTCH1 
 TBX1  
 TBX20  
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Atrioventricular septal defect (partial / complete) 
 Chromosomal 
 Deletions of 3p, 8p, 22q 
 Duplications of 10q, 11q, 22q 
 Trisomies 13, 18, 21 
 Turner (XO) 
 Syndromic (single gene or unknown) 
 CHARGE (CHD7) 
 Chondrodysplasias 
 Ellis-van Creveld (EVC, EVC2) 
 Holt-Oram (TBX5) 
 Hydrolethalus 
 Noonan (PTPN11, KRAS, SOS1) 
 Smith-Lemli-Opitz (SLOS) 
 Non-syndromic (single gene) 
 ALK2 
 BMPR2  
 CFC1 
 CRELD1  
 GATA4  
 
LEFTY2 
NODAL 
  
Conotruncal Anomalies 
Interrupted aortic arch  
 Chromosomal 
 Deletions of 10p, 22q 
 Trisomy 8 
 Non-syndromic (single gene) 
 CFC1 
 NKX2.5 
 TBX1 
 
Truncus arteriosus  
 Chromosomal 
 Deletions of 10p, 22q 
 Trisomy 8 
 Syndromic (single gene or unknown) 
 Kleefstra (EHMT1) 
 Townes-Brocks (SALL1) 
 Non-syndromic (single gene) 
 GATA6 
 NKX2.5 
 NKX2.6  
 TBX1  
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Tetralogy of Fallot  
 Chromosomal 
 Deletions of many (incl. 4p, 8p, 22q) 
 Duplications of many 
 Trisomies 9, 13, 18, 21 
 Alagille (20p12 deletion) 
 Cat-eye (22q11 duplication) 
 Di George (22q11.2 deletion) 
 Syndromic (single gene or unknown) 
 Alagille (JAG1) 
 CHARGE (CHD7) 
 Okihiro (SALL4) 
 Townes-Brocks (SALL1) 
 Numerous other syndromes (see OMIM) 
 Non-syndromic (single gene) 
 ALDH1A2 
 CFC1  
 CITED2  
 FOG2 
 FOXH1 
 GATA4  
 GDF1  
 JAG1  
 NKX2.5  
 NODAL 
 NOTCH1  
 TBX1  
 TDGF1 
 
Transposition of the great arteries  
 Chromosomal 
 Deletions of many 
 Trisomies 18, 21 
 Di George (22q11.2 deletion) 
 Non-syndromic (single gene) 
 ALK2 
 CFC1  
 FOXH1 
 GDF1  
 LEFTY2 
 NKX2.5  
 NODAL 
 PROSIT240  
 THRAP2 
 ZIC3 
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Double outlet right ventricle  
 Chromosomal 
 Duplications of 2p, 12p 
 Trisomies 9, 13, 18 
 Turner (XO) 
 Di George (22q11.2 deletion) 
 Syndromic (single gene or unknown) 
 CHARGE (CHD7) 
 Frank-Ter-Haar (SH3PXD2B) 
 Non-syndromic (single gene) 
 ALK2 
 CFC1  
 FOG2 
 GATA4  
 GDF1 
 NKX2.5  
 NODAL 
 NOTCH1  
 
PROSIT240  
ZIC3 
  
Pulmonary Outflow Obstruction 
Peripheral pulmonary artery stenosis  
 Chromosomal 
 Alagille (20p12 deletion) 
 Williams (7q11.23 deletion) 
 Syndromic (single gene or unknown) 
 Alagille (JAG1, NOTCH2) 
 LEOPARD (PTPN11) 
 
Noonan (PTPN11, KRAS, SOS1) 
Williams (ELN) 
Non-syndromic (single gene) 
ELN 
JAG1 
 
Pulmonary valve atresia  
 Chromosomal 
 Ring chromosome 9 
 Trisomy 9 
 Syndromic (single gene or unknown) 
 Townes-Brocks (SALL1) 
 Non-syndromic (single gene) 
 CFC1  
 NKX2.5  
 NODAL 
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Pulmonary valve stenosis  
 Chromosomal 
 Deletions of 1p, 8p, 10p, 22q 
 Duplications of 6q, 15q, 19q 
 Trisomy 8 
 Alagille (20p12 deletion) 
 Williams (7q11.23 deletion) 
 Syndromic (single gene or unknown) 
 Alagille (JAG1) 
 Cardiofaciocutaneous (KRAS, BRAF, MEK1, MEK2) 
 Costello (HRAS) 
 LEOPARD (PTPN11, RAF1) 
 Neurofibromatosis 1 (NF1) 
 Noonan (PTPN11, KRAS, SOS1,BRAF, NRAS) 
 Rubinstein-Taybi (EP300, CREBBP) 
 Non-syndromic (single gene) 
 CITED2  
 ELN 
 GATA4  
 GATA6 
 MYOCD 
 ZIC3 
  
Aortic Outflow Obstruction 
Aortic valve stenosis  
 Chromosomal 
 Deletions of 10q, 11q 
 Duplications of 1q, 2p, 2q, 6q, 11q 
 Trisomies 13, 18 
 Turner (XO) 
 Syndromic (single gene or unknown) 
 Alagille (JAG1) 
 Noonan (PTPN11, KRAS, SOS1) 
 Non-syndromic (single gene) 
 ELN 
 NKX2.5  
 NOTCH1 
 
Supravalvular aortic stenosis  
 Chromosomal 
 Williams (7q11.23 deletion) 
 Syndromic (single gene or unknown) 
 Williams (ELN) 
 Non-syndromic (single gene) 
 NKX2.5 
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Coarctation of the Aorta  
 Chromosomal 
 Deletions of 10p, 11q, 18p 
 Duplications of 4p, 4q, 6q, 10p 
 Trisomies 8, 9, 13, 18, 21 
 Turner (XO) 
 Syndromic (single gene or unknown) 
 Alagille (JAG1) 
 Kabuki (MLL2, KDM6A) 
 Neurofibromatosis 1 (NF1) 
 Periventricular nodular heterotopia (FLNA) 
 Non-syndromic (single gene) 
 NKX2.5  
 NOTCH1 
 
TBX20 
VEGF 
 
Bicuspid Aortic Valve  
 Chromosomal 
 Deletion of 10p 
 Duplication of 6q 
 Trisomies 13, 18 
 Turner (XO) 
 Syndromic (single gene or unknown) 
 Kabuki (MLL2, KDM6A) 
 Williams (ELN) 
 Non-syndromic (single gene) 
 NOTCH1 
 
Aortic atresia / Hypoplastic left heart syndrome  
 Chromosomal 
 Deletions of 4p, 11q 
 Trisomies 13, 18 
 Turner(XO) 
 Syndromic (single gene or unknown) 
 CHARGE (CHD7) 
 Non-syndromic (single gene) 
 NKX2.5 
 NOTCH1 
 
TBX20 
ZIC3 
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Other defects 
Tricuspid Atresia  
 Chromosomal 
 Deletions of 1p, 4p, 22q 
 
Duplication of 22q 
Non-syndromic (single gene) 
MYH6 
 
Epstein’s Anomaly 
 Chromosomal 
 Trisomy 21 
 Non-syndromic (single gene) 
 MYH7 
 NKX2.5 
 
Patent Ductus Arteriosus  
 Chromosomal 
 Deletions of 4p, 5p 
 Trisomies 8, 13, 18, 
 Klinefelter (XXY) 
 Syndromic (single gene or unknown) 
 CHARGE (CHD7) 
 Mowat-Wilson (ZEB2) 
 Periventricular nodular heterotopia (FLNA) 
 Sotos (NSD1) 
 Non-syndromic (single gene) 
 BMPR2  
 MYH11  
 TBX20 
 TFAP2B 
 
Total / Partial Anomalous Pulmonary Venous Drainage  
 Chromosomal 
 Trisomy 8 
 Non-syndromic (single gene) 
 ANKRD1 
 BMPR2  
 CITED2 
 
GATA4 
NODAL 
PDGFRA 
ZIC3 
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Laterality Defects 
 Chromosomal 
 Trisomies 13, 18 
 ? syndromic (single gene) 
 ACVR2B  
 CFC1  
 CITED2 
 CRELD1 
 FOXH1  
 GDF1 
 LEFTY2  
 NKX2.5 
 NODAL 
 ZIC3 
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1.3.7  Genetic counselling in patients with congenital heart disease  
With the mainstreaming of clinical genetics services and increased awareness 
amongst other medical professionals, there are more patients and families with 
CHD seen by clinical genetics departments for genetic counselling. For many, 
genetic counselling helps to: (a) identify and understand the genetic basis of 
their CHD, (b) provide accurate genetic counselling on recurrence risks, and (c) 
identify and manage extracardiac manifestations (Burchill et al., 2011). Although 
the majority of cases have an isolated anomaly and are sporadic, some will be 
syndromic and/or familial, and this will affect the nature of genetic counselling 
for these individuals. The knowledge and concerns about inheritance of CHD 
has been evaluated in a population of non-syndromic CHD adult patients, and 
showed that only a small proportion (33%) recalled receiving information about 
the inheritance of CHD (and only 18% consulted a clinical geneticist). Only 44% 
were able to estimate the recurrence risk in the correct range of magnitude. 
Many had concerns about future children and thought it important that they 
should be screened for CHD. Insufficient knowledge about the inheritance of 
CHD meant that 41% desired more information (van Engelen et al., 2011). 
There are current guidelines recommending genetic counselling as part of the 
care for adults with CHD (Marelli et al., 2010), but it is clear that this is not 
implemented widely or meeting the needs of patients.  
 
1.3.7.1 Genetic Assessment of proband 
The assessment of any patient with a condition suspected to have a genetic 
basis, always starts with a detailed family history spanning at least three 
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generations, including the presence of consanguinity. This can allow the 
identification of any Mendelian patterns of inheritance. A detailed history and 
clinical examination will help to identify features suggestive of an underlying 
genetic syndrome with CHD (e.g. developmental delay, learning difficulties, 
extracardiac manifestations, behavioural problems, and facial dysmorphism).  
 
1.3.7.2 Genetic testing of proband 
Diagnostic genetic testing aims to identify inherited or de novo variations that 
account for CHD. This can be guided by the information collated from the 
detailed family history and clinical assessment. Various methods currently 
employed in clinical practice include: karyotyping, fluorescent in situ 
hybridisation (FISH) analysis, microarray analysis, and gene sequencing. 
Knowledge of the clinical criteria and molecular basis of genetic conditions 
associated with CHD is an essential prerequisite to genetic testing, and will 
determine the nature of the test utilised. It is important to be aware that although 
positive results can be very informative, in cases with a clinical phenotype and 
family history, a negative result does not disprove a genetic basis.  
 
1.3.7.3 Recurrence risks  
The process of evaluating and discussing recurrence risks has to take into 
account the family history and patient characteristics (nature of defect and 
extracardiac manifestations). For Mendelian patterns of inheritance this is easily 
predicted, but one has to account for intra- and inter-familial variability. The 
challenges lie in sporadic non-syndromic patients with CHD. It has been 
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estimated that familial recurrence of CHD represents 3-5% of non-syndromic 
CHD (Calcagni et al., 2007). A prospective multicentre study reported 
recurrence risks of CHD as 4.1% (with an affected parent) and 2.1% (with an 
affected sibling). There appeared to be gender differences with more CHD 
occurring in the offspring of affected women with CHD (5.7%) than affected men 
(2.2%) (Burn et al., 1998). The recurrence risk for a couple after one affected 
child is ~3%, but increases to 10% if there are two affected children.  
 
The precise type of CHD is also an important factor in recurrence risks and 
concordance (identical to CHD seen in index case), and so an accurate 
diagnosis in the index case is essential to allow accurate counselling on 
recurrence risk (Gill et al., 2003). For families with one recurrence the exact 
concordance has been reported as 33%, which increases to 55% in families 
with two or more recurrences, but overall the exact concordance is 53%. There 
is wide variation between exact concordance for the various CHD (e.g. 80% for 
AVSD, 55% for VSD, 43% for TOF, and 15% for CoA) (Gill et al., 2003).  
 
A population based study of 18,000 Danish patients with CHD estimated an 
individual’s risk of CHD given a family history of CHD. They found that the 
relative risk for the same type of CHD ranged from 3-fold (septal defects) to 80-
fold (heterotaxia) in first degree relatives. The overall relative risk for the same 
type of CHD was 8.15, and for any other type of CHD was 2.68, the latter 
suggesting that some families have a susceptibility to CHD (Oyen et al., 2009; 
Oyen et al., 2010). Demographic studies like these and the evolution of 
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knowledge regarding cardiac development have led to genetic counselling of 
CHD being based on embryological mechanisms of a heart defect rather than 
on its anatomy. 
 
As the population of adults with CHD has increased, and these adults have had 
children themselves, clinicians are now seeing more families with multiply 
affected individuals with CHD. Many of these families will appear to have an 
autosomal dominant inheritance pattern, which can significantly increase the 
risk of CHD to offspring (50%). There are also families with no apparent family 
history of CHD, but parents have had more than one child with CHD, suggesting 
an autosomal recessive pattern of inheritance (25% recurrence risk). There is 
however a great variability in the phenotype between individuals from the same 
family. These familial recurrences of CHD are a fundamental resource for 
molecular studies and identification of genes involved in heart development. 
 
1.3.7.4 Screening at risk relatives  
Clinical geneticists play a major role in counselling at risk individuals of 
numerous genetic conditions. In CHD, if the genetic basis is known, clarification 
of risk can be determined via cascade genetic testing (with appropriate genetic 
counselling). When the aetiology of CHD is unknown in a patient, cardiac 
screening of at risk relatives (especially for milder forms of CHD) can be a 
dilemma for clinicians. Left ventricular outflow tract obstructions (LVOTO) are a 
group of CHD including: bicuspid aortic valve (BAV), sub/supravalvular AS, 
mitral valve stenosis, IAA, CoA, and HLHS. They are generally considered to 
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have high heritability as various LVOTO diagnoses may occur within the same 
family (Wessels et al., 2005). Screening first degree relatives of patients with 
LVOTO showed that 20% of these patients had a first degree relative with a 
cardiac anomaly (most commonly BAV), thereby justifying screening of relatives 
(Kerstjens-Frederikse et al., 2011).  
 
1.4 Gene identification  
1.4.1  Why study the genetics of congenital heart disease?  
It is very important to determine an underlying genetic factor in a patient with 
CHD as there may be: (a) other organ system involvement, (b) prognostic 
information for clinical outcome, (c) important genetic reproductive risks for the 
family, and (d) other family members for whom genetic testing may be 
appropriate. 
 
The research described in this report is primarily focused on the mapping and 
identification of genes causing CHD, as the molecular mechanisms accounting 
for the majority of CHDs still remain to be elucidated. By defining the precise 
mechanisms involved in normal heart development, future targeted strategies at 
specific stages of the molecular pathway may lead to the development of novel 
therapeutic options.  
 
1.4.2  Approaches to gene identification  
There are a number of methods of identifying a disease-causing gene. The two 
most popular methods are functional cloning (candidate gene approach) and 
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positional cloning, but the most efficient and effective way to identify genes is by 
utilising both strategies, the positional-candidate approach. 
 
1.4.2.1 Functional cloning  
Functional cloning requires a detailed knowledge of the phenotype of a 
particular disease and the possible biological mechanisms causing it. In this 
approach candidate genes can be selected based on information about their 
function, tissue expression pattern, role in known developmental pathways, 
homologies to other genes, and/or animal models. These genes are then 
screened for mutations within them. So for CHD one would select genes that 
control the formation and development of the heart. Prior to positional cloning, 
this was the main approach for the identification of disease causing genes.  
 
Chromosomal abnormalities, such as deletions or translocations, in which 
patients have very similar phenotypes, may help to identify a locus for that 
condition. An example would be the occurrence of CHD in 60% of patients with 
deletion of chromosome 8p (8p23.1 in particular) (Pehlivan et al., 1999). GATA4 
is located at this locus and was therefore screened in other patients with CHD 
and mutations identified (Garg et al., 2003). Knockout mouse models of Fog2 
developed Tetralogy of Fallot (TOF) phenotypes, which led to the identification 
of mutations in FOG2 in patients with TOF (Pizzuti et al., 2003). 
 
New methods in this category include whole exome sequencing technology, 
which sequences the entire coding region of the genome in an individual. This 
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method may identify variants in numerous genes, which could then be filtered 
depending on their function and role in biological processes, and any animal 
models. 
 
Once gene identification has linked a specific phenotype to a particular 
biological pathway, this approach of functional cloning allows selection of further 
candidate genes from the same pathway that may cause identical or related 
conditions. This is exemplified by the identification of genes in the RAS-MAPK 
signal transduction pathway (PTPN11, SOS1, RAF1, KRAS, HRAS, BRAF, 
MEK1, and MEK2) that cause a spectrum of genetic syndromes (Noonan 
syndrome, LEOPARD syndrome, Costello syndrome, and Cardiofaciocutaneous 
syndrome) with many overlapping clinical features including CHD (Weismann et 
al., 2005). 
 
Functional cloning has been greatly aided by analysis of mouse mutants which 
have been generated by systematic mutagenesis programs. Completion of the 
mouse genome project has aided this approach (Waterston et al., 2002). 
Human-mouse homologies may be particularly valuable, as mutations in 
specific genes may often cause similar phenotypes.  
 
1.4.2.2 Positional cloning  
Positional cloning studies requires affected individuals from families with 
Mendelian disorders, by utilising linkage analysis to identify and define a portion 
on a chromosome (locus) which must contain the disease-causing gene 
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(Wicking and Williamson, 1991). Once a disease locus is identified, candidate 
genes within this locus can be selected for mutational screening (as described 
above). The Human Genome Project (Venter et al., 2001) has greatly facilitated 
this approach to gene identification, by providing physical and genetic maps 
enabling one to locate markers and genes within a specific chromosomal 
region. Public databases such as ’NCBI‘, ‘Ensembl‘ and ‘UCSC Genome 
Bioinformatics site‘ include detailed information about numerous polymorphic 
markers spread throughout the genome, genetic maps based on these markers, 
a physical map based on latest genomic sequence information, a rapidly 
expanding map of expressed sequences, and information management and 
search tools. A successful example of this approach in CHD was the 
identification of the NKX2.5 gene, which was mapped to the chromosome 
region 5q35 in numerous large families with an autosomal dominant form of 
CHD (ASD, VSD, TOF, and subvalvular AS), with the subsequent identification 
of three different pathogenic mutations (Schott et al., 1998). 
 
The clinical recognition of deletion-specific syndromes (e.g. 4p [Wolf-
Hirschhorn], 5p [Cri du chat], 22q11.2 [Di George]) supports the theory that 
haploinsufficiency for some genes in the deleted region has a direct effect on 
specific developmental processes. Chromosome maps of deletions and 
duplications associated with 47 different congenital malformations have been 
created, using detailed clinical and cytogenetic information from over 3000 
patients (Brewer et al., 1998; 1999). They analysed the frequency of 
deleted/duplicated bands with each malformation to identify any malformation 
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specific regions/bands. They were able to identify a number of highly significant 
associated bands for various heart defects (e.g. 4q31 and 22q11 for VSD; 
20p13-11 and 22q11 for PS; 11q23-23 for AS and HLHS; 2q22 and 22q11 for 
TrA). These maps may help to facilitate the identification of genes important in 
human development, and there have been several successes to localising 
malformation-specific genes (e.g. Holoprosencephaly-SHH gene and Aniridia-
PAX6 gene). 
 
1.4.3  Linkage, genetic markers, and maps  
A haplotype is a set of closely linked alleles on a chromosome (either genes or 
DNA polymorphisms) which are inherited as a block unit. Haplotypes are used 
extensively in genetic mapping and population studies. All genetic mapping 
depends on the behaviour of chromosomes at meiosis. Loci that are on the 
same chromosome will travel together unless there is a crossover between 
paired homologous chromosomes separating the two loci (recombination). This 
can happen more often to loci that are widely separated from each other (or on 
different chromosomes), but rarely to loci close together (Morgan, 1911). The 
chance of recombination is a measure of the distance between them, and 
usually loci separated by recombination in 1% of meioses are defined as being 
1centiMorgan (cM) apart. This genetic distance is not the same as physical 
distance (measured in bp, kb, or Mb of DNA). Some chromosome regions have 
a higher frequency of cross over than others. The order of loci should still be the 
same in genetic and physical maps, but the spacing may be different, and on 
average 1cM corresponds to 1Mb, although the relationship varies across the 
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genome. Linkage between two loci is defined as occurring when recombination 
events occur less that 50% of the time, with a resultant recombination fraction of 
<0.5 (Ott and Bhat, 1999). This indicates that the loci are on the same 
chromosome and close to each other.  
 
Genetic mapping in humans looks at a large number of loci and types them for 
genetic markers. Markers must be: (a) inherited in a Mendelian manner, (b) 
sufficiently polymorphic, (c) relatively easy to type, and (d) available across the 
whole genome at close intervals. DNA polymorphisms can satisfy these 
requirements and the two well known and used types are microsatellites and 
single nucleotide polymorphisms (SNPs). In my project I have utilised both 
types of markers. 
 
Microsatellite markers are short tandem repeats of 2, 3 or 4 bases (e.g. [CA]n 
sequences) that are present in all people at the same specific chromosomal 
location, but the size of the repeat unit can vary from person to person (i.e. 
polymorphic).  They can be analysed by polymerase chain reaction (PCR) of a 
segment of DNA containing the microsatellite and determining the size (using a 
fluorescent label and a DNA sequencing machine). These markers are present 
approximately every 30,000 bases in the genomic sequence (Stallings et al., 
1991), and can be very informative. Many successful mapping projects have 
been achieved by the use of microsatellites to conduct genome-wide scans 
(Aligianis et al., 2005).  
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SNPs are now much more widely used in genetic mapping studies in the study 
of complex multifactorial diseases, diseases with Mendelian inheritance and 
copy number variants (CNVs). They are usually less informative as there are 
likely to be only two alternative nucleotides at a polymorphic site. However they 
are abundant in the human genome, can be typed with high throughput 
technology such as microarrays (‘SNP-chips’), and allow researchers to obtain 
high resolution mapping information. The first SNP array for genome wide scan 
was produced by Affymetrix (GeneChip® 10K Xba Array) containing 11,555 
SNP markers (Affymetrix Inc, Santa Clara, CA). Since 2004, several successful 
mapping projects have been accomplished using this 10K array (Gissen et al., 
2004; Janecke et al., 2004). Currently, the Affymetrix® Genome-Wide Human 
SNP Array 6.0 contains more than 1.8 million genetic markers (>906,600 SNPs 
and >946,000 probes for the detection of copy number variation).  
 
Therefore genetic mapping studies now have a dense framework of markers 
available which are all mapped relative to one another and in defined 
chromosomal locations (Maps). A number of genetic and physical maps of the 
genome have been developed, and these maps are fundamental tools for 
mapping and gene identification. Examples of genetic maps that have been 
constructed over the last two decades include the Généthon map (a 
microsatellite marker-based linkage map) (Weissenbach et al., 1992; Dib et al., 
1996) and the Marshfield map. The Marshfield map was based on the 
genotyping of around 8,000 microsatellite markers in eight large, three 
generation families from the Centre d‘Etude du Polymorphisme Human (CEPH) 
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collection containing 188 meioses (Broman et al., 1998). More recent maps 
include those generated by deCODE Genetics in Iceland, with substantially 
improved resolution of up to five times the resolution of previous maps (Kong et 
al., 2002). This map was based on the genotyping of 5,136 microsatellite 
markers, in 146 nuclear families containing 1,257 meioses. The construction of 
these genetic maps and intermediate physical maps significantly contributed to 
sequencing the entire human genome in the Human Genome Project (Venter et 
al., 2001). Recent advances in SNP genotyping have also facilitated the 
construction of a detailed human haplotype map of over 3.1 million SNPs 
(International HapMap consortium 2007). Once markers have been typed, the 
genotypes of each marker must be aligned to the pedigrees and checked for co-
segregation with the disease being studied. 
 
1.4.4  Autozygosity mapping  
1.4.4.1  Introduction  
It has been recognised that searching for homozygous regions by descent in 
consanguineous families offers a powerful strategy for mapping autosomal 
recessive disorders. The development of genetic maps allowed researchers to 
reintroduce this concept and formulate a technique called ‘homozygosity 
mapping‘ for the mapping of autosomal recessive disorders in consanguineous 
kindreds (Lander and Botstein, 1987). As a locus can be homozygous by virtue 
of parental descent from a common ancestor, and thus autozygous, this 
methodology is also termed autozygosity mapping (Mueller and Bishop, 1993). 
One of the first disorders to be mapping this way was alkaptonuria (Pollak et al., 
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1993) and over the last 17 years a multitude of disorders have been 
successfully mapped this way (Aligianis et al., 2005; Morgan et al., 2006a). 
 
1.4.4.2 Consanguinity 
Successful autozygosity mapping relies on the identification of consanguineous 
families in which there are multiple affected children with an identical disorder. 
Consanguinity is defined as a union between couples who are related as 
second cousins or closer. A second cousin couple share 1/32 of their autosomal 
genes. Their children have identical gene copies at 1/64 of all loci. A first cousin 
couple share 1/8 of their autosomal genes. Their children have identical gene 
copies at 1/16 of all loci.  
 
Consanguineous marriages are common practice in a number of communities 
worldwide. The effect of a consanguineous marriage depends on the frequency 
and nature of all recessive diseases in that population. Documented effects 
include increased infant mortality, congenital malformations, learning difficulties, 
blindness, hearing difficulties and metabolic disorders. An average increase of 
infant mortality by 4.4% was shown amongst offspring of first cousins compared 
with unrelated controls (meta-analysis of numerous studies mainly from 
developing countries) (Bittles and Neel, 1994). However some of these 
disorders may be successfully treated in developed countries but lead to death 
in undeveloped countries (partially skewing these figures). In unrelated parents, 
the prevalence of serious congenital abnormalities and genetic disorders is 2-
2.5% (Congenital Anomalies Register) and around 4% in some longer term 
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studies. These risks are doubled for children from first cousin relationships. A 
study performed in Birmingham in 1993 found 0.4% of Northern European 
couples were related, whereas amongst the British Pakistani couples, 69% 
were related and 57% were first cousins. The birth prevalence of all congenital 
and genetic disorders was 7.9% in the children of the British Pakistani couples, 
almost double that of children from the Northern European couples (4.3%). The 
prevalence of recessive disorders was 3.0–3.3% in the British Pakistani children 
(~10 times higher than in the Northern European children-0.28%) (Bundey and 
Alam, 1993).  
 
These genetic risks are recognised within these communities but there are 
many social advantages that outweigh these risks. A consanguineous marriage 
is believed to strengthen family ties, minimise the costs of dowry payments, and 
remove any uncertainties that arise through marriage to an individual outside 
the family or community. Consanguineous couples usually marry and have 
children earlier with larger family sizes, thereby increasing the likelihood of 
expression of a recessive disorder. The clinical approach has always been to 
offer improved access to genetic counselling, and identify at risk individuals and 
perform cascade testing of extended family members for carrier status of 
recessive conditions.  
 
1.4.4.3 Consanguinity and congenital heart disease  
The relationship between the incidence of CHD and the degree of consanguinity 
has been tested in a study of the largest cohort (1500 patients) reported to date 
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(Chehab et al., 2007). The relative contributions to this cohort from 
consanguineous families were: 19.4% (first degree cousins), 5.9% (second 
degree cousins), and 2.1% (other parental consanguinity). In comparison the 
contributions from consanguineous families in the control group without CHD 
were: 14.4% (first degree cousins), 5.9% (second degree cousins), and 3.6% 
(other parental consanguinity), showing statistical difference between the two 
groups. However the rate of consanguinity varied greatly between types of 
CHD. The defects with a high incidence of consanguineous parents were ASD, 
TOF, and valvular AS, supporting the role of autosomal recessive genes in 
these lesions. Many other studies have also reported a significant higher 
proportion of parental consanguinity amongst patients with CHD (Gatrad et al., 
1984; Gev et al., 1986; Badaruddoza et al., 1994; Becker and Al Halees, 1999; 
Bassili et al., 2000; Becker et al., 2001; Nabulsi et al., 2003; Ul Haq et al., 2011; 
Shieh et al., 2012). Some very important factors have been highlighted, that 
could more accurately assess the impact of consanguinity on health, and could 
have improved the outcome of many of the above studies (Bittles, 2011). These 
factors include: more accurate diagnosis and classification of CHD type, 
improved matching of cases and controls, and clarification of type of 
consanguinity (e.g. cousin-cousin, uncle-niece). 
 
The role of consanguinity has been established in many autosomal recessive 
diseases, but it may also play a part in structural malformations, including CHD. 
This may seem peculiar in relation to the recent advances in molecular genetics 
of CHD, especially as autosomal dominant families with ASD and mutations in 
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NKX2.5 and GATA4, and aortic valve anomalies and NOTCH1 mutations have 
been reported (Schott et al., 1998; Garg et al., 2003; Garg et al., 2005). It is still 
unknown if genes responsible for CHD in autosomal dominant families may also 
be implicated in autosomal recessive families.   
 
1.4.4.4 Principles of autozygosity mapping  
Figure 13 illustrates an example of a pedigree of a consanguineous family with 
two children affected with an autosomal recessive condition. The disease allele 
has been passed down through successive generations from the common 
ancestor (CA). The affected children have thus inherited both copies of this 
disease allele from their parents, and are thus homozygous-by-descent for this 
gene. In addition, the chromosomal segment surrounding the gene is also 
homozygous (shaded in red). Recombination events during meiosis lead to a 
reduction in the size of the homozygous chromosomal segment (red) over 
successive generations. Disease loci in consanguineous families are thus 
normally (but not always) located in such homozygous regions of the genome. 
These homozygous regions can be identified using genome-wide SNP arrays 
and microsatellite markers. Once homozygous regions are identified, the region 
of interest can be examined for candidate genes for sequencing.  
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Figure 13: The principle of autozygosity mapping. 
The specific mutation of a disease gene (indicated by the black arrow) can be 
passed on from a common ancestor (CA) to offspring and the product of a 
consanguineous marriage, can result in affected offspring CA.  
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1.4.4.5 Advantages / disadvantages of autozygosity mapping  
Autozygosity mapping and positional candidate gene analysis is a highly 
effective strategy for gene identification in consanguineous families, much more 
than the identification of recessive genes in non-consanguineous families. A 
single affected child from a consanguineous marriage provides as much 
information as a non-consanguineous family with three affected children. 
Autozygosity mapping represents a highly efficient and effective approach for 
generating disease gene localisation even in the presence of locus 
heterogeneity.  
 
Over the past decade, Professor Maher’s research group have developed a 
major interest in autozygosity mapping studies and identified a large number of 
novel genes for autosomal recessive disorders including genes for: 
Achromatopsia (GNAT2)(Aligianis et al., 2002), ARC syndrome (VPS33B, 
VIPAR)(Gissen et al., 2004; Cullinane et al., 2010), Beckwith-Wiedemann 
syndrome (NLRP2)(Meyer et al., 2009), Faisalabad histiocytosis/3 Rosai-
Dorfman disease (SLC29A3)(Morgan et al., 2010), Fowler syndrome 
(FLVCR2)(Meyer et al., 2010), Hermansky-Pudlak syndrome 
(BLOC1S3)(Morgan et al., 2006b), Immunodeficiency syndromes 
(TRAC)(Morgan et al., 2011), Infantile neuraxonal dystrophy (PLA2G6)(Morgan 
et al., 2006a), Infantile parkinsonism (DAT)(Kurian et al., 2009), Martsolf 
syndrome (RAB3GAP2)(Aligianis et al., 2006), Meckel-Gruber syndrome 
(MKS3)(Smith et al., 2006), Multiple pterygium/Fetal akinesia syndrome 
(CHRNG, RAPSN, DOK7)(Morgan et al., 2006c; Vogt et al., 2008; Vogt et al., 
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2009), Trichohepaticenteric syndrome (TTC37)(Hartley et al., 2010), and 
Warburg MICRO syndrome (RAB3GAP1)(Aligianis et al., 2005). 
 
Many of the recessively inherited diseases are rare and it can be very difficult to 
ascertain a sufficient number of patients with the same phenotype to perform 
autozygosity mapping studies. If family sizes are small it is less likely for there 
to be more than two affected siblings within a sibship, and so a solution would 
be to set up collaborative projects between centres. A number of families will 
have a ‘private mutation‘ for a genetic disorder, and so it can be difficult to find 
other families who have mutations in the same gene. Sometimes autosomal 
recessive diseases in consanguineous families may be caused by compound 
heterozygous mutations, and in this situation the disease locus may not be 
within a homozygous region, and will not be detected with genome-wide scans 
for homozygous regions. Autosomal recessive diseases can also be extremely 
heterogeneous with more than one genetic locus for the disease, so it is 
important to identify any previously mapped disease loci. Linkage studies 
performed in one large consanguineous family with multiple affected individuals 
can be much more powerful than using several different families with one or two 
affected individuals. Once linkage is established in that large family, other 
smaller consanguineous families can be investigated for linkage to the same 
region. Such approaches may help to overcome this problem of locus 
heterogeneity. 
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1.4.5  DNA sequencing 
The development of Sanger sequencing provided an enormous leap forward in 
molecular genetics, and has had a great impact in understanding the genetic 
basis of various diseases. The finished sequence of the human genome in 2004 
was facilitated by the automation of this process (Levy et al., 2007). The advent 
of high throughput machines has led to a significant decrease in time and cost 
of Sanger sequencing (‘First-Generation Sequencing’), and this has been 
further reduced by the introduction of massive parallel sequencing techniques 
(‘Next-Generation Sequencing’) (Brenner et al., 2000). The latter method has 
the ability to sequence the entire human genome in days at a fraction of the 
previous costs, and parallelises the sequencing process, producing thousands 
or millions of sequences at once. With advances in bioinformatics tools to 
analyse the data and the production of portable sized machines, it is possible 
that we will enter an era of bringing the sequencer to the bedside to impact 
medical management of patients (Marian, 2011).  
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1.5 Conclusion  
I have given an overview of the complex nature of heart development and 
congenital heart disease (CHD). The specific advances which are altering our 
understanding of the aetiology of CHD include the: (a) detection of subtle 
chromosomal abnormalities due to high resolution chromosomal analysis, (b) 
delineation of the genetic defect in familial CHD via linkage analysis and 
reverse genetics, and (c) advances in animal genetics allowing detailed studies 
of animal models of CHD. All these methods should provide further information 
on this complex physiological process and how mutations in heart development 
genes can cause CHD.  
 
For families with CHD, the identification of a genetic cause is very beneficial, as 
it allows the clinician to explain the exact genetic mechanism and pathogenesis 
to the family, and accurately counsel them regarding recurrence risks. It guides 
further investigations to identify other associated organ system involvement, 
and early intervention if needed to reduce co-morbidities. It also provides an 
opportunity to evaluate extended family members to accurately assess the risk 
of CHD to them and their offspring.  
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1.6 Aim of project  
The principal aim of the project was to identify novel CHD genes by 
investigating familial cases of non-syndromic CHD. I was particularly interested 
in consanguineous families likely to have recessively inherited CHD (in order to 
utilise an autozygosity mapping approach), but also decided to collect non-
consanguineous families that might have other types of inheritance, as these 
would be investigated for genes identified in the consanguineous families.  
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CHAPTER 2 
GENERAL METHODS 
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2.1 Acquisition and assessment of patients and controls 
2.1.1  Patient recruitment  
In this project, familial cases of non-syndromic CHD were being selected for 
molecular genetic analysis, therefore families who fulfilled the following criteria 
were recruited:-  
a) Consanguineous, one or more affected children with non-syndromic CHD 
b) Non-consanguineous, two or more affected children with non-syndromic 
CHD 
c) Outflow tract CHD anomalies (e.g. TOF / TGA / LVOTO) and an 
autosomal dominant pattern of inheritance. 
 
I used a number of different strategies to identify families suitable for the 
project. Families were initially identified from those previously seen by the West 
Midlands Clinical Genetics department (regional service) for genetic 
counselling. I manually reviewed all 490 files disease coded with CHD 
(electronically) to select familial cases of CHD. Of these 490 files, 54 files were 
identified to be familial CHD and were then reviewed in more detail to clarify if 
they fulfilled the above criteria for familial non-syndromic CHD. Only 30 of these 
files were deemed suitable to take to the next stage in which these families 
were contacted by letter or telephone and invited to participate in the project. Of 
these 30 families, 5 refused, 11 did not ever respond, and 14 accepted the 
invite and were recruited (see later).  
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To identify further families from around the UK, I designed a project flyer/advert 
(Appendix C1) which i sent via email to clinicians from all the regional Clinical 
Genetics departments, and a selection of paediatric cardiologists with a special 
interest in CHD (including the tertiary paediatric cardiology service in the West 
Midlands). A total of 3 families were recruited after referrals from the above 
group. At the same time I directly liaised with some of the UK CHD patient 
support groups (e.g. Grown Up Congenital Heart Disease Patient Association, 
Children’s Heart Federation, Heartline, and CHD-UK). They all kindly posted a 
link advertising the research project on their websites (Appendix C2), and I was 
also invited to lecture at their patient information conferences (Chapter 8). A 
number of families subsequently telephoned me for further information and I 
eventually visited and recruited 6 further families to the project. In total 23 
families were recruited via the above processes from July 2009 to March 2011 
(see Appendix A for timeline). 
 
2.1.2  Consent and ethics approval  
I was involved in the process of ethics approval applications, which also 
consisted of designing patient information sheets and informed consent forms 
(Appendix C3). The project was approved by the LREC (Local Research Ethics 
Committee), and informed consent was obtained from all participants and all 
clinical research adhered to principles outlined by the Declaration of Helsinki 
(see Appendix A for timeline). 
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2.1.3  Clinical assessment and acquisition of blood/saliva samples 
I designed a designed a proforma for assessing all families (Appendix C4), in 
which a detailed family history and clinical assessment was performed, 
including a full medical history and search for dysmorphic and extra cardiac 
features to rule out syndromic causes of CHD. The medical notes were 
examined for details of CHD type, disease evolution and surgery performed. 
Blood or saliva samples (for DNA extraction) were taken from all available 
affected individuals, parents and any unaffected siblings. Routine cytogenetic 
analysis and FISH testing for 22q11.2 deletion syndrome (by the NHS West 
Midlands Regional Genetics Laboratory, UK) was also performed in one 
affected individual from each family.  
 
2.1.4  DNA from control subjects  
Control DNA samples were kindly donated by the West Midlands Regional 
Genetics Laboratory for assessing population frequencies of identified genomic 
variants. The surnames of the families were used to select which control panel 
they fitted into, after which they were anonymised.  
 
2.2 Materials  
2.2.1  Chemical reagents  
Acetamide         Sigma  
Agarose         Bioline  
2X BiomixTM Red        Bioline  
dNTPs (diluted from 100mM to a working stock of 2mM)  Bioline  
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EDTA (ethylenediaminetetraacetic acid)     Sigma  
Ethanol         Fisher Scientific  
Ethidium bromide        Sigma  
GC rich solution of FastStart Taq DNA Polymerase Kit  Roche  
Genescan-500 LIZ Size Standard              Applied biosystems  
Hi-Di Formamide                 Applied biosystems  
HyperladderTM I (Separation range 200 – 10000bp)   Bioline  
MicroCLEAN®        Web Scientific  
Primers         Sigma  
10X TBE Electrophoresis Buffer (diluted to 1X)    Geneflow  
Water (distilled-RNase/DNase free, dH2O)    Invitrogen  
 
2.2.2  Kits  
Affymetrix Genome-Wide SNP 5.0 Array    Affymetrix Ltd  
BigDye Terminator Cycle Sequencing Kit version 3.1            Applied biosystems  
BigDye 5X Sequencing Buffer               Applied biosystems 
(25nM Tris pH 8.7, 4mM MgCl2)   
Puregene Genomic DNA Purification Kit    Gentra systems  
 
2.3 Molecular genetic investigation  
2.3.1  DNA extraction  
DNA extraction was kindly performed by the West Midlands Regional Genetics 
Laboratory. DNA was extracted from cells using the Puregene Genomic DNA 
Purification kit according to the manufacturer‘s instructions. Extracted genomic 
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samples were then quantified by spectrophotometry (by measurement of 
A260:A280 ratios).  
 
2.3.2  SNP genotyping arrays  
Autozygosity mapping strategies were utilised to establish disease loci and 
identify novel disease-causing genes in consanguineous families. In order to 
identify regions of common homozygosity and/or genomic copy number 
variants, a genome-wide scan using the Affymetrix SNP 5.0 Array (Affymetrix 
UK Ltd) was undertaken in affected children and their unaffected siblings.  
 
This microarray technology allows the simultaneous genotyping of a subject‘s 
DNA for >500,000 single nucleotide polymorphisms (SNPs). SNP genotyping 
was kindly performed by Louise Tee (a research laboratory technician), 
according to the manufacturer‘s instructions (Affymetrix GeneChip Human 
Mapping SNP 5.0 Assay Manual).  
 
In brief, 250ng genomic DNA was digested with Sty 1 and 250ng genomic DNA 
was digested with Nsp 1. The Sty and Nsp adaptor molecules were then ligated 
to the product accordingly. PCR reactions were set up for each sample (Sty-3 
reactions, Nsp-4 reactions) using a universal PCR primer and the PCR products 
run on a 1.5% agarose (product sizes ranged from 200-1100bp). The PCR 
products were then pooled and cleaned up using magnetic beads (Ampure). 
The amplified DNA was then fragmented (to create products of <200bp), then 
labelled and hybridised to the SNP 5.0 chip (Affymetrix) for 16-18 hours. 
 92 
Washing and staining of the arrays was then performed on a fluidics station 
(Affymetrix) and the chips were subsequently scanned using a gene-chip 
scanner (Affymetrix GeneChip Scanner 3000) using Affymetrix Genechip 
Command Console software. Data analysis was then undertaken using 
Genotyping Console v3.0.2 software to derive SNP genotypes, marker order 
and linear chromosomal location. 
 
2.3.3  Microsatellite marker genotyping  
2.3.3.1 Primers for PCR  
The details of all microsatellite markers (and their UNISTS identification 
number) used for genotyping and fine mapping are tabulated in Table 6. 
Forward and reverse primer sequences for known microsatellite markers were 
obtained from each marker’s entry on the UNISTS database. Di- tri- and tetra-
nucleotide markers with high heterozygosity scores were selected using NCBI 
UNISTS and Ensembl genome browsers. Fluorescent dyes (FAM-blue, HEX-
yellow, TET-green) were added to the 5’ end of the forward primer.  
 
2.3.3.2 PCR amplification for microsatellite marker genotyping  
PCR amplification was performed in 10μl reactions as follows:-  
 1.0μl genomic DNA (20ng/μl) 
 5.0μl BiomixTM Red 1X  
 3.6μl dH2O  
 0.2μl (2.0pmol) forward primer (tagged with fluorescent dye)  
 0.2μl (2.0pmol) reverse primer  
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BiomixTM Red is a premixed, pre-optimised 2X solution designed for high 
throughput PCR applications. It contains an ultra-stable Taq DNA polymerase 
and an inert red dye, permitting easy visualisation and direct gel loading.  
 
After an initial denaturation at 95oC for 5 min, a standard PCR protocol was 
followed: 30 cycles of 95oC for 30s, annealing at 55oC for 30s and extension at 
72oC for 30s, followed by a final extension step at 72oC for 5 min. Each set of 
PCR reactions included a negative control (in which dH2O was added instead of 
DNA) to check for contamination.  
 
2.3.3.3 Analysis of microsatellite marker PCR products  
Markers run on the ABI 3730 DNA Analyzer were initially diluted 1:15 with 
dH2O. 1μl of the diluted PCR product was added to 10μl Hi-Di Formamide and 
0.04μl Genescan-500 LIZ size standard. PCR product sizes were determined 
using Genemapper v4.0 software (Applied Biosystems). Scored genotypes 
were assembled as haplotypes and analysed for evidence of linkage. 
 
2.3.4  Gene sequencing  
2.3.4.1 Primers for sequencing candidate genes  
All annotations and physical positions are recorded as in NCBI Genome 37.1 
build. The DNA template for each gene sequenced in this report was 
downloaded from the Ensembl database. All coding transcripts for each gene 
were examined and intronic primer pairs flanking the exonic coding sequence, 
for exon-specific PCR amplification of the genomic exons and flanking exon-
 94 
intron boundaries were designed for exon-specific PCR amplification, either 
manually or using ExonPrimer and Primer3 software (Tables 7 & 8). 
 
2.3.4.2 PCR amplification for gene sequencing  
Standard conditions for PCR amplification were used. PCR amplification was 
performed in 25μl reactions as follows:-  
 5.0μl genomic DNA (20ng/μl)  
 12.5μl BiomixTM Red 1X  
 6.5μl dH2O  
 0.5μl (5.0pmol) forward primer  
 0.5μl (5.0pmol) reverse primer  
 
For GC-rich fragments, PCR amplification was performed in 25μl reactions:-  
 5.0μl genomic DNA (20ng/μl)  
 12.5μl BiomixTM Red 1X 
 5μl GC rich solution 
 1.5μl dH2O 
 0.5μl (5.0pmol) forward primer 
 0.5μl (5.0pmol) reverse primer  
 
PCR conditions were an initial denaturation of 95oC for 5 min followed by 30 
cycles of 45s denaturation at 95oC, 45s annealing at 50-65oC (temperature 
optimised specifically for each amplification reaction) and 1 min extension at 
72oC. This was followed by a final extension step at 72oC for 5 min. Each set of 
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PCR reactions included a negative control (in which dH2O was added instead of 
DNA) to check for contamination.  
 
2.3.4.3 Agarose gel electrophoresis  
PCR products were checked on 1.5% horizontal agarose gels to separate the 
PCR products and to ensure that the PCR reaction had worked without 
contamination. The agarose gels were made by melting agarose with 1X TBE in 
a domestic 600W microwave oven, then cooling the mixture before adding 
ethidium bromide (0.5g/ml final concentration) and casting the gel in a gel 
casting tray. The PCR products were loaded directly. Loading buffer was not 
required with the use of BiomixTM Red as the mix is of sufficient density to sink 
to the bottom of each well in the gel. A DNA sizing ladder (Hyperladder I) was 
added to lane 1 to check for correct PCR product size. Separation of DNA was 
achieved by electrophoresis at 60-140V for 30-120 min (depending on the gel 
size and PCR product size). The bands were visualised using Ethidium Bromide 
and a UV transilluminator (254nm wavelength).  
 
2.3.4.4 PCR product clean-up  
The PCR product was cleaned up (to remove unwanted dNTPs and primer) by 
using MicroCLEAN. 2.5μl MicroCLEAN was added to 2.5μl of PCR product, 
incubated at room temperature for 5 min and then centrifuged at 4000rpm at 
20oC for 40 min. The supernatant was removed by briefly spinning the plate 
upside down at 500rpm at 20oC for 30s. The pellet was left to air-dry and then 
reconstituted with 4.5μl dH2O.  
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2.3.4.5 Cycle sequencing  
The purified PCR product was then sequenced in both forward and reverse 
directions using relevant primers. Each 10μl reaction was set up as follows:-  
 4.5μl purified PCR product 
 0.5μl BigDye Reaction Mix 
 2.0μl 5X Sequencing buffer 
 1.0μl dH2O 
 2.0μl forward or reverse primer (4pmol)  
The cycling conditions were 96oC for 3 min followed by 30 cycles of 96oC (30s), 
50oC (15s) and 60oC (4 min).  
 
2.3.4.6 Sequencing reaction clean-up preparation  
Sequencing reactions were cleaned up to remove any incorporated dye 
terminators. The EDTA method of precipitation was used. To the 10μl 
sequencing reaction, 1μl EDTA (250nM) was added and mixed before adding 
30μl of absolute ethanol. This was incubated for 5-10 min at room temperature 
and then centrifuged for 20 min at 2000rpm (20oC). The supernatant was 
removed by briefly spinning the plate upside down to a maximum of 400rpm. 
90μl of 70% ethanol was then added, mixed and the plate centrifuged again for 
a further 10 min at 2000rpm (20
o
C). The supernatant was discarded by inverting 
the plate and spinning to 400rpm. The pellet was left to air dry.  
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2.3.4.7 Preparation and analysis of sequencing reactions  
Pellets were resuspended in 10μl Hi-Di Formamide and then denatured for 5 
minutes before snap-chilling on ice. Sequencing reactions were run on the ABI 
3730 DNA Analyzer. Analysed sequences were then downloaded using 
‘Chromas‘ software, printed and assessed manually for mutations.  
 
2.3.5  Whole exome sequencing 
DNA (1-3μg) was sheared to 100-400 bp using a Covaris E210 or LE220 
(Covaris, Woburn, MA, USA). Sheared DNA was subjected to Illumina paired-
end DNA library preparation and enriched for target sequences (Agilent 
Technologies; Human All Exon 50 Mb - ELID S02972011) according to 
manufacturer's recommendations (Agilent Technologies; SureSelectXT 
Automated Target Enrichment for Illumina Paired-End Multiplexed Sequencing). 
Enriched libraries were sequenced using the HiSeq platform (Illumina) as 
paired-end 75 base reads according to manufacturer's protocol. This 
methodology was utilised by both our collaborative groups at the Beijing 
Genomics Institute (BGI) (Beijing, China) and the Wellcome Trust Sanger 
Institute (WTSI) (Hinxton, UK). 
 
2.3.6  Assessment of Mutation Pathogenicity  
Variants identified by molecular genetic investigations were evaluated by:  
(a) determining the predicted effect on the gene product using bioinformatics 
resources (PolyPhen-2, SIFT) (e.g. putative missense mutations were 
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inspected to determine if they affect amino acids that are evolutionarily 
conserved and if they have a deleterious effect on protein function)  
(b) identifying if candidate genes are known to be involved in cardiac 
development and/or members of developmental pathways (Ensembl, 
GeneDistiller, OMIM, PubMed, UCSC Genome Bioinformatics)  
(c) identifying animal models of disease associated with the candidate gene 
(Mouse Genome Informatics, PubMed) 
(d) demonstrating appropriate segregation within a family 
(e) demonstrating absence in >360 ethnically matched control 
chromosomes. 
 
2.4 Website addresses for internet resources  
A number of websites were utilised for various aspects of experimental design 
and data analysis (Table 4).  
 
2.5 Timescale for all processes within the project  
See Appendix A for a summary of the timescale for all the processes involved 
within the project.  
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Table 4: Web based resources. 
1000 Genomes http://www.1000genomes.org 
Affymetrix http://www.affymetrix.com/estore 
BioGRID http://thebiogrid.org 
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi  
CHDWiki http://homes.esat.kuleuven.be/~bioiuser/chdwiki/index.php/Main_Page 
dbSNP http://www.ncbi.nlm.nih.gov./projects/SNP 
DECIPHER https://decipher.sanger.ac.uk/application 
Ensembl http://www.ensembl.org  
ExonPrimer http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html  
Gene cards http://www.genecards.org 
Gene Distiller 2 http://www.genedistiller.org 
Homozygosity Mapper http://www.homozygositymapper.org 
KOMP https://www.komp.org 
London Medical Databases http://www.lmdatabases.com 
Mouse Genome Informatics http://www.informatics.jax.org 
NCBI http://www.ncbi.nlm.nih.gov 
NCBI Nucleotide http://www.ncbi.nlm.nih.gov/sites/nuccore  
OMIM http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM 
PolyPhen-2 http://genetics.bwh.harvard.edu/pph2 
Primer3 http://frodo.wi.mit.edu/primer3 
PubMed http://www.ncbi.nlm.nih.gov./pubmed 
SIFT http://sift.jcvi.org 
Splice Site Prediction by Neural Network http://www.fruitfly.org/seq_tools/splice.html 
UCSC http://www.genome.ucsc.edu 
UK10K http://www.uk10k.org 
UNISTS http://www.ncbi.nlm.nih.gov./unists 
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CHAPTER 3 
RESULTS 
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3.1 Clinical studies of familial CHD cohort  
In this project, molecular genetic analysis was undertaken in consanguineous 
and non-consanguineous families containing individuals affected with a form of 
non-syndromic CHD. A total of 23 families who fulfilled our criteria were visited, 
clinically examined, and recruited into the project. The ethnic backgrounds of 
the families were: Pakistani (4), Indian (1), Irish (2), and White British (16). A 
total of 58 affected individuals were identified, of which consent and blood/saliva 
(and in one case tissue) samples were taken from 41 available affected 
individuals (~71%) (highlighted in blue in Table 5). Consent and blood/saliva 
samples were also taken from 64 unaffected family members (siblings, parents 
and offspring). Despite appearing to be a non-syndromic familial CHD cohort, to 
exclude frequent chromosomal abnormalities, routine cytogenetic analysis and 
FISH testing for 22q11.2 deletion syndrome was performed in one affected 
individual from all families and the results were normal in all cases. We did not 
use microarray analysis in each family as they were deemed to be non-
syndromic CHD, and therefore less likely to have a chromosome 
deletion/duplication, and funding was not available to perform testing in the 
NHS laboratory for our cases.  
 
3.1.1  Clinical phenotype of each individual CHD family 
For each individual family, details of the family history (simplified pedigree 
diagram), clinical phenotypes, and results of routine cytogenetics and FISH 
studies are described below. Appendix D summarises the data collected fo 
each family using the recruitment proforma.  
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3.1.1.1 Clinical phenotype of family CHD1  
 
This is a large consanguineous Pakistani family (parents of affected siblings are 
first cousins) with suspected autosomal recessive inheritance of CHD. IV:1 was 
diagnosed at birth with TOF (absent pulmonary valve type) due to a murmur on 
clinical examination, and she had corrective surgery at 3 months of age. IV:2 
was born with a right sided cleft lip and palate, pyloric stenosis, trachea-
oesophageal fistula with oesophageal atresia, right sided talipes, and a right 
undescended testicle. The trachea-oesophageal fistula with oesophageal 
atresia was repaired by 1 day of age, and the cleft lip and palate were repaired 
at 3 months and 2 years of age respectively. He had a normal renal ultrasound 
and ophthalmology assessment. At the age of 6 years he collapsed with loss of 
consciousness and diagnosed with VSD which was surgically closed at that 
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time. IV:3 was diagnosed antenatally with VSD, but a postnatal ECHO clarified 
this as TOF (absent pulmonary valve type), and she had corrective surgery at 5 
years of age. IV:4 was diagnosed antenatally with TOF (absent pulmonary valve 
type), which was confirmed on a postnatal ECHO, and he had corrective 
surgery at 2 years of age.  
 
Clinical history and examination of IV:1, IV:3 and IV:4 did not identify any 
features suggestive of syndromic CHD. No dysmorphic features were noted in 
IV:2, but in light of his clinical features, a syndromic form of CHD could not be 
excluded (though there were no obvious diagnoses that counted for his 
problems). Samples were taken from all affected siblings and their parents. 
Routine cytogenetic analysis and FISH testing for 22q11.2 deletion in IV:2 and 
IV:4 was normal. A chromosomal abnormality in IV:2 was further excluded with 
a normal array CGH (performed using the Affymetrix 2.7M Cytogenetics 
microarray by the NHS West Midlands Regional Genetics Laboratory). 
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3.1.1.2  Clinical phenotype of family CHD2  
 
 
 
 
 
 
 
 
 
 
This is a consanguineous Pakistani family (parents of IV:1 are first cousins) with 
suspected autosomal recessive inheritance of CHD. IV:1 was diagnosed with 
pulmonary atresia (PA) and VSD (TOF spectrum) at birth, and had a Blalock–
Taussig (BT) shunt inserted and corrective surgery at 6 days and 1 year of age 
respectively. Clinical history and examination of IV:1 did not identify any 
features suggestive of syndromic CHD. Samples were taken from IV:1, both 
unaffected siblings (IV:2 and IV:3), and their parents. Routine cytogenetic 
analysis and FISH testing for 22q11.2 deletion in IV:1 was normal. 
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3.1.1.3  Clinical phenotype of family CHD3  
 
 
 
 
 
 
 
 
 
 
This is a consanguineous Pakistani family (parents of IV:2 are first cousins) with 
suspected autosomal recessive inheritance of CHD. The maternal and paternal 
grandparents of IV:2 are also distantly related.  IV:2 was diagnosed at 2 years 
of age with AS and branch pulmonary artery stenosis due to a murmur on 
clinical examination, but has not required any surgical interventions yet. Clinical 
history and examination of IV:2 did not identify any features suggestive of 
syndromic CHD. Samples were taken from IV:2, the unaffected sibling, and their 
parents. Routine cytogenetic analysis and FISH testing for 22q11.2 and 
7q11.23 deletions in IV:2 was normal. 
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3.1.1.4  Clinical phenotype of family CHD4  
 
This is a large consanguineous Pakistani family with suspected autosomal 
recessive inheritance of CHD. There are two branches of the family affected 
with CHD, and the parents of both affected individuals are first cousins. IV:4 
was diagnosed at birth with DORV and VSD and surgically corrected at 1 month 
of age. IV:6 was diagnosed with a congenitally corrected TGA, VSD and 
Ebstein’s anomaly at 6 weeks of age due to a murmur on clinical examination. 
He had a double switch procedure and VSD closure at 9 months of age. Clinical 
history and examination of IV:4 and IV:6 did not identify any features suggestive 
of syndromic CHD. Samples were taken from both affected individuals, all 
unaffected siblings (IV:1, IV:2, IV:3, IV:5, and IV:7), and both sets of parents. 
Routine cytogenetic analysis and FISH testing for 22q11.2 deletion in IV:6 was 
normal. 
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3.1.1.5  Clinical phenotype of family CHD5 
  
 
 
 
 
 
 
 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. III:1 was diagnosed at 2 weeks of age with VSD 
and RV hypoplasia due to a murmur on clinical examination. She had a 
pulmonary artery band, cavopulmonary shunt, and then a Fontan procedure at 
9 years of age. Due to the history her sister (III:2) was diagnosed antenatally 
with a heart defect and a postnatal ECHO confirmed ASD and RV hypoplasia, 
but she has not required any surgical intervention yet. Clinical history and 
examination (III:1 and III:2) did not identify any features suggestive of syndromic 
CHD. Samples were taken from the affected siblings and their parents. Routine 
cytogenetic analysis and FISH testing for 22q11.2 deletion in III:1 was normal. 
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3.1.1.6  Clinical phenotype of family CHD6 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The eldest of four siblings (III:1) was diagnosed 
with TOF and right sided AA at 3 months of age due to cyanosis and a heart 
murmur on examination. She had a Waterston shunt inserted at 2 years of age, 
and subsequently had corrective surgery at 3 years of age. Her sister (III:2) was 
diagnosed antenatally with a heart defect, and a postnatal ECHO confirmed 
TOF. She had a BT shunt inserted and subsequently corrective surgery at 7 
months and 2 years of age respectively. Clinical history and examination (III:1 
and III:2) did not identify any features suggestive of syndromic CHD. Samples 
were taken from the affected siblings, both the unaffected siblings (III:3 and 
III:4), and their parents. Routine cytogenetic analysis and FISH testing for 
22q11.2 deletion in III:1 was normal. 
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3.1.1.7  Clinical phenotype of family CHD7  
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The second eldest of three siblings (III:3) was 
diagnosed with TAPVD at 13 days of age due to cyanosis and feeding 
problems. She required multiple surgical procedures but died at 4 months of 
age due to post operative complications. Her sibling (III:4) was also diagnosed 
with TAPVD at 10 days of age due to cyanosis and feeding problems, and had 
corrective surgery at 11 days of age. Clinical history and examination of III:4 did 
not identify any features suggestive of syndromic CHD. Samples were taken 
from III:4, unaffected sibling (III:2), and their parents. Routine cytogenetic 
analysis and FISH testing for 22q11.2 deletion in III:4 was normal. 
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3.1.1.8  Clinical phenotype of family CHD8  
 
 
 
 
 
 
 
 
 
This is a non-consanguineous White British family with suspected autosomal 
dominant inheritance of CHD. The father (II:3) was diagnosed at 4 years of age 
with TOF due to cyanotic spells, and had corrective surgery at 4 years of age. 
His son (III:1) was diagnosed with a heart defect on antenatal scans and a 
postnatal ECHO confirmed TOF. He had a pulmonary artery patch at 3 months 
of age, and corrective surgery at 8 years of age. Clinical history and 
examination of II:3 and III:1 did not identify any features suggestive of 
syndromic CHD. Samples were taken from the affected father, affected son, 
and unaffected mother (II:4). Routine cytogenetic analysis and FISH testing for 
22q11.2 deletion in III:1 was normal 
 111 
3.1.1.9  Clinical phenotype of family CHD9 
 
 
 
 
 
 
 
 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The second eldest of four siblings (III:2) was 
diagnosed with TGA, VSD, and PS at birth, and had an arterial switch 
procedure at 2 weeks of age. His sibling (III:3) was also diagnosed with TGA, 
VSD, and PS at birth, but died due to post operative complications after he had 
an arterial switch procedure at 1 week of age. Both unaffected siblings had a 
normal ECHO. Clinical history and examination of III:2 did not identify any 
features suggestive of syndromic CHD. Samples were taken from III:2, two 
unaffected siblings (III:1 and III:4), and their parents. Routine cytogenetic 
analysis and FISH testing for 22q11.2 deletion in III:2 was normal. 
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3.1.1.10  Clinical phenotype of family CHD10 
 
 
 
 
 
 
 
 
 
This is a non-consanguineous White British family with suspected autosomal 
dominant inheritance of CHD. The daughter (III:1) was diagnosed at 6 weeks of 
age, due to a murmur on clinical examination, with a complex CHD consisting of 
dextrocardia, left atrial isomerism, AVSD, PS, RV hypoplasia, right sided AA, 
and bilateral superior vena cavae (SVC). She had palliative surgery with a BT 
shunt inserted at 6 months of age, and then a cavopulmonary shunt and Fontan 
procedure at 18 months and 9 years of age respectively. She also has 
abdominal situs inversus. Subsequently an ECHO in both parents identified that 
her mother (II:2) (at age 33 years) had a congenitally corrected TGA and 
dextrocardia, but normal situs of abdominal organs. She has never required any 
surgical inventions. Clinical history and examination of II:2 and III:1 did not 
identify any features suggestive of syndromic CHD. Samples were taken from 
the affected mother, affected daughter, and unaffected father. Routine 
cytogenetic analysis and FISH testing for 22q11.2 deletion in III:1 was normal. 
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3.1.1.11  Clinical phenotype of family CHD11 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. III:2 was diagnosed with VSD at 4 months of age 
due to a murmur detected on clinical examination, and is awaiting a surgical 
closure when older. His younger brother (III:3) was diagnosed with AS, BAV, 
and mild CoA at 5 weeks of age due to feeding problems. He had a balloon 
dilatation for the AS at 5 weeks of age. Both parents and the unaffected half 
brother had a normal ECHO. Clinical history and examination (III:2 and III:3) did 
not identify any features suggestive of syndromic CHD. Samples were taken 
from the affected siblings, their parents, and the unaffected half sibling (III:1). 
Routine cytogenetic analysis and FISH testing for 22q11.2 deletion in III:2 was 
normal. 
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3.1.1.12  Clinical phenotype of family CHD12 
 
This is a non-consanguineous White British family with suspected autosomal 
dominant inheritance of CHD. The father (II:4) was diagnosed with TOF and 
ASD at birth due to cyanosis, and surgery was performed to correct the TOF 
and ASD at 16 months and 7 years of age respectively. His daughter (III:1) was 
also diagnosed with TOF and ASD after a murmur was detected on her routine 
8 week baby check, and had corrective surgery at 15 months of age. His son 
(III:2) had an ECHO at 2 weeks of age due to the family history and was 
diagnosed with VSD, ASD, and PDA, which were surgically corrected at 4 
months of age. Clinical history and examination (II:4, III:1, and III:2) did not 
identify any features suggestive of syndromic CHD. Samples were taken from 
II:4 only and routine cytogenetic analysis and FISH testing for 22q11.2 deletion 
was normal. 
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3.1.1.13  Clinical phenotype of family CHD13 
 
 
 
 
 
 
 
 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The eldest of four siblings (III:1) was diagnosed 
with TGA, VSD and PS at 10 days of age due to a murmur on clinical 
examination and feeding problems. He had a BT shunt inserted at 2 weeks of 
age, and subsequently had a Norwood procedure and Fontan procedure at 1 
year and 6 years respectively. His youngest sister (III:4) was diagnosed 
antenatally (due to the family history) with TGA, and had corrective surgery (via 
an arterial switch procedure) at 2 weeks of age. Both the unaffected siblings 
had a normal ECHO in the antenatal and postnatal period. Clinical history and 
examination (III:1 and III:4) did not identify any features suggestive of syndromic 
CHD. Samples were taken from the affected siblings, both unaffected siblings 
(III:2 and III:3), and their parents. Routine cytogenetic analysis and FISH testing 
for 22q11.2 deletion in III:1 was normal. 
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3.1.1.14  Clinical phenotype of family CHD14 
 
This is a non-consanguineous White British family with suspected autosomal 
dominant inheritance of CHD. The eldest daughter (III:1) was diagnosed with 
CoA, VSD, and BAV at 6 weeks of age due to a murmur on clinical examination 
and feeding problems. The CoA and VSD were surgically corrected at 4 months 
and 8 months of age respectively. Her youngest brother (III:3) had an antenatal 
ultrasound diagnosis of HLHS, and was a stillbirth at 26 weeks gestation. A post 
mortem confirmed HLHS, and identified CoA and BAV. After his birth both 
parents had an ECHO and the father (II:5) (aged 42 years) was diagnosed with 
BAV. There was a family history of CHD affecting two sisters (II:3 and II:4) on 
the paternal side of the family. Unfortunately they died within the first week of 
life in the 1940’s and therefore details were unavailable for further clarification. 
The parents of II:3, II:4, and II:5 were distantly related (3rd cousins). Clinical 
history and examination (II:5 and III:1) did not identify any features suggestive 
of syndromic CHD. Samples were taken from III:1, unaffected sibling (III:2), their 
affected father (II:5) and unaffected mother. Routine cytogenetic analysis and 
FISH testing for 22q11.2 deletion in III:1 was normal. 
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3.1.1.15  Clinical phenotype of family CHD15 
 
 
 
 
 
 
 
 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The second eldest of five siblings (III:2) was 
diagnosed with TGA at birth, but unfortunately died at 3 years of age due to 
post operative complications. Her sibling (III:3) was diagnosed with TGA, VSD, 
and ASD at 3 weeks of age due to feeding problems and a cardiac arrest. He 
had a Mustard procedure at 3 weeks of age and then an arterial switch 
procedure at 4 years of age. Clinical history and examination of III:3 did not 
identify any features suggestive of syndromic CHD. Samples were taken from 
III:3, two unaffected siblings (III:1 and III:5), and their father. Routine 
cytogenetic analysis and FISH testing for 22q11.2 deletion in III:3 was normal. 
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3.1.1.16  Clinical phenotype of family CHD16 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The eldest of six siblings (III:1) was diagnosed 
with TOF at birth due to cyanosis. He had a pulmonary artery band inserted at 2 
weeks of age and the VSD was repaired at 2 years of age. Due to his history all 
his subsequent siblings had an ECHO at birth. III:2 was diagnosed with CoA, 
BAV, and VSD, and had surgical correction of the CoA at 9 days of age, but the 
VSD closed spontaneously at 1 year of age. III:4 was diagnosed with ASD 
which closed spontaneously by 6 months of age. The other three siblings and 
both parents had a normal ECHO. Clinical history and examination of III:1, III:2, 
and III:4 did not identify any features suggestive of syndromic CHD. Samples 
were taken from all three affected siblings, unaffected siblings (III:3, III:5, and 
III:6), and their parents. Routine cytogenetic analysis and FISH testing for 
22q11.2 deletion in III:1 was normal. 
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3.1.1.17  Clinical phenotype of family CHD17  
 
This is a large non-consanguineous White British family with suspected 
autosomal recessive inheritance of CHD. There are two branches of the family 
affected with CHD. III:2 was diagnosed with CoA at 4 days of age due to 
feeding problems, and had surgery at 5 days of age, but required further 
surgical intervention at 4 years of age. His sibling (III:3) was diagnosed with 
HLHS and CoA in the neonatal period but died at 4 days of age before surgery. 
They had three cousins with CHD from their paternal side of the family. III:5 
died at 2 days of age and a post mortem identified HLHS. III:6 presented at 2 
days of age with severe cardiac failure and died at 5 days of age. A post 
mortem identified HLHS, CoA and VSD. III:7 was diagnosed with TGA, VSD 
and ASD at 2 weeks of age and had a pulmonary artery band fitted at 1 month 
of age. She then had a Fontan procedure at 8 years of age but died post 
operatively. Clinical history and examination of III:2 did not identify any features 
suggestive of syndromic CHD. Samples were taken from III:2, one unaffected 
sibling (III:4), and their father (II:3). I obtained stored tissue from the post-
mortem of III:6 for DNA extraction, and samples from her mother (II:7). Routine 
cytogenetic analysis and FISH testing for 22q11.2 deletion in III:2 was normal. 
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3.1.1.18  Clinical phenotype of family CHD18  
 
This is a non-consanguineous Irish family with an unknown inheritance of CHD. 
The parents reported to come from the same town in Ireland. Full details were 
unavailable for four affected individuals (IV:2, IV:3, IV:4, and IV:5) but were 
based on the history given by the parents of IV:1, who was diagnosed at birth 
with HLHS due to cyanosis and feeding problems. He had a Norwood type 
procedure and Bidirectional Glenn procedure at 1 week and 5 months of age 
respectively. Clinical history and examination of IV:1 did not identify any 
features suggestive of syndromic CHD. Samples were taken from IV:1 and his 
parents. Routine cytogenetic analysis and FISH testing for 22q11.2 deletion in 
IV:1 was normal. 
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3.1.1.19  Clinical phenotype of family CHD19 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The eldest of four siblings (III:1) was diagnosed 
antenatally with HLHS, and had stages I and II of the Norwood procedure at  4 
days and 14 months of age respectively. Her youngest brother (III:4) was also 
diagnosed antenatally with HLHS, and had stages I and II of the Norwood 
procedure at  4 days and 5 months of age respectively. Clinical history and 
examination of III:1 and III:4 did not identify any features suggestive of 
syndromic CHD. Samples were taken from III:4, one unaffected sibling (III:2) 
and their parents. Routine cytogenetic analysis and FISH testing for 22q11.2 
deletion in III:4 was normal. 
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3.1.1.20  Clinical phenotype of family CHD20 
 
 
 
 
 
 
 
 
This is a non-consanguineous Indian family with suspected autosomal 
recessive inheritance of CHD. The eldest of three siblings (III:1) was diagnosed 
antenatally with a heart defect and postnatal ECHO confirmed tricuspid atresia 
and VSD. He had a pulmonary artery band at 3 weeks of age, and then a 
cavopulmonary shunt and Fontan procedure at 18 months and 5 years of age 
respectively. His sister (III:2) was also diagnosed antenatally with a heart defect 
and postnatal ECHO confirmed TGA, VSD, RV hypoplasia, and AA hypoplasia . 
She had stages I and II of the Norwood procedure at 1 day and 4 months of age 
respectively. The youngest sibling and both parents had a normal ECHO. 
Clinical history and examination of III:1 and III:2 did not identify any features 
suggestive of syndromic CHD. Samples were taken from both affected siblings 
and their parents. Routine cytogenetic analysis and FISH testing for 22q11.2 
deletion in III:2 was normal. 
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3.1.1.21  Clinical phenotype of family CHD21 
 
 
 
 
 
 
 
 
This is a non-consanguineous White British family with suspected autosomal 
dominant inheritance of CHD. The father (II:4) was diagnosed at 6 weeks of age 
with CoA and BAV due to cyanosis and feeding problems. He had corrective 
surgery at 18 months of age. His son (III:1) was diagnosed with a heart defect 
on antenatal scans, and a postnatal ECHO confirmed HLHS. He had stages I 
and II of the Norwood procedure at 3 days and 3 months of age respectively. 
Clinical history and examination of II:4 and III:1 did not identify any features 
suggestive of syndromic CHD. Samples were taken from both the affected 
father and son. Routine cytogenetic analysis and FISH testing for 22q11.2 
deletion in III:1 was normal 
 
 124 
3.1.1.22  Clinical phenotype of family CHD22 
 
This is a non-consanguineous White British family with suspected autosomal 
recessive inheritance of CHD. The eldest of three siblings (III:1) was diagnosed 
with HLHS on antenatal scans. He had stage I of the Norwood procedure at 1 
day of age, and then a cavopulmonary shunt and Fontan procedure at 4 months 
and 4 years of age respectively. His brother (III:2) was diagnosed with VSD 
after a murmur was detected on his routine 8 week baby check, and has not 
required any surgery. Both parents had a normal ECHO, and antenatal scans of 
the expected baby (III:3) were normal. Clinical history and examination of III:1 
and III:2 did not identify any features suggestive of syndromic CHD. Samples 
were taken from both affected siblings and their parents. Routine cytogenetic 
analysis and FISH testing for 22q11.2 deletion in III:1 was normal. 
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3.1.1.23  Clinical phenotype of family CHD23  
 
This is a non-consanguineous Irish family with suspected autosomal recessive 
inheritance of CHD. Two siblings (III:1 and III:3) were diagnosed with AS and 
sub aortic stenosis at 6 weeks of age due to a murmur on clinical examination, 
and neither have required any surgical intervention yet. Two other siblings (III:2 
and III:4) and both parents had a normal ECHO. More recently the youngest 
sibling (III:5) has been diagnosed with sub aortic stenosis, despite having a 
normal ECHO at birth. Clinical history and examination of III:1 and III:3 did not 
identify any features suggestive of syndromic CHD. Samples were taken from 
both affected siblings (III:1 and III:2) and their parents. Routine cytogenetic 
analysis and FISH testing for 22q11.2 deletion in III:1 was normal. 
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3.1.2  Overview of clinical phenotype of familial CHD cohort  
The 23 families recruited were clinically and genetically heterogeneous (Table 
5). Thus there were 4 consanguineous and 13 non-consanguineous families 
with a familial pattern of non-syndromic CHD that could be consistent with 
autosomal recessive inheritance. In addition there were 5 non-consanguineous 
families with non-syndromic CHD in which the pattern of CHD within the family 
might suggest autosomal dominant inheritance, and 1 non-consanguineous 
family in which the pattern of CHD was undeterminable. According to the family 
histories the types and numbers of CHD seen in affected individuals are as 
follows: ASD (7), VSD (17), AVSD (1), PDA (1), TOF (11), TGA (10), DORV (1), 
PS (4), AS (5), CoA (8), BAV (6), HLHS (9), TAPVD (2), Ebstein’s anomaly 
variants (2), RV hypoplasia (4), laterality defects (2), and undetermined CHD 
(6). Some individuals had more than one type of CHD making their phenotype 
quite complex. Although there are a good range of CHDs in our cohort, outflow 
tract anomalies (e.g. TOF, TGA, LVOTO) seem to be more prominent. A 
number of families (16/23) had more than one individual with the same CHD 
(concordance), such as TOF (families CHD1/6/8/12), TGA (families 
CHD9/13/15), left sided obstructive lesions (families CHD14/17/19/21/23), RV 
hypoplasia/Ebstein’s anomaly spectrum (families CHD5/20), TAPVD (family 
CHD7], or laterality defects (family CHD10). 
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Table 5: Summary of clinical phenotype of familial CHD cohort. 
(Ф = consanguineous, blue = samples obtained) 
FAMILY INHERITANCE PEDIGREE No. SEX TYPE OF CHD 
CHD 1 Ф AR IV:1 F TOF spectrum (absent PV) 
 
IV:2 M VSD 
IV:3 F TOF spectrum (absent PV) 
IV:4 M TOF spectrum (absent PV) 
CHD 2 Ф ? AR IV:1 F TOF spectrum ( PA) 
CHD 3 Ф ? AR IV:2 M AS, PPAS 
CHD 4 Ф AR IV:4 M DORV, VSD 
 IV:6 M 
TGA, VSD,  
Ebstein's anomaly 
CHD 5 AR III:1 F VSD, RV hypoplasia 
 III:2 F ASD, RV hypoplasia 
CHD 6 AR III:1 F TOF, RT AA 
 III:2 F TOF 
CHD 7 AR III:3 F TAPVD 
 III:4 M TAPVD 
CHD 8 AD II:3 M TOF 
 III:1 M TOF 
CHD 9 AR III:2 M TGA, VSD, PS 
 III:3 M TGA, VSD, PS 
CHD 10 AD II:2 F TGA, dextrocardia 
 III:1 F 
LT atrial isomerism,  
RT AA, AVSD, PS,  
RV hypoplasia, bilateral 
SVCs, dextrocardia 
CHD 11 AR III:2 M VSD 
 III:3 M AS, BAV, CoA 
CHD 12 AD II:4 M TOF, ASD 
 
III:1 F TOF, ASD 
III:2 M ASD, VSD, PDA 
CHD 13 AR III:1 M TGA, VSD, PS 
 III:4 F TGA 
CHD 14 AD II:3 F CHD 
 
II:4 F CHD 
II:5 M BAV 
III:1 F CoA, BAV, VSD 
III:3 M HLHS, CoA, BAV 
CHD 15 AR III:2 F TGA 
 III:3 M TGA, VSD, ASD 
CHD 16 AR III:1 M TOF 
 
III:2 M VSD, CoA, BAV 
III:4 M ASD 
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CHD 17 AR III:2 M CoA 
 
III:3 M HLHS, CoA 
III:5 M HLHS 
III:6 F VSD, CoA, HLHS 
III:7 F TGA, VSD, ASD 
CHD 18 ? AR/AD IV:1 M HLHS 
 
IV:2 M Septal defect 
IV:3 F Univentricular heart 
IV:4 F Septal defect 
IV:5 M Septal defect 
CHD 19 AR III:1 F HLHS 
 III:4 M HLHS 
CHD 20 AR III:1 M Tricuspid Atresia, VSD 
 III:2 F 
TGA, VSD,  
RV hypoplasia, 
AA hypoplasia 
CHD 21 AD II:4 M CoA, BAV 
 III:1 M HLHS 
CHD 22 AR III:1 M HLHS 
 III:2 M VSD 
CHD 23 AR III:1 M AS, sub-AS 
 
III:3 F AS, sub-AS 
III:5 M sub-AS 
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3.1.3  Discussion of clinical phenotype of familial CHD cohort. 
Familial cases of CHD imply a genetic factor and are suitable for further 
molecular analysis. Although there are no reports of genes associated with 
autosomal recessive non-syndromic CHD, as autozygosity studies are powerful 
in identifying autosomal recessive disease genes, it is reasonable to utilise a 
similar tool for families with autosomal recessive non-syndromic CHD. It is 
plausible that these ‘apparently’ autosomal recessive families are actually 
families with autosomal dominant CHD with reduced penetrance in the parents, 
however to disprove this theory we need to identify gene variants in affected 
individuals and in one of their clinically unaffected parents. 
 
Clinical heterogeneity is clearly observed in the familial cohort recruited, as the 
numbers would be too small if a particular sub group of CHD were selected. 
Despite the various methods of ascertaining suitable families for the project, 
outflow tract anomalies (e.g. TOF, TGA, LVOTO) seem to be more prominent in 
the cohort. This could be partially explained by ascertainment bias for two 
reasons. Firstly, I noticed that a number of the initial families I recruited had 
outflow tract anomalies, so I added a third category for recruitment (families with 
outflow tract anomalies and any inheritance pattern). Secondly, families with 
certain types of CHD may be less enthusiastic to identify the cause for the CHD 
within the family, due to the minimal impact of the disease. These families are 
likely to have isolated structural CHDs that are asymptomatic, incidental 
findings, or sometimes require little medical or surgical intervention (e.g. ASD, 
VSD).  
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From our familial cohort it is apparent that some CHDs show exact 
concordance, and imply genetic factors in their aetiology. Overall the exact 
concordance is 70% (16/23) in our cohort which is higher than that seen in 
previous reports where overall the exact concordance was 53% (Gill et al., 
2003). This is more than likely to be due to the sample being studied, as our 
cohort is based on familial cases, whereas Gill et al. (2003) performed a study 
of recurrence in all cases of CHD (sporadic and familial). Of note in our cohort, 
are the families with more than one child with TOF (families CHD1/6), TGA 
(families CHD9/13/15), or left sided obstructive lesions (families CHD17/19/23), 
which imply an autosomal recessive inheritance pattern. Studies of familial 
recurrence of TOF have shown a 2.5-3% recurrence risk, and families have 
shown a horizontal pattern of recurrence, further suggesting a possible 
autosomal recessive genetic mechanism (Sanchez-Cascos, 1978; Miller and 
Smith, 1979; Wulfsberg et al., 1991; Digilio et al., 1997). Familial recurrence of 
TGA is reported to be 1-1.8% (Digilio et al., 2001), but some studies have 
shown this to be as high as 5.2% (Piacentini et al., 2005). As seen in our cohort, 
the different types of left sided obstructive lesions (HLHS, CoA, AS, and BAV) 
may even segregate together within the same family, and previously autosomal 
dominant and recessive patterns of inheritance have been observed in families 
with left sided obstructive lesions (Loffredo et al., 2004; McBride et al., 2005; 
Wessels et al., 2005). 
 
During the diagnostic process in genetic counselling it is important to exclude 
different diagnoses within the same family, which may account for varying 
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clinical features despite some overlap, before assuming the same aetiology and 
variation in expression of the phenotype. This issue was seen in family CHD1, 
where despite having four affected siblings with CHD, it was clear that one of 
the siblings (IV:2) could have an alternate genetic diagnosis and aetiology that 
accounts for all his other congenital malformations. This created an analytical 
dilemma with regards to further molecular genetic studies, and therefore a 
decision was made to include or exclude him at each point in the process of 
molecular genetic analysis of this family.  
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3.2 Molecular genetic analysis: autozygosity mapping and  
conventional sequencing studies (family CHD1) 
This large consanguineous family contained three siblings who were concordant 
for the same type of CHD (TOF spectrum) and one sibling with CHD and other 
congenital malformations. As this appeared to be the most suitable family for 
further genetic studies, I started with traditional autozygosity mapping 
approaches.  
 
3.2.1  Autozygosity mapping  
3.2.1.1 Genome wide scan  
In order to identify recessively inherited candidate CHD genes using an 
autozygosity mapping strategy, genome-wide SNP genotyping (with the 
Affymetrix SNP 5.0 microarray) was performed in all four ‘affected’ individuals 
(IV:1, IV:2, IV:3, and IV:4) from this family. Prior to further molecular studies it 
was decided to analyse the results of genetic studies under the analytical 
conditions that individual IV:2 was a phenocopy and might have a different 
genotype to the other siblings affected by CHD. The SNP genotyping results 
were analysed to identify regions of homozygosity >2Mb (common to IV:1, IV:3, 
and IV:4) and five possible regions of extended homozygosity were detected 
on: chromosomes 2 (2.4Mb), 10 (5.9Mb), 13 (13.1Mb), 16 (16.4Mb), and 19 
(28.9Mb).  
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3.2.1.2 Microsatellite marker analysis  
In order to confirm or refute and then refine the five candidate homozygous 
regions identified from SNP genotyping in individuals IV:1, IV:3, and IV:4, each 
of these regions was further evaluated using polymorphic microsatellite markers 
mapping to these regions of interest (Table 6). Linkage to the candidate regions 
on chromosome 2, 10, 13, and 16 was excluded by segregation of the 
microsatellite marker alleles. Genotyping of the family with microsatellite 
markers within the interval on chromosome 19 confirmed linkage but did not 
refine the homozygous region detected by the SNP array (19:16,925,673-
45,862,515bp) (Figure 14).  
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Table 6: Microsatellite markers used for linkage analysis of the 
homozygous regions identified in the affected siblings of family CHD1.  
(N) = novel 
 
Marker Start Position (bp) End Position (bp) Approximate Size (bp) 
 
D2S2238 40178312 40178496 185-203 
D2S2328 40678813 40678952 132-156 
D2S2272 40896211 40896420 205-213 
 
D10S37.9(N) 37942703 37942742 194 
D10S38.4(N) 38444001 38444050 222 
D10S39.0(N) 39045056 39045102 240 
 
D13S153 48890820 48890954 89-121 
D13S788 51892627 51892894 240-270 
D13S1228 53749089 53749357 264-268 
D13S1807 55106096 55106291 186-218 
D13S803 57750278 57750439 139-163 
D13S233 59448112 59448200 89-109 
 
D16S46.3(N) 46392429 46392475 105 
D16S46.6(N) 46615154 46615203 215 
D16S46.8(N) 46890039 46890082 210 
 
D19S593 17308106 17308361 252-288 
D19S898 18473781 18473960 178-200 
D19S566 19162094 19162254 139-169 
D19S546 20360262 20360586 306 
D19S568 22495143 22495401 249-275 
D19S1036 23652821 23653029 204-216 
D19S222 28725945 28726177 233-241 
D19S433 30417027 30417232 195-225 
D19S430 32302506 32302635 127-135 
D19S245 34098157 34098361 187-211 
D19S224 36528072 36528329 240-262 
D19S220 38431554 38431826 267-291 
D19S228 38489538 38489695 201-209 
D19S47 40314188 40314286 88 
D19S718 41458419 41458759 340-376 
D19S420 43808799 43809061 95-117 
D19S900 44167407 44167579 141-177 
D19S559 45330223 45330408 162-198 
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Figure 14: Microsatellite marker analysis on chr 19 in family CHD1.  
The affected children are shaded in black. Microsatellite markers are positioned 
according to physical distance (MB). Haplotypes for these markers are shown 
and the disease associated haplotypes are boxed in blue. 
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3.2.2  Candidate gene analysis from autozygosity mapping 
3.2.2.1 Candidate gene selection 
Having identified a linked homozygous region I then considered likely candidate 
CHD genes from within this region. As the microsatellite markers could not 
refine this candidate region, which contained 664 genes (Appendix E), this 
involved evaluating each gene for whether it had already been implicated in the 
pathogenesis of CHD or a CHD-related disorder. I therefore prioritised 
candidate genes according to: (a) putative function (Ensembl, OMIM, PubMed, 
UCSC Genome Bioinformatics), (b) published literature (PubMed), and (c) 
information from model organism genomic databases (MGI).  
 
Initially growth differentiation factor 1 (GDF1, chromosome 19:18,979,361-
19,006,953bp)(highlighted in yellow - Appendix E) was considered the most 
promising candidate gene as it encodes a transforming growth factor beta 
superfamily (TGFβ) protein involved in left-right axis development. Mutations in 
this gene have been associated with CHD in both humans and mouse models, 
and other members of this protein family have also been linked to CHD. I 
therefore proceeded to undertake mutation analysis of GDF1 in this family.  
 
3.2.2.2 Mutational analysis of candidate genes 
3.2.2.2.1  Mutational analysis of GDF1 gene  
GDF1 sequencing and mutational analysis (using primer pairs in Table 7) was 
undertaken in all affected individuals (IV:1, IV:2, IV:3, and IV:4) of family CHD1, 
but no pathogenic mutations were detected. Not all pathogenic mutations can 
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be detected by sequencing exons and flanking intronic regions but I did not 
detect any PCR failures which might suggest homozygous exon deletions, and 
no copy number abnormalities were apparent on the Affymetrix SNP 5.0 arrays 
performed on IV:1, IV:3, and IV:4. Nevertheless, I considered the possibility that 
although family CHD1 might harbour a pathogenic GDF1 mutation that was not 
detectable by direct sequencing of exons and flanking sequences, other familial 
CHD kindreds might harbour a detectable mutation. I therefore proceeded to 
undertake GDF1 mutation analysis in one affected individual from other CHD 
families with a similar cardiac outflow tract phenotype, who had been recruited 
into the project by this time. Mutational analysis in these nine other CHD 
families (CHD 2/5/6/7/8/9/10/12/13) did not detect any GDF1 mutations.  
 
3.2.2.2.2  Mutational analysis of NODAL pathway genes  
One of the reasons GDF1 was highlighted as a candidate CHD gene within the 
homozygous region on chromosome 19 in CHD1, was because of the known 
interaction between GDF1 and components of the NODAL pathway. Previous 
studies have implicated NODAL pathway genes in cardiac development and 
mutations in NODAL pathway genes (e.g. NODAL and FOXH1) have been 
reported in human CHD patients (especially those with outflow tract anomalies 
(see discussion). I therefore proceeded to perform mutation analysis (using 
primer pairs in Table 7) of four further NODAL pathway genes (NODAL, CFC1, 
TDGF1, and FOXH1) in individual IV:1 from family CHD1, and one affected 
individual from the same nine CHD families studied for GDF1 mutations (CHD 
2/5/6/7/8/9/10/12/13). However no pathogenic mutations were detected. 
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Table 7: Primers used for sequencing of coding regions of GDF1, 
NODAL, CFC1, TDGF1, and FOXH1 in selected familial CHD cohort (CHD 
1/2/5/6/7/8/9/10/12/13). 
Gene / 
 Exon 
Primer Pairs  
(5’ – 3’) 
PCR Product  
Size (bp) 
Annealing  
Temperature  
(oC) 
    
GDF1  
7 
CTCAGCCCACTGGTCCC 
CCGAAGTTGCTAGTAGCCTG 
524 60 
8.1 
AGCCCCAGCGTTCACCTTCCTCC 
CACCAGCAGCAGCGAGGCCTC 
485 60 
8.1 (alt) 
AGCCCCAGCGTTCACCTTCCTCC 
ACCTCGCGGAAGCTCAC 
607 60 
8.2 
CTCGCAACGCCTCATGG 
ATCACCAAGACTGAGGGGC 
622 60 
    
NODAL  
Pre-1 
CAGAGAGCCACGAGATCACA 
TAACTGCCCACTGTTTGCTG 
200 62 
1 
TGAGGCCCAGGATATAAGGG 
CACAGCACTTCCCGAGTCC 
333 62 
2.1 
GTGACACTGACTGAGGCTGG 
CACCCAGCTGCCTCTGC 
500 62 
2.1 (alt) 
AAGGTAAGGCCTCCAGCAAG 
AGGTGGACCCACCCAGC 
542 60 
2.2 
CTGGGGCCCTGGAGAAG 
AGCAAAGCTAGAGCCCTGTC 
465 62 
3 
TTGCACTCAGGAACTGACTTTAAC 
TTTGCCCCTCTCTGTTTCTC 
372 58 
    
CFC1  
1-2 
ACTCGTCCATTCTGTGTCCC 
ACCGCCGTTATGTTTCTCTC 
626 60 
3 
GCATTACAGATCATCAATTTGGG 
GGTCCTAAACTCTGAGTCCGC 
363 60 
4-5 
TGATTTTACTGCCTCCCCTG 
ACTGTGGATCGGTATGGAGG 
678 60.3 
4-5 (alt) 
GCTGATTTTACTGCCTCCCC 
CACTGGAAGATGCACTGTGG 
693 60 
6 
AGCAGGCGTTTCTATTGCAC 
CCAGTGCTTCAGCTTACGG 
335 60 
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TDGF1  
1 
TTTTCCTTTGGCTGTTTTGG 
GCAGCTCTTTTAAGGCTTGAG 
229 58 
1 (alt) 
ATTGCCATTTTCGCTTTAGG 
GCAGCTCTTTTAAGGCTTGAG 
258 58 
2-3 
GGTGTTAACTTGTAAGGTTTTATTTCC 
TGTTGGAAAGATACTCAGGAGAC 
405 58 
4-5 
GAATTGCCCTTGCACTTTTC 
CCCCAAGGCAACTACGTAAC 
437 58 
6 
AGCAGGATGAACTGCCAGAG 
AGCAGCAGCCTTTACTGGTC 
249 58 
    
FOXH1  
1 
CTTCTACACTGCCCCACCG 
CTTGAACCTGGAAGTGGGTG 
312 60 
2 
CCTGAGCCCGGTAGTGG 
CCTTGGATGCTCAGGACTTC 
254 50 
2 (alt) 
CCCTGAGCCCGGTAGTG  
CCTTGGATGCTCAGGACTTC 
255 48.5 
3.1 
GGAAGTCCTGAGCATCCAAG 
GCTCTGGGGAGAGGGTTG 
518 60 
3.2 
CTCTGTGGCCCCTCTGC 
CCTGTCAACAAGGTGGGG 
513 60 
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3.2.3  Discussion of autozygosity mapping and  
candidate gene analysis 
3.2.3.1 Autozygosity mapping analysis 
Autozygosity mapping has been used as a powerful tool in investigating the 
genetic basis for many autosomal recessive disorders (as discussed in the 
introduction). In family CHD1 with a suspected autosomal recessive pattern of 
inheritance for non-syndromic CHD, it aided in identifying regions of 
homozygosity for further analysis. The dilemma faced when interpreting the 
results was whether to include sibling IV:2 to identify candidate regions. 
Although variable expression of disease is common in many autosomal 
dominant disorders, it is less common in autosomal recessive disorders, where 
the phenotype is usually consistent. The decision was made that he has an 
alternate genetic diagnosis and aetiology that accounts for all his other 
congenital malformations, as none of these were present in the other three 
siblings, and therefore he was excluded from autozygosity mapping analysis. 
 
One of the disadvantages of autozygosity mapping is the possibility of 
identifying large regions of homozygosity that are not always possible to refine 
using microsatellite markers. This proved to be the case for the region on 
chromosome 19 which included a large number of genes (664 genes). 
Conventional methods of identifying candidate genes using the various tools 
previously described can, if lucky, help to identify a promising candidate. It was 
fortunate that GDF1 was the one promising candidate gene in our linked region. 
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3.2.3.2 Mutational analysis of GDF1 and NODAL pathway genes 
GDF1 is a gene belonging to the transforming growth factor beta superfamily 
(TGFβ), and is expressed throughout the embryo and then in the primitive node, 
ventral neural tube, and intermediate and lateral plate mesoderm. Knockout 
mice (with a homozygous deletion) had laterality defects (annular pancreas, 
malformed spleen, bilateral right sidedness of lungs, randomised heart 
positioning) and heart malformations ranging from ASD, VSD, AVSD, and TGA 
(Rankin et al., 2000). GDF1 has been found to be an upstream regulator of 
other heart development genes (NODAL, LEFTY1, LEFTY2, and PITX2), and 
acts early in embryogenesis to establish laterality. Similarities in the expression 
domains and mutant phenotypes of Gdf1 and Nodal suggests that GDF1 plays 
a role in signal transfer to the lateral plate mesoderm from the node by 
interacting with Nodal (Rankin et al., 2000). It functions as a co-ligand for Nodal 
and its expression is necessary and sufficient to initiate asymmetric expression 
of Nodal in the lateral plate mesoderm (Tanaka et al., 2007).  
 
As described in the introduction the Nodal pathway of genes is important in left-
right body patterning. Reduced Nodal signalling has been shown to lead to 
several abnormalities of left-right patterning including CHD in mice (Lowe et al., 
2001). NODAL and GDF1 signal via an Activin/TGFβ-like pathway through 
several Activin-like receptors (e.g. type I Activin receptor [Alk4] and type II 
Activin receptor [ActRIIB]) (Figure 15). The EGF-CFC (epidermal growth factor-
Cripto/FRL-1/Cryptic) proteins are essential for signalling by Nodal and GDF1. 
Criptic (CFC1) and Cripto (TDGF1) (the mammalian homologues of EGF-CFCs) 
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are required for mesoderm and endoderm induction and for proper left-right axis 
formation (Gritsman et al., 1999; Yan et al., 1999; Shen and Schier, 2000; 
Bianco et al., 2002; Schier, 2003). Mice deficient in Criptic showed right 
pulmonary isomerism, AVSD, randomisation of cardiac looping, and TGA (Gaio 
et al., 1999). Cripto and Criptic act as co-receptors for Nodal and GDF1 to bind 
and activate Activin-like receptors (Alk4 and ActRIIB). Activin itself however 
does not need EGF-CFC co-receptors, despite using the same receptors as 
Nodal and GDF1 (Mathews et al., 1992). The NODAL activated receptor 
complex phoshorylates intracellular receptor regulated Smads (Smad2/3), and 
the Smad2/3 complex then binds to Smad4 which results in direct DNA binding 
or interaction with other transcription factors (e.g. Foxh1) (Saijoh et al., 2000). 
The transcription factor (FOXH1) has a role in establishing a positive feedback 
loop by binding to Nodal and Lefty2, thereby controlling Nodal gene expression 
and signalling in embryogenesis (Saijoh et al., 2000; Yamamoto et al., 2001; 
Norris et al., 2002). It is likely that GDF1 also relies on FOXH1 activity as 
FOXH1 mutant embryos showed similar malformations as those which were 
Gdf1-/- ; Nodal+/- (Yamamoto et al., 2001).   
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Figure 15: Diagram illustrating essential components of NODAL signalling.  
Adapted from (Cheng et al., 2004; Roessler et al., 2008) 
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Eight different GDF1 mutations were found in 8/375 sporadic cases of CHD, 
with phenotypes very similar to the mouse models (TOF, TGA, DORV) (Karkera 
et al., 2007). CFC1 mutations have been found in a number of human cases of 
left right asymmetry and CHDs (including TGA, AVSD, and DORV) (Bamford et 
al., 2000; Goldmuntz et al., 2002). Screening the NODAL gene in a large cohort 
of 269 sporadic cases with laterality defects and cardiac looping anomalies 
identified seven different variants in a total of 14 patients (Mohapatra et al., 
2009).  
 
Mutational screening studies of parts of the Nodal pathway in sporadic cases of 
CHD have identified variants in the following genes: NODAL, GDF1, TDGF1, 
FOXH1, and CFC1. Some of the variants were specific to the family but others 
were common population variants, with reduced bioassay activity, implying that 
these latter variants act as modifiers and may contribute to the overall CHD 
phenotype (Roessler et al., 2008; Roessler et al., 2009). In cases of TGA with a 
family history of concordant or disconcordant CHD, screening the NODAL 
pathway/laterality genes identified variants in FOXH1, ZIC3, and NODAL in two 
patients, where one patient had a mutation in FOXH1 and ZIC3 (De Luca et al., 
2010). This further supports the theory of a ‘multiple hit’ genetic model whereby 
independently inherited gene variants act together to influence the cardiac 
phenotype. Roessler et al. (2009) implied that NODAL pathway defects are 
detectable in 5-10% of individuals with conotruncal CHDs (higher than 
chromosome 22q11.2 deletion – 5%), and suggest that future studies of the 
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molecular causes of CHD should entail analysis of entire signalling pathways 
rather than individual genes. 
 
Due to the developmental pathway involved, reports in human CHD, animal 
models, and the possible role in the pathogenesis of CHD, I further investigated 
selected genes from the NODAL pathway (NODAL, CFC1, TDGF1, and 
FOXH1) in relevant families in our project but did not detect mutations or 
potentially pathogenic variants.  
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3.3 Molecular genetic analysis: whole exome sequencing  
(family CHD1) 
The absence of a detectable GDF1 mutation in family CHD1 suggested that 
another gene in the chromosome 19 candidate region might harbour pathogenic 
mutations. However, the candidate interval contained another 663 genes and 
none of these had been previously implicated in CHD. Hence prioritising 
candidate genes and sequencing them individually was likely to be a long 
manually laborious and time consuming process. Furthermore, though the 
chromosome 19 homozygous region was the only candidate interval confirmed 
by microsatellite marker studies, it was possible that the pathogenic mutation 
might reside in a gene that was contained in a smaller region of homozygosity 
(<2Mb). It was even possible that the family, despite being consanguineous, 
might harbour compound heterozygous mutations or even a non-autosomal 
recessive mechanism of inheritance.  
 
It was therefore decided that the most efficient approach was to proceed to 
“whole exome sequencing” (WES) and a DNA sample from the affected 
individual IV:4 was sent to the Beijing Genomics Institute (BGI)(Beijing, China) 
for exome sequencing (June 2010). Subsequently further exome sequencing of 
the two remaining affected siblings (IV:1 and IV:3), and affected individuals from 
8 other families in the familial CHD cohort, was performed at the Wellcome 
Trust Sanger Institute (WTSI)(Hinxton, UK). Therefore the results of WES are 
reported in two stages. 
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3.3.1  Whole exome sequencing (WES) at BGI 
Our first collaboration was with BGI where the WES laboratory work and read 
analysis for individual IV:4 from family CHD1 was performed. They used the 
SureSelect automated target enrichment technology (Agilent) with a 94.3% 
overall coverage of the whole exome (read depth 1X) but this was only 68.4% 
coverage with a read depth of 10X.  
 
The raw data was transferred to Birmingham (September 2010) and all variants 
were annotated as novel or as being reported on the dbSNP (but not the 1000 
Genomes) databases. The annotation also included the functional category of 
the variants and whether they were heterozygous or homozygous variants. A 
total of 61,421 variants were identified, of which 10,776 were reported to be 
novel (September 2010) as they were not present in the dbSNP database.  
 
3.3.2  Candidate gene analysis from WES  
The BGI WES data provided a large number of variants (61,421) and using 
Excel (Microsoft) I manually analysed the variants using various filtering 
strategies. From this large number, only 2,945 variants remained after I 
selectively filtered out all dbSNPs, and included only potentially pathogenic 
variants, by focusing on those annotated as functionally significant, such as 
nonsynonymous (nonsense and missense) and splice acceptor and donor site, 
anticipating that synonymous variants were less likely to be pathogenic. 
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I then reviewed all these variants to remove those reported on the 1000 
Genomes database, to result in truly novel variants. As the family history and 
parental consanguinity suggested autosomal recessive inheritance of CHD in 
family CHD1, I focussed my attention on homozygous variants to assess them 
for mutation pathogenicity, and was left with a total of 103 variants in 95 
different genes (8 nonsense, 93 missense, and 2 splice site). I proceeded to 
annotate each variant for pathogenicity to determine the predicted effect on the 
gene product using bioinformatics resources (PolyPhen-2, SIFT). I used a 
functional approach to prioritise candidate genes according to: (a) putative 
function (Ensembl, OMIM, PubMed, UCSC Genome Bioinformatics), (b) 
published literature (PubMed), and (c) information from model organism 
genomic databases (MGI). Appendix F summaries the list of novel, 
homozygous, functionally significant variants, and the results of various 
interpretation approaches to identify candidate genes (published literature, 
mouse model databases, putative function, and pathogenicity software 
programmes). 
 
As well as analysis of variants throughout the exome, I also performed a 
genomic approach to prioritise candidate genes (with variants) limited to the 
homozygous region on chromosome 19. In total there were 959 variants from 
the raw data received, which were then narrowed down to only 4 variants (1 
nonsense and 3 missense) using the filtering strategies of novel, homozygous, 
and functionally significant (highlighted in orange - Appendix F). 
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3.3.2.1 Candidate gene selection and analysis 
3.3.2.1.1  Analysis of WNT11 and DVL2 genes 
Two members of the Wnt pathway demonstrated candidate homozygous 
missense mutations by second generation sequencing of the affected individual 
IV:4 from family CHD1. The missense mutation in WNT11 (c.519T>A, p.D173E, 
exon 3) occurred in a highly conserved nucleotide and amino acid and 
analytical software predicted it to be probably damaging and affect protein 
function. WNT11 (chromosome 11:75,897,369-75,921,803bp) is part of the Wnt 
gene family that encode a set of signalling molecules thought to play an 
important role in embryonic development, with embryonic lethal mouse models. 
The missense mutation in DVL2 (c.152C>T, p.A51V, exon 1), occurred in a 
highly conserved nucleotide and moderately conserved amino acid, however 
analytical software predicted it to be benign and to be tolerated at protein 
function level. DVL2 (chromosome 17:7,128,660-7,137,868bp) is part of a gene 
family which encodes proteins homologous to the Drosophila dishevelled (dsh) 
protein and it is suggested that they function in Wnt signalling, with mouse 
models displaying cardiac outflow tract anomalies, similar to those in family 
CHD1. As both of these genes are members of the Wnt pathway and well 
known for their role in murine cardiac development, I further evaluated the 
variants in both of these genes with Sanger sequencing. 
 
Despite the functional evidence supporting WNT11 and DVL2 as candidate 
CHD genes, Sanger sequencing (using primers in Table 8) did not reveal the 
putative variants in either IV:4, the affected siblings (IV:1 and IV:3), the 
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phenocopy (IV:2), or the parents. They were therefore considered to be false 
positive findings and no further studies in control samples or other CHD families 
were performed. 
 
3.3.2.1.2  Analysis of GMFG gene 
Within the chromosome 19 homozygous region only one gene (GMFG) 
contained a putative homozygous novel truncating mutation (c.70C>T, 
p.Arg24X, exon 2). Glia maturation factor gamma (GMFG) (chromosome 
19:39,819,010-39,826,726bp) has been reported to have a putative role in cell 
differentiation and proliferation but has not previously been linked to cardiac 
development. Nevertheless as the only gene with a homozygous nonsense 
mutation in the candidate region in this family it was selected for further analysis 
(highlighted in blue - Appendix E and orange - Appendix F). 
 
I performed Sanger sequencing analysis (using primers in Table 8) of GMFG 
was undertaken in all affected siblings (IV:1, IV:3,  and IV:4), the phenocopy 
(IV:2), and both unaffected parents from family CHD1, to validate the variant 
identified from WES (Arg24X). This variant was confirmed by re-sequencing 
analysis and segregation analysis. All affected individuals were homozygous for 
this nonsense mutation, and both parents were heterozygous carriers (Figure 
16). Interestingly sibling IV:2 was neither heterozygous or homozygous for this 
variant. Due to the availability, sequencing of GMFG was only undertaken in 
~200 ethnically matched control chromosomes, and this did not identify this 
mutation in any controls.  
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Table 8: Primers used for sequencing of selected exons of GMFG, WNT11 
and DVL2 in family CHD1. 
Gene /  
Exon 
Primer Pairs (5’ – 3’) 
PCR 
Product 
Size (bp) 
Annealing 
Temperature  
(oC) 
 
GMFG  
2-3 
AGAAACAGGTTTGGGGAAGG 
TTGGTTCTCCCAGTCTCACC 
408 60 
    
WNT11  
3 
CGAAGGTGGAGGACCTCTG 
GCCCTTTTCTGGCCAATG 
417 60 
    
DVL2  
1 
GCCATTAGCCCTTTGGG 
AAAGTAGACGTGTGCCCCTC 
326 58 
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Figure 16: Sequencing analysis of GMFG in family CHD1.  
Confirmation of the Arg24X mutation via segregational analysis. 
An affected child is homozygous 
An unaffected parent is a heterozygous carrier 
 
Wild type / Mutant 
Mutant / Mutant 
Wild Type 
c.70C>T (p.Arg24X) 
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3.3.3  Discussion of WES at BGI and candidate gene analysis 
The analysis of the results of WES in an individual (IV:4) with familial CHD 
clearly demonstrates both the advantages and challenges of the large data sets 
generated by this technology. Whereas Sanger sequencing of individual genes 
from the homozygous candidate region would have taken years to complete, 
WES provided a wealth of sequencing data on genes not only within the 
candidate region but also across the genome. Not all exons are represented in 
“whole exome sequencing” data but the major challenge for interpreting such 
data is how to prioritise further investigation knowing that both false positive and 
false negative variant calling may occur. I therefore adopted two approaches. 
Firstly I took a “functional approach” and looked for putative mutations in genes 
whose function suggested that they might be implicated in cardiac development 
(WNT11 and DVL2). Secondly I took a “genomic approach” in which I put the 
emphasis on the likelihood of a variant in a gene mapping within a candidate 
region being pathogenic, even if there was no known functional evidence to 
implicate the gene in cardiac development.   
 
3.3.3.1 “Functional approach” to WES data analysis: WNT11 / DVL2  
The Wnt proteins are a large family of secreted signalling molecules that 
regulate crucial aspects of development, including cell-fate specification, 
proliferation, survival, migration and adhesion. These effects are mediated via 
two Wnt pathways, the canonical and non-canonical pathways (Figure 17) 
(Flaherty and Dawn, 2008). The canonical pathway is activated by Wnt proteins 
binding to a co-receptor complex of frizzled (Fzd) and lipoprotein receptor 
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related proteins (Lrp5/6). Binding activates the intracellular protein, dishevelled 
(Dvl), resulting in inactivation of the protein complex that includes glycogen 
synthase kinase 3 (Gsk3), axin, and adenomatosis polyposis coli (APC). This 
complex normally phosphorylates β-catenin and targets it for degradation. Wnt 
stimulation inhibits the Gsk3/axin/APC complex leading to high levels of β-
catenin accumulation in the nucleus, where it complexes with the LEF/TCF 
family of DNA binding proteins to activate the transcription of Wnt target genes. 
The non-canonical pathway (also known as the planar cell polarity pathway) is 
mediated through either of the Ca2+/protein kinase C (PKC) or RhoA/JNK 
pathways. In Ca2+/PKC signalling, Wnt binding activates the heterotrimeric G-
protein dependent activity of Fzd receptors, and intracellular Ca2+ signalling, as 
well as Ca2+-dependent protein kinases, such as protein kinase C (PKC) and 
calmodulin-dependent protein kinase II (CaMKII). In RhoA/JNK signalling, Wnt 
proteins through the Dvl protein activate Rho family GTPases (RhoA and Rac), 
and subsequently JNK, their downstream effector (Cohen et al., 2008). 
 
The Wnt gene family is critical for the developmental process of organogenesis, 
including specifically cardiogenesis. Canonical Wnt signals appear essential for 
the proliferation of SHF cells (Ai et al., 2007; Kwon et al., 2007), whereas the 
non-canonical pathway is thought to be necessary for the polarised migration of 
myocardial cells required in the outflow tract septum (Henderson et al., 2006).  
Wnt11 acts via the non-canonical pathway and its expression overlaps with the 
first and second heart fields, and in the outflow tract region (Zhou et al., 2007). 
A critical function for Wnt11 is in shaping embryonic ventricular cardiomyocyte 
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spatial organisation and differentiation during heart development (Flaherty and 
Dawn, 2008; Nagy et al., 2010). This is through regulation of the expression of 
the Gata4, Nkx2.5, Mef2C, and ANP genes, which are transcribed at reduced 
levels compared with controls in Wnt11-deficient hearts (Nagy et al., 2010). 
 
Dishevelled functions in Wnt signalling downstream to the canonical and non-
canonical pathways (Figure 17). In mammalian species, three Dishevelled 
isoforms are expressed, termed Dvl1, Dvl2, and Dvl3 (Nemer, 2008). At present 
no human diseases have been linked to defects in DVL1, DVL2 or DVL3. All 
three of the murine Dishevelled genes are widely expressed in embryonic and 
adult tissues suggesting that there may be functional redundancy among the 
three genes. Mice carrying null mutations in Dvl2 have been found to be 
perinatally lethal because of defects in cardiac morphogenesis, specifically, 
outflow tract septation defects, indicating Dvl2 as a key mediator in conotruncal 
development (DeLaughter et al., 2011).  
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Figure 17: Diagram illustrating Wnt/Dvl signalling. 
Taken from Flaherty and Dawn (2008) 
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Pitx2 (also part of the Nodal pathway) is a downstream target of the canonical 
Wnt pathway, and mice that are null for Pitx2 show cardiac outflow tract 
anomalies. These anomalies are similar to those seen in Dvl2 mutants, and 
there is a marked decrease in Pitx2 expression in cardiac neural crest cells 
migrating to the cardiac outflow tract in Dvl2 mutants. This suggests that Pitx2 is 
a downstream target of Dvl2 (and Wnt) mediated pathways (Kioussi et al., 
2002). Pitx2 mutants also have downregulated Wnt11 expression in the 
mesoderm of the second heart field and in the outflow tract. As Wnt11 mutants 
show the same cardiac defects as Pitx2 mutants, Wnt11 seems like a critical 
downstream effector of Pitx2 and a direct target of the canonical pathway in the 
developing heart (Zhou et al., 2007). The similar phenotypes seen with Pitx2, 
Wnt11 and Dvl2 mutants highlight the interactions that occur between the 
canonical and non-canonical Wnt signalling pathways.  
 
It is clear that many components of the Wnt/Dvl/Pitx2 pathway are dose 
dependent and involved in cardiac development (especially the outflow tract), 
and there is an overlap with the Nodal pathway. It is possible that the polygenic 
model of CHD in humans may be explained by variants in numerous genes 
within these pathways, and future studies investigating genetic causes of CHD 
in humans should screen for some or all of the genes in these pathways.  
 
Unfortunately the variants in WNT11 and DVL2 identified from WES in family 
CHD1 were not verified by Sanger sequencing and therefore are likely to be 
false positive results. This highlights the issue of data analysis from WES and 
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some of the challenges of false positive results, which can lead to unnecessary 
and time consuming validation work in the laboratories. 
 
3.3.3.2 “Genomic approach” to WES data analysis: GMFG 
The homozygous nonsense mutation (Arg24X) in GMFG in family CHD1 was 
shown to segregate with affected individuals in the family and with parents as 
heterozygous carriers. Sibling IV:2 did not have this variant on segregational 
analysis, but if a homozygous Arg24X mutation had been identified in IV:2, 
GMFG may have been dismissed as a significant candidate gene, due to the 
variable phenotype. These findings therefore may in fact provide further 
evidence for this gene as a candidate in this family, and confirm the suspicion of 
an alternative genetic aetiology for the CHD and malformations seen in IV:2.  
 
A more recent review of international SNP databases revealed the Arg24X 
variant has been identified in one individual from African ancestry in the 1000 
Genomes project. Our family is from a South Asian origin (Pakistan), which is a 
population poorly represented in these international SNP databases and 
therefore there is a potential concern that this might represent a rare 
polymorphic variant that is present in the South Asian population (though it was 
not detected in 200 ethnically matched controls). Nevertheless, previous 
experience within our research group, suggests that pathogenic recessive 
mutations can be an incidental finding in studies of normal control individuals. 
We identified a homozygous deletion in the PLCB1 gene in a family with 
infantile epilepsy and did not detect the mutation in ethnically matched control 
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samples, however a heterozygous deletion with similar breakpoints had been 
reported in 1/540 HapMap chromosomes (www.sanger.ac.uk/resources/ 
downloads/human/hapmap3.html) (Kurian et al., 2010). Nevertheless, since a 
homozygous PLCB1 mutation was reported as a cause of infantile epileptiform 
encephalopathy, a further family with a related disorder (malignant migrating 
partial seizures in infancy (MMPEI)) has also been reported to have a 
homozygous deletion in the PLCB1 gene, confirming the validity of the original 
report of a pathogenic mutation (Poduri et al., 2012). Though I did not identify 
the GMFG nonsense mutation in other affected families within our cohort (see 
section 3.4), the finding of a carrier for this candidate mutation in a population 
control suggests that mutation analysis of GMFG, and particularly for the 
Arg24X mutation should be performed in large cohorts of CHD patients.   
 
GMFG was first isolated and shown to have 82% identity with human glia 
maturation factor beta (GMFB) (Asai et al., 1998). They examined the tissue 
distribution of GMFG mRNA and detected predominant expression in human 
lung, heart, and placenta, and trace expression in brain, liver, skeletal muscle, 
kidney, and pancreas. The cDNA length of GMFG is 646 bases and encodes a 
protein of 142 amino acids. The amino acid sequence is highly conserved 
amongst species (Figure 18), with 95% homology between human and mouse, 
and 98% between human and bovine. The function of GMFG is relatively 
unclear, but GMFB has been well studied and was initially identified as a growth 
and differentiation factor acting on neurons as well as glia in the vertebrate 
brain. A new aspect of the intracellular functions of GMFB showed that protein 
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kinase A-phosphorylated GMFB is a potent inhibitor of the extracellular signal-
regulated kinases (ERK1 and ERK2), a subfamily of mitogen-activated protein 
(MAP) Kinases (Zaheer and Lim, 1996). 
 
Figure 18: Diagram illustrating the amino acids (including R24) are highly 
conserved through evolution.  
Taken from UCSC 
 
Expression of rat GMFG is predominantly in the thymus, testis, and spleen 
(Tsuiki et al., 2000). These tissues contain cells going through rapid 
differentiation and proliferation, thereby suggesting GMFG may play a role in 
cellular differentiation and growth, through intracellular signalling mechanisms 
(similar to GMFB, as described above). GMFG has been show to play an 
important role in maintaining haematopoietic stem cells, and regulating 
haematopoietic lineage development (Shi et al., 2006). They showed that 
GMFG expression is high in blood, thymus, spleen, fetal liver and lung. GMFG 
was identified as a novel factor in actin cytoskeleton reorganisation and showed 
it is expressed preferentially in microvascular endothelial and inflammatory cells 
(Ikeda et al., 2006). During mouse embryogenesis, GMFG was expressed as 
early as embryonic day 9.5, predominantly in blood islands of the yolk sac, in 
endothelial and hematopoietic cells, and possibly in the angioblast precursors to 
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these lineages. This implies that GMFG has a function in embryonic 
vasculogenesis as well as in haematopoiesis. Inflammation and angiogenesis 
take place actively in the pathophysiology of cardiovascular disease, and 
GMFG expression has been shown to be significantly increased in cardiac 
ischemia/reperfusion tissues, suggesting a role for GMFG in cardiovascular 
diseases, and a novel approach to modulate these diseases (Ikeda et al., 
2006).  
 
Actin cytoskeleton reorganisation is a fundamental process for actin-based 
cellular functions such as cytokinesis, phagocytosis, and chemotaxis. Deficient 
actin cytoskeleton reorganisation causes impaired endothelial cell migration, 
reduces macrophage phagocytosis, and results in defective lymphocyte 
development and activation. Actin cytoskeleton reorganisation therefore plays 
an essential role in angiogenesis and immune system function. They showed 
how overexpression of GMFG enhanced actin-based cellular functions such as 
migration and tube-formation in endothelial cells. GMFG has been shown to be 
distributed along the axis of movement of migrating T-lymphocytes, with 
predominance in the leading edge of the cells. Inhibition of its expression 
reduced cellular basal and chemokine induced migration (Lippert and Wilkins, 
2012). This provides further evidence for GMFG in cell movement via actin 
cytoskeleton remodelling, and has therefore been classified as a member of the 
actin-depolymerizing factor homology (ADF-H) family. Interestingly the Arg24X 
mutation lies in the ADF-H domain (residues 7-140) and may result in nonsense 
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mediated decay preventing the expression of a truncated or erroneous protein 
(with only part of this domain).  
 
The pattern of blood flow in the developing heart is hypothesised to determine 
the extent of cardiac development (as described in the introduction). As GMFG 
has been shown to be involved in angiogenesis and actin based cell migration, 
there may be a clear pathogenic mechanism for CHD in cases of GMFG loss of 
function. It is known that understanding the haemodynamics during heart 
development can be important for the correction of CHD, as shown by the 
improvement of left ventricular function and prevention of development of HLHS 
by in utero surgical interventions for severe aortic stenosis (Selamet Tierney et 
al., 2007).  
 
3.3.4  Conclusions 
I have demonstrated that GMFG is a potential candidate gene for autosomal 
recessive non-syndromic CHD. Further sequencing analysis of GMFG in other 
isolated and familial cases of CHD, and demonstrating the functional effects of 
the mutation and role of GMFG in heart development in animal models, is 
required before this finding can be considered conclusive.  
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3.4 Molecular genetic analysis: whole exome sequencing  
(familial CHD cohort) 
3.4.1  Whole exome sequencing (WES) at WTSI 
The availability of “whole exome sequencing” data from a single affected 
individual from family CHD1 illustrated the potential for using exome sequencing 
to identify candidate novel CHD genes in kindreds with familial CHD. However a 
major limitation to my project was the cost of exome sequencing which meant 
that only a single individual (IV:4) was analysed. Though there was relatively 
strong genetic evidence for GMFG inactivation causing CHD in Family CHD1, 
there was the possibility that the exon containing the mutation in the responsible 
gene might not have been captured or sequenced in sufficient depth to detect 
the “real pathogenic mutation”.  
 
Subsequently we established our second collaboration with Dr Matt Hurles 
(Human Genetics Division, Wellcome Trust Sanger Institute [WTSI], Hinxton, 
UK), which enabled WES on the 2 remaining affected siblings from CHD1 (IV:1 
and IV:3) and a total of 17 affected siblings from a further 8 CHD families (CHD 
4/5/6/13/16/20/22/23). These families were chosen on the basis of multiple 
affected individuals in one generation, implying an autosomal recessive 
inheritance pattern.  
 
The DNA samples from a total of 19 individuals from the 9 CHD families were 
sent in batches throughout 2011 (February, May, and August). They performed 
the WES laboratory work and read analysis using a newer version of the 
SureSelect automated target enrichment technology (Agilent) compared to BGI, 
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with a 100% overall coverage of the whole exome (read depth 1X), which fell to 
only 92% coverage with a read depth of 10X.  
 
The final complete raw dataset for all families was transferred to Birmingham 
(August 2011) and all variants were annotated as novel or as being reported on 
the dbSNP, 1000 Genomes, and UK10K databases. The annotation also 
included the functional category of the variants, whether they were 
heterozygous or homozygous variants, and details of the predicted effect on the 
gene product using SIFT and PolyPhen prediction programmes.  
 
3.4.2  Candidate gene analysis from WES 
As had been observed with the WES data from BGI for individual IV:4 (Family 
CHD1), WES can reveal a vast number of variants and therefore a structured 
approach was required to interrogate the huge dataset that was provided by the 
WTSI WES collaboration. As the WTSI analysis was performed after the BGI 
analysis fewer variants were classed as novel (dated February 2012) as more 
data was available in the dbSNP, 1000 Genomes, and UK10K databases. 
Using the Exome Variants Analysis (EVA) software programme and Excel 
(Microsoft), I manually analysed the variants using various filtering strategies. 
As performed with the BGI WES data, I selectively filtered out all dbSNPs, and 
included only potentially pathogenic variants (i.e. nonsense, missense, and 
splice acceptor and donor site).  
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Prior to receiving the data I decided that I would analyse the data in a variety of 
ways so that I would be able to address the evidence available for a variety of 
different genetic scenarios. For example, even assuming an autosomal 
recessive model of inheritance, it was possible that in any particular family CHD 
might result from a mutation in a known CHD gene (that could have been 
associated with the type of CHD observed in the family or a different type of 
CHD) or a novel CHD gene. In preparation for this next step in the analysis I 
assembled a list of candidate CHD genes (similar to Table 3) by analysing data 
from a large number of sources. 
 
I then used a functional approach to prioritise candidate genes according to: (a) 
putative function (Ensembl, OMIM, PubMed, UCSC Genome Bioinformatics), 
(b) published literature (PubMed), (c) information from model organism genomic 
databases (MGI), and (d) protein-interaction resources (to identify potential 
interactions with known CHD genes)(BioGRID).  
 
3.4.3  WES data for families with “autosomal recessive” inheritance 
 of CHD  
Firstly I will summarise the relevant sequence information for each of the 
families analysed at the WTSI individually and then the overview analysis. As 
multiple affected individuals in all families had been sequenced, I was able to 
filter in variants that were only present in all affected individuals. For individual 
families, the data was analysed in light of the inheritance pattern in that 
particular family and the presence or absence of consanguinity. Thus in 
consanguineous families I expected to find homozygous variants (over 
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compound heterozygous variants) in a candidate gene. In non-consanguineous 
families either compound heterozygous variants or homozygous variants might 
be detected. The WES data analysis for all the CHD families studied is 
summarised in Table 9. Appendix G tabulates all the novel, functionally 
significant variants with the results of pathogenicity software programmes, for 
each family studied using WES. 
 
3.4.3.1 Family CHD1  
The WTSI dataset for family CHD1 revealed that a total of 64,675 variants were 
shared by both affected individuals (IV:1 and IV:4), and 6,490 of these were 
reported to be novel, as they were not present in the dbSNP databases. Using 
the various filtering strategies (described previously), only 1,376 potentially 
pathogenic variants remained. As the family history and parental consanguinity 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
homozygous variants and was left with a total of 59 variants (1 nonsense, 49 
missense, and 9 splice site/indels) in 48 genes. When compared to the BGI 
dataset (with 95 different genes containing homozygous variants), there were 
only five genes in common, but only three of them had the same variant 
identified previously (i.e. GMFG, NDUFA13 and KIA1683). Interestingly these 
three genes are within the homozygous region identified on autozygosity 
mapping, and none have been associated with cardiac development. The 
GMFG mutation (but not the false positive variants -WNT11 and DVL2) from the 
BGI dataset was detected in the WTSI data in all affected siblings (confirming 
previous segregational analysis). The only variants in known CHD genes were 
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the compound heterozygous variants in EVC (Ellis-Van Creveld syndrome) and 
NOTCH1 (non-syndromic CHD, mainly aortic disease). Interestingly a 
homozygous missense variant in MESP1 was identified, and mice with targeted 
mutations in this gene die in the embryonic period with CHD (MGI). Mesp1 is 
throught to promote cardiovascular differentiation during embryonic 
development, and lineage tracing in mice showed it to represent the earliest 
marker of cardiovascular progenitors, including derivatives of the primary and 
second heart fields (Bondue and Blanpain, 2010).  
 
3.4.3.2 Family CHD4  
The WTSI dataset for family CHD4 revealed that a total of 52,463 variants were 
shared by both affected individuals, 4,019 of these were reported to be novel, 
and only 732 were potentially pathogenic variants. As the family history and 
parental consanguinity suggested autosomal recessive inheritance of CHD, I 
was left with a total of 53 homozygous variants (1 nonsense, 44 missense, and 
8 splice site/indels) in 37 genes. Compound heterozygous variants were 
identified in the MLL3 gene, which is closely related to MLL2 (Kabuki 
syndrome), but not known to be involved in heart development. Compound 
heterozygous variants were also identified in NOTCH1 (non-syndromic CHD. 
Without further analysis they can not be excluded as potentially disease 
causing. There were no variants in other known CHD genes or any of the 
candidate genes analysed in family CHD1 (GDF1, WNT11, DVL2 and GMFG).  
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3.4.3.3 Family CHD5  
The WTSI dataset for family CHD5 revealed that a total of 59,691 variants were 
shared by both affected individuals, 3,742 of these were reported to be novel, 
and only 522 were potentially pathogenic variants. As the family history 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
both homozygous variants and compound heterozygous variants, due to 
absence of consanguinity. There were a total of 30 homozygous variants (29 
missense, and 1 splice site/indels) in 21 genes. There were a total of 492 
heterozygous variants (4 nonsense, 442 missense, and 46 splice site/indels), 
and further analysis showed 42 genes had more than one heterozygous variant. 
The same two compound heterozygous variants seen in family CHD4 in MLL3 
and NOTCH1 were identified in this family. There were no variants in other 
known CHD genes or any of the candidate genes analysed in family CHD1 
(GDF1, WNT11, DVL2 and GMFG). 
 
3.4.3.4 Family CHD6  
The WTSI dataset for family CHD6 revealed that a total of 63,010 variants were 
shared by both affected individuals, 7,477 of these were reported to be novel, 
and only 2,204 were potentially pathogenic variants. As the family history 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
both homozygous variants and compound heterozygous variants, due to 
absence of consanguinity. There were a total of 42 homozygous variants (39 
missense, and 3 splice site/indels) in 33 genes. There were a total of 2,162 
heterozygous variants (69 nonsense, 1,986 missense, and 107 splice 
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site/indels), and further analysis showed 236 genes had more than one 
heterozygous variant. The same two compound heterozygous variants seen in 
family CHD4 in MLL3 and NOTCH1 were identified in this family. There were 
also three heterozygous missense variants identified in TBX20 (non-syndromic 
CHD). There were no variants in other known CHD genes or any of the 
candidate genes analysed in family CHD1 (GDF1, WNT11, DVL2 and GMFG). 
 
3.4.3.5 Family CHD13  
The WTSI dataset for family CHD13 revealed that a total of 64,176 variants 
were shared by both affected individuals, 4,335 of these were reported to be 
novel, and only 554 were potentially pathogenic variants. As the family history 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
both homozygous variants and compound heterozygous variants, due to 
absence of consanguinity. There were a total of 36 homozygous variants (31 
missense, and 5 splice site/indels) in 24 genes. There were a total of 518 
heterozygous variants (7 nonsense, 462 missense, and 49 splice site/indels), 
and further analysis showed 53 genes had more than one heterozygous variant.  
The same two compound heterozygous variants seen in family CHD4 in MLL3 
and NOTCH1 were identified in this family. There were no variants in other 
known CHD genes or any of the candidate genes analysed in family CHD1 
(GDF1, WNT11, DVL2 and GMFG). 
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3.4.3.6 Family CHD16   
The WTSI dataset for family CHD16 revealed that a total of 49,664 variants 
were shared by all three affected individuals, 5,894 of these were reported to be 
novel, and only 1,808 were potentially pathogenic variants. As the family history 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
both homozygous variants and compound heterozygous variants, due to 
absence of consanguinity. There were a total of 29 homozygous variants (27 
missense, and 2 splice site/indels) in 20 genes. There were a total of 1,779 
heterozygous variants (52 nonsense, 1,642 missense, and 85 splice 
site/indels), and further analysis showed 193 genes had more than one 
heterozygous variant. The same two compound heterozygous variants seen in 
family CHD4 in MLL3 and NOTCH1 were identified in this family. Two out of the 
three heterozygous missense variants identified in TBX20 in family CHD6 were 
also present. There were no variants in other known CHD genes or any of the 
candidate genes analysed in family CHD1 (GDF1, WNT11, DVL2 and GMFG). 
 
3.4.3.7 Family CHD20 
The WTSI dataset for family CHD20 revealed that a total of 57,734 variants 
were shared by both affected individuals, 3,617 of these were reported to be 
novel, and only 608 were potentially pathogenic variants. As the family history 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
both homozygous variants and compound heterozygous variants, due to 
absence of consanguinity. There were a total of 30 homozygous variants (26 
missense, and 4 splice site/indels) in 19 genes. There were a total of 578 
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heterozygous variants (8 nonsense, 538 missense, and 32 splice site/indels), 
and further analysis showed 42 genes had more than one heterozygous variant. 
The same two heterozygous variants seen in family CHD4 in MLL3 (but not 
NOTCH1) were identified in this family. There were no variants in other known 
CHD genes or any of the candidate genes analysed in family CHD1 (GDF1, 
WNT11, DVL2 and GMFG). 
 
3.4.3.8 Family CHD22 
The WTSI dataset for family CHD22 revealed that a total of 64,117 variants 
were shared by both affected individuals, 3,929 of these were reported to be 
novel, and only 594 were potentially pathogenic variants. As the family history 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
both homozygous variants and compound heterozygous variants, due to 
absence of consanguinity. There were a total of 42 homozygous variants (35 
missense, and 7 splice site/indels) in 26 genes. There were a total of 552 
heterozygous variants (6 nonsense, 498 missense, and 48 splice site/indels), 
and further analysis showed 49 genes had more than one heterozygous variant. 
None of the variants in MLL3, NOTCH1 and TBX20 seen in other families were 
seen in this family. There were no variants in other known CHD genes or any of 
the candidate genes analysed in family CHD1 (GDF1, WNT11, DVL2 and 
GMFG). 
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3.4.3.9 Family CHD23 
The WTSI dataset for family CHD23 revealed that a total of 59,906 variants 
were shared by both affected individuals, 3,728 of these were reported to be 
novel, and only 527 were potentially pathogenic variants. As the family history 
suggested autosomal recessive inheritance of CHD, I focussed my attention on 
both homozygous variants and compound heterozygous variants, due to 
absence of consanguinity. There were a total of 51 homozygous variants (47 
missense, and 4 splice site/indels) in 35 genes. There were a total of 476 
heterozygous variants (7 nonsense, 425 missense, and 44 splice site/indels), 
and further analysis showed 48 genes had more than one heterozygous variant. 
The same two heterozygous variants seen in family CHD4 in MLL3 (but not 
NOTCH1) were identified in this family. There were no variants in other known 
CHD genes or any of the candidate genes analysed in family CHD1 (GDF1, 
WNT11, DVL2 and GMFG). 
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Table 9: Summary of the numbers of variants identified in the familial CHD cohort studied via WES at WTSI. 
 
‘Novel’ = not in SNP databases (dbSNP, 1000 Genomes, UK10K) HMZ = homozygous  HTZ = heterozygous 
 ‘Pathogenic variants’ = non-synonymous (nonsense and missense), splice site, and indels 
CHD FAMILY 1 4 5 6 13 16 20 22 23 
No. affected  
siblings sequenced 2 2 2 2 2 3 2 2 2 
Total No.  
variants 64675 52463 59691 63010 64176 49664 57734 64117 59906 
No. ‘novel’ 
variants 6490 4019 3742 7477 4335 5894 3617 3929 3728 
No. ‘pathogenic’  
variants 1376 732 522 2204 554 1808 608 594 527 
No.  
HMZ variants 59 53 30 42 36 29 30 42 51 
nonsense 1 1 0 0 0 0 0 0 0 
missense 49 44 29 39 31 27 26 35 47 
splice site/indels 9 8 1 3 5 2 4 7 4 
No. genes  
with HMZ variant 48 37 21 33 24 20 19 26 35 
No. 
 HTZ variants 1317 679 492 2162 518 1779 578 552 476 
nonsense 21 6 4 69 7 52 8 6 7 
missense 1217 635 442 1986 462 1642 538 498 425 
splice site/indels 79 38 46 107 49 85 32 48 44 
No. genes  
with >HTZ variant 143 58 42 236 53 193 42 49 48 
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3.4.4  Overview analysis of WES data for families with “autosomal  
recessive” inheritance of CHD  
Table 9 summarises the numbers of variants in each family using all the various 
filtering strategies, and Appendix G tabulates all the homozygous and 
compound heterozygous pathogenic variants identified in each family. The 
candidate genes (GDF1, WNT11, DVL2, and GMFG) evaluated in family CHD1 
(from previous molecular studies) were reviewed in the datasets from the 
additional 8 CHD families (CHD4/5/6/13/16/20/22/23) but no candidate 
mutations were identified.  
 
There was the possibility that there might be: (a) a ‘major’ gene accounting for 
CHD in the majority of the families (with phenotypic variability resulting from 
allelic heterogeneity or stochastic or modifier effects), or (b) extreme locus 
heterogeneity with CHD in each of the families resulting from mutations in a 
different gene. Therefore inspection of the datasets was undertaken to 
represent a variety of scenarios. Firstly I queried if homozygous or compound 
heterozygous mutations (or allelic variants) in known CHD genes might account 
for all or a subset of families (e.g. families of a common ethnic origin), but no 
evidence was found to favour this hypothesis. Secondly I queried if 
homozygous or compound heterozygous mutations (or allelic variants) in novel 
CHD genes might account for all or a subset of families (e.g. families of a 
common ethnic origin). When the data from both consanguineous families 
(Pakistani origin) was analysed together, 16 genes were identified in which both 
families harboured a homozygous variant. When the data from all the non-
consanguineous families was analysed together, 172 genes were identified in 
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which more than one family harboured a compound heterozygous variant. 
When the data from all families was combined, 41 genes were identified in 
which more than one family (consanguineous and non-consanguineous) 
harboured a homozygous variant, and 246 genes were identified in which more 
than one family harboured either a homozygous variant or a compound 
heterozygous variant (Table 10). Appendix H contains the individual lists of 
genes from the above analyses across families. 
 
Table 10: Summary of the no. of genes identified via different analytical 
methods across the familial CHD cohort studied via WES at WTSI. 
The lists of genes from the different analytical methods are in Appendix H 
HMZ = homozygous,  
cHTZ = compound heterozygous (>1 variant in the gene) 
 
 
 
3.4.5  Discussion of WES at WTSI 
The WTSI WES datasets became available towards the end of the project and 
the analysis of the data was still ongoing at the time that this thesis was written. 
The analysis within a family and across all families was complicated (especially 
without bioinformatics tools), and still requires more time before making any firm 
conclusions.  
ANALYSIS TYPE NO. 
No. genes with HMZ variants 
in > 1 consanguineous family 
16 
No. genes with HMZ variants in > 1 family 
(consanguineous or non-consanguineous) 
41 
No. genes with cHTZ variants 
in >1 non-consanguineous family 
172 
No. genes with HMZ or cHTZ variants in > 1 family 
(consanguineous or non-consanguineous) 
246 
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The analysis performed so far identified some interesting points for discussion. 
Firstly, there were some genes (not known to be linked to CHD) common 
across the families, where a number of the variants in these genes 
(homozygous or compound heterozygous) were the same across the families 
(e.g. MESP2 [family CHD1/4/5/13/22] and RYR [family CHD4/13/20/23]), 
implying either polymorphisms or false positives from WES (e.g. indel/frameshift 
variants), especially as none seemed like good candidate CHD genes.  
 
Secondly, I identified a number of variants (missense and indels) in genes 
associated with known Mendelian disorders, but the families did not display any 
clinical features of these conditions (e.g. CUL7 – 3M syndrome [family CHD16], 
MESP2 – Spondylocostal dysostosis, OPA1 – autosomal dominant optic 
atrophy [family CHD16], PKHD1 – autosomal recessive polycystic kidney 
disease [family CHD6/16], and POLG – mitochondrial depletion syndrome 
[family CHD16]). Without further characterisation of these variants it poses a 
dilemma on the information given back to the families, and highlights one of the 
pitfalls and ethical issues relating to use of WES. 
 
Thirdly, in a number of families I identified variants (compound heterozygous 
missense only) in genes associated with syndromic or non-syndromic CHD or 
cardiac disease, like cardiomyopathy). Examples include: EVC [family CHD1], 
NOTCH1 [family CHD1/4/5/6/13/16], TBX20 [family CHD6/16], and TTN [family 
CHD1/6/16/20/23]. There were also some potential candidate genes due to 
homology to known CHD genes (e.g. MLL3 - CHD4/5/6/13/16/20/23). However 
177 
 
for both these scenarios, all of these variants were the same across those 
families, and without further clarification and laboratory analysis, it is hard to 
conclude on their significance. As the families were from various ethnic 
backgrounds there would be less evidence for a founder mutation effect or a 
common disease mutation. 
 
Due to limitations of time and funding I was not able to fully analyse or 
characterise many of these variants identified, but further data from population 
studies, animal models, and large cohorts of CHD patients will help to narrow 
down and identify potential candidate genes. Nevertheless, it seems likely that 
the eventual conclusion of the analysis will be that “clinically autosomally 
recessively inherited CHD” demonstrates extreme genetic heterogeneity as 
there was no evidence that a substantial fraction of the families might be 
accounted for by a single gene, or indeed, multiple genes in a single pathway. It 
might be argued that focussing on specific subgroups of families that have an 
identical phenotype that is concordant within the family might facilitate gene 
discovery. However, ascertaining a significant number of such families is 
challenging and there are multiple examples of instances in which mutations in 
a single CHD gene can result in variable forms of CHD.  
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3.4.6  Conclusions 
From the data available at the time of writing up the thesis, I would suggest that 
the absence of other candidate mutations (apart from that in GMFG) in family 
CHD1, despite WES data on three affected siblings, supports the case for 
GMFG representing a novel CHD gene. It should be noted that frameshift 
variants are more likely to be false positive calls than nonsense variants, which 
can be seen by the presence of the same frameshift variant in a number of 
families from different ethnic backgrounds (e.g. RYR and MESP2). With the 
proviso that second generation sequencing may result in false positive variants 
(e.g. WNT11 and DVL2), other potential candidate genes include MLL3 
(numerous families) and MESP1 (family CHD1). Therefore the variants within 
these genes (and those seen in NOTCH1, TBX20) would be the ones I would 
initially prioritise for validation and further analysis. 
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CHAPTER 4 
GENERAL DISCUSSION 
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4.1 General discussion 
Advances in genetic analysis methodologies in CHD are very likely to lead to a 
shift in medical management of these patients. Currently diagnostic and 
therapeutic approaches are based on the anatomical and physiological 
differences between a normal heart and that seen in CHD. Declining mortality 
rates due to improved surgical repair, of even complex CHDs, has changed the 
population demographics of CHD patients, with an enlarging ‘Grown Up 
Congenital Heart disease’ (GUCH) population. The lack of knowledge of the 
underlying aetiology of many patients with CHD, reduces our ability to predict 
disease course and outcome, or to develop primary and secondary intervention.    
 
4.2 Whole exome sequencing (WES) 
Linkage analysis and sequencing large numbers of candidate genes in a 
disease interval can be time consuming and expensive (as seen before). Whole 
exome sequencing (also known as targeted exome capture) has 
revolutionalised human genetics since its initial demonstration to identify 
uncommon variants and disease genes in both rare Mendelian and more 
complex diseases (Ng et al., 2009a). To date the majority of disease causing 
mutations in human genetic diseases have been located in or around the coding 
sequences (exons) of genes. Sequencing of the entire exome (~1% of 
genome), rather than the entire human genome, is therefore a well justified and 
efficient strategy to search for causes of rare Mendelian disorders. Variants in 
non-coding sequences are rarely detected due to various technical issues and 
are more likely to have neutral or weak effects on phenotypes, even in well 
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conserved non-coding sequences. The exome therefore represents a highly 
enriched subset of the genome in which to search for variants with large effect 
sizes. 
Figure 19: Whole exome sequencing using a target-enrichment method.  
Taken from Agilent Technologies (www.agilent.com) 
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4.2.1  Principles of whole exome sequencing 
The technical platforms used to carry out exome sequencing are: (1) DNA 
microarrays and magnetic bead based systems for the enrichment of the exome 
DNA, and (2) next-generation sequencing technologies. Target-enrichment 
methods allow to selectively capture genomic regions of interest from a DNA 
sample prior to sequencing. Several target-enrichment strategies have been 
developed, but in-solution capture methods were used in my project. To capture 
genomic regions of interest using in-solution capture, a pool of 
custom oligonucleotides (bait probes) is synthesised and generally biotinylated. 
The bait probes are mixed with fragmented genomic DNA, and the desired 
fragments hybridise to baits in solution. Streptavidin beads are then added to 
allow physical separation. The bead-bait complexes can be pulled down and 
washed to clear excess material. The beads are then removed and the genomic 
fragments can be sequenced allowing for selective DNA sequencing of genomic 
regions (e.g. exons) of interest (Figure 19). The next step in any analysis is to 
map sequence reads, calibrate base qualities, and call variants. Variants can 
then be tabulated using Excel spreadsheets and manually analysed with 
varying filtration strategies, however with advances in bioinformatics these 
processes are becoming more automated. 
 
All next-generation sequencing approaches require every base in a sample to 
be sequenced several times for two reasons. Firstly, despite the high 
sequencing accuracy for each individual nucleotide, the very large number of 
nucleotides in the exome means that if an individual exome is only sequenced 
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once, there will be a significant number of sequencing errors. Secondly, reads 
are not distributed evenly over an entire exome, because the reads sample the 
exome in a random and independent manner, therefore some bases will be 
covered more and some may be very less than the average value. The 
‘depth’ in sequencing refers to the number of times a nucleotide is read during 
the sequencing process. So a depth of 10x means on average each base has 
been read by 10 sequences. Therefore you need multiple observations per 
base (increasing the sequencing accuracy) to come to a reliable base call and 
help distinguish between sequencing errors and true SNPs.  
 
4.2.2  Data filtering strategies 
The major challenge with this methodology of gene discovery is the vast 
number of variants identified in an individual exome (typically ~20,000) (Ng et 
al., 2009a). Many of these variants will be found in databases of common 
variants (e.g. dbSNP, 1000 genomes, in-house databases), and these can 
essentially be filtered out of the data, on the assumption that variants which are 
common in the population are unlikely to cause rare Mendelian diseases. This 
can help to narrow down causal variants in cases with the disease. 
  
Another layer of data filtering is based on the potential effect of the variant on 
protein structure and function, and also by conservation scores. These can be 
determined by computerised online tools (e.g. PolyPhen-2 and SIFT) with the 
rationale that mutations which are disruptive to proteins and/or at more 
conserved sites are more likely to be pathogenic. These tools have limited 
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specificity and sensitivity, and should be used in conjunction with other 
strategies and not as a stand-alone filter (Wei et al., 2010). 
 
Candidate genes can then be selected on the basis of the presumed inheritance 
of the disorder. For autosomal dominant disorders, the candidate gene must 
have one mutation per individual, and for autosomal recessive disorders, the 
candidate gene must have homozygous/compound heterozygous mutations. By 
pooling together data from unrelated individuals with the same disorder, the 
number of candidate genes can be reduced, with the assumption that all 
affected individuals will have mutations in the same gene. Further selection of 
candidate genes relies on traditional methods of phenotypes in animal models 
and literature reviews of confirmed or suspected function of the genes. 
 
Ideally these data filtering strategies and candidate gene selection processes 
could be automated with bioinformatics tools, but despite the rapid advances in 
sequencing technologies, the tools to analyse the data are still undeveloped, 
complex and both resource and time consuming.  
 
4.2.3  Gene identification in Mendelian disorders 
Publications from many groups have demonstrated the power of exome 
sequencing for gene identification and Mendelian disease analysis (Choi et al., 
2009; Ng et al., 2009a; Ng et al., 2009b; Bolze et al., 2010; Edvardson et al., 
2010; Hoischen et al., 2010; Johnston et al., 2010; Lalonde et al., 2010; Otto et 
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al., 2010; Rehman et al., 2010; Sirmaci et al., 2010; Ng et al., 2010a; Ng et al., 
2010b). 
 
In consanguineous families (with multiple autozygous regions) and non-
consanguineous families with patterns of recessive disease, the new practice is 
to perform WES to identify homozygous and compound heterozygous 
mutations. Unpublished studies, from Professor Maher’s group, of exome 
resequencing in recessive disorders (n=29) in 5 consanguineous families are 
also encouraging and have demonstrated the feasibility of this approach for 
establishing the genetic basis of Mendelian disorders. Though differentiating 
disease causing mutations from rare polymorphic variants can be challenging, 
the increasing availability of publically accessible data on genome variation has 
facilitated greatly the differentiation of mutations from infrequent non-pathogenic 
variants (e.g. 1000 Genomes Project and the UK10K study). In addition, the 
combination of autozygosity mapping data with exome sequencing data can 
enable candidate mutations to be prioritised more easily. Thus in the most 
recent exome sequencing studies (by Professor Maher’s group) in 
consanguineous families with recessive disorders each proband (n=14) 
harboured on average 40 previously unreported non synonymous variants 
(nonsense, frameshift, splice-site or missense) but only 1 in 4 of these mapped 
within a previously identified autozygous interval.  
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4.2.4  Advantages / disadvantages of whole exome sequencing 
The trend is now towards cheaper and higher throughput DNA sequencing, and 
the molecular basis of many of the remaining Mendelian disorders will be 
quickly elucidated. This technique allows the identification of not only causal 
variants but also modifier variants in Mendelian diseases. The molecular basis 
of many Mendelian disorders has been known for many years, but the trends in 
research with WES can now focus on modifying factors/variants that account for 
variable expression and incomplete penetrance of diseases. 
 
The challenges are no longer limitations in technology, but the interpretation of 
variants and specifically identifying the causal variants. This is particularly 
difficult in common autosomal dominant diseases where several novel and 
known variants are identified co-segregating with the disease phenotype. In 
contrast causal variants may be more easily identified in autosomal recessive 
diseases or rare autosomal dominant diseases (due to de novo mutations). 
Advances are therefore required in analytical software programmes and 
bioinformatics tools. Distinguishing benign polymorphisms and disease causing 
variants can be difficult in certain ethnic populations whose genetic variation 
has not been fully characterised, and therefore more population based studies 
need to be conducted (e.g. 1000 Genomes Project).  
 
There are many reasons for failure of this method in correctly identifying the 
genetic basis of disease in a patient or family. The major problem in studying 
one individual with a rare disorder is that one can never be entirely certain that 
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a suspected disease gene is the correct gene, until a second unrelated 
individual with a similar phenotype is found to have a mutation in the same gene 
(Ng et al., 2010a; Robinson et al., 2011). If the depth of coverage is poor for a 
particular nucleotide there is an increased risk of false positives. For genetically 
heterogeneous disorders (like CHD), there may be a number of different genes 
accounting for the disorder in a particular study group, thereby making this a 
difficult group to study for gene identification. The strategy of identifying 
variants/genes shared between a number of unrelated affected individuals can 
have false-positive results, if candidate genes have a large coding sequence, 
and so there is a higher chance of an unrelated sequence variant being present 
amongst different individuals. Another issue is the number of false negative 
results due to incomplete penetrance of disease, type of variant, and poor 
coverage. If a causal variant is present in phenotypically affected and 
unaffected individuals (not fully penetrant) it may be filtered out. Synonymous 
variants are also usually filtered out, but some may induce exon skipping and 
potentially still be pathogenic. Typically reasonable coverage is up to around 
90% of the exome using most current technologies, and so mutations in regions 
of the exome that are poorly covered by this technology will be missed (high GC 
content), and a candidate gene may therefore be falsely removed from further 
analysis. The analysis of our familial CHD cohort benefited from improvements 
in coverage of the WES technology, allowing very good coverage of all families 
studied (including family CHD1). These continuous competitive improvements 
between companies in the design of various platforms for WES will help to 
improve the coverage even further with time.  
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The issues with false positive and false negative results were clearly highlighted 
in the investigation of the genetic basis of Kabuki syndrome using WES. Initially 
the MUC16 gene was identified as a candidate gene as it had a novel variant 
(non-synonymous, splice site, frameshift indels) in all 10 cases screened with 
WES, but this was considered a false positive due to the size of the gene. By 
using less stringent criteria for variant identification and the notion that it could 
be a genetically heterogeneous disorder, the MLL2 gene was finally identified 
as the causative gene with a novel significant variant in 7/10 cases. Despite an 
average coverage of 96% of the MLL2 gene with WES, using conventional 
Sanger sequencing they then identified frameshift indels mutations (not 
detected by WES) in 2/3 of the remaining cases (Ng et al., 2010b). 
 
The WES dataset from our familial CHD cohort illustrates a number of possible 
false positives. There were a number of genes that harboured numerous 
variants (mainly missense), sometimes exceeding five variants, in a number of 
the families (e.g. MUC, PRAMEF, IGHV, TRBV, ZNF genes). There were some 
genes in which the same variants (homozgygous or compound heterozygous) 
were seen in a number of families (e.g. MESP2 and RYK), however they did not 
seem like candidate genes on further analysis of the literature and animal 
models. The recurrence of the same variants in a number of genes across 
families, could suggest common mutations, but are more likely to be accounted 
for by false positives/polymorphisms.  
 
 
189 
 
Current testing strategies would also miss mutations in non-coding sequences 
acting as distant enhancers or regulatory elements, which can be associated 
with genetic disorders. A good example of alterations in regulatory elements 
and human genetic disease is the PAX6 gene and aniridia. Submicroscopic de 
novo deletions of 11p13 were reported, located more than 11kb from the 3-
prime end of the PAX6 gene, in unrelated patients with sporadic aniridia 
(Lauderdale et al., 2000). The clinical features were indistinguishable from 
cases with mutations in the coding region of PAX6, suggesting that remote 3-
prime regulatory elements are required for initiation of PAX6 expression. More 
recently over 6000 candidate enhancer sequences were identified directly from 
fetal and adult human heart tissue. They were significantly enriched near genes 
implicated in heart development, function and disease, and some drove 
reproducible reporter gene expression in the heart (May et al., 2012). As I can 
not exclude the effects of variants in enhancer elements in our familial CHD 
cohort recruited, future strategies would include whole genome sequencing to 
identify variants in the non-coding regions. 
 
There are also ethical implications relating to the vast amount of data produced 
from this technology and what information is transmitted back to the patients 
and families. Standards for consenting, reporting and counselling patients and 
families will be required in the future due to the complexity of the information 
obtained, especially with the possibilty of identifying ‘incidental’ mutations in 
genes causing other Mendelian disorders for which the patient may be a carrier 
or at risk of developing (as seen in our dataset). As the technology is 
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transferred from the research environment to mainstream clinical practice, this 
area of genomics will become a major tool and challenge for medical practice in 
the 21st century. 
 
4.3 Animal Models 
The successful completion of the Human Genome Project and advances in 
technologies associated with forward genetics, has directed biological research 
into the reverse genetics era where strategies for deciphering the function of 
each gene are being developed. Emerging technologies are promising for 
detecting genomic alterations in CHD (microarrays and next generation 
sequencing), however evidence for the pathogenicity of a gene variant or the 
function and role of a gene in cardiac development, can be a short-coming of 
these technologies. Bioinformatics tools can predict the effect of a variant on 
protein coding, structure and possible alterations in function. Testing the in vivo 
effects of these variants is challenging but important, and can be mediated 
through animal studies which allow the pathophysiological effects to be 
determined. This can be particularly beneficial when numerous variants have 
been identified in genes not known to be associated with cardiovascular 
development, or in cases where family studies are lacking or inclusive (Smith et 
al., 2009). In order to study the role of GMFG and the effects of the mutation 
identified in family CHD1 we have set up collaborations to establish animal 
models in both mice (Sanger Institute, UK) and zebrafish (University of 
Birmingham, UK).  
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4.3.1  Mouse (Mus musculus) 
Mouse models of cardiac development have been extensively studied as it 
shares similar embryogenesis, anatomy, and physiology with humans. 
Comparative genomics have shown that many genes, proteins and regulatory 
elements have high homology and are highly conserved between mouse and 
human (Gregory et al., 2002). Now that the entire mouse genome is known, it is 
possible to knock out, mutate, misexpress, and replace every gene. The two 
main methods utilised in mice are gene trapping and gene targeting. Gene 
trapping is a high throughput and random mutation technique, allowing large 
numbers of mouse genes to be knocked out, but is not as specific as gene 
targeting. Gene targeting (via homologous recombination) can be used to knock 
out genes or introduce alterations at specific locations in the genome (knock-in) 
(Guan et al., 2010). Transgenic mice, via the use of multiple fluorescent 
proteins, can also be used to study cell-cell interactions, whole body imaging (to 
track cell movement/proliferation during development), and the cell cycle in real 
time (Miller, 2011). Transgenic mouse models have not only changed our 
understanding of normal and abnormal heart development, but are also being 
used to identify new avenues for medical therapy (Snider and Conway, 2011). 
The Knock Out Mouse Project (KOMP) with its repositories, was set up to 
develop, archive, and distribute a comprehensive library of embryonic stem 
cells with null mutations in every protein coding gene in the mouse (Lloyd, 
2011). There are a number of practical disadvantages of mouse models 
including: small numbers of embryos per mouse, inability to monitor embryos, 
extensive laws regarding their use, and high costs of breeding (Moon, 2006).   
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4.3.2  African clawed frog (Xenopus) 
The Xenopus has many similarities with humans genetically and anatomically, 
and has been used in studying vertebrate heart development. The Xenopus 
embryo develops externally and is relatively large, making it more accessible to 
surgical manipulation, and can develop in the absence of a functional 
cardiovascular system during embryogenesis. It has a unique ability to heal 
after microsurgery, allowing excision and culture of targeted regions and the 
subsequent analysis of downstream transcriptional effects of exogenous 
agents. Transgenic procedures have been used for promoter and enhancer 
analyses and introducing heritable modifications into the frog genome. 
Transgenesis has the advantage of tightly controlling the spatial and temporal 
expression of a transgene with a tissue specific manner. The most commonly 
used method of studying protein depletion is through morpholino 
oligonucleotides (see below). Numerous genes involved in cardiac development 
and heart defects have been well studied in the Xenopus (Kaltenbrun et al., 
2011). 
 
4.3.3  Zebrafish (Danio rerio) 
Zebrafish have become an excellent genetic and embryonic model system to 
study cardiovascular development and diseases (Bakkers, 2011). Similar to 
Xenopus they also have the advantage of not being fully dependent on a 
functioning cardiovascular system during embryogenesis, as oxygen can still 
reach tissues through passive diffusion. Avian and mammalian embryos would 
die rapidly in the absence of a functioning cardiovascular system, and therefore 
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zebrafish with severe cardiac defects can be analysed. They are very cost 
effective as they require minimal equipment, can produce large numbers of 
progeny, and develop very rapidly with organogenesis complete 72hrs post 
fertilisation. They are externally fertilised and transparent allowing easy 
manipulation and observations (Yelon, 2001). There are many techniques to 
perform loss-of-function studies, and the use of antisense morpholino 
oligonucleotides is the most frequent. These are short chains of 25 nucleotides 
which act via a steric blocking mechanism, either translation initiation or 
modifying pre-RNA splicing. They do not always efficiently knock down the gene 
of interest (lack of specificity) and can be prone to off-target effects (Nasevicius 
and Ekker, 2000). Zinc finger nuclease (ZFN) and Transcription Activator-Like 
Effector Nuclease (TALEN) technologies are new techniques that allow 
specificity of the target gene with fewer off-target effects. Each ZFN monomer 
comprises of 3-6 zinc finger motifs which bind to 9-18bp of target DNA (i.e. 3bp 
per zinc finger). The TALEN has a highly conserved 33-35 amino acid 
transcription activator-like effector repeat domain, which binds to a single bp of 
DNA. These effector domains can be ligated together to create extended arrays 
that then bind to longer DNA sequences. The ZFNs or TALENs can then be 
fused with the nuclease domain of the Fok1 restriction enzyme, and functioning 
as dimers can create targeted double strand DNA breaks. These breaks are 
then repaired via non-homologous end joining recombination, creating insertion 
/deletion mutations and often premature termination (Moore et al., 2012). The 
limitations of ZFNs are that there may not be any target sites in small genes, 
and that a lot of work is needed to select the proper ZFN which will recognise 
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and cleave the target sequence (Urnov et al., 2010). TALENs have higher 
targeting ranges and success rates for mutagenesis compared to ZFNs, but due 
to the relative newness of this technique, the reasons for failure remain largely 
unknown (Kiefer, 2011; Moore et al., 2012). Despite their complexities, these 
emerging techniques do allow specific gene disruptions in a tissue specific 
manner, and due to their success in zebrafish are being employed in other 
animal models. The overall advantages of the nucleases and zebrafish, may 
make this the preferred animal model in the future.     
 
4.4 Complex inheritance of CHD 
As clinical management drives towards long term outcomes, it is evident that 
phenotypically similar cases can have very different outcomes (taking into 
consideration effects of clinical variables like surgical techniques). It is therefore 
very likely that genetic factors contribute to this difference, and research is now 
directed to identifying genetic variants involved in pathogenesis or outcome of 
CHD.  
 
The complex pathogenesis of CHD, genetic heterogeneity, and the multifactorial 
theory of inheritance, makes it difficult to identify genetic causes of CHD. 
Variable expression and incomplete penetrance of CHD has been 
demonstrated in familal cases of CHD, as seen in NKX2.5 and GATA4 
mutations (Schott et al., 1998; Benson et al., 1999; Garg et al., 2003). The 
strong familial disposition and presence of discordant phenotypes observed 
suggests that the model of compound heterozygous hits in different genes, or 
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multiple hits, in related developmental pathways could occur in the CHD 
population. Population studies have shown a high heritability of many forms of 
CHD implying an oligogenic model of inheritance (Oyen et al., 2009). Roessler 
et al., (2008) highlighted how multiple variants in genes in a developmental 
pathway (Nodal/TGFB), acting in a cumulative and incremental manner, may 
cause human CHD. A multiple gene analysis method in large CHD patient 
cohorts has therefore been shown to be more useful in identifying variants 
whose combined effect results in a phenotype (Granados-Riveron et al., 2012).  
It is also possible polymorphisms in epigenetic factors (e.g. chromatin 
remodelers) may affect the penetrance and resulting phenotypes of disease-
causing mutations in genes involved in cardiac development. Variants in all 
these complex networks could act in a syngergistic or antagonistic manner to 
provide a buffering effect on the phenotype (Schlesinger et al., 2011). 
Identifying new genes associated with CHD should therefore involve the 
analysis of all interacting factors, upstream regulators, and downstream 
effectors of the currently known genes linked to CHD.  
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4.5 Future Direction 
Limitations in funding and time prevented any future developments of this 
project, but as highlighted in this thesis, there are a number of possible future 
directions. Familial cases of CHD (like many other congenital defects) are a 
valuable source to undertake genetic research and identify the genetic basis of 
CHD. Identification and recruitment of more familial cases of CHD will aid the 
discovery of the molecular basis for CHD. Conventional autozygosity mapping 
in further consanguineous families may help to identify any new candidate 
regions/genes. Whole exome sequencing in familial CHD (sometimes in 
conjunction with autozygosity mapping in selected families) will aid in identifying 
new candidate genes. Collaboration with large CHD research networks will 
allow molecular analysis in sporadic cases of CHD for mutations in candidate 
genes or variants that increase the susceptibility to CHD (multifactorial model). 
Sequencing parent-child trios in cases of severe isolated (non-familial) CHD, 
may aid in identifying novel cardiac genes by filtering the data for de novo 
variants. With improvements in cost and time, whole genome sequencing will 
become the next tool for investigating genetic diseases (including CHD) to allow 
the detection of both coding and non-coding sequence variants. Methods of 
identifying and studying epigenetic factors and miRNAs will further elucidate 
their role not only in the pathogenesis but management of CHD. Finally 
functional studies in animal models will characterise the pathogenicity of 
mutations in genes/regulatory regions via their molecular, physiological, and 
anatomical effects.   
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In this project I identified and recruited a cohort of familial non-syndromic CHD, 
which are rare but a very good resource for identifying candidate genes 
involved in CHD. Genome wide scans and microsatellite analysis identified one 
region of homozygosity on chromosome 19 in one family (family CHD1). GDF1 
a candidate gene in this region was sequenced for mutations, as well as other 
genes in the same developmental pathway (NODAL, CFC1, TDGF1, and 
FOXH1), in family CHD1 and in affected members of other CHD families with a 
similar phenotype (outflow tract anomalies), but no pathogenic mutations were 
identified. Whole exome sequencing in family CHD1 identified variants in 
numerous genes, some of which were good candidate genes for cardiac 
development (DVL2 and WNT11), but the variants were not confirmed by 
conventional sequencing and therefore further studies were not performed 
(false positives). Despite no mutations being identified in any of these selected 
genes in the families studied with WES, I feel it would be important to consider 
these developmental pathways (WNT and NODAL) and these genes in any 
future studies of familial and sporadic cases of CHD. Our results imply that 
there are further genes to be identified that may explain these familial cases of 
CHD. 
 
The benefit of combining autozygosity mapping and whole exome sequencing is 
highlighted with the identification of a novel candidate gene, not previously 
thought to be involved in cardiac development (GMFG) in family CHD1. WES 
identified a homozygous nonsense mutation in this gene, which is located in the 
same homozygous region on chromosome 19. Segregational analysis within the 
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family and negative sequence analysis in >200 ethnically matched control 
chromosomes implies this is a potential candidate gene. Further functional 
studies in animal models (mouse and zebrafish) are being undertaken with our 
collaborators, and will be required to determine the phenotypic effects of the 
identified mutation, and the role of this gene in cardiac development. Mutational 
analysis of this gene in large cohorts of CHD sporadic/familial cases is also 
needed, but the absence of variants in this gene in the other CHD families 
studied could implicate this gene as a rare cause of CHD (<1%). 
 
I have shown the power of emerging genetic technologies, like whole exome 
sequencing, in the search for new candidate genes for diseases with a genetic 
basis. Although a powerful tool for variant detection with both cost and time 
saving benefits, there are many hurdles to overcome before conclusive results 
can be obtained. Advances in bioinformatics tools are required to aid in the 
interpretation of the vast amount of data generated. It is only once we have 
mastered the ability to distinguish significant from insignificant variants, can we 
utilise this technology in everyday practice to tailor medical management of 
patients dependent on their genotype.  
  
The issues researchers in CHD will face in the coming years are highlighted in 
the discussion, and in order to be successful in identifying new genetic 
determinants of CHD, one will require: (a) accurate phenotyping of patients (and 
their family members), (b) improved training of researchers in applying 
innovative genetic techniques, (c) advances in bioinformatics tools to interpret 
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data from exome/genome sequencing, and (d) large collaborative networks to 
interpret rare alleles (through genotyping of cases and controls). 
 
Advances in diagnosis and management of CHD has improved the survival of 
many patients but has not reduced the incidence of this birth defect. More 
information is needed about the genetic and molecular pathways involved in 
heart development and specific advances that are changing our understanding 
of CHD aetiology include: (a) detection of chromosomal microdeletions and 
translocations by higher resolution chromosomal analysis and FISH, (b) 
delineation of the genetic defects in familial CHD through linkage analysis, and 
(c) advances in animal genetics allowing studies of animal models of CHD. Both 
genetic heterogeneity and phenotypic heterogeneity imply the existence of 
modifying factors in CHD, which are being described by the emerging evidence 
of multiple-hit models of variants in related developmental pathways, and 
epigenetic factors in heart development. An improved understanding of the 
genetic and molecular controls of normal heart development will allow for: (a) 
accurate genetic counselling, (b) identification of possible targets of gene 
therapy, and (c) development of possible methods of CHD prevention in future 
generations.  
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APPENDIX B: Types of CHD and other clinical features associated with chromosomal abnormalities registered on 
DECIPHER (DatabasE of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources)  
(www.decipher.sanger.ac.uk) 
 
ACC: agenesis of corpus callosum; BW: birth weight; CNV = Copy number variation; DD: developmental delay; EAM: external auditory 
meatus; IUGR: intrauterine growth retardation; MI: mitral incompetence; SN: sensorineural; TeF: tracheo-esophageal fistula; USPF: 
upslanting palpebral fissures; TA: tricuspid atresia; TI: tricuspid incompetence  Red = Deletion Green = Duplication 
 
CHR  
ID 
KARYOTYPE 
SIZE OF  
CNV (Mb) 
TYPE OF 
CHD 
OTHER CLINICAL DETAILS 
     
1 del(1)(p13.3;p13.3) 2.76 PDA 
DD, hypotonia, seizures, lower limb mesomelia, small penis, early puberty, hand/foot 
anomalies, sacral dimple, dysmorphic 
1 del(1)(p36.12;p36.12) 2.88 
PDA, 
CoA/IAA 
DD, hypospadias, arthrogryposis, bifid thumb 
1 del(1)(p36.13;p36.13) 1.50 ASD DD, hypotonia, larngeal/tracheal anomaly, feeding problems, dysmorphic 
1 del(1)(p36.13;p36.32) 12.54 AVSD 
DD, short stature, microcephaly, scoliosis, speech delay, submucous cleft palate, feeding 
problems, dysmorphic 
1 del(1)(p36.21;p36.23) 5.63 PS 
DD, short stature, larngeal/tracheal anomaly, SN deafness, undescended testes, speech 
delay, feeding problems, recurrent infections, dysmorphic 
1 del(1)(p36.31;p36.32) 2.83 VSD 
DD, microcephaly, hypotonia, inguinal hernia, undescended testes, sacral dimple, 
macrocornea, dysmorphic 
1 del(1)(q24.3;q31.2) 20.95 ASD 
DD, short stature, obesity, deafness, vertebral fusion, undescended testes, constipation, 
finger/toe anomalies, auricular pits, ptosis, hypermetropia, eczema, dysmorphic 
1 del(1)(q41;q41) 2.33 VSD DD, cleft palate 
1 del(1)(q41;q42.12) 5.25 VSD diaphragmatic hernia, cleft palate, talipes, dysmorphic 
1 del(1)(q42.3;q44) 12.81 
PDA, 
CoA/IAA 
biliary atresia, absent gallbladder, hypogonadism, cleft palate, hemivertebrae, ACC, 
encephalocele, hypopituitarism, overlapping fingers, rocker bottom feet, dysmorphic 
1 del(1)(q42.3;q44) 12.72 AVSD DD, ACC 
1 dup(1)(p12;p13.2) 3.98 PS DD, ear anomalies, dysmorphic 
1 dup(1)(p31.1;p31.1) 0.15 PS DD, microcephaly, squint, hypotonia 
1 dup(1)(q21.1;q21.1) 2.00 ASD DD, short stature, sleep problems, inguinal hernia, dysmorphic 
     
2 del(2)(p15;p15) 0.00 AS DD, tall stature, pectus excavatum, scoliosis, inguinal hernia, small testes, flat feet, 
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dysmorphic 
2 del(2)(p16.3;p16.3) 0.12 
Ebstein's, TI, 
ASD 
obesity, DD, macrocephaly, hydrocephalus, ACC, delayed myelination, deafness, small 
testes/scrotum/penis, joint laxity, perthes hip, dysmorphic 
2 del(2)(q22.2;q22.3) 4.30 AS DD, ACC, seizures, squint 
2 del(2)(q22.2;q23.3) 5.39 PS DD, microcephaly, behaviour problems, small hands/feet, dysmorphic 
2 del(2)(q22.3;q23.1) 0.34 ASD, VSD DD, joint laxity, fetal pads, dysmorphic 
2 dup(2)(p14;p14) 4.16 VSD DD, short stature, microcephaly, SN deafness 
2 dup(2)(p15;p16.1) 0.92 ASD DD, speech delay, short stature, toe syndactyly, dysmorphic 
2 dup(2)(p24.1;p25.3) 21.20 AS DD, macrocephaly, short stature, scoliosis 
2 dup(2)(q12.2;q13) 3.86 AVSD 
DD, deafness, squint, recurrent infections, feeding problems, oligodontia, small feet, 
dysmorphic 
2 dup(2)(q33.1;q33.3) 6.66 CoA/IAA DD, dysmorphic 
     
3 del(3)(p12.3;p12.3) 1.15 VSD, PS thumb anomaly 
3 del(3)(p22.2;p22.2) 1.62 TGA 
short stature, craniosynostosis, small penis, nipple anomalies, triphalangeal thumbs, rocker-
bottom feet, ear anomalies, dysmorphic 
3 del(3)(p25.3;p26.1) 3.29 AVSD 
DD, microcephaly, seizures, deafness, horseshoe kidneys, sacral dimple, toe post-axial 
polydactyly, dysmorphic 
3 del(3)(p25.2;p25.3) 3.16 CHD DD, short stature 
3 dup(3)(q26.13;q26.3) 10.11 AS, CoA/IAA DD, symphalangism, scoliosis, choanal atresia, deafness, coarse hair, dysmorphic, microtia 
3 dup(3)(q29;q29) 1.77 ASD, AVSD coloboma, lipodystrophy, dysmorphic 
     
4 del(4)(p16.2;p16.3) 3.09 PS DD, short stature, microcephaly, febrile convulsions, small kidneys, hypospadias, dysmorphic 
4 del(4)(q21.21;q21.23) 3.12 ASD 
DD, high BW, hypotonia, speech delay, cleft uvula, cleft palate, urine reflux, small hands/feet, 
dysmorphic 
4 del(4)(q21.23;q23) 15.29 ASD hypotonia, autism, small/undescended testes, ptosis, arthrogryposis 
4 del(4)(q28.3;q31.23) 10.16 VSD, PS thumb anomaly 
4 del(4)(q35.1;q35.2) 6.73 VSD ACC, hypospadias, small penis, cleft lip/palate 
4 dup(4)(p16.3;p16.3) 0.19 ASD 
DD, short stature, microcephaly, seizures, choanal atresia/stenosis, anaemia, prominent 
clitoris, macroglossia, rocker-bottom feet, dysmorphic 
4 dup(4)(q12;q12) 0.17 AVSD DD, feeding problems 
4 dup(4)(q32.3;q32.3) 0.38 PS short stature, auricular pits, ptosis, dysmorphic 
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5 del(5)(p13.2;p13.2) 0.18 VSD undescended testes, feeding problems, ear helix anomaly 
5 del(5)(q23.1;q31.1) 12.60 ASD DD, cleft palate, talipes, ear anomalies, glossoptosis, 
5 del(5)(q31.1;q31.2) 1.72 PDA DD, hypotonia, tracheal/laryngeal anomaly, coarse features 
5 del(5)(q35.1;q35.1) 0.16 TOF dysmorphic 
5 dup(5)(p12;p13.2) 6.62 PDA DD, pectus excavatum, auricular tags, dysmorphic 
5 dup(5)(p15.31;p15.33) 6.55 PDA, MI 
DD, short stature, seizures, cerebellar ataxia, hirschsprung, adrenal hyperplasia, uterine 
fibroid, hypoplastic breasts, scoliosis, premature ageing, hirsutism, small hands 
5 dup(5)(q11.2;q11.2) 0.22 PDA 
DD, microcephaly, seizures, speech delay, patchy pigmentation, small teeth, dysmorphic, ? 
Cardiomyopathy 
5 dup(5)(q15;q15) 4.31 VSD DD, craniosynostosis, joint laxity 
     
6 del(6)(p21.1;p21.1) 2.41 MI DD, hydrocephalus, hypotonia, speech delay, joint laxity, dysmorphic 
6 del(6)(q24.3;q25.1) 2.45 ASD DD, short stature, ear/helix anomalies, dysmorphic 
6 del(6)(q25.2;q25.3) 1.60 
VSD, AVSD, 
PDA 
deafness, craniosynostosis, broad thumbs, clinodactyly, brachydactyly, prominent forehead, 
malocclusion teeth 
6 del(6)(q25.3;q25.3) 2.62 ASD 
DD, asymmetrical skull, lung cysts, wide spaced nipples, small ears, abnormal nails, 
dysmorphic 
6 dup(6)(q22.31;q22.31) 0.78 TGA microphthalmia, hypospadias 
     
7 del(7)(p12.1;p15.1) 21.92 VSD 
diabetes, diastasis recti, hydrocele testis, flexible joints, broad thumbs, large tongue, 
dysmorphic 
7 del(7)(p12.3;p14.1) 8.28 VSD DD, cortical atrophy, squint, hypermetropia, toe syndactyly, broad thumbs, bifid hallux 
7 del(7)(p13;p14.2) 8.04 ASD, AS 
DD, macrocephaly, umbilical hernia, hirsutism, febrile convulsions, feeding problems, 
recurrent infections, ear anomalies, finger skin syndactyly, dysmorphic 
7 del(7)(p14.1;p14.3) 5.36 ASD low BW, short stature, microcephaly, hypotonia, cleft palate, clinodactyly 
7 del(7)(q11.21;q22.1) 35.55 VSD 
DD, microcephaly, hydrocephalus, inguinal hernia, cleft palate, hand/foot ectrodactyly, small 
ears, dysmorphic 
7 del(7)(q22.1;q22.2) 3.40 ASD DD, hypotonia 
7 del(7)(q36.3;q36.3) 0.08 TOF DD 
7 dup(7)(p21.3;p21.3) 0.41 
PI, single 
ventricle 
overriding toes, toe syndactyly, borad nasal tip 
     
8 del(8)(p23.1;p23.1) 1.01 CHD no 
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8 del(8)(p23.1;p23.1) 3.77 
AVSD, PS, 
TAPVD 
DD, hyperactive, urine reflux 
8 del(8)(p23.1;p23.1) 3.65 ASD diaphragmatic hernia, undescended testes 
8 del(8)(p23.1;p23.1) 3.78 CHD no 
8 del(8)(p23.1;p23.1) 3.31 
AVSD, PS, 
MI 
DD, diaphragmatic hernia, low set ears 
8 del(8)(p23.1;p23.1) 3.77 
ASD, VSD, 
PS, MI 
DD, speech delay 
8 del(8)(p23.1;p23.1) 5.31 ASD DD, microcephaly, undescended testes, synophyrys, large ears, dysmorphic 
8 del(8)(q21.3;q22.1) 3.60 PS DD, USPF, prominent nasal bridge 
8 del(8)(q22.2;q23.1) 4.92 PDA 
DD, microcephaly, hyperactive, undescended testes, hypospadias, hiatus hernia, pyloric 
stenosis 
8 dup(8)(p22;p22) 0.56 CoA/IAA no 
     
9 del(9)(p21.1;p21.1) 0.06 AI 
DD, short stature, dolicocephaly, patchy skin pigmentation, recurrent infections, speech delay, 
cleft palate, dysmorphic 
9 del(9)(p22.3;p23) 6.78 TI DD, deafness, cystic hygroma, dysmorphic 
9 del(9)(p23;p24.3) 11.34 
ASD, VSD, 
PDA 
female genitalia anomaly, submucous cleft palate, thumb anomaly, dysmorphic 
9 del(9)(p24.2;p24.3) 2.46 AVSD DD, low BW, deafness, micrognathia, single palmar crease, feeding problems 
9 del(9)(q31.3;q32) 2.05 VSD DD, cortical atrophy, joint laxity, hypermetropia 
9 del(9)(q34.3;q34.3) 3.01 
VSD, 
CoA/IAA 
DD, hypotonia, pyramidal signs, asymmetrical limbs, dysmorphic 
9 del(9)(q34.3;q34.3) 2.20 ASD, VSD 
DD, hypotonia, microcephaly, multiple renal cysts, small penis, undescended testes, 
hypospadias, recurrent infections 
9 dup(9)(q31.1;q33.1) 17.24 VSD, TA DD, speech delay, undescended testes, cyclic vomiting, dysmorphic 
9 dup(9)(q31.3;q32) 3.05 VSD, TA DD, speech delay, undescended testes, cyclic vomiting, dysmorphic 
     
10 del(10)(p11.23;p11.23) 0.99 PDA DD, autism, pyramidal signs, short metacarpals, small ears, squint, scoliosis 
10 del(10)(p12.1;p12.1) 0.50 PDA DD, short stature, hypotonia, speech delay, squint 
10 del(10)(p15.3;p15.3) 0.15 CHD microcephaly, IUGR, short stature, cleft uvula, dysmorphic, speech delay 
10 del(10)(q21.1;q21.1) 0.17 VSD, PDA DD, microcephaly, short stature, hyperactive, oligodontia, toe syndactyly, blepharophimosis 
10 del(10)(q21.1;q21.2) 4.95 PS DD, autism, dysmorphic 
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10 del(10)(q24.31;q24.32) 0.55 PS 
DD, short stature, obesity, deafness, cleft lip/palate, microphthalmia, urine reflux, soft skin, 
short phalanges, 
10 del(10)(q25.2;q26.11) 6.70 PDA DD, autism, ptosis, seizures, hypoplastic toes, dysmorphic 
10 del(10)(q25.3;q25.3) 0.33 VSD DD, radio-ulnar synostosis, dysmorphic 
10 dup(10)(q23.33;q25.1) 17.19 VSD 
DD, short stature, macrocephaly, behaviour problems, speech delay, pectus excavatum, 
constipation 
     
11 del(11)(p11;q12.1) 3.46 VSD 
DD, short stature, microcephaly, hyperactive, speech delay, undescended testes, inguinal 
hernia, finger skin syndactyly, supernumerary nipples, dysmorphic 
11 del(11)(q22.3;q23.1) 5.47 VSD, PS DD, hypotonia, ACC, hydrocephalus, cleft uvula, auricular pits, abnormal labia 
     
12 del(12)(p13.2;p13.2) 1.28 AI DD, high palate, expressionless face 
12 del(12)(q13.3;q14.2) 6.03 PS DD, speech delay, pectus excavatum 
12 del(12)(q13.3;q14.3) 10.12 ASD DD, short stature, autism, feeding problems, sacral dimple, speech delay, dysmorphic 
12 del(12)(q21.31;q21.33) 6.90 VSD, PS thumb anomaly 
12 dup(12)(q14.1;q14.1) 0.33 PDA 
DD, pleural effusion/chylothorax, hydronephrosis, ureteral anomaly, hypospadias, hydrocele 
testis, speech delay, auricular tags+pits, squint, flat feet, dysmorphic 
12 dup(12)(q24.23;q24.31) 3.48 VSD DD, craniosynostosis, joint laxity 
     
13 del(13)(q33.2;q34) 9.63 TOF DD, microcephaly, speech delay, myopia 
13 del(13)(q14.11;q14.11) 0.16 TOF no 
13 dup(13)(q13.2;q13.2) 0.60 CoA/IAA excessive skin folds, dysmorphic 
     
14 del(14)(q11.2;q11.2) 1.62 CHD DD, hypotonia, dysmorphic 
14 del(14)(q21.3;q21.3) 0.16 VSD undescended testes, feeding problems, ear helix anomaly 
14 del(14)(q22.1;q23.1) 5.65 TGA 
anophthalmia, renal dysplasia, finger post-axial polydactyly, hypotonia, ear anomaly, absent 
EAM, sacral dimple, 
14 del(14)(q32.31;q32.33) 4.21 ASD DD, hypotonia, sleep apnoea, feeding problems 
14 del(14)(q32.33;q32.33) 1.07 ASD ACC, cleft palate, dysmorphic 
14 dup(14)(q12;q12) 1.21 PS DD, pyramidal signs, ACC, speech delay, dysmorphic 
14 dup(14)(q32.12;q32.33) 10.65 PDA 
laryngeal anomalies, DD, hypotonia, microcephaly, sleep disorder, recurrent infections, 
feeding problems, dysmorphic 
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15 del(15)(q21.1;q22.2) 10.56 CoA/IAA DD, ACC 
15 dup(15)(q13.3;q13.3) 0.49 ASD DD, microcephaly, squint 
15 dup(15)(q26.1;q26.3) 8.56 AVSD DD, ACC 
     
16 del(16)(p13.3;p13.3) 0.04 ASD DD, oligodactyly, cleft uvula, flexion deformities, dysmorphic 
16 del(16)(q22.3;q22.3) 1.19 PDA DD, short stature, dysmorphic 
16 del(16)(q22.3;q23.1) 0.17 PS DD, hypotonia, tall stature, small ears, dysmorphic 
16 del(16)(q23.3;q23.3) 0.13 ASD, AS 
cystic hygroma, oedema, arthrogryposis, microphthalmia, ear anomalies, talipes, finger skin 
syndactyly, dysmorphic 
16 del(16)(q24.1;q24.1) 1.49 PDA abnormal placement anus, oesophageal atresia/stenosis 
16 del(16)(q24.2;q24.3) 1.09 VSD cardiomyopathy, DD, DW malformation, dysmorphic 
16 del(16)(q24.3;q24.3) 0.18 AVSD, MI low BW, short stature, microcephaly, clinodactyly 
16 dup(16)(p11.1;q22.3) 37.19 VSD 
DD, hypotonia, deafness, auricular pits, finger post-axial polydactyly, inguinal hernia, 
scoliosis, bound tongue, squint, macula pigmentary anomaly, small feet 
16 dup(16)(p12.3;p13.11) 1.90 ASD 
renal agenesis, ureteral anomaly, primary amenorrhoea, facial nerve palsy, choanal 
atresia/stenosis, coloboma, ear anomaly, vestibular anomaly, squint 
16 dup(16)(p12.3;p13.11) 2.73 ASD 
larngeal/tracheal anomaly, narrow chest, absent ribs, bifid thumb, hypoplastic/absent tibia, 
hemivertebrae, abnormal sacrum, talipes, scoliosis, auricular pits 
16 dup(16)(q24.2;q24.3) 2.00 ASD DD 
     
17 del(17)(p13.3;p13.3) 2.09 PDA, PS DD, short stature, coloboma, cleft palate, arachnodactyly, feeding problems, dysmorphic 
17 del(17)(p13.3;p13.3) 2.12 TOF DD, short stature, sacrosciatic notch, undescended testes, dysmorphic 
17 del(17)(q21.31;q21.31) 0.46 PS 
DD, hypotonia, ACC, wide spaced nipples, dislocated elbows, brittle nails, overriding toes, 
dysmorphic 
17 del(17)(q25.3;q25.3) 1.11 ASD, VSD DD, speech delay, scoliosis, cleft tongue, oligodontia, brachydactyly, dysmorphic 
17 dup(17)(p13.1;p13.3) 6.95 VSD DD, short stature, ptosis, feeding problems, immunoglobulin abnormality, dysmorphic 
17 dup(17)(q12;q12) 1.80 ASD 
DD, peter's anomaly, microphthalmia, glaucoma, cleft palate, female pseudohermaphroditism, 
multiple renal cysts 
17 dup(17)(q12;q12) 1.84 AVSD 
short stature, microcephaly, nasal speech, hypospadias, pectus excavatum, scoliosis, broad 
neck, bound tongue, ear anomaly, unusual hair pattern, dysmorphic 
17 dup(17)(q24.3;q25.3) 11.43 TOF DD 
     
18 dup(18)(p11.21;p11.32) 14.00 ASD, low BW, toe syndactyly, sacral dimple, dysmorphic 
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CoA/IAA 
18 dup(18)(p11.32;p11.32) 1.11 TOF DD, short stature, sacrosciatic notch, undescended testes, dysmorphic 
     
19 del(19)(p13.11;p13.11) 0.96 TOF 
DD, hand/foot ectrodactyly, skin depigmentation, hand pre-axial polydactyly, bifid nails, 
speech delay, small penis, squint, dysmorphic 
19 del(19)(p13.2;p13.2) 3.42 ASD 
DD, sleep disorder, behavioural problems, hypospadias, nasolacrimal duct anomaly, bound 
tongue, sacral dimple, dysmorphic 
19 del(19)(p13.3;p13.3) 2.79 VSD 
DD, microcephaly, hypotonia, inguinal hernia, undescended testes, sacral dimple, 
macrocornea, dysmorphic 
19 del(19)(p13.3;p13.3) 0.58 ASD DD 
19 dup(19)(p13.11;p13.12) 1.77 PDA, ASD 
DD, microcephaly, short stature, speech delay, finger skin syndactyly, sacral dimple, 
dysmorphic 
19 dup(19)(p13.3;p13.3) 0.01 ASD short stature, thin, speech delay, hypothyroidism, recurrent infections, microtia 
     
20 dup(20)(p11.23;p13) 20.24 
ASD, VSD, 
PDA 
female genitalia anomaly, submucous cleft palate, thumb anomaly, dysmorphic 
20 dup(20)(q13.32;q13.33) 4.81 VSD, CoA DD, hypotonia, pyramidal signs, asymmetrical limbs, dysmorphic 
20 dup(20)(q13.33;q13.33) 0.00 VSD 
kidney anomalies, DD, short stature, asymmetrical skull, deafness, osteopetrosis/sclerosis, 
abnormal placement anus, thumb/toe anomaly, dysmorphic 
     
21 dup(21)(q21.1;q21.1) 1.69 HLH broad neck 
     
22 del(22)(q11.21;q11.21) 2.52 TOF meningocele 
22 del(22)(q11.21;q11.21) 2.75 CoA/IAA DD, psychotic behaviour, obesity, dysmorphic 
22 del(22)(q11.21;q11.21) 2.72 VSD 
DD, short stature, speech delay, facial cleft, coloboma, cleft palate, 4 limb post-axial 
polydactyly, dysmorphic 
22 del(22)(q11.21;q11.22) 1.39 ASD, VSD short stature, microcephaly, anal atresia/stenosis 
22 del(22)(q11.21;q11.22) 0.15 CHD 
DD, deafness, heterochromia, CAL, patchy depigmentation skin, hypertension, 
hypothyroidism, pyramidal signs 
22 del(22)(q11.21;q11.23) 1.94 VSD DD, low BW, obesity, duodenal anomalies, speech delay, USPF 
22 dup(22)(q11.1;q11.22) 5.60 
duplicated/Rt 
AA 
horseshoe kidneys, TeF, laryngeal/tracheal anomaly, deafness, coloboma 
22 dup(22)(q11.21;q11.21) 0.00 TA DD, hydronephrosis, short neck, cleft lip/palate, auricular pits, dysmorphic 
22 dup(22)(q12.3;q13.33) 18.22 VSD ACC, hypospadias, small penis, cleft lip/palate 
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X del(X)(p11.23;p11.23) 0.20 AVSD dysmorphic 
X del(X)(p22.13;p22.2) 2.88 TOF DD, hypotonia, seizures, cataracts 
X del(X)(p22.2;p22.31) 1.18 ASD DD, retinal anomalies, skin anomalies, urethral valves, small penis, nystagmus, dysmorphic 
X dup(X)(p21.3;p21.3) 0.22 VSD abdominal situs inversus, DD, hypotonia, microcephaly, pyramidal signs, seizures, 
X dup(X)(p22.31;p22.31) 0.58 TI DD, short stature, autism 
X dup(X)(p22.31;p22.31) 1.52 ASD DD, microcephaly 
X dup(X)(p22.33;p22.33) 0.57 AS DD, cleft palate, dysmorphic 
X dup(X)(q28;q28) 2.08 ASD DD, microcephaly, hypothyroidism, ptosis 
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APPENDIX C1:  
Flyer designed to send to medical professionals and  
patient support groups to recruit families into the project 
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APPENDIX C2:  
Adverts placed on patient support group websites 
to recruit families into the project 
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APPENDIX C3:  
Patient information sheets and consent forms used  
to recruit families into the project 
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APPENDIX C4:  
Proforma used for assessment of families recruited into the project 
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APPENDIX D: Data collected for each CHD family using the recruitment proforma  
Dx= Diagnosis, DD= developmental delay, LD= learning difficulties, M= male, F= female, D= deceased, AN= antenatal,  
Y= yes, N= no, NA= not available/applicable, ND= not done, NEG= negative,  
RT= right, CL/P= cleft lip & palate, ToF= tracheo-oesophageal fistula, OA= oesophageal atresia, UDT= undescended testis  
 
FAMILY 
ETHNIC 
ORIGIN 
PEDIGREE 
NUMBER 
SEX AGE 
TYPE OF 
CHD 
AGE OF 
DX 
AGE 
OF 
SURGERY 
CONGENITAL 
ANOMALIES 
DD / 
LD 
BEHAVIOUR / 
NEURO 
PROBLEMS 
GROWTH 
PROBLEMS 
DYSMORPHIC 
FEATURES 
SAMPLE 
TAKEN 
KARYOTYPE 
FISH 
22q11 
DELETION 
CHD  
1 
Pakistani 
IV:1 F 12yrs 
TOF 
spectrum 
(absent PV) 
Birth 3mths N N N N N Y ND ND 
IV:2 M 10yrs VSD 6mths 6mths 
RT CL/P, 
ToF, OA,   
PyS, RT UDT,  
RT talipes  
N N N N Y 
46,XY 
(normal 
aCGH) 
ND 
IV:3 F 4yrs 
TOF 
spectrum 
(absent PV) 
AN 
& Birth  
5yrs N N N N N Y ND ND 
IV:4 M 2yrs 
TOF 
spectrum 
(absent PV) 
AN 
& Birth 
2yrs N N N N N Y 46,XY NEG 
CHD 
 2 
Pakistani IV:1 F 19yrs 
TOF 
spectrum 
( PA) 
Birth 
6days  
& 1yr 
N N N N N Y 46,XX NEG 
CHD  
3 
Pakistani IV:2 M 3yrs AS, PPAS 2yrs ND N N N N N Y 46,XY NEG 
CHD  
4 
Pakistani 
IV:4 M 16yrs DORV, VSD Birth 1mth N N N N N Y ND ND 
IV:6 M 17yrs 
TGA, VSD, 
Ebstein's 
anomaly 
6wks 9mths N N N N N Y 46,XY NEG 
CHD  
5 
White 
British 
III:1 F 10yrs 
VSD, RV 
hypoplasia 
2wks 9yrs N N N N N Y 46,XX NEG 
III:2 F 5yrs 
ASD, RV 
hypoplasia 
AN 
& Birth 
ND N N N N N Y ND ND 
CHD  
6 
White 
British 
III:1 F 24yrs TOF, RT AA 3mths 
2yrs 
& 3yrs 
N N N N N Y 46,XX NEG 
III:2 F 22yrs TOF 
AN 
& Birth 
7mths 
& 2yrs 
N N N N N Y ND ND 
CHD  
7 
White 
British 
III:3 F D TAPVD 13days NA NA NA NA NA NA NA NA NA 
III:4 M 10yrs TAPVD 10days 11days N N N N N Y 46,XY NEG 
CHD  
8 
White 
British 
II:3 M 50yrs TOF 4yrs 4yrs N N N N N Y ND ND 
III:1 M 18yrs TOF 
AN 
& Birth 
8yrs N N N N N Y 46,XY NEG 
248 
 
FAMILY 
ETHNIC 
ORIGIN 
PEDIGREE 
NUMBER 
SEX AGE 
TYPE OF 
CHD 
AGE OF 
DX 
AGE 
OF 
SURGERY 
CONGENITAL 
ANOMALIES 
DD / 
LD 
BEHAVIOUR / 
NEURO 
PROBLEMS 
GROWTH 
PROBLEMS 
DYSMORPHIC 
FEATURES 
SAMPLE 
TAKEN 
KARYOTYPE 
FISH 
22q11 
DELETION 
CHD  
9 
White 
British 
III:2 M 17yrs 
TGA,  
VSD, PS 
Birth 2wks N N N N N Y 46,XY NEG 
III:3 M D 
TGA,  
VSD, PS 
Birth 1wk NA NA NA NA NA NA NA NA 
CHD 
10 
White 
British 
II:2 F 44yrs 
TGA, 
dextrocardia 
33yrs ND N N N N N Y ND ND 
III:1 F 13yrs 
LT atrial 
isomerism, 
RT AA, 
AVSD, 
bil. SVCs, 
PS, RV 
hypoplasia, 
dextrocardia 
6wks 
6mths, 
18mths, 
& 9yrs 
abdominal 
situs 
inversus 
N N N N Y 46,XX NEG 
CHD 
11 
White 
British 
III:2 M 5yrs VSD 4mths ND N N N N N Y 46,XY NEG 
III:3 M 2yrs 
AS, BAV,  
CoA 
5wks 5wks N N N N N Y ND ND 
CHD 
12 
White 
British 
II:4 M 31yrs TOF, ASD Birth 
16mths 
& 7yrs 
N N N N N Y 46,XY NEG 
III:1 F 5yrs TOF, ASD 8wks 15mths N N N N N ND NA NA 
III:2 M 7mths 
ASD, VSD, 
PDA 
2wks 4mths N N N N N ND NA NA 
CHD 
13 
White 
British 
III:1 M 11yrs 
TGA,  
VSD, PS 
10days 
2wks, 
1yr, 
& 6yrs 
N N N N N Y 46,XY NEG 
III:4 F 4yrs TGA 
AN 
& Birth 
2wks N N N N N Y ND ND 
CHD 
14 
White 
British 
II:3 F D CHD Birth ND NA NA NA NA NA NA NA NA 
II:4 F D CHD Birth ND NA NA NA NA NA NA NA NA 
II:5 M 56yrs BAV 42yrs ND N N N N N Y ND ND 
III:1 F 21yrs 
CoA, BAV, 
VSD 
6wks 
4mths 
& 8mths 
N N N N N Y 46,XX NEG 
III:3 M D 
HLHS,  
CoA, BAV 
AN 
& PM 
ND NA NA NA NA NA NA NA NA 
CHD 
15 
White 
British 
III:2 F D TGA Birth NA NA NA NA NA NA NA NA NA 
III:3 M 39yrs 
TGA,  
VSD, ASD 
3wks 
3wks 
& 4yrs 
N N N N N Y 46,XY NEG 
CHD 
16 
White 
British 
III:1 M 24yrs TOF Birth 
2wks 
& 2yrs 
N N N N N Y 46,XY NEG 
III:2 M 20yrs 
VSD,  
CoA, BAV 
Birth ND N N N N N Y ND ND 
III:4 M 15yrs ASD Birth ND N N N N N Y ND ND 
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FAMILY 
ETHNIC 
ORIGIN 
PEDIGREE 
NUMBER 
SEX AGE 
TYPE OF 
CHD 
AGE OF 
DX 
AGE 
OF 
SURGERY 
CONGENITAL 
ANOMALIES 
DD / 
LD 
BEHAVIOUR / 
NEURO 
PROBLEMS 
GROWTH 
PROBLEMS 
DYSMORPHIC 
FEATURES 
SAMPLE 
TAKEN 
KARYOTYPE 
FISH 
22q11 
DELETION 
CHD 
17 
White 
British 
III:2 M 30yrs CoA 4days 
5days 
& 4yrs 
N N N N N Y 46,XY NEG 
III:3 M D HLHS, CoA Birth ND NA NA NA NA NA NA NA NA 
III:5 M D HLHS PM ND NA NA NA NA NA NA NA NA 
III:6 F D 
HLHS, 
VSD, CoA 
PM ND NA NA NA NA NA Y ND ND 
III:7 F D 
TGA,  
VSD, ASD 
2wks 
1mth 
& 8yrs 
NA NA NA NA NA NA NA NA 
CHD 
18 
Irish 
IV:1 M 5mths HLHS Birth 
1wk 
& 5mths 
N N N N N Y 46,XY NEG 
IV:2 M NA Septal defect NA NA NA NA NA NA NA NA NA NA 
IV:3 F NA 
Univentricular 
heart 
NA NA NA NA NA NA NA NA NA NA 
IV:4 F NA Septal defect NA NA NA NA NA NA NA NA NA NA 
IV:5 M NA Septal defect NA NA NA NA NA NA NA NA NA NA 
CHD 
19 
White 
British 
III:1 F 4yrs HLHS 
AN 
& Birth 
4days 
& 14mths 
N N N N N ND NA NA 
III:4 M 5mths HLHS 
AN 
& Birth 
4days 
& 5mths 
N N N N N Y 46,XY NEG 
CHD 
20 
Indian 
III:1 M 5yrs 
Tricuspid 
Atresia, VSD 
AN 
& Birth 
3wks, 
18mths, 
& 5yrs 
N N N N N Y 46,XY NEG 
III:2 F 9mths 
TGA, VSD, 
RV 
hypoplasia, 
AA 
hypoplasia 
AN 
& Birth 
1day 
& 4mths 
N N N N N Y ND ND 
CHD 
21 
White 
British 
II:4 M 38yrs CoA, BAV 6wks 18mths N N N N N Y 46,XY NEG 
III:1 M 8mths HLHS 
AN 
& Birth 
3days 
& 3mths 
N N N N N Y ND ND 
CHD 
22 
White 
British 
III:1 M 4yrs HLHS 
AN 
& Birth 
1day, 
4mths, 
& 4yrs 
N N N N N Y 46,XY NEG 
III:2 M 14mths VSD 8wks ND N N N N N Y ND ND 
CHD 
23 
Irish 
III:1 M 10yrs AS, sub-AS 6wks ND N N N N N Y 46,XY NEG 
III:3 F 7yrs AS, sub-AS 6wks ND N N N N N Y ND ND 
III:5 M 4yrs sub-AS 4yrs ND N N N N N ND NA NA 
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APPENDIX E: Genes in Homozygous region on Chromosome 19 in family CHD1 (GChr37 Build)  
 
Genetic 
Location 
(start) 
Genetic 
Location 
stop 
Gene 
Symbol 
Description 
16925673 Start of HMZ region 
16830787 16928774 NWD1 NACHT and WD repeat domain containing 1 
16940218 16991164 SIN3B SIN3 homolog B, transcription regulator (yeast) 
16987750 16989811 LOC100288045 hypothetical protein LOC100288045 
16999826 17002830 F2RL3 coagulation factor II (thrombin) receptor-like 3 
17003762 17137625 CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 
17160571 17186343 HAUS8 HAUS augmin-like complex, subunit 8 
17186591 17324104 MYO9B myosin IXB 
17326155 17330638 USE1 unconventional SNARE in the ER 1 homolog (S. cerevisiae) 
17337055 17340028 OCEL1 occludin/ELL domain containing 1 
17342694 17346865 LOC100287051 hypothetical protein LOC100287051 
17342694 17356151 NR2F6 nuclear receptor subfamily 2, group F, member 6 
17360849 17375544 USHBP1 Usher syndrome 1C binding protein 1 
17378232 17390162 C19orf62 chromosome 19 open reading frame 62 
17392454 17398454 ANKLE1 ankyrin repeat and LEM domain containing 1 
17402940 17414282 ABHD8 abhydrolase domain containing 8 
17416477 17417652 MRPL34 mitochondrial ribosomal protein L34 
17420337 17434107 DDA1 DET1 and DDB1 associated 1 
17434034 17445638 ANO8 anoctamin 8 
17448356 17453540 GTPBP3 GTP binding protein 3 (mitochondrial) 
17462257 17463157 LOC100287090 hypothetical protein LOC100287090 
17462264 17488137 PLVAP plasmalemma vesicle associated protein 
17513755 17516384 BST2 bone marrow stromal cell antigen 2 
17530912 17536140 FAM125A family with sequence similarity 125, member A 
17547267 17559370 TMEM221 transmembrane protein 221 
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17566234 17571725 NXNL1 nucleoredoxin-like 1 
17581300 17616977 SLC27A1 solute carrier family 27 (fatty acid transporter), member 1 
17622432 17632097 PGLS 6-phosphogluconolactonase 
17634110 17664648 FAM129C family with sequence similarity 129, member C 
17666511 17693965 GLT25D1 glycosyltransferase 25 domain containing 1 
17700379 17700918 RPL21P130 ribosomal protein L21 pseudogene 130 
17712137 17799401 UNC13A unc-13 homolog A (C. elegans) 
17830303 17845324 MAP1S microtubule-associated protein 1S 
17862336 17899366 FCHO1 FCH domain only 1 
17905919 17924385 B3GNT3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 
17927322 17932320 INSL3 insulin-like 3 (Leydig cell) 
17935591 17958841 JAK3 Janus kinase 3 
17970731 17974124 RPL18A ribosomal protein L18a 
17973397 17973529 SNORA68 small nucleolar RNA, H/ACA box 68 
17982782 18005983 SLC5A5 solute carrier family 5 (sodium iodide symporter), member 5 
18043824 18054794 CCDC124 coiled-coil domain containing 124 
18062111 18109930 KCNN1 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 
18111944 18124911 ARRDC2 arrestin domain containing 2 
18141221 18144330 LOC440514 citrate synthase, mitochondrial-like 
18151047 18152054 LOC646666 apolipoprotein A-I binding protein pseudogene 
18159439 18159944 RPS18P13 ribosomal protein S18 pseudogene 13 
18170371 18197697 IL12RB1 interleukin 12 receptor, beta 1 
18208603 18262499 MAST3 microtubule associated serine/threonine kinase 3 
18264016 18281343 PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) 
18284579 18288927 IFI30 interferon, gamma-inducible protein 30 
18304040 18307552 MPV17L2 MPV17 mitochondrial membrane protein-like 2 
18307611 18314874 RAB3A RAB3A, member RAS oncogene family 
18318771 18359010 PDE4C phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce homolog, Drosophila) 
18360946 18363235 LOC729966 similar to hCG2001482 
18367906 18385319 KIAA1683 KIAA1683 
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18390563 18392432 JUND jun D proto-oncogene 
18395976 18396355 RPL39P38 ribosomal protein L39 pseudogene 38 
18417717 18434001 LSM4 LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
18451408 18480763 PGPEP1 pyroglutamyl-peptidase I 
18496968 18499986 GDF15 growth differentiation factor 15 
18498887 18516324 LOC100287132 hypothetical protein LOC100287132 
18501954 18508415 LRRC25 leucine rich repeat containing 25 
18530136 18545459 SSBP4 single stranded DNA binding protein 4 
18545625 18548943 ISYNA1 inositol-3-phosphate synthase 1 
18553473 18632918 ELL elongation factor RNA polymerase II 
18642568 18654383 FKBP8 FK506 binding protein 8, 38kDa 
18650365 18653005 LOC100288150 hypothetical protein LOC100288150 
18668604 18680188 C19orf50 chromosome 19 open reading frame 50 
18682614 18688270 UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 
18699495 18703147 C19orf60 chromosome 19 open reading frame 60 
18704047 18717660 CRLF1 cytokine receptor-like factor 1 
18723682 18731849 TMEM59L transmembrane protein 59-like 
18747838 18781302 KLHL26 kelch-like 26 (Drosophila) 
18794425 18893143 CRTC1 CREB regulated transcription coactivator 1 
18893583 18902114 COMP cartilage oligomeric matrix protein 
18942744 18979039 UPF1 UPF1 regulator of nonsense transcripts homolog (yeast) 
18979361 19006953 GDF1 growth differentiation factor 1 
18979361 19006953 LASS1 LAG1 homolog, ceramide synthase 1 
18979361 19006953 LASS1-GDF1 LAG1 longevity assurance homolog 1 (S. cerevisiae), growth differentiation factor 1 transcription unit 
19010323 19030199 COPE coatomer protein complex, subunit epsilon 
19030494 19039436 DDX49 DEAD (Asp-Glu-Ala-Asp) box polypeptide 49 
19040010 19052041 HOMER3 homer homolog 3 (Drosophila) 
19101697 19144380 SFRS14 splicing factor, arginine/serine-rich 14 
19144403 19153687 LOC100288184 hypothetical protein LOC100288184 
19144471 19168980 ARMC6 armadillo repeat containing 6 
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19174808 19223697 SLC25A42 solute carrier family 25, member 42 
19230430 19249267 TMEM161A transmembrane protein 161A 
19256376 19281098 MEF2B myocyte enhancer factor 2B 
19256376 19303400 LOC729991-MEF2B LOC729991-MEF2B readthrough transcript 
19287713 19303400 LOC729991 hypothetical protein LOC729991 
19303008 19312678 RFXANK regulatory factor X-associated ankyrin-containing protein 
19312224 19314238 NR2C2AP nuclear receptor 2C2-associated protein 
19322782 19363061 NCAN neurocan 
19366450 19373596 HAPLN4 hyaluronan and proteoglycan link protein 4 
19375174 19384074 TM6SF2 transmembrane 6 superfamily member 2 
19387322 19431307 SF4 splicing factor 4 
19431630 19469563 KIAA0892 KIAA0892 
19496642 19619741 GATAD2A GATA zinc finger domain containing 2A 
19545872 19545967 MIR640 microRNA 640 
19625028 19626469 TSSK6 testis-specific serine kinase 6 
19626540 19639073 NDUFA13 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 
19639720 19648393 YJEFN3 YjeF N-terminal domain containing 3 
19649074 19657468 CILP2 cartilage intermediate layer protein 2 
19672522 19729439 PBX4 pre-B-cell leukemia homeobox 4 
19698415 19699248 PHF5CP PHD finger protein 5C pseudogene 
19734464 19739039 LPAR2 lysophosphatidic acid receptor 2 
19740285 19754455 GMIP GEM interacting protein 
19756007 19774503 ATP13A1 ATPase type 13A1 
19779663 19791138 ZNF101 zinc finger protein 101 
19821281 19843921 ZNF14 zinc finger protein 14 
19855363 19856658 LOC100287160 hypothetical protein LOC100287160 
19861426 19863215 LOC100130292 similar to sorting nexin 18 
19867180 19887222 LOC284440 hypothetical LOC284440 
19903520 19932560 ZNF506 zinc finger protein 506 
19937823 19938285 LOC100288250 hypothetical LOC100288250 
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19938863 19948229 ZNF56 zinc finger protein 56 
19953229 19960434 LOC100288321 similar to zinc finger protein 253 
19976714 20004293 ZNF253 zinc finger protein 253 
20011787 20045766 ZNF93 zinc finger protein 93 
20047657 20067681 LOC100128975 similar to zinc finger protein 626 
20115227 20150277 ZNF682 zinc finger protein 682 
20142085 20145144 LOC100288389 hypothetical LOC100288389 
20162863 20174094 LOC100129544 similar to BCL2/adenovirus E1B 19kD-interacting protein 3 
20188803 20231977 ZNF90 zinc finger protein 90 
20235789 20236359 RPS16P10 ribosomal protein S16 pseudogene 10 
20244181 20249926 LOC100288458 hypothetical LOC100288458 
20278083 20308984 ZNF486 zinc finger protein 486 
20349076 20361381 LOC100288487 hypothetical LOC100288487 
20368457 20370504 LOC284441 actin-related protein 2 pseudogene 
20371834 20379200 LOC100129684 similar to BCL2/adenovirus E1B 19kD-interacting protein 3 
20403962 20414581 LOC100129265 similar to Zinc finger protein 66 
20493212 20493826 LOC100131306 similar to BCL2/adenovirus E1B 19kD-interacting protein 3 
20508134 20522519 LOC100288623 similar to zinc finger protein 208 
20574520 20607762 ZNF826 zinc finger protein 826 
20579240 20579322 MIR1270 microRNA 1270 
20720320 20748620 ZNF737 zinc finger protein 737 
20802745 20844402 ZNF626 zinc finger protein 626 
20874148 20879252 LOC100131603 similar to zinc finger protein 107 
20944462 21094143 ZNF66 zinc finger protein 66 
21106080 21133503 ZNF85 zinc finger protein 85 
21143864 21146231 KRT18P40 keratin 18 pseudogene 40 
21203497 21241653 ZNF430 zinc finger protein 430 
21264971 21307897 ZNF714 zinc finger protein 714 
21324840 21368805 ZNF431 zinc finger protein 431 
21332392 21333261 RPL7AP10 ribosomal protein L7a pseudogene 10 
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21332392 21333261 RPL7AP68 ribosomal protein L7a pseudogene 68 
21416108 21416500 RPL36AP51 ribosomal protein L36a pseudogene 51 
21473963 21512212 ZNF708 zinc finger protein 708 
21541735 21571384 ZNF738 zinc finger protein 738 
21579921 21610297 ZNF493 zinc finger protein 493 
21688437 21721079 ZNF429 zinc finger protein 429 
21832470 21841410 LOC400682 similar to hCG1776607 
21906843 21950430 ZNF100 zinc finger protein 100 
21933547 21936240 LOC641367 cyclin Y-like pseudogene 
21983282 21983998 LOC100129976 similar to BRI3-binding protein 
21987752 22018970 ZNF43 zinc finger protein 43 
22148897 22193745 ZNF208 zinc finger protein 208 
22178393 22181653 LOC100132200 similar to BCL2/adenovirus E1B 19kD-interacting protein 3 
22235266 22273905 ZNF257 zinc finger protein 257 
22320778 22322900 PCGF7P polycomb group ring finger 7 pseudogene 
22361903 22379753 ZNF676 zinc finger protein 676 
22382880 22386813 LOC100128854 similar to BCL2/adenovirus E1B 19kD-interacting protein 3 
22481766 22485151 LOC100288830 hypothetical LOC100288830 
22485979 22495580 LOC100130518 similar to Zinc finger protein ENSP00000350085 
22496619 22499978 LOC100287226 similar to hCG1773661 
22551386 22551896 RPL34P34 ribosomal protein L34 pseudogene 34 
22573899 22605148 ZNF98 zinc finger protein 98 (F7175) 
22630686 22643433 LOC100288899 hypothetical LOC100288899 
22644946 22655682 LOC441843 similar to zinc finger protein 208 
22714890 22716293 LOC100128139 hypothetical LOC100128139 
22728770 22786235 LOC440518 similar to Golgin subfamily A member 8A/B (Golgi autoantigen golgin-67) (88 kDa Golgi protein) (Gm88 autoantigen) 
22786822 22791303 LOC100129536 similar to testis expressed 264 
22817239 22850428 ZNF492 zinc finger protein 492 
22867595 22869129 ZNF849P zinc finger protein 849 pseudogene 
22882154 22882493 RPL34P33 ribosomal protein L34 pseudogene 33 
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22939007 22952784 ZNF99 zinc finger protein 99 
22954394 22957226 LOC100128849 similar to BCL2/adenovirus E1B 19kD-interacting protein 3 
23026880 23041725 LOC646864 similar to hCG36734 
23108179 23178656 LOC645118 similar to BCL2/adenovirus E1B 19kD-interacting protein 3 
23157936 23185989 ZNF728 zinc finger protein 728 
23305988 23307378 LOC100289129 hypothetical LOC100289129 
23308643 23310602 LOC126506 sorting nexin 6 pseudogene 
23311198 23329586 ZNF730 zinc finger protein 730 
23404789 23415422 ZNF724P zinc finger protein 724 pseudogene 
23444850 23445906 LOC100132815 hypothetical protein LOC100132815 
23540498 23578269 ZNF91 zinc finger protein 91 
23567332 23568095 LOC100128845 similar to Cdc42 effector protein 3 
23674864 23676177 ZNF725 zinc finger protein 725 
23778968 23779895 LOC100131479 similar to hCG1645503 
23780109 23780451 RPS27P29 ribosomal protein S27 pseudogene 29 
23835708 23870017 ZNF675 zinc finger protein 675 
23921997 23941693 ZNF681 zinc finger protein 681 
23945816 24010937 RPSAP58 ribosomal protein SA pseudogene 58 
24015084 24015272 ZNF67P zinc finger protein 67 pseudogene 
24060209 24065223 LOC100132393 hypothetical LOC100132393 
24092390 24118276 ZNF726 zinc finger protein 726 
24225742 24250053 LOC100289269 hypothetical LOC100289269 
24269976 24312654 ZNF254 zinc finger protein 254 
24344995 24346249 LOC100101266 hepatitis A virus cellular receptor 1 pseudogene 
28267033 28294967 LOC100131141 similar to hCG2041551 
28281401 28284848 LOC148189 hypothetical LOC148189 
28296332 28318506 LOC642290 similar to solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 
28383387 28393759 LOC100132081 similar to ladinin 1 
28427672 28475650 LOC100131694 similar to CG14939 
29218572 29282883 LOC100129507 similar to mannosidase, alpha, class 1A, member 2 
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29456040 29460055 LOC148145 hypothetical LOC148145 
29698167 29704136 UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 
29903721 30016659 LOC284395 hypothetical protein LOC284395 
29997873 29999948 LOC100288823 hypothetical protein LOC100288823 
30017491 30055097 VSTM2B V-set and transmembrane domain containing 2B 
30097201 30106707 POP4 processing of precursor 4, ribonuclease P/MRP subunit (S. cerevisiae) 
30156327 30166384 PLEKHF1 pleckstrin homology domain containing, family F (with FYVE domain) member 1 
30189793 30206452 C19orf12 chromosome 19 open reading frame 12 
30302901 30315219 CCNE1 cyclin E1 
30412089 30412559 LOC126170 similar to TRIM5/CypA fusion protein 
30433425 30506616 C19orf2 chromosome 19 open reading frame 2 
30447213 30447920 RPL9P32 ribosomal protein L9 pseudogene 32 
30528245 30529197 TAF2GL TAF2G-like gene 
30863328 31048965 ZNF536 zinc finger protein 536 
31640783 31641313 DKFZp566F0947 hypothetical LOC94023 
31765851 31840190 TSHZ3 teashirt zinc finger homeobox 3 
32836514 32878573 ZNF507 zinc finger protein 507 
32897031 32975236 DPY19L3 dpy-19-like 3 (C. elegans) 
33072104 33078331 PDCD5 programmed cell death 5 
33087907 33166102 ANKRD27 ankyrin repeat domain 27 (VPS9 domain) 
33126984 33127381 RPS12P31 ribosomal protein S12 pseudogene 31 
33166313 33169206 RGS9BP regulator of G protein signaling 9 binding protein 
33182653 33200106 LOC100288796 hypothetical protein LOC100288796 
33182867 33204702 NUDT19 nudix (nucleoside diphosphate linked moiety X)-type motif 19 
33210679 33281714 TDRD12 tudor domain containing 12 
33321417 33360683 SLC7A9 solute carrier family 7 (cationic amino acid transporter, y+ system), member 9 
33369904 33462869 CCDC123 coiled-coil domain containing 123 
33454414 33454771 RPL31P60 ribosomal protein L31 pseudogene 60 
33463148 33467974 C19orf40 chromosome 19 open reading frame 40 
33469498 33555794 RHPN2 rhophilin, Rho GTPase binding protein 2 
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33571786 33621318 GPATCH1 G patch domain containing 1 
33622998 33666705 WDR88 WD repeat domain 88 
33667963 33668036 TRNAT-AGU transfer RNA threonine (anticodon AGU) 
33685599 33699773 LRP3 low density lipoprotein receptor-related protein 3 
33699570 33716756 SLC7A10 solute carrier family 7, (neutral amino acid transporter, y+ system) member 10 
33790936 33793320 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 
33793763 33795963 LOC80054 hypothetical LOC80054 
33832109 33832890 RPS3AP50 ribosomal protein S3a pseudogene 50 
33851203 33852371 AKR1B1P7 aldo-keto reductase family 1, member B1 pseudogene 7 
33864413 33870793 LOC100288824 hypothetical protein LOC100288824 
33864609 33873592 CEBPG CCAAT/enhancer binding protein (C/EBP), gamma 
33877861 34012801 PEPD peptidase D 
34080073 34080634 RPL21P131 ribosomal protein L21 pseudogene 131 
34112861 34264414 CHST8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 
34287751 34306666 KCTD15 potassium channel tetramerisation domain containing 15 
34378039 34399296 LOC100288860 hypothetical protein LOC100288860 
34513470 34514355 RPS4P20 ribosomal protein S4X pseudogene 20 
34583381 34584271 RPS4P21 ribosomal protein S4X pseudogene 21 
34617877 34618328 LOC100128110 similar to coiled-coil-helix-coiled-coil-helix domain containing 2 
34663352 34720420 LSM14A LSM14A, SCD6 homolog A (S. cerevisiae) 
34745456 34846471 KIAA0355 KIAA0355 
34787071 34787689 RPL29P33 ribosomal protein L29 pseudogene 33 
34856069 34891236 GPI glucose phosphate isomerase 
34895303 34917073 PDCD2L programmed cell death 2-like 
34919268 34960798 UBA2 ubiquitin-like modifier activating enzyme 2 
34972880 34992085 WTIP Wilms tumor 1 interacting protein 
35024259 35024991 RPS26P55 ribosomal protein S26 pseudogene 55 
35032110 35038293 LOC100129800 similar to zinc finger protein 181 
35084346 35085490 SCGBL secretoglobin-like 
35125467 35128440 LOC100130632 similar to ZNF304 protein 
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35136567 35136746 LOC100130342 hypothetical LOC100130342 
35168567 35177302 ZNF302 zinc finger protein 302 
35224203 35225024 LOC100288954 hypothetical LOC100288954 
35225480 35233774 ZNF181 zinc finger protein 181 
35248979 35264134 ZNF599 zinc finger protein 599 
35353888 35358033 LOC401913 
like ABO blood gp (transferase A, a-1-3-N-acetylgalactosaminyltransferase; transferase B, a-1-3-
galactosyltransferase) 
35417807 35436076 ZNF30 zinc finger protein 30 
35447258 35454953 ZNF792 zinc finger protein 792 
35491246 35517373 GRAMD1A GRAM domain containing 1A 
35521534 35531353 SCN1B sodium channel, voltage-gated, type I, beta 
35531410 35557475 HPN hepsin 
35549963 35597208 LOC100128675 hypothetical LOC100128675 
35596873 35598150 LOC731797 similar to Fc fragment of IgG binding protein 
35606732 35615228 FXYD3 FXYD domain containing ion transport regulator 3 
35615416 35617602 LOC100288990 hypothetical protein LOC100288990 
35615417 35626178 LGI4 leucine-rich repeat LGI family, member 4 
35629732 35633954 FXYD1 FXYD domain containing ion transport regulator 1 
35634154 35645205 FXYD7 FXYD domain containing ion transport regulator 7 
35645627 35660785 FXYD5 FXYD domain containing ion transport regulator 5 
35715704 35719628 FAM187B family with sequence similarity 187, member B 
35739559 35758867 LSR lipolysis stimulated lipoprotein receptor 
35759896 35770718 USF2 upstream transcription factor 2, c-fos interacting 
35773410 35776046 HAMP hepcidin antimicrobial peptide 
35783038 35804707 MAG myelin associated glycoprotein 
35820079 35838264 CD22 CD22 molecule 
35842455 35843357 FFAR1 free fatty acid receptor 1 
35849488 35851391 FFAR3 free fatty acid receptor 3 
35862262 35863302 GPR42P G protein-coupled receptor 42 pseudogene 
35873074 35874957 EEF1AL5 eukaryotic translation elongation factor 1 alpha-like 5 pseudogene 
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35898650 35899549 LOC100128682 hypothetical protein LOC100128682 
35940617 35941609 FFAR2 free fatty acid receptor 2 
35978228 35981356 KRTDAP keratinocyte differentiation-associated protein 
35988122 36004560 DMKN dermokine 
36014271 36019253 SBSN suprabasin 
36017724 36019213 LOC100289024 hypothetical protein LOC100289024 
36024314 36036221 GAPDHS glyceraldehyde-3-phosphate dehydrogenase, spermatogenic 
36036545 36038428 TMEM147 transmembrane protein 147 
36041095 36054560 ATP4A ATPase, H+/K+ exchanging, alpha polypeptide 
36103646 36116251 HAUS5 HAUS augmin-like complex, subunit 5 
36119980 36128587 RBM42 RNA binding motif protein 42 
36132647 36135773 ETV2 ets variant 2 
36139155 36149684 COX6B1 cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous) 
36157715 36169367 UPK1A uroplakin 1A 
36159135 36164193 LOC100132622 hypothetical LOC100132622 
36203830 36207940 ZBTB32 zinc finger and BTB domain containing 32 
36208921 36229779 MLL4 myeloid/lymphoid or mixed-lineage leukemia 4 
36230151 36233351 TMEM149 transmembrane protein 149 
36233428 36236336 U2AF1L4 U2 small nuclear RNA auxiliary factor 1-like 4 
36236494 36237903 PSENEN presenilin enhancer 2 homolog (C. elegans) 
36239512 36245420 LIN37 lin-37 homolog (C. elegans) 
36245470 36247930 HSPB6 heat shock protein, alpha-crystallin-related, B6 
36246281 36247960 LOC100289054 hypothetical protein LOC100289054 
36249044 36260077 C19orf55 chromosome 19 open reading frame 55 
36266476 36279724 SNX26 sorting nexin 26 
36280496 36288739 LOC644050 similar to gene model 1082, (NCBI) 
36290892 36304201 PRODH2 proline dehydrogenase (oxidase) 2 
36290896 36297504 LOC100289119 hypothetical protein LOC100289119 
36316274 36342739 NPHS1 nephrosis 1, congenital, Finnish type (nephrin) 
36347810 36358048 KIRREL2 kin of IRRE like 2 (Drosophila) 
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36359401 36370699 APLP1 amyloid beta (A4) precursor-like protein 1 
36379143 36391552 NFKBID nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta 
36393382 36395173 HCST hematopoietic cell signal transducer 
36395303 36399186 TYROBP TYRO protein tyrosine kinase binding protein 
36428022 36436097 LRFN3 leucine rich repeat and fibronectin type III domain containing 3 
36486101 36487214 LOC644096 hypothetical protein LOC644096 
36494002 36499672 C19orf46 chromosome 19 open reading frame 46 
36500022 36505141 ALKBH6 alkB, alkylation repair homolog 6 (E. coli) 
36505563 36523775 CLIP3 CAP-GLY domain containing linker protein 3 
36525887 36545664 THAP8 THAP domain containing 8 
36540048 36540123 RNY5P10 RNA, Ro-associated Y5 pseudogene 10 
36545783 36596012 WDR62 WD repeat domain 62 
36602105 36604563 LOC728361 similar to OVO homolog-like 1 
36604611 36606206 POLR2I polymerase (RNA) II (DNA directed) polypeptide I, 14.5kDa 
36605888 36616849 TBCB tubulin folding cofactor B 
36630918 36641255 CAPNS1 calpain, small subunit 1 
36641824 36643771 COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) 
36673187 36705986 ZNF565 zinc finger protein 565 
36705504 36729676 ZNF146 zinc finger protein 146 
36827162 36870078 ZFP14 zinc finger protein 14 homolog (mouse) 
36882861 36909550 ZFP82 zinc finger protein 82 homolog (mouse) 
36912439 36913799 LOC644189 similar to peroxisomal long-chain acyl-coA thioesterase 
36936021 36980463 ZNF566 zinc finger protein 566 
36980535 36981942 LOC728752 similar to chromosome 14 open reading frame 126 
36987815 36989118 LOC401914 similar to C-terminal binding protein 2 
37001594 37019170 ZNF260 zinc finger protein 260 
37034517 37096178 ZNF529 zinc finger protein 529 
37096189 37098647 LOC100289147 hypothetical protein LOC100289147 
37096221 37119499 ZNF382 zinc finger protein 382 
37128283 37157739 ZNF461 zinc finger protein 461 
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37180302 37212226 ZNF567 zinc finger protein 567 
37239025 37253350 ZNF850P zinc finger protein 850 pseudogene 
37264026 37267978 LOC728485 hypothetical protein LOC728485 
37308330 37329284 ZNF790 zinc finger protein 790 
37341260 37370471 ZNF345 zinc finger protein 345 
37382253 37407190 ZNF829 zinc finger protein 829 
37392621 37393060 RPL31P61 ribosomal protein L31 pseudogene 61 
37407234 37442450 ZNF568 zinc finger protein 568 
37464463 37488621 LOC100289218 similar to zinc finger protein 30 homolog 
37569382 37620662 ZNF420 zinc finger protein 420 
37640990 37663615 ZNF585A zinc finger protein 585A 
37675722 37701451 ZNF585B zinc finger protein 585B 
37717366 37734574 ZNF383 zinc finger protein 383 
37825580 37855357 HKR1 GLI-Kruppel family member HKR1 
37862059 37883966 ZNF527 zinc finger protein 527 
37892306 37894748 LOC100289217 hypothetical protein LOC100289217 
37902059 37958339 ZNF569 zinc finger protein 569 
37959982 37976242 ZNF570 zinc finger protein 570 
37997841 38034239 ZNF793 zinc finger protein 793 
38055155 38085673 ZNF571 zinc finger protein 571 
38089275 38104996 ZNF540 zinc finger protein 540 
38123389 38146313 ZFP30 zinc finger protein 30 homolog (mouse) 
38158650 38183216 ZNF781 zinc finger protein 781 
38184187 38184465 LOC100129085 similar to HSPC297 
38187276 38210691 ZNF607 zinc finger protein 607 
38229188 38270200 ZNF573 zinc finger protein 573 
38282412 38284715 LOC728533 similar to CG10103 
38293667 38294692 LOC100128948 similar to zinc finger protein 345 
38307890 38310933 LOC644554 hypothetical LOC644554 
38313745 38346630 LOC728853 similar to RIKEN cDNA 4930432E11 
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38375472 38397317 WDR87 WD repeat domain 87 
38397868 38699009 SIPA1L3 signal-induced proliferation-associated 1 like 3 
38701649 38720317 DPF1 D4, zinc and double PHD fingers family 1 
38741877 38747172 PPP1R14A protein phosphatase 1, regulatory (inhibitor) subunit 14A 
38755202 38783108 SPINT2 serine peptidase inhibitor, Kunitz type, 2 
38794200 38806606 YIF1B Yip1 interacting factor homolog B (S. cerevisiae) 
38794804 38795646 C19orf33 chromosome 19 open reading frame 33 
38810484 38819654 KCNK6 potassium channel, subfamily K, member 6 
38826443 38861589 C19orf15 chromosome 19 open reading frame 15 
38865190 38874464 PSMD8 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 
38874992 38878668 GGN gametogenetin 
38877054 38878674 LOC100289362 hypothetical protein LOC100289362 
38880939 38886871 SPRED3 sprouty-related, EVH1 domain containing 3 
38893775 38899728 FAM98C family with sequence similarity 98, member C 
38899698 38916945 RASGRP4 RAS guanyl releasing protein 4 
38924340 39078204 RYR1 ryanodine receptor 1 (skeletal) 
39078281 39108643 MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 
39109722 39127595 EIF3K eukaryotic translation initiation factor 3, subunit K 
39138327 39221170 ACTN4 actinin, alpha 4 
39220832 39235114 CAPN12 calpain 12 
39261608 39264157 LGALS7 lectin, galactoside-binding, soluble, 7 
39279850 39282394 LGALS7B lectin, galactoside-binding, soluble, 7B 
39292311 39303740 LGALS4 lectin, galactoside-binding, soluble, 4 
39306062 39322497 ECH1 enoyl Coenzyme A hydratase 1, peroxisomal 
39306914 39322636 LOC100289396 hypothetical protein LOC100289396 
39327028 39342979 HNRNPL heterogeneous nuclear ribonucleoprotein L 
39358470 39368894 RINL Ras and Rab interactor-like 
39369200 39390361 SIRT2 sirtuin (silent mating type information regulation 2 homolog) 2 (S. cerevisiae) 
39390615 39399534 NFKBIB nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta 
39399655 39402798 LOC643669 similar to mCG2980 
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39405906 39421536 SARS2 seryl-tRNA synthetase 2, mitochondrial 
39421348 39423660 MRPS12 mitochondrial ribosomal protein S12 
39432042 39466380 FBXO17 F-box protein 17 
39514661 39523198 FBXO27 F-box protein 27 
39574945 39601478 PAPL iron/zinc purple acid phosphatase-like protein 
39616420 39670046 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 
39687604 39692522 NCCRP1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 
39693562 39694906 SYCN syncollin 
39734272 39735611 IL28B interleukin 28B (interferon, lambda 3) 
39745556 39745909 LOC441849 similar to selenoprotein X, 1 
39759157 39760732 IL28A interleukin 28A (interferon, lambda 2) 
39786965 39789312 IL29 interleukin 29 (interferon, lambda 1) 
39797457 39805976 LRFN1 leucine rich repeat and fibronectin type III domain containing 1 
39819010 39826726 GMFG glia maturation factor, gamma 
39832484 39847707 LOC100289492 hypothetical protein LOC100289492 
39833108 39875542 SAMD4B sterile alpha motif domain containing 4B 
39876269 39881679 PAF1 Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) 
39881963 39891203 MED29 mediator complex subunit 29 
39897487 39900045 ZFP36 zinc finger protein 36, C3H type, homolog (mouse) 
39902808 39902900 TRNAI-UAU transfer RNA isoleucine (anticodon UAU) 
39903750 39919055 PLEKHG2 pleckstrin homology domain containing, family G (with RhoGef domain) member 2 
39923847 39926618 RPS16 ribosomal protein S16 
39930212 39934173 LOC723805 interleukin-like 
39936186 39967310 SUPT5H suppressor of Ty 5 homolog (S. cerevisiae) 
39971052 39981528 TIMM50 translocase of inner mitochondrial membrane 50 homolog (S. cerevisiae) 
39989557 39999121 DLL3 delta-like 3 (Drosophila) 
40005753 40011326 SELV selenoprotein V 
40006086 40009448 LOC100289327 hypothetical protein LOC100289327 
40021630 40023494 EID2B EP300 interacting inhibitor of differentiation 2B 
40025103 40025661 LOC100129080 similar to Teratocarcinoma-derived growth factor 1 
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40029446 40030838 EID2 EP300 interacting inhibitor of differentiation 2 
40030894 40045990 LOC390930 similar to lectin, galactoside-binding, soluble, 13 
40079595 40079765 RPS29P24 ribosomal protein S29 pseudogene 24 
40081621 40081791 RPS29P25 ribosomal protein S29 pseudogene 25 
40088475 40088642 RPS29P26 ribosomal protein S29 pseudogene 26 
40093169 40098114 LGALS13 lectin, galactoside-binding, soluble, 13 
40129325 40133041 LOC100129935 lectin, galactoside-binding, soluble, 14 pseudogene 
40135142 40135510 LOC100289395 similar to ribosomal protein S29 
40146581 40151287 LOC148003 similar to lectin, galactoside-binding, soluble, 14 
40170014 40176361 LOC400696 lectin, galactoside-binding, soluble, 14-like 
40188546 40188713 RPS29P27 ribosomal protein S29 pseudogene 27 
40194946 40200088 LGALS14 lectin, galactoside-binding, soluble, 14 
40221895 40228668 CLC Charcot-Leyden crystal protein 
40267234 40276775 LEUTX leucine twenty homeobox 
40315990 40324841 DYRK1B dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B 
40325093 40337054 FBL fibrillarin 
40353963 40440533 FCGBP Fc fragment of IgG binding protein 
40357458 40364320 LOC100289588 hypothetical protein LOC100289588 
40448563 40449659 LOC440525 proline rich 13 pseudogene 
40477073 40487353 PSMC4 proteasome (prosome, macropain) 26S subunit, ATPase, 4 
40502943 40523514 ZNF546 zinc finger protein 546 
40529287 40531409 LOC390933 similar to FLJ36874 protein 
40540264 40556239 ZNF780B zinc finger protein 780B 
40575059 40596845 ZNF780A zinc finger protein 780A 
40627230 40628137 LOC100127969 similar to vomeronasal 1 receptor 1 
40697651 40721482 MAP3K10 mitogen-activated protein kinase kinase kinase 10 
40697821 40721169 LOC100289661 hypothetical protein LOC100289661 
40721965 40724306 TTC9B tetratricopeptide repeat domain 9B 
40728115 40732597 CNTD2 cyclin N-terminal domain containing 2 
40736224 40791265 AKT2 v-akt murine thymoma viral oncogene homolog 2 
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40788450 40788548 MIR641 microRNA 641 
40826970 40854293 C19orf47 chromosome 19 open reading frame 47 
40854332 40884390 PLD3 phospholipase D family, member 3 
40885178 40896094 HIPK4 homeodomain interacting protein kinase 4 
40899671 40919271 PRX periaxin 
40928408 40931932 SERTAD1 SERTA domain containing 1 
40946748 40950282 SERTAD3 SERTA domain containing 3 
40953691 40971725 BLVRB biliverdin reductase B (flavin reductase (NADPH)) 
40973126 41082365 SPTBN4 spectrin, beta, non-erythrocytic 4 
41082757 41097305 SHKBP1 SH3KBP1 binding protein 1 
41099072 41135725 LTBP4 latent transforming growth factor beta binding protein 4 
41171810 41196556 NUMBL numb homolog (Drosophila)-like 
41197434 41222790 ADCK4 aarF domain containing kinase 4 
41223008 41246765 ITPKC inositol 1,4,5-trisphosphate 3-kinase C 
41246761 41255828 C19orf54 chromosome 19 open reading frame 54 
41256779 41271294 SNRPA small nuclear ribonucleoprotein polypeptide A 
41281300 41283395 MIA melanoma inhibitory activity 
41284171 41302847 RAB4B RAB4B, member RAS oncogene family 
41305048 41314337 EGLN2 egl nine homolog 2 (C. elegans) 
41314400 41317297 CYP2T2P cytochrome P450, family 2, subfamily T, polypeptide 2 pseudogene 
41324580 41332676 CYP2F1P cytochrome P450, family 2, subfamily F, polypeptide 1 pseudogene 
41349443 41356352 CYP2A6 cytochrome P450, family 2, subfamily A, polypeptide 6 
41381344 41388657 CYP2A7 cytochrome P450, family 2, subfamily A, polypeptide 7 
41397124 41406057 CYP2G1P cytochrome P450, family 2, subfamily G, polypeptide 1 pseudogene 
41414136 41533990 CYP2A7P1 cytochrome P450, family 2, subfamily A, polypeptide 7 pseudogene 1 
41430172 41456563 CYP2B7P1 cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1 
41497204 41524301 CYP2B6 cytochrome P450, family 2, subfamily B, polypeptide 6 
41556357 41568349 CYP2G2P cytochrome P450, family 2, subfamily G, polypeptide 2 pseudogene 
41594368 41602099 CYP2A13 cytochrome P450, family 2, subfamily A, polypeptide 13 
41620353 41634281 CYP2F1 cytochrome P450, family 2, subfamily F, polypeptide 1 
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41640624 41643258 CYP2T3P cytochrome P450, family 2, subfamily T, polypeptide 3 pseudogene 
41675766 41676071 RPL36_7_1657 ribosomal protein L36 pseudogene 
41699115 41713444 CYP2S1 cytochrome P450, family 2, subfamily S, polypeptide 1 
41725108 41767671 AXL AXL receptor tyrosine kinase 
41748142 41748214 TRNAK38P transfer RNA lysine 38 (anticodon UUU) pseudogene 
41768391 41813811 HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 
41816094 41830788 CCDC97 coiled-coil domain containing 97 
41836651 41859816 TGFB1 transforming growth factor, beta 1 
41860326 41870037 B9D2 B9 protein domain 2 
41869871 41889988 TMEM91 transmembrane protein 91 
41892275 41903256 EXOSC5 exosome component 5 
41903704 41930910 BCKDHA branched chain keto acid dehydrogenase E1, alpha polypeptide 
41931264 41934635 B3GNT8 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 
41937224 41945810 ATP5SL ATP5S-like 
41949063 41950670 C19orf69 chromosome 19 open reading frame 69 
42011984 42014104 LOC644330 tropomyosin 3 pseudogene 
42026588 42028305 PLEKHA3P1 pleckstrin homology domain containing, family A member 3 pseudogene 1 
42082531 42093197 CEACAM21 carcinoembryonic antigen-related cell adhesion molecule 21 
42107611 42107858 CEACAMP3 carcinoembryonic antigen-related cell adhesion molecule pseudogene 3 
42111265 42112093 LOC100286885 hypothetical LOC100286885 
42125344 42133442 CEACAM4 carcinoembryonic antigen-related cell adhesion molecule 4 
42144529 42145267 LOC100286912 hypothetical LOC100286912 
42177235 42192096 CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7 
42212530 42234437 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 
42259398 42276113 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 
42300534 42315591 CEACAM3 carcinoembryonic antigen-related cell adhesion molecule 3 
42333722 42334991 LOC645001 similar to heterogeneous nuclear ribonucleoprotein A1 
42341150 42348508 LYPD4 LY6/PLAUR domain containing 4 
42349086 42356398 DMRTC2 DMRT-like family C2 
42363988 42375484 RPS19 ribosomal protein S19 
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42381190 42385439 CD79A CD79a molecule, immunoglobulin-associated alpha 
42387267 42411604 ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1 
42412380 42417071 LOC390937 similar to hCG2040171 
42460833 42463528 RABAC1 Rab acceptor 1 (prenylated) 
42470734 42498382 ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide 
42502473 42569957 GRIK5 glutamate receptor, ionotropic, kainate 5 
42580290 42585719 ZNF574 zinc finger protein 574 
42592650 42636630 POU2F2 POU class 2 homeobox 2 
42702752 42721813 DEDD2 death effector domain containing 2 
42724492 42732353 ZNF526 zinc finger protein 526 
42734338 42746736 GSK3A glycogen synthase kinase 3 alpha 
42747003 42747458 LOC100132272 hypothetical LOC100132272 
42751717 42759309 ERF Ets2 repressor factor 
42788817 42799949 CIC capicua homolog (Drosophila) 
42801185 42806723 PAFAH1B3 platelet-activating factor acetylhydrolase, isoform Ib, subunit 3 (29kDa) 
42806284 42814973 PRR19 proline rich 19 
42817477 42829214 TMEM145 transmembrane protein 145 
42829761 42882921 MEGF8 multiple EGF-like-domains 8 
42856948 42880182 LOC100286981 hypothetical protein LOC100286981 
42891171 42894444 CNFN cornifelin 
42905666 42931578 LIPE lipase, hormone-sensitive 
42912383 42914974 LOC100289577 hypothetical protein LOC100289577 
42932695 42947136 CXCL17 chemokine (C-X-C motif) ligand 17 
42989139 42989871 LOC732229 similar to zinc finger, AN1-type domain 5 
43011458 43032639 CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 
43064619 43064907 CEACAMP2 carcinoembryonic antigen-related cell adhesion molecule pseudogene 2 
43084395 43099082 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 
43135957 43136496 CEACAMP1 carcinoembryonic antigen-related cell adhesion molecule pseudogene 1 
43158203 43167268 CEACAMP5 carcinoembryonic antigen-related cell adhesion molecule pseudogene 5 
43174130 43175013 RPS10P28 ribosomal protein S10 pseudogene 28 
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43225794 43244668 PSG3 pregnancy specific beta-1-glycoprotein 3 
43256839 43269831 PSG8 pregnancy specific beta-1-glycoprotein 8 
43289863 43290773 CEACAMP6 carcinoembryonic antigen-related cell adhesion molecule pseudogene 6 
43325963 43327433 LOC100289650 hypothetical protein LOC100289650 
43341149 43359870 PSG10 pregnancy specific beta-1-glycoprotein 10 
43371358 43383871 PSG1 pregnancy specific beta-1-glycoprotein 1 
43406240 43422043 PSG6 pregnancy specific beta-1-glycoprotein 6 
43406244 43530631 PSG11 pregnancy specific beta-1-glycoprotein 11 
43428284 43441330 PSG7 pregnancy specific beta-1-glycoprotein 7 
43453655 43454567 CEACAMP7 carcinoembryonic antigen-related cell adhesion molecule pseudogene 7 
43544526 43545426 CEACAMP8 carcinoembryonic antigen-related cell adhesion molecule pseudogene 8 
43568362 43586814 PSG2 pregnancy specific beta-1-glycoprotein 2 
43600601 43601512 CEACAMP9 carcinoembryonic antigen-related cell adhesion molecule pseudogene 9 
43671895 43690688 PSG5 pregnancy specific beta-1-glycoprotein 5 
43696854 43709790 PSG4 pregnancy specific beta-1-glycoprotein 4 
43724140 43725051 CEACAMP10 carcinoembryonic antigen-related cell adhesion molecule pseudogene 10 
43757435 43773682 PSG9 pregnancy specific beta-1-glycoprotein 9 
43787588 43788498 CEACAMP11 carcinoembryonic antigen-related cell adhesion molecule pseudogene 11 
43807354 43807650 CEACAMP4 carcinoembryonic antigen-related cell adhesion molecule pseudogene 4 
43853208 43853700 PRG1 p53-responsive gene 1 
43857825 43867480 CD177 CD177 molecule 
43875887 43883275 CD177P CD177 molecule pseudogene 
43892763 43922767 TEX101 testis expressed 101 
43964946 43969831 LYPD3 LY6/PLAUR domain containing 3 
43979255 44008985 PHLDB3 pleckstrin homology-like domain, family B, member 3 
44005790 44009073 LOC100287012 hypothetical protein LOC100287012 
44010871 44031396 ETHE1 ethylmalonic encephalopathy 1 
44037340 44040290 ZNF575 zinc finger protein 575 
44047464 44079730 XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 
44078790 44079899 LOC100287043 hypothetical protein LOC100287043 
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44081344 44086271 LOC390940 similar to R28379_1 
44088519 44100287 IRGQ immunity-related GTPase family, Q 
44100544 44104587 ZNF576 zinc finger protein 576 
44111376 44124014 ZNF428 zinc finger protein 428 
44116253 44118650 LOC100170229 hypothetical protein LOC100170229 
44126522 44143991 CADM4 cell adhesion molecule 4 
44150248 44174502 PLAUR plasminogen activator, urokinase receptor 
44220214 44224173 IRGC immunity-related GTPase family, cinema 
44235301 44259142 C19orf61 chromosome 19 open reading frame 61 
44270685 44285409 KCNN4 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 
44300079 44324808 LYPD5 LY6/PLAUR domain containing 5 
44331473 44353050 ZNF283 zinc finger protein 283 
44376515 44388116 ZNF404 zinc finger protein 404 
44416781 44429558 ZNF45 zinc finger protein 45 
44455397 44471752 ZNF221 zinc finger protein 221 
44488355 44502477 ZNF155 zinc finger protein 155 
44507077 44518072 ZNF230 zinc finger protein 230 
44529494 44537263 ZNF222 zinc finger protein 222 
44555520 44559299 LOC100286904 hypothetical protein LOC100286904 
44556164 44572142 ZNF223 zinc finger protein 223 
44576297 44591623 ZNF284 zinc finger protein 284 
44598497 44612477 ZNF224 zinc finger protein 224 
44617548 44637255 ZNF225 zinc finger protein 225 
44645710 44664462 ZNF234 zinc finger protein 234 
44669249 44681838 ZNF226 zinc finger protein 226 
44716691 44741421 ZNF227 zinc finger protein 227 
44764076 44779468 ZNF233 zinc finger protein 233 
44790501 44809178 ZNF235 zinc finger protein 235 
44794791 44795083 MRPS15P2 mitochondrial ribosomal protein S15 pseudogene 2 
44801257 44801511 LOC100131388 similar to NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa 
271 
 
44830706 44860856 ZFP112 zinc finger protein 112 homolog (mouse) 
44875990 44876685 LOC100286969 hypothetical LOC100286969 
44889808 44905777 ZNF285A zinc finger protein 285A 
44930426 44952665 ZNF229 zinc finger protein 229 
44968405 44977566 ZNF285B zinc finger protein 285B 
44979856 45004574 ZNF180 zinc finger protein 180 
45010211 45033548 CEACAM20 carcinoembryonic antigen-related cell adhesion molecule 20 
45041045 45060150 FLJ41856 hypothetical LOC388550 
45116956 45138792 LOC147710 hypothetical LOC147710 
45147098 45169429 PVR poliovirus receptor 
45174724 45187627 CEACAM19 carcinoembryonic antigen-related cell adhesion molecule 19 
45202358 45213986 CEACAM16 carcinoembryonic antigen-related cell adhesion molecule 16 
45251978 45263301 BCL3 B-cell CLL/lymphoma 3 
45281126 45303903 CBLC Cas-Br-M (murine) ecotropic retroviral transforming sequence c 
45312338 45324678 BCAM basal cell adhesion molecule (Lutheran blood group) 
45349393 45392485 PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B) 
45394477 45406946 TOMM40 translocase of outer mitochondrial membrane 40 homolog (yeast) 
45409039 45412650 APOE apolipoprotein E 
45411802 45431701 LOC100129500 hypothetical LOC100129500 
45417921 45422606 APOC1 apolipoprotein C-I 
45430017 45434450 APOC1P1 apolipoprotein C-I pseudogene 1 
45445495 45448751 APOC4 apolipoprotein C-IV 
45449243 45452818 APOC2 apolipoprotein C-II 
45458638 45496599 CLPTM1 cleft lip and palate associated transmembrane protein 1 
45504712 45541452 RELB v-rel reticuloendotheliosis viral oncogene homolog B 
45542298 45574214 SFRS16 splicing factor, arginine/serine-rich 16 
45574758 45579688 ZNF296 zinc finger protein 296 
45582518 45594782 GEMIN7 gem (nuclear organelle) associated protein 7 
45596431 45649730 LRRC68 leucine rich repeat containing 68 
45631783 45632340 EIF5AP3 eukaryotic translation initiation factor 5A pseudogene 3 
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45655161 45661984 NKPD1 NTPase, KAP family P-loop domain containing 1 
45666186 45681485 TRAPPC6A trafficking protein particle complex 6A 
45682003 45685058 BLOC1S3 biogenesis of lysosomal organelles complex-1, subunit 3 
45715879 45737469 EXOC3L2 exocyst complex component 3-like 2 
45754842 45808541 MARK4 MAP/microtubule affinity-regulating kinase 4 
45809671 45810899 LOC100287143 hypothetical protein LOC100287143 
45809671 45826134 CKM creatine kinase, muscle 
45835887 45836446 RPS16P9 ribosomal protein S16 pseudogene 9 
45841038 45842639 LOC100287076 similar to malignancy-associated protein 
45843998 45854778 KLC3 kinesin light chain 3 
45854649 45873845 ERCC2 excision repair cross-complementing rodent repair deficiency, complementation group 2 
45862515 End of HMZ region 
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APPENDIX F: Analysis of whole exome sequencing data from BGI in family CHD1: Homozygous variants 
 
POLYPHEN: Prediction of mutation pathogenicity, scores range from 0.000 (most probably benign) to 0.999 (most probably damaging) 
SIFT: Amino acid substitution is predicted to be damaging if score is <= 0.05, and tolerated if score is > 0.05 
Blue = nonsense  Yellow = splice site  Green = missense 
Orange = genes in candidate region on chr19 
Purple = genes with variants predicted to be highly pathogenic or mouse models of CHD 
 
CHR ID 
GENE 
NAME 
mRNA 
POSITION 
CODON 
CHANGE 
CODON 
NO. 
RESIDUE 
CHANGE 
FUNCTION 
OF 
MUTATION 
MOUSE 
MODELS 
POLYPHEN 
conserved 
nucleotide 
POLYPHEN 
conserved 
amino acid 
POLYPHEN 
prediction 
SIFT 
prediction of effect 
of amino acid 
substitution 
SIFT 
prediction of 
pathogenicty 
chr3 CCNL1 997 GGA=>TGA 333 G=>* nonsense no data      
chr7 RSPH10B2 961 CGA=>TGA 321 R=>* nonsense no data      
chr7 NPC1L1 2608 GGA=>TGA 870 G=>* nonsense no data      
chr10 UTF1 1020 TGC=>TGA 340 C=>* nonsense no data      
chr13 P2RY5 520 GAA=>TAA 174 E=>* nonsense no data      
chr14 POTEG 1498 CAG=>TAG 500 Q=>* nonsense no data      
chr17 RASD1 355 CAG=>TAG 119 Q=>* nonsense no data      
chr19 GMFG 70 CGA=>TGA 24 R=>* nonsense no data      
chr2 FAM128B     spliceSite no data      
chr3 LIMD1     spliceSite no data      
chr1 PLEKHN1 1642 GCC=>TCC 548 A=>S missense no data weak weak 0 tolerated 0.67 
chr1 WDR8 1148 CCG=>CTG 383 P=>L missense no data high high 0.999 
affect protein 
function 
0 
chr1 CHD5 4901 CAG=>CGG 1634 Q=>R missense no data high high 0.26 tolerated 0.38 
chr1 PLEKHG5 3058 GGC=>AGC 1020 G=>S missense no data weak weak 0 tolerated 1 
chr1 KLHL21 43 CCC=>ACC 15 P=>T missense no data high mod 0.002 tolerated 0.6 
chr1 PRAMEF4 457 GTA=>ATA 153 V=>I missense no data weak weak 0 tolerated 0.5 
chr1 PRAMEF10 1402 GTG=>CTG 468 V=>L missense no data weak weak 0 tolerated 0.5 
chr1 PRAMEF10 1012 GAG=>CAG 338 E=>Q missense no data weak weak 0.914 tolerated 0.32 
chr1 PRAMEF7 187 CGC=>TGC 63 R=>C missense no data weak weak 0.001 tolerated 0.16 
chr1 PRAMEF5 578 CGC=>CAC 193 R=>H missense no data weak weak 0 tolerated 0.48 
chr1 SH2D5 953 AGG=>ATG 318 R=>M missense no data      
chr1 MUTYH 3 ATG=>ATA 1 M=>I missense no data      
chr1 HRNR 3385 GGC=>AGC 1129 G=>S missense no data weak high unk 
affect protein 
function 
0 
chr1 UBE2Q1 223 CTG=>ATG 75 L=>M missense no data high mod 0.005 
affect protein 
function 
0 
chr1 FMN2 3302 CCT=>CTT 1101 P=>L missense no data weak weak unk 
affect protein 
function 
0 
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chr2 OTOF 2858 ACG=>ATG 953 T=>M missense no data weak mod 0.153 
affect protein 
function 
0.04 
chr2 ABCG5 40 GGT=>AGT 14 G=>S missense no data weak mod 0.011 tolerated 0.65 
chr2 FBLN7 116 CAG=>CGG 39 Q=>R missense no data      
chr2 IMP4 61 GCG=>ACG 21 A=>T missense no data weak weak unk tolerated 0.38 
chr2 MGC50273 254 GCC=>GTC 85 A=>V missense no data      
chr3 ITIH1 1927 TTC=>CTC 643 F=>L missense no data weak high 0.01 
affect protein 
function 
0 
chr3 CCDC37 506 CGG=>CAG 169 R=>Q missense no data weak high 0.837 
affect protein 
function 
0.03 
chr4 MFSD7 920 CGG=>CAG 307 R=>Q missense no data weak mod 0.91 tolerated 0.11 
chr4 IDUA 1210 GAA=>AAA 404 E=>K missense 
lysosomal 
storage 
disorder 
high mod 0.548 
affect protein 
function 
0.02 
chr4 TACC3 1919 AGC=>AAC 640 S=>N missense no data high high 0.285 
affect protein 
function 
0.02 
chr5 BTNL8 1429 GCA=>ACA 477 A=>T missense no data weak weak 0.003 tolerated 1 
chr6 PGBD1 360 GAG=>GAT 120 E=>D missense no data weak mod 0.933 
affect protein 
function 
0 
chr6 OR2H1 110 CTG=>CCG 37 L=>P missense no data weak high 0.956 
affect protein 
function 
0 
chr6 HSPA1L 1007 ATT=>ACT 336 I=>T missense no data high high 0.622 
affect protein 
function 
0 
chr6 AIM1 503 AGC=>AAC 168 S=>N missense no data weak weak 0.956 
affect protein 
function 
0 
chr6 C6orf170 1085 GCA=>GTA 362 A=>V missense no data high mod 0.765 
affect protein 
function 
0.02 
chr7 GTF2IRD1 2362 CCT=>ACT 788 P=>T missense 
embryonic 
lethal, 
abnormal 
angiogenesis, 
neural tube 
defects 
high high 0.141 tolerated 0.23 
chr7 HIP1 1245 GAT=>GAG 415 D=>E missense 
skeletal 
malformations, 
hematopoeitic 
anomalies 
high weak 0 tolerated 1 
chr8 DUB3 1481 CGG=>CCG 494 R=>P missense no data weak weak 0 tolerated 0.21 
chr8 DUB3 1319 CCC=>CTT 440 P=>L missense no data weak weak 0 tolerated 1 
chr8 DUB3 1268 CGC=>CAC 423 R=>H missense no data weak weak 0 tolerated 0.76 
chr8 DUB3 1070 TGT=>TCT 357 C=>S missense no data weak weak 0.003 tolerated 0.85 
chr8 DUB3 994 GAC=>AAC 332 D=>N missense no data weak weak 0 tolerated 1 
chr8 ZNF517 1427 CGC=>CAC 476 R=>H missense no data weak high 0 
affect protein 
function 
0 
chr9 DMRTA1 578 GCG=>GTG 193 A=>V missense no data weak mod 0 tolerated 0.72 
chr9 TESK1 1606 CGG=>TGG 536 R=>W missense no data weak high 0.984 
affect protein 
function 
0 
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chr9 ANKRD20A3 2017 GCC=>ACC 673 A=>T missense no data weak weak 0 tolerated 1 
chr10 RET 1118 GCG=>GTG 373 A=>V missense 
lethal, 
neurogenic 
defects, 
abnormal GU 
system 
weak mod 0 tolerated 0.5 
chr10 SYNPO2L 871 CCC=>TCC 291 P=>S missense no data weak mod 0.007 
affect protein 
function 
0 
chr11 IGHMBP2 2042 GAG=>GGG 681 E=>G missense no data weak mod 0.068 tolerated 0.06 
chr11 WNT11 519 GAT=>GAA 173 D=>E missense 
lethal, 
? heart devl in 
humans 
high high 0.999 
affect protein 
function 
0 
chr12 NOC4L 164 CGT=>CAT 55 R=>H missense no data mod mod 0.99 tolerated 0.13 
chr15 GOLGA6 481 CGC=>TGC 161 R=>C missense no data      
chr15 STARD5 16 GCA=>ACA 6 A=>T missense no data weak mod 0.103 tolerated 0.94 
chr15 MESP2 554 GGG=>GCG 185 G=>A missense 
perinatal lethal, 
absent 
segmental 
somites 
weak weak 0.075 
affect protein 
function 
0 
chr15 MESP2 556 CAG=>GAG 186 Q=>E missense 
perinatal lethal, 
absent 
segmental 
somites 
weak weak 0.011 
affect protein 
function 
0 
chr16 RHBDF1 560 GCC=>GTC 187 A=>V missense no data weak mod 0.004 tolerated 0.07 
chr16 TPSAB1 8 AAT=>AGT 3 N=>S missense no data weak weak unk tolerated 0.75 
chr16 TPSAB1 9 AAT=>AGC 3 N=>S missense no data weak weak unk tolerated 0.75 
chr16 TELO2 533 GAG=>GTG 178 E=>V missense 
embryonic 
lethal 
weak weak 0 tolerated 0.5 
chr16 NDUFB10 424 GCC=>ACC 142 A=>T missense no data high mod 0.062 tolerated 0.05 
chr16 PKD1 361 AAC=>GAC 121 N=>D missense renal cysts high high 0.98 tolerated 0.8 
chr16 BTBD12 2323 CAC=>TAC 775 H=>Y missense no data      
chr16 ATMIN 503 AGT=>AAT 168 S=>N missense no data high mod 0.001 tolerated 0.33 
chr16 CDH15 1304 CAC=>CGC 435 H=>R missense no data weak weak 0 tolerated 1 
chr16 CPNE7 1133 GGC=>GAC 378 G=>D missense no data high high 0.985 
affect protein 
function 
0 
chr17 DVL2 152 GCG=>GTG 51 A=>V missense CHD OFT+++ high mod 0.07 tolerated 0.31 
chr17 LGALS9B 550 GTG=>ATG 184 V=>M missense no data weak weak 0.013 
affect protein 
function 
0.04 
chr17 GHDC 1561 GCC=>ACC 521 A=>T missense no data weak high 0.871 tolerated 0.06 
chr17 FMNL1 2555 AAG=>AGG 852 K=>R missense no data high high unk 
affect protein 
function 
0 
chr17 ICAM2 7 TCT=>CCT 3 S=>P missense no data weak weak 0 tolerated 0.39 
chr17 CBX2 428 CCG=>CTG 143 P=>L missense 
skeletal 
malformations 
high high 0.999 
affect protein 
function 
0 
chr19 DAZAP1 574 GAC=>AAC 192 D=>N missense no data high high unk 
affect protein 
function 
0 
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chr19 REXO1 2623 GCC=>ACC 875 A=>T missense no data weak weak 0 tolerated 0.55 
chr19 FAM108A1 557 GGC=>GCC 186 G=>A missense no data high high 0.176 
affect protein 
function 
0.04 
chr19 CSNK1G2 248 GCC=>GTC 83 A=>V missense no data high high 0.102 
affect protein 
function 
0 
chr19 DOT1L 1357 TAC=>CAC 453 Y=>H missense 
embryonic 
lethal, 
poor yolk sac 
angiogenesis 
high mod 0.006 tolerated 0.14 
chr19 INSR 2941 GCT=>TCT 981 A=>S missense no data high high 0.208 
affect protein 
function 
0 
chr19 FBN3 6952 GCT=>ACT 2318 A=>T missense no data weak mod 0.002 tolerated 0.29 
chr19 DNMT1 2575 GAC=>TAC 859 D=>Y missense 
embryonic 
lethal, 
lack of 
imprinting 
at several loci 
high mod 0.995 
affect protein 
function 
0 
chr19 CDC37 275 CGC=>CAC 92 R=>H missense no data high weak 0.941 tolerated 0.1 
chr19 RGL3 1402 CGC=>TGC 468 R=>C missense no data weak mod 0.999 tolerated 0.08 
chr19 OR7A10 806 CAC=>CCC 269 H=>P missense no data weak weak 0.986 tolerated 0.28 
chr19 CYP4F22 484 GCC=>ACC 162 A=>T missense no data high high 0.174 
affect protein 
function 
0 
chr19 KIAA1683 394 GCC=>ACC 132 A=>T missense no CHD high high 0.445 
affect protein 
function 
0 
chr19 NDUFA13 200 GTG=>GCG 67 V=>A missense 
embryonic 
lethal, 
absent 
organogenesis 
weak weak 0.151 
affect protein 
function 
0.02 
chr19 SPTBN4 4166 CGC=>CAC 1389 R=>H missense 
neurological 
phenotype 
high high 0.037 
affect protein 
function 
0.02 
chr19 ZFP28 107 CCA=>CGA 36 P=>R missense no data weak mod 0.048 tolerated 0.11 
chr19 ZIM2 902 CCT=>CTT 301 P=>L missense no data weak high unk 
affect protein 
function 
0 
chr19 ZNF530 1079 TTT=>TGT 360 F=>C missense no data high high 1 
affect protein 
function 
0 
chr20 THBD 203 GCC=>GTC 68 A=>V missense no data weak high 0.883 tolerated 0.09 
chr20 LAMA5 9826 GTA=>ATA 3276 V=>I missense no data weak mod 0.563 tolerated 0.08 
chr20 LAMA5 1487 TGC=>TAC 496 C=>Y missense 
embryonic 
lethal with 
brain, limb, 
kidney defects 
high mod 1 
affect protein 
function 
0 
chr20 LIME1 845 AGC=>AAC 282 S=>N missense no data weak mod 0.683 tolerated 0.29 
chr21 ERG 739 GGC=>TGC 247 G=>C missense no data high weak 0.137 tolerated 0.19 
chr22 RHBDD3 160 CTG=>GTG 54 L=>V missense no data high high 0.094 
affect protein 
function 
0.04 
chr22 SFI1 2678 CGC=>CAC 893 R=>H missense no data weak mod 0.001 tolerated 0.49 
chr22 SGSM3 1187 GTT=>GCT 396 V=>A missense no data      
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APPENDIX G: Analysis of whole exome sequencing data from WTSI 
 
POLYPHEN: Prediction of mutation pathogenicity, scores range from 0.000 (most probably benign) to 0.999 (most probably damaging) 
SIFT: Amino acid substitution is predicted to be damaging if score is <= 0.05, and tolerated if score is > 0.05 
Blue = nonsense  Yellow = splice site  Green = missense  Purple = genes for ?further investigation 
 
CHD1: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF  
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE  
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
19 39826105 GMFG G A 24 R/* STOP_GAINED . . 
10 46321904 AGAP4 C T 260 R/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
10 51464656 AGAP7 G C 600 D/E NON_SYNONYMOUS_CODING probably_damaging(0.995) tolerated(0.06) 
10 51465650 AGAP7 C T 269 R/Q NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.03) 
9 117110115 AKNA T G 556 H/P NON_SYNONYMOUS_CODING probably_damaging(0.979) tolerated(0.07) 
9 66553727 ENSG00000170161 T C 60 V/A NON_SYNONYMOUS_CODING benign(0) . 
15 22709060 ENSG00000185182 C G 147 E/Q NON_SYNONYMOUS_CODING benign(0.313) tolerated(0.08) 
15 30696517 ENSG00000186399 C T 501 R/H NON_SYNONYMOUS_CODING possibly_damaging(0.509) deleterious(0.02) 
15 30696515 ENSG00000186399 C A 502 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.862) tolerated(0.17) 
15 82932518 ENSG00000215749 T C 502 E/G NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.24) 
15 82932561 ENSG00000215749 T C 488 S/G NON_SYNONYMOUS_CODING possibly_damaging(0.737) deleterious(0) 
15 82932833 ENSG00000215749 C A 467 V/F NON_SYNONYMOUS_CODING possibly_damaging(0.951) deleterious(0) 
1 146215113 ENSG00000232637 G A 84 H/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.05) 
9 46386902 ENSG00000237198 G A 34 T/I NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
10 51859751 FAM21A C A 521 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.13) 
10 47915891 FAM21B C A 270 S/Y NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.13) 
9 97080827 FAM22F C G 565 G/R NON_SYNONYMOUS_CODING benign(0.424) tolerated(0.07) 
15 82637079 GOLGA6L10 C T 336 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 31324931 HLA-B A C 3 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 31324547 HLA-B G C 88 N/K NON_SYNONYMOUS_CODING benign(0.192) deleterious(0.02) 
13 53217540 HNRNPA1L2 T C 305 Y/H NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
19 18177378 IL12RB1 C T 486 R/Q NON_SYNONYMOUS_CODING benign(0.009) tolerated(0.35) 
19 18377956 KIAA1683 C T 131 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.93) deleterious(0) 
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19 54725835 LILRB3 G C 175 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
19 7051376 MBD3L2 G A 124 G/S NON_SYNONYMOUS_CODING possibly_damaging(0.6) tolerated(0.19) 
1 3431168 MEGF6 G A 267 R/C NON_SYNONYMOUS_CODING probably_damaging(0.972) tolerated(0.14) 
15 90294245 MESP1 C G 73 G/A NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(0.43) 
7 100637605 MUC12 A C 1254 K/T NON_SYNONYMOUS_CODING unknown(0) . 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195510515 MUC4 C T 2646 A/T NON_SYNONYMOUS_CODING unknown(0) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 148023040 NBPF14 G C 162 S/C NON_SYNONYMOUS_CODING possibly_damaging(0.939) deleterious(0.02) 
1 148741720 NBPF16 T C 69 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 19626998 NDUFA13 T C 67 V/A NON_SYNONYMOUS_CODING possibly_damaging(0.547) tolerated(0.1) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 2434460 PLCH2 G T 1038 V/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
2 130832358 POTEF T C 896 H/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 20010235 POTEM A G 393 V/A NON_SYNONYMOUS_CODING benign(0.006) tolerated(1) 
1 147955256 PPIAL4A A G 30 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13696022 PRAMEF19 A G 246 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
22 18901004 PRODH C T 166 R/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.6) 
19 43528921 PSG11 C G 118 G/R NON_SYNONYMOUS_CODING probably_damaging(0.982) deleterious(0.04) 
19 41056166 SPTBN4 C T 212 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.533) deleterious(0.01) 
7 72436652 TRIM74 A G 13 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
19 35434387 ZNF30 G A 174 E/K NON_SYNONYMOUS_CODING benign(0.43) tolerated(0.05) 
19 13318672 CACNA1A CCTGCTG C 2330-2331 QQ/- NON_SYNONYMOUS_CODING . . 
2 187559029 FAM171B A ACAG 43-44 -/Q NON_SYNONYMOUS_CODING . . 
15 90320134 MESP2 AGGGCAGGGGCAG A 183-186 GQGQ/- NON_SYNONYMOUS_CODING . . 
18 30352057 ENSG00000228835 GCGCCGGCC G 119-121 . FRAMESHIFT_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
7 100371476 ZAN T TG 1923 . FRAMESHIFT_CODING . . 
3 75790810 ZNF717 G GT 38 . FRAMESHIFT_CODING . . 
1 1022582 C1orf159 C A 119 A/S SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.606) tolerated(0.07) 
3 75790427 ZNF717 C T 43 A/T SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.85) tolerated(0.4) 
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CHD1: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF  
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE  
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
2 148676128 ACVR2A T A 310 L/Q NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.29) 
2 148676144 ACVR2A A C 315 K/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 127724751 ADAM12 T G 834 R/S NON_SYNONYMOUS_CODING benign(0.028) tolerated(0.42) 
10 127708330 ADAM12 C T 868 R/Q NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.53) 
10 127787029 ADAM12 T C 321 I/V NON_SYNONYMOUS_CODING probably_damaging(0.992) tolerated(0.43) 
10 4879755 AKR1E2 C A 188 F/L NON_SYNONYMOUS_CODING benign(0.055) deleterious(0.03) 
10 4875551 AKR1E2 A C 73 T/P NON_SYNONYMOUS_CODING benign(0.426) deleterious(0) 
4 114275541 ANK2 G A 1890 E/K NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
4 114275548 ANK2 A C 1892 H/P NON_SYNONYMOUS_CODING probably_damaging(0.996) . 
5 94030836 ANKRD32 C A 999 T/N NON_SYNONYMOUS_CODING benign(0.144) deleterious(0.01) 
5 94030832 ANKRD32 G A 998 E/K NON_SYNONYMOUS_CODING probably_damaging(0.955) deleterious(0) 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97845632 ANKRD36 T C 566 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.23) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
12 101368637 ANO4 A C 191 Y/S NON_SYNONYMOUS_CODING probably_damaging(0.983) tolerated(0.39) 
12 101368625 ANO4 G A 187 R/K SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
22 39498015 APOBEC3H C G 171 R/G NON_SYNONYMOUS_CODING benign(0.057) deleterious(0.01) 
22 39498005 APOBEC3H T A 167 D/E NON_SYNONYMOUS_CODING benign(0.18) tolerated(0.35) 
22 39498012 APOBEC3H A G 170 S/G NON_SYNONYMOUS_CODING probably_damaging(0.984) deleterious(0) 
22 39498014 APOBEC3H T G 170 S/R NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
12 14613915 ATF7IP T A 882 V/E NON_SYNONYMOUS_CODING possibly_damaging(0.837) deleterious(0.01) 
12 14613917 ATF7IP C A 883 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.882) deleterious(0.04) 
11 64666179 ATG2A A G 1338 S/P NON_SYNONYMOUS_CODING benign(0.403) deleterious(0.02) 
11 64666176 ATG2A A G 1339 S/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
11 64666182 ATG2A C G 1337 A/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
11 108175543 ATM A G 1880 T/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.7) 
11 108175544 ATM C G 1880 T/R NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.03) 
16 84495404 ATP2C2 A C 705 T/P NON_SYNONYMOUS_CODING benign(0.269) deleterious(0.01) 
16 84456242 ATP2C2 T C 110 V/A NON_SYNONYMOUS_CODING possibly_damaging(0.949) deleterious(0) 
20 3565431 ATRN C A 956 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.72) 
20 3565356 ATRN T G 931 C/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 121436478 BAG3 A G 471 E/G NON_SYNONYMOUS_CODING benign(0.145) deleterious(0.04) 
10 121436483 BAG3 C G 473 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.939) deleterious(0) 
1 147092352 BCL9 G T 797 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.91) tolerated(0.13) 
1 147092353 BCL9 C T 798 R/W NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.19) 
5 137503739 BRD8 G A 224 S/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
5 137503737 BRD8 C A 225 G/C NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
10 128192708 C10orf90 T G 307 H/P NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
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10 128192711 C10orf90 A C 306 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.819) deleterious(0) 
11 76256857 C11orf30 T C 779 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.689) deleterious(0) 
11 76171068 C11orf30 A C 184 R/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.33) 
12 112622338 C12orf51 T G 3056 T/P NON_SYNONYMOUS_CODING benign(0.187) . 
12 112688167 C12orf51 A C 822 V/G NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
12 112688164 C12orf51 T C 823 E/G NON_SYNONYMOUS_CODING probably_damaging(0.98) . 
20 18433273 C20orf12 T G 179 T/P NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.15) 
20 18433277 C20orf12 T G 25 H/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
6 48036327 C6orf138 A C 5 V/G NON_SYNONYMOUS_CODING benign(0.235) deleterious(0.02) 
6 48036051 C6orf138 A C 97 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.493) deleterious(0) 
11 76795985 CAPN5 G A 18 R/Q NON_SYNONYMOUS_CODING benign(0.056) tolerated(0.41) 
11 76796027 CAPN5 T C 32 F/S NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 77807917 CBX4 T TGCCGCC 508 A/AAA NON_SYNONYMOUS_CODING . . 
17 77808584 CBX4 T C 286 E/G NON_SYNONYMOUS_CODING benign(0.372) deleterious(0.01) 
17 77808570 CBX4 A G 291 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.727) deleterious(0.04) 
17 77808572 CBX4 C G 290 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.14) 
2 219893096 CCDC108 T G 494 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
2 219883763 CCDC108 C A 113 L/F NON_SYNONYMOUS_CODING unknown(0) . 
13 37012869 CCNA1 A G 252 E/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
13 37012872 CCNA1 T G 253 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
17 45214528 CDC27 A T 635 Y/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
9 131186822 CERCAM A C 154 Y/S NON_SYNONYMOUS_CODING benign(0.099) tolerated(0.13) 
9 131185203 CERCAM C G 7 A/G NON_SYNONYMOUS_CODING benign(0.22) tolerated(0.38) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
16 839702 CHTF18 C T 198 A/V NON_SYNONYMOUS_CODING benign(0.004) deleterious(0.03) 
16 846830 CHTF18 A G 857 E/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.04) 
19 42795827 CIC G C 939 G/A NON_SYNONYMOUS_CODING benign(0.106) tolerated(0.44) 
19 42795826 CIC G C 939 G/R NON_SYNONYMOUS_CODING possibly_damaging(0.765) deleterious(0.03) 
16 10995954 CIITA A C 181 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.05) 
16 11001733 CIITA G A 747 R/Q NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.33) 
12 122812699 CLIP1 A T 46 M/K NON_SYNONYMOUS_CODING benign(0.03) tolerated(0.05) 
12 122812697 CLIP1 C T 47 E/K NON_SYNONYMOUS_CODING possibly_damaging(0.918) deleterious(0.03) 
12 122845694 CLIP1 C A 273 A/S NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.06) 
12 122812709 CLIP1 C T 43 E/K SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.33) 
22 19213150 CLTCL1 C A 652 V/F NON_SYNONYMOUS_CODING benign(0.419) deleterious(0) 
22 19213138 CLTCL1 C A 656 G/C NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0) 
7 147926842 CNTNAP2 A C 177 T/P NON_SYNONYMOUS_CODING probably_damaging(0.961) deleterious(0.04) 
7 147183121 CNTNAP2 A C 589 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
6 56044835 COL21A1 C A 61 V/F NON_SYNONYMOUS_CODING possibly_damaging(0.775) deleterious(0.02) 
6 56044818 COL21A1 G T 66 N/K NON_SYNONYMOUS_CODING probably_damaging(0.982) tolerated(0.26) 
2 9599739 CPSF3 T A 593 I/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.51) 
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2 9599742 CPSF3 G A 594 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.93) 
1 207726161 CR1 G T 572 Q/H NON_SYNONYMOUS_CODING possibly_damaging(0.475) tolerated(0.57) 
1 207755348 CR1 C T 1318 H/Y SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.611) tolerated(0.09) 
8 68062165 CSPP1 G A 703 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.64) 
8 68062160 CSPP1 T A 701 N/K NON_SYNONYMOUS_CODING benign(0.153) tolerated(0.98) 
6 132030560 CTAGE9 G A 533 T/M NON_SYNONYMOUS_CODING benign(0.062) tolerated(0.07) 
6 132030966 CTAGE9 G C 398 L/V NON_SYNONYMOUS_CODING probably_damaging(0.973) deleterious(0.01) 
10 126678128 CTBP2 T A 433 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
10 126678251 CTBP2 C A 392 V/L NON_SYNONYMOUS_CODING benign(0.103) tolerated(0.12) 
10 126714884 CTBP2 G A 482 T/M NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.02) 
16 50828259 CYLD C A 866 T/K NON_SYNONYMOUS_CODING possibly_damaging(0.847) deleterious(0) 
16 50828255 CYLD G A 865 E/K NON_SYNONYMOUS_CODING possibly_damaging(0.945) deleterious(0.01) 
15 51766636 DMXL2 G A 1736 A/V NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 51766637 DMXL2 C A 1736 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.57) 
5 13754366 DNAH5 C T 3501 E/K NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.31) 
5 13754379 DNAH5 C A 3496 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
6 56422200 DST C A 4318 V/L NON_SYNONYMOUS_CODING benign(0.221) . 
6 56422262 DST T C 4297 E/G NON_SYNONYMOUS_CODING probably_damaging(1) . 
2 55071278 EML6 C A 314 D/E NON_SYNONYMOUS_CODING probably_damaging(0.994) tolerated(0.8) 
2 54952332 EML6 T G 45 V/G NON_SYNONYMOUS_CODING probably_damaging(0.997) deleterious(0) 
16 15457629 ENSG00000183793 T A 314 T/S NON_SYNONYMOUS_CODING benign(0.158) tolerated(0.82) 
16 15457628 ENSG00000183793 G T 314 T/N NON_SYNONYMOUS_CODING benign(0.348) tolerated(0.39) 
7 100549540 ENSG00000228273 A C 41 S/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.86) 
7 100550327 ENSG00000228273 C T 303 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.45) tolerated(0.43) 
18 11619510 ENSG00000257513 A C 351 */E STOP_LOST . . 
18 11619549 ENSG00000257513 T G 338 K/Q NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.03) 
12 132445256 EP400 A C 31 H/P NON_SYNONYMOUS_CODING unknown(0) . 
12 132445273 EP400 T C 37 S/P NON_SYNONYMOUS_CODING unknown(0) . 
12 132534944 EP400 C G 2425 T/R NON_SYNONYMOUS_CODING unknown(0) . 
1 16474927 EPHA2 T G 257 I/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.08) 
1 16474932 EPHA2 A C 255 V/G NON_SYNONYMOUS_CODING benign(0.006) deleterious(0) 
4 5733216 EVC A C 150 H/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.07) 
4 5754777 EVC G A 438 R/Q SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.31) 
2 62066569 FAM161A C T 524 E/K NON_SYNONYMOUS_CODING probably_damaging(0.977) tolerated(0.41) 
2 62066566 FAM161A G T 525 Q/K NON_SYNONYMOUS_CODING probably_damaging(0.98) tolerated(0.24) 
1 179783089 FAM163A T G 90 V/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.15) 
1 179783095 FAM163A C G 92 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.481) tolerated(0.1) 
15 41043735 FAM82A2 C G 138 R/P NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.15) 
15 41029923 FAM82A2 A C 376 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
5 150925475 FAT2 G C 1738 A/G NON_SYNONYMOUS_CODING benign(0.287) tolerated(0.44) 
5 150948147 FAT2 T G 116 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.491) tolerated(0.14) 
11 92616488 FAT3 T C 624 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.542) tolerated(0.12) 
11 92616485 FAT3 A C 623 N/T NON_SYNONYMOUS_CODING probably_damaging(0.978) tolerated(1) 
7 100187851 FBXO24 A C 65 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.462) deleterious(0) 
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7 100192051 FBXO24 A C 266 D/A NON_SYNONYMOUS_CODING possibly_damaging(0.907) deleterious(0.03) 
3 99568956 FILIP1L A C 98 S/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.27) 
3 99567984 FILIP1L A G 422 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.462) tolerated(0.13) 
9 117995 FOXD4 G C 42 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
9 117411 FOXD4 C G 237 A/P NON_SYNONYMOUS_CODING probably_damaging(0.981) deleterious(0.02) 
20 29628328 FRG1B C G 110 I/M NON_SYNONYMOUS_CODING benign(0.191) deleterious(0.03) 
20 29632672 FRG1B C T 163 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
4 48559517 FRYL G T 231 Q/K NON_SYNONYMOUS_CODING benign(0.042) deleterious(0.02) 
4 48559529 FRYL A C 227 W/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
14 39601195 GEMIN2 G T 223 E/* STOP_GAINED . . 
14 39601192 GEMIN2 C T 222 L/F NON_SYNONYMOUS_CODING probably_damaging(0.958) deleterious(0.01) 
15 34678933 GOLGA8A C T 60 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.63) 
15 34673973 GOLGA8A C T 513 R/Q NON_SYNONYMOUS_CODING benign(0.003) tolerated(1) 
1 37319269 GRIK3 G A 387 R/W NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 37319270 GRIK3 C A 386 L/F NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.75) 
14 106757786 IGHV2-26 G A 74 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.6) 
14 106757799 IGHV2-26 C A 70 A/S NON_SYNONYMOUS_CODING probably_damaging(0.955) tolerated(0.17) 
14 106573354 IGHV3-11 A G 77 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573357 IGHV3-11 G T 76 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.62) 
14 106573358 IGHV3-11 T A 76 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573378 IGHV3-11 T G 69 Y/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.39) 
14 106573352 IGHV3-11 A T 78 Y/N NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.23) 
14 106866406 IGHV3-38 A C 116 Y/* STOP_GAINED . . 
14 106866414 IGHV3-38 C T 114 A/T NON_SYNONYMOUS_CODING benign(0.008) tolerated(0.09) 
14 106866408 IGHV3-38 A T 116 Y/N NON_SYNONYMOUS_CODING possibly_damaging(0.462) tolerated(0.06) 
14 107113742 IGHV3-64 C T 118 R/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.18) 
14 107113745 IGHV3-64 G A 117 A/V NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.06) 
14 107034847 IGHV5-51 C T 78 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.37) 
14 107034854 IGHV5-51 C A 76 D/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
14 107034869 IGHV5-51 A C 71 Y/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
14 107034873 IGHV5-51 G C 69 I/M NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
14 107034874 IGHV5-51 A C 69 I/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.41) 
14 107034846 IGHV5-51 T G 78 R/S NON_SYNONYMOUS_CODING benign(0.136) tolerated(0.44) 
2 90139156 IGKV1D-16 C T 18 P/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.46) 
2 90139485 IGKV1D-16 G A 86 G/S NON_SYNONYMOUS_CODING benign(0.226) deleterious(0.02) 
1 117122285 IGSF3 G GTCC 1041 D/ED NON_SYNONYMOUS_CODING . . 
1 117159050 IGSF3 C T 25 V/I NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.68) 
14 105174274 INF2 T G 25 V/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.09) 
14 105180963 INF2 C T 1155 A/V NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
3 4725969 ITPR1 G A 1159 G/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
3 4725973 ITPR1 T A 1160 N/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.94) 
3 4725976 ITPR1 C A 1161 N/K NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.94) 
16 15696466 KIAA0430 A G 1296 F/S NON_SYNONYMOUS_CODING benign(0.014) . 
16 15696475 KIAA0430 G A 1293 P/L NON_SYNONYMOUS_CODING benign(0.014) . 
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16 15696509 KIAA0430 G A 1282 P/S NON_SYNONYMOUS_CODING benign(0.014) . 
1 209796950 LAMB3 A C 753 V/G NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.04) 
1 209791293 LAMB3 T G 1004 T/P NON_SYNONYMOUS_CODING probably_damaging(0.954) deleterious(0.01) 
1 152777625 LCE1C A C 110 S/R NON_SYNONYMOUS_CODING unknown(0) . 
1 152777627 LCE1C T C 110 S/G NON_SYNONYMOUS_CODING unknown(0) . 
13 76287349 LMO7 A T 86 D/V NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.01) 
13 76287354 LMO7 C G 88 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
12 57592066 LRP1 C T 3137 T/M NON_SYNONYMOUS_CODING probably_damaging(0.976) tolerated(0.06) 
12 57550649 LRP1 A C 503 T/P NON_SYNONYMOUS_CODING probably_damaging(0.991) tolerated(0.2) 
2 141259399 LRP1B A C 2841 C/G NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
2 141625828 LRP1B G A 1330 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
17 62892071 LRRC37A3 G C 435 H/Q NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.66) 
17 62892031 LRRC37A3 C T 449 V/I NON_SYNONYMOUS_CODING benign(0.048) tolerated(0.14) 
7 20198700 MACC1 G T 428 D/E NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.57) 
7 20198702 MACC1 C T 428 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.604) tolerated(0.18) 
1 117944954 MAN1A2 T A 150 I/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.96) 
1 117944964 MAN1A2 C A 153 N/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.96) 
5 71490953 MAP1B G A 608 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.792) tolerated(0.27) 
5 71490955 MAP1B C A 608 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.792) tolerated(0.67) 
3 152174078 MBNL1 G C 277 R/P NON_SYNONYMOUS_CODING benign(0.013) tolerated(0.33) 
3 152174076 MBNL1 A C 272 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.512) tolerated(0.11) 
9 123476542 MEGF9 ACGGCGG A 22-24 AAV/V NON_SYNONYMOUS_CODING . . 
9 123384940 MEGF9 C G 336 L/F NON_SYNONYMOUS_CODING probably_damaging(0.961) deleterious(0.05) 
11 12225829 MICAL2 G T 99 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.03) 
11 12225830 MICAL2 C T 100 R/C NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
11 12315177 MICALCL A G 67 R/G NON_SYNONYMOUS_CODING benign(0.09) deleterious(0) 
11 12315180 MICALCL C G 68 R/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
10 129901721 MKI67 G T 2794 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.806) tolerated(0.13) 
10 129901702 MKI67 G T 2800 A/D NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0) 
7 131128354 MKLN1 G T 430 A/S NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.74) 
7 131128350 MKLN1 G T 428 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.69) tolerated(0.08) 
8 17611546 MTUS1 T C 591 T/A NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.08) 
8 17601155 MTUS1 G C 749 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 100646199 MUC12 T C 4119 F/L NON_SYNONYMOUS_CODING possibly_damaging(0.662) . 
7 100645825 MUC12 C A 3994 T/K NON_SYNONYMOUS_CODING probably_damaging(0.992) . 
7 100636722 MUC12 G C 960 V/L NON_SYNONYMOUS_CODING unknown(0) . 
7 100637008 MUC12 C A 1055 A/E NON_SYNONYMOUS_CODING unknown(0) . 
7 100637547 MUC12 G A 1235 A/T NON_SYNONYMOUS_CODING unknown(0) . 
7 100637839 MUC12 C G 1332 P/R NON_SYNONYMOUS_CODING unknown(0) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9002636 MUC16 C T 35 V/I NON_SYNONYMOUS_CODING benign(0.051) tolerated(0.37) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 8961997 MUC16 C A 1101 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.448) deleterious(0) 
19 9002659 MUC16 C T 27 G/E NON_SYNONYMOUS_CODING possibly_damaging(0.582) tolerated(0.19) 
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19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
19 9002660 MUC16 C T 27 G/R NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.5) 
3 195510636 MUC4 C G 2605 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195510649 MUC4 G A 2601 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510396 MUC4 A C 2685 H/Q NON_SYNONYMOUS_CODING unknown(0) . 
3 195510415 MUC4 G T 2679 S/Y NON_SYNONYMOUS_CODING unknown(0) . 
3 195510509 MUC4 A C 2648 S/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510553 MUC4 G A 2633 A/V NON_SYNONYMOUS_CODING unknown(0) . 
3 195510611 MUC4 G T 2614 L/I NON_SYNONYMOUS_CODING unknown(0) . 
3 195510613 MUC4 C T 2613 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510614 MUC4 T C 2613 S/G NON_SYNONYMOUS_CODING unknown(0) . 
11 1018095 MUC6 G A 1569 P/L NON_SYNONYMOUS_CODING benign(0.014) deleterious(0.01) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1017693 MUC6 T A 1703 H/L NON_SYNONYMOUS_CODING probably_damaging(0.978) tolerated(0.82) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1017655 MUC6 G A 1716 P/S NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.14) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1017596 MUC6 T G 1735 Q/H NON_SYNONYMOUS_CODING unknown(0) tolerated(0.18) 
11 1018207 MUC6 T C 1532 T/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.28) 
11 1018552 MUC6 G A 1417 P/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.73) 
11 1018561 MUC6 T C 1414 S/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.07) 
11 1019464 MUC6 G T 1281 Q/K NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
11 1024858 MUC6 T G 1071 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.14) 
11 69062844 MYEOV C T 8 T/I NON_SYNONYMOUS_CODING unknown(0) . 
11 69062879 MYEOV C T 20 R/C NON_SYNONYMOUS_CODING unknown(0) . 
1 145367800 NBPF10 G A 586 D/N NON_SYNONYMOUS_CODING benign(0.009) deleterious(0.03) 
1 145302775 NBPF10 T G 330 Y/D NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
9 139413211 NOTCH1 T G 311 T/P NON_SYNONYMOUS_CODING benign(0.004) deleterious(0) 
9 139413097 NOTCH1 T G 349 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 9143043 NTN1 A G 525 T/A NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.47) 
17 9143044 NTN1 C G 525 T/R NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.43) 
1 228430947 OBSCN C G 998 A/G NON_SYNONYMOUS_CODING benign(0.003) . 
1 228434292 OBSCN C G 1274 A/G NON_SYNONYMOUS_CODING benign(0.006) . 
1 228464168 OBSCN G C 2080 V/L NON_SYNONYMOUS_CODING probably_damaging(0.998) . 
11 35016535 PDHX C T 129 A/V NON_SYNONYMOUS_CODING probably_damaging(0.989) deleterious(0) 
11 35016479 PDHX G A 110 M/I NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 95216415 PDK4 C A 298 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 95222084 PDK4 T TGG 136-137 . FRAMESHIFT_CODING . . 
8 110463218 PKHD1L1 C A 2064 Q/K NON_SYNONYMOUS_CODING benign(0.023) tolerated(1) 
8 110455187 PKHD1L1 A T 1469 Y/F NON_SYNONYMOUS_CODING possibly_damaging(0.799) tolerated(0.33) 
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8 110455184 PKHD1L1 C T 1468 S/F NON_SYNONYMOUS_CODING probably_damaging(0.982) deleterious(0.01) 
2 159519467 PKP4 T G 757 V/G NON_SYNONYMOUS_CODING benign(0.389) deleterious(0) 
2 159519458 PKP4 A G 754 E/G NON_SYNONYMOUS_CODING probably_damaging(0.991) tolerated(0.08) 
19 4511679 PLIN4 C T 751 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.26) 
19 4512933 PLIN4 C A 333 V/L NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.08) 
1 208252715 PLXNA2 A C 826 C/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 208272311 PLXNA2 G C 537 C/W NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 208272313 PLXNA2 A C 537 C/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
2 131414338 POTEJ G A 669 A/T NON_SYNONYMOUS_CODING benign(0.011) deleterious(0.01) 
2 131414878 POTEJ A C 849 T/P NON_SYNONYMOUS_CODING probably_damaging(0.988) tolerated(0.31) 
19 42596242 POU2F2 G A 399 Q/* STOP_GAINED . . 
19 42596244 POU2F2 C A 443 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.45) deleterious(0) 
1 12887211 PRAMEF11 T A 257 I/F NON_SYNONYMOUS_CODING benign(0) tolerated(0.59) 
1 12887253 PRAMEF11 T C 243 M/V NON_SYNONYMOUS_CODING benign(0) tolerated(0.36) 
1 12887121 PRAMEF11 C T 287 D/N NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.64) 
1 12837570 PRAMEF12 G A 427 G/E NON_SYNONYMOUS_CODING benign(0.004) tolerated(1) 
1 12837548 PRAMEF12 G A 420 A/T NON_SYNONYMOUS_CODING benign(0.007) tolerated(0.62) 
1 12837564 PRAMEF12 G T 425 C/F NON_SYNONYMOUS_CODING possibly_damaging(0.446) tolerated(0.7) 
1 12837669 PRAMEF12 G T 460 G/V NON_SYNONYMOUS_CODING probably_damaging(0.988) deleterious(0) 
6 106546559 PRDM1 A G 4 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.878) . 
6 106546576 PRDM1 A C 10 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.901) deleterious(0) 
1 186276217 PRG4 C A 322 P/T NON_SYNONYMOUS_CODING unknown(0) deleterious(0.03) 
1 186276229 PRG4 A T 326 T/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.68) 
1 186276358 PRG4 C A 369 P/T NON_SYNONYMOUS_CODING unknown(0) deleterious(0.01) 
1 186276370 PRG4 G T 373 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.38) 
19 40901647 PRX A G 871 V/A NON_SYNONYMOUS_CODING benign(0.019) tolerated(0.26) 
19 40901648 PRX C G 871 V/L NON_SYNONYMOUS_CODING benign(0.404) tolerated(0.24) 
10 27702786 PTCHD3 A C 132 W/G NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.36) 
10 27700857 PTCHD3 A C 364 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
1 117487406 PTGFRN C T 34 S/L NON_SYNONYMOUS_CODING benign(0.031) tolerated(0.17) 
1 117492036 PTGFRN A C 211 D/A NON_SYNONYMOUS_CODING benign(0.044) tolerated(0.15) 
1 117491894 PTGFRN C G 164 R/G NON_SYNONYMOUS_CODING benign(0.282) tolerated(0.67) 
3 191179127 PYDC2 T C 59 F/S NON_SYNONYMOUS_CODING benign(0.29) deleterious(0) 
3 191179129 PYDC2 A C 60 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.817) tolerated(0.06) 
2 87205020 RGPD1 G T 810 R/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 87205031 RGPD1 T C 814 C/R NON_SYNONYMOUS_CODING possibly_damaging(0.85) tolerated(0.78) 
13 25416217 RNF17 G A 841 D/N NON_SYNONYMOUS_CODING benign(0.019) tolerated(0.12) 
13 25451175 RNF17 C G 1542 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.751) tolerated(0.07) 
7 4259872 SDK1 C A 139 Q/K NON_SYNONYMOUS_CODING benign(0.253) tolerated(0.31) 
7 4247821 SDK1 A C 17 T/P NON_SYNONYMOUS_CODING probably_damaging(0.975) tolerated(0.11) 
18 12948136 SEH1L A C 6 S/R NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.55) 
18 12948134 SEH1L G C 5 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.778) deleterious(0.02) 
17 48626182 SPATA20 A C 109 T/P NON_SYNONYMOUS_CODING probably_damaging(0.957) deleterious(0.02) 
17 48628510 SPATA20 C A 496 P/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
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1 16258610 SPEN C G 1959 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.536) tolerated(0.05) 
1 16203071 SPEN G A 260 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.1) 
1 16262471 SPEN A C 3246 T/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0.02) 
16 2812468 SRRM2 T G 647 S/A NON_SYNONYMOUS_CODING unknown(0) . 
16 2816107 SRRM2 C G 1112 P/A NON_SYNONYMOUS_CODING unknown(0) . 
6 36489582 STK38 G A 107 Q/* STOP_GAINED . . 
6 36489585 STK38 C A 106 V/F NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
6 33410691 SYNGAP1 T C 729 S/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
6 33410683 SYNGAP1 G C 726 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
1 152084213 TCHH C G 494 E/Q NON_SYNONYMOUS_CODING unknown(0) . 
1 152084216 TCHH C G 493 E/Q NON_SYNONYMOUS_CODING unknown(0) . 
7 100228635 TFR2 T C 297 E/G NON_SYNONYMOUS_CODING benign(0.002) . 
7 100228633 TFR2 G C 168 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.849) . 
12 83251115 TMTC2 T G 137 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.926) deleterious(0) 
12 83251120 TMTC2 C G 139 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
9 117838699 TNC G T 944 Q/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.91) 
9 117849170 TNC G T 280 N/K NON_SYNONYMOUS_CODING benign(0.003) deleterious(0.05) 
9 117838707 TNC G T 941 P/Q NON_SYNONYMOUS_CODING probably_damaging(0.994) deleterious(0.01) 
2 218713552 TNS1 C T 438 R/Q NON_SYNONYMOUS_CODING benign(0.404) tolerated(0.3) 
2 218696268 TNS1 G A 970 R/W SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142008750 TRBV3-1 A T 75 I/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
7 142008783 TRBV3-1 A G 86 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008675 TRBV3-1 A G 50 T/A NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
7 142008727 TRBV3-1 G T 67 S/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.4) 
7 142008785 TRBV3-1 A C 86 K/N NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.02) 
7 142008718 TRBV3-1 T C 64 I/T NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
7 142008672 TRBV3-1 G A 49 D/N NON_SYNONYMOUS_CODING benign(0.006) tolerated(0.61) 
7 142008745 TRBV3-1 T C 73 L/P NON_SYNONYMOUS_CODING probably_damaging(0.993) tolerated(0.27) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142180566 TRBV6-5 A T 98 L/Q NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180567 TRBV6-5 G C 98 L/V NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
7 142180573 TRBV6-5 T C 96 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.12) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
287 
 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142247230 TRBV7-3 C T 76 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.38) 
7 142247236 TRBV7-3 C G 74 A/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142247271 TRBV7-3 G A 62 P/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142247380 TRBV7-3 T A 26 T/S NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.87) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099581 TRBV7-8 A G 74 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
22 38120532 TRIOBP G A 657 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.28) 
22 38120563 TRIOBP T C 667 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.75) 
22 38120575 TRIOBP A G 671 N/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.9) 
22 38120573 TRIOBP G C 670 E/D NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.75) 
22 38120524 TRIOBP G T 654 R/L NON_SYNONYMOUS_CODING benign(0.192) tolerated(0.3) 
2 179544685 TTN C CTCT 9928 E/EE NON_SYNONYMOUS_CODING . . 
2 179634421 TTN T G 2917 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.539) . 
2 179419226 TTN A C 20676 I/M NON_SYNONYMOUS_CODING possibly_damaging(0.789) . 
2 179440352 TTN A C 14563 C/G NON_SYNONYMOUS_CODING probably_damaging(0.969) . 
2 179621111 TTN C T 3527 A/T NON_SYNONYMOUS_CODING unknown(0) . 
22 18640569 USP18 G C 47 A/P NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.2) 
22 18640566 USP18 AGG A 46 . FRAMESHIFT_CODING . . 
6 41774681 USP49 T G 14 Q/P NON_SYNONYMOUS_CODING possibly_damaging(0.883) tolerated(0.06) 
6 41774685 USP49 C G 13 A/P NON_SYNONYMOUS_CODING probably_damaging(0.986) deleterious(0.01) 
6 33423203 ZBTB9 G C 109 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.936) tolerated(0.38) 
6 33423200 ZBTB9 T C 108 L/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
16 87448068 ZCCHC14 T G 382 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.15) 
16 87448079 ZCCHC14 C G 378 R/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.13) 
8 102213947 ZNF706 A T 8 I/N NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
8 102213962 ZNF706 C G 3 R/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
19 52887918 ZNF880 A G 362 N/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 52887974 ZNF880 G A 381 E/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 52887982 ZNF880 A T 383 K/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.56) 
19 52887950 ZNF880 A G 373 I/V NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.25) 
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CHD4: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
1 51584465 C1orf185 C T 84 Q/* STOP_GAINED . . 
1 13448180 PRAMEF13 A G 432 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.34) 
10 51225724 AGAP8 G C 420 L/V NON_SYNONYMOUS_CODING probably_damaging(0.99) tolerated(0.12) 
17 58499989 C17orf64 C A 12 D/E NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.42) 
2 96551974 ENSG00000174501 A G 54 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 146215113 ENSG00000232637 G A 84 H/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.05) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
12 123335170 HIP1R A G 202 T/A NON_SYNONYMOUS_CODING unknown(0) . 
6 31324931 HLA-B A C 3 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 31324547 HLA-B G C 88 N/K NON_SYNONYMOUS_CODING benign(0.192) deleterious(0.02) 
19 50832152 KCNC3 T C 63 D/G NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
19 7051376 MBD3L2 G A 124 G/S NON_SYNONYMOUS_CODING possibly_damaging(0.6) tolerated(0.19) 
19 7032648 MBD3L5 G A 124 G/S NON_SYNONYMOUS_CODING benign(0.266) tolerated(0.23) 
19 9048362 MUC16 A G 11090 V/A NON_SYNONYMOUS_CODING unknown(0) . 
19 9088228 MUC16 G T 1196 P/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195514471 MUC4 A G 1327 M/T NON_SYNONYMOUS_CODING benign(0.057) . 
3 195514768 MUC4 T C 1228 D/G NON_SYNONYMOUS_CODING benign(0.144) . 
3 195506704 MUC4 T C 3916 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507494 MUC4 C T 3653 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195514733 MUC4 C A 1240 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.533) . 
3 195506914 MUC4 G A 3846 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195514948 MUC4 G A 1168 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195510601 MUC4 A G 2617 V/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510610 MUC4 A G 2614 L/P NON_SYNONYMOUS_CODING unknown(0) . 
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1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 145359049 NBPF10 A G 2997 K/E NON_SYNONYMOUS_CODING benign(0.049) tolerated(1) 
1 148023040 NBPF14 G C 162 S/C NON_SYNONYMOUS_CODING possibly_damaging(0.939) deleterious(0.02) 
1 148741720 NBPF16 T C 69 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248802469 OR2T35 C T 31 V/I NON_SYNONYMOUS_CODING benign(0) tolerated(0.2) 
19 15586705 PGLYRP2 G A 259 T/M NON_SYNONYMOUS_CODING possibly_damaging(0.884) deleterious(0) 
1 89273249 PKN2 A G 610 R/G NON_SYNONYMOUS_CODING probably_damaging(0.959) deleterious(0) 
2 130832358 POTEF T C 896 H/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 131221622 POTEI C T 665 M/I NON_SYNONYMOUS_CODING possibly_damaging(0.539) deleterious(0) 
14 20010235 POTEM A G 393 V/A NON_SYNONYMOUS_CODING benign(0.006) tolerated(1) 
1 13448184 PRAMEF13 C T 431 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
1 13448185 PRAMEF13 G C 430 F/L NON_SYNONYMOUS_CODING benign(0.006) tolerated(0.65) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696090 PRAMEF19 T C 223 K/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.47) 
22 18901004 PRODH C T 166 R/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.6) 
2 108479432 RGPD4 G A 805 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.67) tolerated(0.2) 
1 40318469 TRIT1 C T 85 R/H NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.55) 
19 21366170 ZNF431 G A 355 R/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.32) 
9 123476542 MEGF9 ACGGCGG A 22-24 AAV/V NON_SYNONYMOUS_CODING . . 
18 31319034 ASXL3 ACAGAACATAAGGAGT A 556-561 TEHKES/T NON_SYNONYMOUS_CODING . . 
11 66512290 C11orf80 G GGGC 26 G/GA NON_SYNONYMOUS_CODING . . 
22 37964408 CDC42EP1 CCAGCGCCTGCTGCAAACCCCT C 253-260 PAPAANPS/P NON_SYNONYMOUS_CODING . . 
15 90320134 MESP2 AGGGCAGGGGCAG A 183-186 GQGQ/- NON_SYNONYMOUS_CODING . . 
18 30352057 ENSG00000228835 GCGCCGGCC G 119-121 . FRAMESHIFT_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
3 133969437 RYK A AG 19-20 . SPLICE_SITE:FRAMESHIFT_CODING . . 
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CHD4: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID  
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97845632 ANKRD36 T C 566 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.23) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97783875 ANKRD36 T C 91 L/P NON_SYNONYMOUS_CODING probably_damaging(0.983) deleterious(0) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
22 39498015 APOBEC3H C G 171 R/G NON_SYNONYMOUS_CODING benign(0.057) deleterious(0.01) 
22 39498005 APOBEC3H T A 167 D/E NON_SYNONYMOUS_CODING benign(0.18) tolerated(0.35) 
11 64666179 ATG2A A G 1338 S/P NON_SYNONYMOUS_CODING benign(0.403) deleterious(0.02) 
11 64666182 ATG2A C G 1337 A/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
5 137503739 BRD8 G A 224 S/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
5 137503737 BRD8 C A 225 G/C NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
17 56386386 BZRAP1 G T 1416 P/Q NON_SYNONYMOUS_CODING possibly_damaging(0.948) deleterious(0) 
17 56386402 BZRAP1 A G 1411 S/P NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
17 56386383 BZRAP1 C CTT 1417 S/KS FRAMESHIFT_CODING . . 
12 112622338 C12orf51 T G 3056 T/P NON_SYNONYMOUS_CODING benign(0.187) . 
12 112688167 C12orf51 A C 822 V/G NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
19 16614150 C19orf44 T G 345 V/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.53) 
19 16614154 C19orf44 C G 346 D/E NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.95) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
17 45214528 CDC27 A T 635 Y/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
9 135947051 CEL G A 690 G/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 135947056 CEL C G 692 P/A NON_SYNONYMOUS_CODING benign(0.015) tolerated(0.92) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
12 122812697 CLIP1 C T 47 E/K NON_SYNONYMOUS_CODING possibly_damaging(0.918) deleterious(0.03) 
12 122812709 CLIP1 C T 43 E/K SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.33) 
22 19223229 CLTCL1 T C 320 K/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
22 19213150 CLTCL1 C A 652 V/F NON_SYNONYMOUS_CODING benign(0.419) deleterious(0) 
8 68062165 CSPP1 G A 703 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.64) 
8 68062160 CSPP1 T A 701 N/K NON_SYNONYMOUS_CODING benign(0.153) tolerated(0.98) 
10 126678128 CTBP2 T A 433 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
10 126678177 CTBP2 G T 416 N/K NON_SYNONYMOUS_CODING benign(0.01) tolerated(0.46) 
15 51766636 DMXL2 G A 1736 A/V NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 51766637 DMXL2 C A 1736 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.57) 
2 96614324 ENSG00000174501 C T 439 R/H NON_SYNONYMOUS_CODING possibly_damaging(0.923) deleterious(0.01) 
2 96610395 ENSG00000174501 C CA 490-491 . FRAMESHIFT_CODING . . 
12 10658524 ENSG00000180574 T G 8 V/G NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.07) 
12 10658616 ENSG00000180574 C A 39 Q/K NON_SYNONYMOUS_CODING probably_damaging(0.994) deleterious(0.01) 
16 15457629 ENSG00000183793 T A 314 T/S NON_SYNONYMOUS_CODING benign(0.158) tolerated(0.82) 
16 15457628 ENSG00000183793 G T 314 T/N NON_SYNONYMOUS_CODING benign(0.348) tolerated(0.39) 
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2 132021023 ENSG00000188219 G A 665 M/I NON_SYNONYMOUS_CODING possibly_damaging(0.539) deleterious(0) 
2 132021946 ENSG00000188219 G A 973 G/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
19 56283297 ENSG00000229292 G A 43 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.52) 
19 56284090 ENSG00000229292 G A 137 A/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.41) 
19 56283289 ENSG00000229292 A G 40 K/R NON_SYNONYMOUS_CODING benign(0.39) tolerated(0.51) 
9 46386995 ENSG00000237198 C A 3 R/M NON_SYNONYMOUS_CODING benign(0.013) tolerated(0.36) 
9 46386902 ENSG00000237198 G A 34 T/I NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
9 46386956 ENSG00000237198 C G 16 R/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
9 46386806 ENSG00000237198 C T 66 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(0.75) 
11 92616488 FAT3 T C 624 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.542) tolerated(0.12) 
11 92616485 FAT3 A C 623 N/T NON_SYNONYMOUS_CODING probably_damaging(0.978) tolerated(1) 
10 135440159 FRG2B T A 30 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.45) 
10 135440222 FRG2B C T 9 D/N NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.17) 
1 37319269 GRIK3 G A 387 R/W NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 37319270 GRIK3 C A 386 L/F NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.75) 
8 21983120 HR C G 511 A/P NON_SYNONYMOUS_CODING benign(0.255) tolerated(0.23) 
8 21973850 HR G C 1157 P/R NON_SYNONYMOUS_CODING possibly_damaging(0.441) tolerated(0.29) 
22 23247142 IGLJ3 T C 30 F/L NON_SYNONYMOUS_CODING unknown(0) . 
22 23247169 IGLJ3 T G 39 W/G NON_SYNONYMOUS_CODING unknown(0) . 
22 23247170 IGLJ3 G T 39 W/L NON_SYNONYMOUS_CODING unknown(0) . 
3 4725969 ITPR1 G A 1159 G/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
3 4725976 ITPR1 C A 1161 N/K NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.94) 
17 39346592 KRTAP9-1 ACCT A 152-153 TC/S NON_SYNONYMOUS_CODING . . 
17 39346433 KRTAP9-1 A C 99 T/P SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.08) 
1 152777625 LCE1C A C 110 S/R NON_SYNONYMOUS_CODING unknown(0) . 
1 152777627 LCE1C T C 110 S/G NON_SYNONYMOUS_CODING unknown(0) . 
17 35298121 LHX1 G C 204 K/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 35298125 LHX1 A C 206 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
4 151509276 LRBA G A 2085 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.909) deleterious(0.03) 
4 151236754 LRBA T G 2551 D/A NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.3) 
7 151927025 MLL3 A G 987 Y/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932997 MLL3 C T 892 G/R NON_SYNONYMOUS_CODING probably_damaging(1) . 
19 9005678 MUC16 G A 83 P/L NON_SYNONYMOUS_CODING benign(0) deleterious(0) 
19 9005645 MUC16 T C 94 Q/R NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.21) 
19 9005649 MUC16 G C 93 Q/E NON_SYNONYMOUS_CODING benign(0.002) tolerated(1) 
19 9005679 MUC16 G C 83 P/A NON_SYNONYMOUS_CODING benign(0.002) deleterious(0) 
19 9005714 MUC16 A C 71 V/G NON_SYNONYMOUS_CODING benign(0.015) tolerated(0.31) 
19 9005721 MUC16 C G 69 D/H NON_SYNONYMOUS_CODING benign(0.02) tolerated(0.14) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 9005697 MUC16 C T 77 A/T NON_SYNONYMOUS_CODING benign(0.138) tolerated(0.19) 
19 9005706 MUC16 T C 74 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.847) tolerated(0.65) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
3 195513846 MUC4 C G 1535 M/I NON_SYNONYMOUS_CODING benign(0.012) . 
3 195506387 MUC4 G T 4022 P/T NON_SYNONYMOUS_CODING benign(0.025) . 
3 195513847 MUC4 A G 1535 M/T NON_SYNONYMOUS_CODING benign(0.042) . 
3 195506549 MUC4 A G 3968 S/P NON_SYNONYMOUS_CODING benign(0.044) . 
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3 195506590 MUC4 G A 3954 P/L NON_SYNONYMOUS_CODING benign(0.057) . 
3 195505910 MUC4 T C 4181 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195505945 MUC4 A G 4169 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506137 MUC4 A G 4105 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506150 MUC4 T C 4101 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506215 MUC4 C G 4079 S/T NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508343 MUC4 A T 3370 S/T NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508777 MUC4 A G 3225 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508790 MUC4 T C 3221 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506364 MUC4 G C 4029 H/Q NON_SYNONYMOUS_CODING benign(0.118) . 
3 195506473 MUC4 A G 3993 V/A NON_SYNONYMOUS_CODING benign(0.137) . 
3 195505859 MUC4 T C 4198 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506099 MUC4 T C 4118 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506987 MUC4 T C 3822 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195508667 MUC4 T C 3262 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195510228 MUC4 C G 2741 E/D NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506582 MUC4 C T 3957 D/N NON_SYNONYMOUS_CODING benign(0.183) . 
3 195505836 MUC4 G C 4205 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195505909 MUC4 C T 4181 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195506149 MUC4 C T 4101 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195507228 MUC4 G C 3741 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195508716 MUC4 A C 3245 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195508789 MUC4 C T 3221 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195515017 MUC4 A G 1145 V/A NON_SYNONYMOUS_CODING benign(0.231) . 
3 195506569 MUC4 A G 3961 V/A NON_SYNONYMOUS_CODING benign(0.243) . 
3 195507428 MUC4 T A 3675 T/S NON_SYNONYMOUS_CODING benign(0.352) . 
3 195508787 MUC4 G T 3222 L/I NON_SYNONYMOUS_CODING benign(0.352) . 
3 195510194 MUC4 G C 2753 L/V NON_SYNONYMOUS_CODING benign(0.352) . 
3 195506076 MUC4 C G 4125 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195510636 MUC4 C A 2605 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195508661 MUC4 A G 3264 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195508709 MUC4 A G 3248 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195506533 MUC4 C A 3973 S/I NON_SYNONYMOUS_CODING possibly_damaging(0.473) . 
3 195505849 MUC4 G A 4201 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195505897 MUC4 G A 4185 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506650 MUC4 G A 3934 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506746 MUC4 G A 3902 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506963 MUC4 C T 3830 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507155 MUC4 C T 3766 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507193 MUC4 G A 3753 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507385 MUC4 G A 3689 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507398 MUC4 C T 3685 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507434 MUC4 C A 3673 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507446 MUC4 C T 3669 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508070 MUC4 C T 3461 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
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3 195508500 MUC4 G C 3317 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508502 MUC4 C T 3317 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508668 MUC4 G C 3261 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195510649 MUC4 G A 2601 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195505906 MUC4 G A 4182 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195506213 MUC4 T G 4080 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195506983 MUC4 G A 3823 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507443 MUC4 T G 3670 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507475 MUC4 G C 3659 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507827 MUC4 G A 3542 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195508678 MUC4 G T 3258 S/Y NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195506602 MUC4 G C 3950 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.717) . 
3 195511285 MUC4 T C 2389 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511286 MUC4 C T 2389 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511525 MUC4 T C 2309 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511526 MUC4 C T 2309 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195512117 MUC4 C T 2112 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195506501 MUC4 G A 3984 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.768) . 
3 195507604 MUC4 C G 3616 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.811) . 
3 195514844 MUC4 C G 1203 V/L NON_SYNONYMOUS_CODING possibly_damaging(0.817) . 
3 195506516 MUC4 T A 3979 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.862) . 
3 195507445 MUC4 T A 3669 D/V NON_SYNONYMOUS_CODING possibly_damaging(0.862) . 
3 195506117 MUC4 G T 4112 P/T NON_SYNONYMOUS_CODING possibly_damaging(0.864) . 
3 195507461 MUC4 G A 3664 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.864) . 
3 195515314 MUC4 A G 1046 F/S NON_SYNONYMOUS_CODING possibly_damaging(0.873) . 
3 195506146 MUC4 A G 4102 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195507694 MUC4 A G 3586 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195508786 MUC4 A G 3222 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195506294 MUC4 T C 4053 N/D NON_SYNONYMOUS_CODING possibly_damaging(0.9) . 
3 195506507 MUC4 C T 3982 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.916) . 
3 195506522 MUC4 C A 3977 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.916) . 
3 195505870 MUC4 G A 4194 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195508018 MUC4 G A 3478 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195506990 MUC4 C G 3821 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195507614 MUC4 C G 3613 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195508238 MUC4 C G 3405 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195508670 MUC4 C G 3261 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195515414 MUC4 T C 1013 S/G NON_SYNONYMOUS_CODING possibly_damaging(0.943) . 
3 195506554 MUC4 G A 3966 A/V NON_SYNONYMOUS_CODING probably_damaging(0.959) . 
3 195507605 MUC4 G A 3616 R/C NON_SYNONYMOUS_CODING probably_damaging(0.965) . 
3 195515008 MUC4 C G 1148 G/A NON_SYNONYMOUS_CODING probably_damaging(0.972) . 
3 195513826 MUC4 G A 1542 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195515449 MUC4 A T 1001 V/E NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
3 195515435 MUC4 C T 1006 A/T NON_SYNONYMOUS_CODING probably_damaging(0.985) . 
3 195513398 MUC4 C T 1685 G/S NON_SYNONYMOUS_CODING probably_damaging(0.99) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
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3 195508336 MUC4 C T 3372 G/D NON_SYNONYMOUS_CODING probably_damaging(0.994) . 
3 195510910 MUC4 G T 2514 P/H NON_SYNONYMOUS_CODING probably_damaging(0.997) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510347 MUC4 T C 2702 T/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510373 MUC4 T C 2693 D/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510374 MUC4 C T 2693 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510389 MUC4 A G 2688 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510396 MUC4 A C 2685 H/Q NON_SYNONYMOUS_CODING unknown(0) . 
3 195510492 MUC4 C A 2653 Q/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510611 MUC4 G T 2614 L/I NON_SYNONYMOUS_CODING unknown(0) . 
3 195510613 MUC4 C T 2613 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510614 MUC4 T C 2613 S/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195505742 MUC4 G C 963 H/D SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.662) tolerated(0.09) 
11 1018095 MUC6 G A 1569 P/L NON_SYNONYMOUS_CODING benign(0.014) deleterious(0.01) 
11 1016957 MUC6 T G 1948 R/S NON_SYNONYMOUS_CODING benign(0.034) tolerated(0.84) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1017307 MUC6 G A 1832 P/S NON_SYNONYMOUS_CODING benign(0.34) tolerated(0.21) 
11 1016919 MUC6 C T 1961 R/K NON_SYNONYMOUS_CODING possibly_damaging(0.496) tolerated(0.33) 
11 1017693 MUC6 T A 1703 H/L NON_SYNONYMOUS_CODING probably_damaging(0.978) tolerated(0.82) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1018207 MUC6 T C 1532 T/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.28) 
11 1018552 MUC6 G A 1417 P/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.73) 
17 12659746 MYOCD G A 397 D/N NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.71) 
17 12666520 MYOCD C A 792 S/R NON_SYNONYMOUS_CODING benign(0.073) tolerated(0.16) 
17 12661424 MYOCD A G 694 D/G NON_SYNONYMOUS_CODING benign(0.153) tolerated(0.44) 
9 139413211 NOTCH1 T G 311 T/P NON_SYNONYMOUS_CODING benign(0.004) deleterious(0) 
9 139413097 NOTCH1 T G 349 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 228430947 OBSCN C G 998 A/G NON_SYNONYMOUS_CODING benign(0.003) . 
1 228434292 OBSCN C G 1274 A/G NON_SYNONYMOUS_CODING benign(0.006) . 
1 248436582 OR2T33 T C 179 T/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 248436638 OR2T33 A G 160 V/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.4) 
7 95216407 PDK4 G A 301 S/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 95216415 PDK4 C A 298 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
8 110455187 PKHD1L1 A T 1469 Y/F NON_SYNONYMOUS_CODING possibly_damaging(0.799) tolerated(0.33) 
8 110455184 PKHD1L1 C T 1468 S/F NON_SYNONYMOUS_CODING probably_damaging(0.982) deleterious(0.01) 
12 106820987 POLR3B C T 314 L/F NON_SYNONYMOUS_CODING benign(0.088) deleterious(0) 
12 106820975 POLR3B C T 310 L/F SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.102) deleterious(0) 
6 106546559 PRDM1 A G 4 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.878) . 
6 106546576 PRDM1 A C 10 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.901) deleterious(0) 
9 33798075 PRSS3 T C 150 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33798574 PRSS3 G A 182 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 85571228 RETSAT G C 265 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.43) 
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2 85571225 RETSAT T C 266 E/G NON_SYNONYMOUS_CODING benign(0.048) tolerated(0.28) 
2 87205020 RGPD1 G T 810 R/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 87205031 RGPD1 T C 814 C/R NON_SYNONYMOUS_CODING possibly_damaging(0.85) tolerated(0.78) 
12 109017692 SELPLG G A 147 A/V ESSENTIAL_SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.52) 
12 109017693 SELPLG C T 147 A/T ESSENTIAL_SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.55) 
19 51920115 SIGLEC10 C T 171 E/K NON_SYNONYMOUS_CODING benign(0.124) tolerated(0.42) 
19 51920112 SIGLEC10 C T 172 E/K NON_SYNONYMOUS_CODING benign(0.16) tolerated(0.77) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142008783 TRBV3-1 A G 86 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008675 TRBV3-1 A G 50 T/A NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
7 142008785 TRBV3-1 A C 86 K/N NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.02) 
7 142008718 TRBV3-1 T C 64 I/T NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
7 142008672 TRBV3-1 G A 49 D/N NON_SYNONYMOUS_CODING benign(0.006) tolerated(0.61) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142168414 TRBV5-4 G C 103 D/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142168466 TRBV5-4 A C 86 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
7 142180566 TRBV6-5 A T 98 L/Q NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099581 TRBV7-8 A G 74 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
7 142099533 TRBV7-8 T C 90 E/G NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142099537 TRBV7-8 G T 89 P/T NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.39) 
6 41774681 USP49 T G 14 Q/P NON_SYNONYMOUS_CODING possibly_damaging(0.883) tolerated(0.06) 
6 41774685 USP49 C G 13 A/P NON_SYNONYMOUS_CODING probably_damaging(0.986) deleterious(0.01) 
6 33423203 ZBTB9 G C 109 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.936) tolerated(0.38) 
6 33423200 ZBTB9 T C 108 L/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
16 87448068 ZCCHC14 T G 382 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.15) 
16 87448079 ZCCHC14 C G 378 R/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.13) 
19 56701618 ZSCAN5B C T 356 A/T NON_SYNONYMOUS_CODING benign(0.043) tolerated(0.64) 
19 56703359 ZSCAN5B C G 150 A/P NON_SYNONYMOUS_CODING probably_damaging(0.975) tolerated(0.27) 
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CHD5: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
9 66553727 ENSG00000170161 T C 60 V/A NON_SYNONYMOUS_CODING benign(0) . 
1 146215113 ENSG00000232637 G A 84 H/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.05) 
10 81609619 FAM22E T G 632 S/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 148741720 NBPF16 T C 69 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 130832358 POTEF T C 896 H/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13696054 PRAMEF19 G A 235 S/F NON_SYNONYMOUS_CODING benign(0) tolerated(0.69) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696022 PRAMEF19 A G 246 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 13696047 PRAMEF19 A T 237 D/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
1 13329354 PRAMEF3 T C 309 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13329350 PRAMEF3 A T 310 V/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.46) 
15 82932518 ENSG00000215749 T C 502 E/G NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.24) 
14 20010235 POTEM A G 393 V/A NON_SYNONYMOUS_CODING benign(0.006) tolerated(1) 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
1 146409969 NBPF12 A C 263 I/L NON_SYNONYMOUS_CODING benign(0.036) deleterious(0) 
1 145359049 NBPF10 A G 2997 K/E NON_SYNONYMOUS_CODING benign(0.049) tolerated(1) 
2 108479432 RGPD4 G A 805 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.67) tolerated(0.2) 
9 40705798 FAM75A3 C A 1152 P/Q NON_SYNONYMOUS_CODING probably_damaging(0.968) tolerated(0.1) 
16 65561 WASH4P G C 385 A/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.04) 
3 195510526 MUC4 A G 2642 L/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510610 MUC4 A G 2614 L/P NON_SYNONYMOUS_CODING unknown(0) . 
14 20020201 POTEM G A 7 S/L NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
6 1611802 FOXC1 G GGGC 374-375 -/G NON_SYNONYMOUS_CODING . . 
15 90320134 MESP2 AGGGCAGGGGCAG A 183-186 GQGQ/- NON_SYNONYMOUS_CODING . . 
15 31776210 OTUD7A TGGC T 696 A/- NON_SYNONYMOUS_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
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CHD5: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
10 51464656 AGAP7 G C 600 D/E NON_SYNONYMOUS_CODING probably_damaging(0.995) tolerated(0.06) 
10 51465650 AGAP7 C T 269 R/Q NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.03) 
14 105415264 AHNAK2 G A 2175 S/L NON_SYNONYMOUS_CODING benign(0.104) tolerated(0.13) 
14 105415265 AHNAK2 A T 2175 S/T NON_SYNONYMOUS_CODING benign(0.104) tolerated(0.32) 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97845632 ANKRD36 T C 566 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.23) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
12 101368637 ANO4 A C 191 Y/S NON_SYNONYMOUS_CODING probably_damaging(0.983) tolerated(0.39) 
12 101368625 ANO4 G A 187 R/K SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
22 39498015 APOBEC3H C G 171 R/G NON_SYNONYMOUS_CODING benign(0.057) deleterious(0.01) 
22 39498005 APOBEC3H T A 167 D/E NON_SYNONYMOUS_CODING benign(0.18) tolerated(0.35) 
5 137503739 BRD8 G A 224 S/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
5 137503737 BRD8 C A 225 G/C NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
17 56386386 BZRAP1 G T 1416 P/Q NON_SYNONYMOUS_CODING possibly_damaging(0.948) deleterious(0) 
17 56386402 BZRAP1 A G 1411 S/P NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
12 112622338 C12orf51 T G 3056 T/P NON_SYNONYMOUS_CODING benign(0.187) . 
12 112688167 C12orf51 A C 822 V/G NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
20 18433273 C20orf12 T G 179 T/P NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.15) 
20 18433277 C20orf12 T G 25 H/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
1 40535481 CAP1 T C 310 S/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
1 40535490 CAP1 C G 313 R/G NON_SYNONYMOUS_CODING benign(0.048) tolerated(0.34) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
17 45214528 CDC27 A T 635 Y/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
17 7796819 CHD3 T C 301 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.88) . 
2 9599739 CPSF3 T A 593 I/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.51) 
2 9599742 CPSF3 G A 594 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.93) 
8 68062165 CSPP1 G A 703 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.64) 
8 68062160 CSPP1 T A 701 N/K NON_SYNONYMOUS_CODING benign(0.153) tolerated(0.98) 
15 51766636 DMXL2 G A 1736 A/V NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 51766637 DMXL2 C A 1736 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.57) 
16 15457629 ENSG00000183793 T A 314 T/S NON_SYNONYMOUS_CODING benign(0.158) tolerated(0.82) 
16 15457628 ENSG00000183793 G T 314 T/N NON_SYNONYMOUS_CODING benign(0.348) tolerated(0.39) 
16 15474873 ENSG00000183793 C T 11 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
19 56283297 ENSG00000229292 G A 43 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.52) 
19 56283289 ENSG00000229292 A G 40 K/R NON_SYNONYMOUS_CODING benign(0.39) tolerated(0.51) 
10 135440122 FRG2B T C 42 E/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
10 135440159 FRG2B T A 30 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.45) 
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22 30952000 GAL3ST1 T C 71 E/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
22 30951998 GAL3ST1 A C 72 C/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
15 82635194 GOLGA6L10 T C 459 E/G NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.33) 
15 82637069 GOLGA6L10 C G 339 E/D NON_SYNONYMOUS_CODING unknown(0) tolerated(0.47) 
15 82637079 GOLGA6L10 C T 336 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
1 37319269 GRIK3 G A 387 R/W NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 37319270 GRIK3 C A 386 L/F NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.75) 
14 106573358 IGHV3-11 T A 76 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573357 IGHV3-11 G T 76 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.62) 
14 107034854 IGHV5-51 C A 76 D/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
14 107034869 IGHV5-51 A C 71 Y/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
14 107034873 IGHV5-51 G C 69 I/M NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
14 107034874 IGHV5-51 A C 69 I/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.41) 
14 107034847 IGHV5-51 C T 78 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.37) 
14 107034846 IGHV5-51 T G 78 R/S NON_SYNONYMOUS_CODING benign(0.136) tolerated(0.44) 
12 247865 IQSEC3 C A 446 P/T NON_SYNONYMOUS_CODING possibly_damaging(0.925) deleterious(0.05) 
12 176089 IQSEC3 A G 14 Y/C NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
7 151932991 MLL3 G A 894 R/W NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151927025 MLL3 A G 987 Y/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932997 MLL3 C T 892 G/R NON_SYNONYMOUS_CODING probably_damaging(1) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9002636 MUC16 C T 35 V/I NON_SYNONYMOUS_CODING benign(0.051) tolerated(0.37) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 9002659 MUC16 C T 27 G/E NON_SYNONYMOUS_CODING possibly_damaging(0.582) tolerated(0.19) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
19 9002660 MUC16 C T 27 G/R NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.5) 
3 195513846 MUC4 C G 1535 M/I NON_SYNONYMOUS_CODING benign(0.012) . 
3 195513847 MUC4 A G 1535 M/T NON_SYNONYMOUS_CODING benign(0.042) . 
3 195506150 MUC4 T C 4101 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508790 MUC4 T C 3221 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506137 MUC4 A G 4105 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195507673 MUC4 A G 3593 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195505859 MUC4 T C 4198 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506099 MUC4 T C 4118 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195508667 MUC4 T C 3262 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195510228 MUC4 C G 2741 E/D NON_SYNONYMOUS_CODING benign(0.182) . 
3 195505836 MUC4 G C 4205 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195507228 MUC4 G C 3741 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195506149 MUC4 C T 4101 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195508789 MUC4 C T 3221 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195515017 MUC4 A G 1145 V/A NON_SYNONYMOUS_CODING benign(0.231) . 
3 195510194 MUC4 G C 2753 L/V NON_SYNONYMOUS_CODING benign(0.352) . 
3 195510636 MUC4 C G 2605 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195508661 MUC4 A G 3264 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195507193 MUC4 G A 3753 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507385 MUC4 G A 3689 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
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3 195507434 MUC4 C A 3673 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508500 MUC4 G C 3317 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508668 MUC4 G C 3261 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507446 MUC4 C T 3669 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506983 MUC4 G A 3823 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507827 MUC4 G A 3542 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507475 MUC4 G C 3659 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507443 MUC4 T G 3670 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195511285 MUC4 T C 2389 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511525 MUC4 T C 2309 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511286 MUC4 C T 2389 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511526 MUC4 C T 2309 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195507604 MUC4 C G 3616 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.811) . 
3 195507445 MUC4 T A 3669 D/V NON_SYNONYMOUS_CODING possibly_damaging(0.862) . 
3 195507653 MUC4 G A 3600 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.864) . 
3 195506146 MUC4 A G 4102 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195507694 MUC4 A G 3586 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195506914 MUC4 G A 3846 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195506990 MUC4 C G 3821 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195508670 MUC4 C G 3261 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195515414 MUC4 T C 1013 S/G NON_SYNONYMOUS_CODING possibly_damaging(0.943) . 
3 195515008 MUC4 C G 1148 G/A NON_SYNONYMOUS_CODING probably_damaging(0.972) . 
3 195514948 MUC4 G A 1168 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
3 195508336 MUC4 C T 3372 G/D NON_SYNONYMOUS_CODING probably_damaging(0.994) . 
3 195510347 MUC4 T C 2702 T/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510373 MUC4 T C 2693 D/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510396 MUC4 A C 2685 H/Q NON_SYNONYMOUS_CODING unknown(0) . 
3 195510614 MUC4 T C 2613 S/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510389 MUC4 A G 2688 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510466 MUC4 A G 2662 L/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510367 MUC4 G T 2695 S/Y NON_SYNONYMOUS_CODING unknown(0) . 
3 195510374 MUC4 C T 2693 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510611 MUC4 G T 2614 L/I NON_SYNONYMOUS_CODING unknown(0) . 
3 195510613 MUC4 C T 2613 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195505742 MUC4 G C 963 H/D SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.662) tolerated(0.09) 
11 1018095 MUC6 G A 1569 P/L NON_SYNONYMOUS_CODING benign(0.014) deleterious(0.01) 
11 1016959 MUC6 T C 1948 R/G NON_SYNONYMOUS_CODING benign(0.034) tolerated(0.6) 
11 1016957 MUC6 T G 1948 R/S NON_SYNONYMOUS_CODING benign(0.034) tolerated(0.84) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1017502 MUC6 T C 1767 T/A NON_SYNONYMOUS_CODING possibly_damaging(0.857) tolerated(0.44) 
11 1017693 MUC6 T A 1703 H/L NON_SYNONYMOUS_CODING probably_damaging(0.978) tolerated(0.82) 
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11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
1 145367800 NBPF10 G A 586 D/N NON_SYNONYMOUS_CODING benign(0.009) deleterious(0.03) 
1 145299838 NBPF10 G A 221 R/H NON_SYNONYMOUS_CODING unknown(0) tolerated(0.27) 
9 139413211 NOTCH1 T G 311 T/P NON_SYNONYMOUS_CODING benign(0.004) deleterious(0) 
9 139413097 NOTCH1 T G 349 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 228434292 OBSCN C G 1274 A/G NON_SYNONYMOUS_CODING benign(0.006) . 
1 228437749 OBSCN G A 1373 E/K NON_SYNONYMOUS_CODING probably_damaging(0.999) . 
1 248436582 OR2T33 T C 179 T/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 248436638 OR2T33 A G 160 V/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.4) 
8 110455187 PKHD1L1 A T 1469 Y/F NON_SYNONYMOUS_CODING possibly_damaging(0.799) tolerated(0.33) 
8 110455184 PKHD1L1 C T 1468 S/F NON_SYNONYMOUS_CODING probably_damaging(0.982) deleterious(0.01) 
19 4511376 PLIN4 C A 852 G/C NON_SYNONYMOUS_CODING benign(0) tolerated(0.14) 
19 4511379 PLIN4 G C 851 L/V NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33798574 PRSS3 G A 182 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33798075 PRSS3 T C 150 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 85571228 RETSAT G C 265 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.43) 
2 85571225 RETSAT T C 266 E/G NON_SYNONYMOUS_CODING benign(0.048) tolerated(0.28) 
12 109017672 SELPLG G C 154 P/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.4) 
12 109017674 SELPLG A G 153 V/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.94) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142008783 TRBV3-1 A G 86 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008785 TRBV3-1 A C 86 K/N NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.02) 
7 142008727 TRBV3-1 G T 67 S/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.4) 
7 142008718 TRBV3-1 T C 64 I/T NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
17 5036210 USP6 T G 67 I/M NON_SYNONYMOUS_CODING unknown(0) deleterious(0.04) 
17 5036211 USP6 C T 68 R/W NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
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CHD6: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
10 51748584 AGAP6 A G 37 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.72) 
2 97915896 ANKRD36 G A 1940 E/K NON_SYNONYMOUS_CODING benign(0.043) deleterious(0) 
1 22315762 CELA3B C A 268 A/E NON_SYNONYMOUS_CODING benign(0.203) tolerated(0.09) 
8 7673126 DEFB107A C A 9 V/F NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
15 82932518 ENSG00000215749 T C 502 E/G NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.24) 
15 82932561 ENSG00000215749 T C 488 S/G NON_SYNONYMOUS_CODING possibly_damaging(0.737) deleterious(0) 
15 82934598 ENSG00000215749 A G 314 C/R NON_SYNONYMOUS_CODING unknown(0) tolerated(0.4) 
1 146215113 ENSG00000232637 G A 84 H/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.05) 
1 146248970 ENSG00000232637 A C 6 L/R NON_SYNONYMOUS_CODING benign(0.037) tolerated(0.23) 
15 32686392 ENSG00000249931 T C 417 Q/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
10 47915891 FAM21B C A 270 S/Y NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.13) 
10 47911590 FAM21B G A 193 G/D NON_SYNONYMOUS_CODING benign(0.282) tolerated(0.14) 
10 89120394 FAM22D A C 108 N/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.39) 
9 97080827 FAM22F C G 565 G/R NON_SYNONYMOUS_CODING benign(0.424) tolerated(0.07) 
15 82637079 GOLGA6L10 C T 336 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 34825132 GOLGA8B C G 67 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.21) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 32609236 HLA-DQA1 G A 78 G/R NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.42) 
22 17590582 IL17RA G C 773 A/P NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(0.08) 
19 54725835 LILRB3 G C 175 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
4 151935787 LRBA C T 3 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.812) deleterious(0) 
17 44408066 LRRC37A C A 1141 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.11) 
17 62892071 LRRC37A3 G C 435 H/Q NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.66) 
7 100647338 MUC12 C A 4498 D/E NON_SYNONYMOUS_CODING benign(0.03) . 
7 100647339 MUC12 G A 4499 A/T NON_SYNONYMOUS_CODING benign(0.104) . 
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3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195510389 MUC4 A G 2688 S/P NON_SYNONYMOUS_CODING unknown(0) . 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 146409969 NBPF12 A C 263 I/L NON_SYNONYMOUS_CODING benign(0.036) deleterious(0) 
9 102590845 NR4A3 A C 185 D/A NON_SYNONYMOUS_CODING benign(0.381) tolerated(0.31) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 20010235 POTEM A G 393 V/A NON_SYNONYMOUS_CODING benign(0.006) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696022 PRAMEF19 A G 246 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 13329350 PRAMEF3 A T 310 V/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.46) 
1 13329354 PRAMEF3 T C 309 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 108479432 RGPD4 G A 805 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.67) tolerated(0.2) 
2 179634421 TTN T G 2917 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.539) . 
17 46115072 COPZ2 C CG 22 . FRAMESHIFT_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
4 152201016 PRSS48 T TGGCAG 41 . FRAMESHIFT_CODING . . 
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CHD6: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
19 58862835 A1BG T G 156 T/P NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.02) 
19 58862796 A1BG A C 169 S/A NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.03) 
9 139911506 ABCA2 C G 874 G/A NON_SYNONYMOUS_CODING probably_damaging(0.984) deleterious(0.02) 
9 139908380 ABCA2 C G 1450 A/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.01) 
10 101552060 ABCC2 C A 93 Q/K NON_SYNONYMOUS_CODING benign(0.017) tolerated(0.73) 
10 101544396 ABCC2 A C 22 D/A NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 101569915 ABCC2 G A 614 E/K NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.48) 
17 35631165 ACACA A T 214 N/K NON_SYNONYMOUS_CODING benign(0.016) tolerated(0.94) 
17 35445961 ACACA G T 976 Q/K NON_SYNONYMOUS_CODING benign(0.408) tolerated(0.24) 
17 35548174 ACACA G T 198 L/I NON_SYNONYMOUS_CODING possibly_damaging(0.919) tolerated(0.23) 
17 35445967 ACACA C T 974 E/K NON_SYNONYMOUS_CODING probably_damaging(0.973) deleterious(0) 
10 4879755 AKR1E2 C A 188 F/L NON_SYNONYMOUS_CODING benign(0.055) deleterious(0.03) 
10 4875551 AKR1E2 A C 73 T/P NON_SYNONYMOUS_CODING benign(0.426) deleterious(0) 
10 37482117 ANKRD30A C A 912 P/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
10 37482123 ANKRD30A A G 914 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.18) 
10 37482118 ANKRD30A C A 912 P/H NON_SYNONYMOUS_CODING possibly_damaging(0.596) deleterious(0.03) 
5 94030820 ANKRD32 A T 994 K/* STOP_GAINED . . 
5 94030836 ANKRD32 C A 999 T/N NON_SYNONYMOUS_CODING benign(0.144) deleterious(0.01) 
5 94030832 ANKRD32 G A 998 E/K NON_SYNONYMOUS_CODING probably_damaging(0.955) deleterious(0) 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97845632 ANKRD36 T C 566 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.23) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
22 39498015 APOBEC3H C G 171 R/G NON_SYNONYMOUS_CODING benign(0.057) deleterious(0.01) 
22 39498014 APOBEC3H T G 170 S/R NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
1 155311840 ASH1L C A 2788 D/Y NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 155322556 ASH1L C G 2441 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 1423284 ATAD3B A G 419 K/R NON_SYNONYMOUS_CODING probably_damaging(0.966) tolerated(0.25) 
1 1423286 ATAD3B C G 420 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.03) 
1 1392550 ATAD3C A G 244 K/R NON_SYNONYMOUS_CODING benign(0.184) tolerated(0.23) 
1 1392552 ATAD3C C G 245 R/G NON_SYNONYMOUS_CODING probably_damaging(0.99) deleterious(0) 
12 14613915 ATF7IP T A 882 V/E NON_SYNONYMOUS_CODING possibly_damaging(0.837) deleterious(0.01) 
12 14613917 ATF7IP C A 883 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.882) deleterious(0.04) 
11 64666179 ATG2A A G 1338 S/P NON_SYNONYMOUS_CODING benign(0.403) deleterious(0.02) 
11 64666182 ATG2A C G 1337 A/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
11 63426568 ATL3 G C 120 A/G NON_SYNONYMOUS_CODING probably_damaging(0.988) deleterious(0.01) 
11 63410966 ATL3 A C 220 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.065) deleterious(0.02) 
11 108175544 ATM C G 1880 T/R NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.03) 
11 108114752 ATM T A 190 I/K NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.03) 
11 108114755 ATM T A 191 I/N NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
3 113524266 ATP6V1A G C 552 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.902) tolerated(0.09) 
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3 113508633 ATP6V1A G T 312 V/L NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
20 3565431 ATRN C A 956 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.72) 
20 3565356 ATRN T G 931 C/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
21 30969925 BACH1 A G 184 M/V NON_SYNONYMOUS_CODING unknown(0) deleterious(0.01) 
21 30969926 BACH1 T G 184 M/R NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
6 70048890 BAI3 A C 55 T/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.03) 
6 69758083 BAI3 G A 705 S/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
15 73023727 BBS4 G T 93 A/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.8) 
15 73023725 BBS4 G T 92 C/F NON_SYNONYMOUS_CODING benign(0.119) tolerated(0.07) 
1 147095726 BCL9 A C 1083 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.899) tolerated(0.1) 
1 147092352 BCL9 G T 797 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.91) tolerated(0.13) 
1 147092353 BCL9 C T 798 R/W NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.19) 
5 137503739 BRD8 G A 224 S/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
5 137503737 BRD8 C A 225 G/C NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
3 9785283 BRPF1 T G 772 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.916) deleterious(0.01) 
3 9786696 BRPF1 A C 969 L/F NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.09) 
17 56385918 BZRAP1 T C 1572 K/R NON_SYNONYMOUS_CODING possibly_damaging(0.485) tolerated(0.19) 
17 56386383 BZRAP1 C CTT 1417 S/KS FRAMESHIFT_CODING . . 
12 112667600 C12orf51 T C 1719 K/E NON_SYNONYMOUS_CODING possibly_damaging(0.662) . 
12 112667597 C12orf51 G T 1720 L/I NON_SYNONYMOUS_CODING possibly_damaging(0.806) . 
12 112650430 C12orf51 T C 242 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.875) tolerated(0.17) 
12 112688167 C12orf51 A C 822 V/G NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
12 112688164 C12orf51 T C 823 E/G NON_SYNONYMOUS_CODING probably_damaging(0.98) . 
20 18433273 C20orf12 T G 179 T/P NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.15) 
20 18433277 C20orf12 T G 25 H/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
11 73789554 C2CD3 C G 211 E/D NON_SYNONYMOUS_CODING possibly_damaging(0.485) tolerated(0.52) 
11 73760510 C2CD3 A C 553 Y/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
2 231911622 C2orf72 G C 258 E/D NON_SYNONYMOUS_CODING possibly_damaging(0.741) tolerated(0.42) 
2 231911621 C2orf72 A C 258 E/A NON_SYNONYMOUS_CODING possibly_damaging(0.875) tolerated(0.6) 
3 126915976 C3orf56 T C 150 S/P NON_SYNONYMOUS_CODING benign(0.278) . 
3 126915973 C3orf56 A C 149 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.449) . 
4 100434303 C4orf17 G A 22 R/K NON_SYNONYMOUS_CODING possibly_damaging(0.942) tolerated(0.25) 
4 100434307 C4orf17 T A 23 N/K NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
3 53839025 CACNA1D C A 1887 Y/* STOP_GAINED . . 
3 53700459 CACNA1D T G 24 V/G NON_SYNONYMOUS_CODING benign(0.013) tolerated(0.2) 
3 53756421 CACNA1D T G 243 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
3 49897074 CAMKV T G 321 T/P NON_SYNONYMOUS_CODING probably_damaging(0.958) tolerated(0.08) 
3 49896952 CAMKV T G 367 H/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.24) 
9 138713600 CAMSAP1 G C 969 H/Q NON_SYNONYMOUS_CODING benign(0) tolerated(0.52) 
9 138714963 CAMSAP1 T G 515 N/T NON_SYNONYMOUS_CODING benign(0.284) tolerated(0.05) 
19 38851455 CATSPERG A C 618 T/P NON_SYNONYMOUS_CODING benign(0.18) tolerated(0.51) 
19 38851193 CATSPERG T G 514 C/G NON_SYNONYMOUS_CODING unknown(0) . 
17 77808570 CBX4 A G 291 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.727) deleterious(0.04) 
17 77808572 CBX4 C G 290 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.14) 
2 219893096 CCDC108 T G 494 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
2 219883763 CCDC108 C A 113 L/F NON_SYNONYMOUS_CODING unknown(0) . 
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19 49898378 CCDC155 C G 55 A/G NON_SYNONYMOUS_CODING benign(0.429) tolerated(0.07) 
19 49898375 CCDC155 T G 54 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 78069197 CCDC40 G A 990 D/N NON_SYNONYMOUS_CODING benign(0.027) tolerated(0.41) 
17 78073435 CCDC40 G C 1097 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.936) tolerated(0.3) 
13 37012869 CCNA1 A G 252 E/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
13 37012872 CCNA1 T G 253 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
19 14507228 CD97 A C 141 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.28) 
19 14515315 CD97 A C 475 T/P NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.08) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
1 109801674 CELSR2 A C 1311 T/P NON_SYNONYMOUS_CODING probably_damaging(0.994) deleterious(0.01) 
1 109794709 CELSR2 G C 670 A/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
20 34082403 CEP250 T G 973 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.805) deleterious(0) 
20 34090351 CEP250 G C 1329 R/P NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.14) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
1 6185909 CHD5 T C 771 D/G NON_SYNONYMOUS_CODING benign(0.009) deleterious(0.03) 
1 6185908 CHD5 A C 771 D/E NON_SYNONYMOUS_CODING benign(0.024) tolerated(0.27) 
15 101717654 CHSY1 T C 783 E/G NON_SYNONYMOUS_CODING benign(0.177) deleterious(0.03) 
15 101717647 CHSY1 A T 785 N/K NON_SYNONYMOUS_CODING possibly_damaging(0.452) tolerated(0.18) 
16 74446721 CLEC18B C G 165 S/T NON_SYNONYMOUS_CODING benign(0.08) deleterious(0.04) 
16 74446719 CLEC18B T G 166 T/P NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.03) 
22 19213150 CLTCL1 C A 652 V/F NON_SYNONYMOUS_CODING benign(0.419) deleterious(0) 
22 19213138 CLTCL1 C A 656 G/C NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0) 
5 79025224 CMYA5 C A 212 H/Q NON_SYNONYMOUS_CODING probably_damaging(0.959) deleterious(0) 
5 79034586 CMYA5 C A 3333 T/N NON_SYNONYMOUS_CODING probably_damaging(0.988) deleterious(0) 
7 147926842 CNTNAP2 A C 177 T/P NON_SYNONYMOUS_CODING probably_damaging(0.961) deleterious(0.04) 
7 147183121 CNTNAP2 A C 589 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 48264043 COL1A1 T G 1258 T/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
17 48264054 COL1A1 T G 1254 N/T NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
17 14110449 COX10 G C 417 W/C NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 14110451 COX10 A C 418 H/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 93870839 CPEB3 G T 522 D/E NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.06) 
10 93870841 CPEB3 C T 522 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.873) deleterious(0.03) 
9 99798872 CTSL2 C T 185 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.46) 
9 99797018 CTSL2 C G 299 V/L NON_SYNONYMOUS_CODING benign(0.212) deleterious(0) 
6 43013806 CUL7 C T 979 S/N NON_SYNONYMOUS_CODING benign(0.014) deleterious(0.01) 
6 43006603 CUL7 G T 1557 L/M NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
11 6645186 DCHS1 G C 2574 A/G NON_SYNONYMOUS_CODING probably_damaging(0.984) tolerated(0.17) 
11 6661865 DCHS1 A C 327 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.11) 
1 155004214 DCST2 A G 192 L/P NON_SYNONYMOUS_CODING probably_damaging(0.957) tolerated(0.32) 
1 155005949 DCST2 G C 77 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
1 162745952 DDR2 C A 692 T/N NON_SYNONYMOUS_CODING benign(0.027) deleterious(0.02) 
1 162745958 DDR2 T A 694 I/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 94517736 DDX24 T G 751 H/P NON_SYNONYMOUS_CODING benign(0.35) tolerated(0.2) 
14 94517728 DDX24 A G 754 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.746) deleterious(0.01) 
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14 94521529 DDX24 A C 621 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
13 42734171 DGKH G T 116 E/* STOP_GAINED . . 
13 42742929 DGKH C G 312 R/G NON_SYNONYMOUS_CODING probably_damaging(0.977) deleterious(0.01) 
3 38151765 DLEC1 A C 1146 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
3 38125677 DLEC1 C T 401 T/M NON_SYNONYMOUS_CODING possibly_damaging(0.937) deleterious(0.01) 
3 38157998 DLEC1 T G 1304 V/G NON_SYNONYMOUS_CODING probably_damaging(0.989) deleterious(0) 
17 76503840 DNAH17 G C 1425 H/Q NON_SYNONYMOUS_CODING benign(0.01) tolerated(0.17) 
17 76421666 DNAH17 C G 1509 V/L NON_SYNONYMOUS_CODING benign(0.047) tolerated(0.19) 
5 13866368 DNAH5 C A 1359 L/F NON_SYNONYMOUS_CODING benign(0.407) deleterious(0.01) 
5 13754379 DNAH5 C A 3496 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
6 38816506 DNAH8 G C 1493 V/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.86) 
6 38917321 DNAH8 A C 3858 T/P NON_SYNONYMOUS_CODING benign(0.023) tolerated(0.38) 
12 56221271 DNAJC14 A C 391 V/G NON_SYNONYMOUS_CODING probably_damaging(0.963) deleterious(0) 
12 56221154 DNAJC14 C G 430 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
11 6567433 DNHD1 G A 46 R/H NON_SYNONYMOUS_CODING possibly_damaging(0.449) deleterious(0) 
11 6566731 DNHD1 C G 1521 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.616) tolerated(0.45) 
11 6588672 DNHD1 G C 3978 R/P NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.14) 
19 10935797 DNM2 T G 260 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
19 10935800 DNM2 A G 261 E/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
8 25216495 DOCK5 G T 956 C/F NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.04) 
8 25216524 DOCK5 G C 966 D/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.04) 
8 25216525 DOCK5 A C 966 D/A NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.36) 
21 41648091 DSCAM G T 515 Y/* STOP_GAINED . . 
21 41514605 DSCAM G T 848 Q/K NON_SYNONYMOUS_CODING benign(0.042) tolerated(0.91) 
13 41515337 ELF1 T G 326 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.08) 
13 41556183 ELF1 G C 3 A/G NON_SYNONYMOUS_CODING benign(0.046) . 
16 15457629 ENSG00000183793 T A 314 T/S NON_SYNONYMOUS_CODING benign(0.158) tolerated(0.82) 
16 15457568 ENSG00000183793 C A 334 C/F NON_SYNONYMOUS_CODING benign(0.347) deleterious(0) 
16 15457628 ENSG00000183793 G T 314 T/N NON_SYNONYMOUS_CODING benign(0.348) tolerated(0.39) 
16 15474873 ENSG00000183793 C T 11 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
18 11619510 ENSG00000257513 A C 351 */E STOP_LOST . . 
18 11619549 ENSG00000257513 T G 338 K/Q NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.03) 
1 38227650 EPHA10 T C 93 I/V NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.21) 
1 38227136 EPHA10 A C 264 V/G NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0) 
1 16474932 EPHA2 A C 255 V/G NON_SYNONYMOUS_CODING benign(0.006) deleterious(0) 
1 16474930 EPHA2 G C 256 P/A NON_SYNONYMOUS_CODING probably_damaging(0.994) deleterious(0.02) 
4 66467416 EPHA5 G C 285 P/A NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.03) 
4 66467418 EPHA5 A C 284 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
1 6504703 ESPN T C 385 S/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
1 6488413 ESPN C T 141 P/L NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
16 74761211 FA2H T G 146 H/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
16 74761247 FA2H A C 134 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
6 71187018 FAM135A A C 131 T/P NON_SYNONYMOUS_CODING benign(0.013) deleterious(0) 
6 71187020 FAM135A A C 133 H/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
15 41043735 FAM82A2 C G 138 R/P NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.15) 
15 41029923 FAM82A2 A C 376 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
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2 207651481 FASTKD2 T A 484 S/R NON_SYNONYMOUS_CODING benign(0.291) deleterious(0.05) 
2 207651480 FASTKD2 G A 484 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.712) tolerated(0.34) 
11 92616488 FAT3 T C 624 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.542) tolerated(0.12) 
11 92616485 FAT3 A C 623 N/T NON_SYNONYMOUS_CODING probably_damaging(0.978) tolerated(1) 
3 13679659 FBLN2 T G 106 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.811) deleterious(0) 
3 13677992 FBLN2 A C 60 T/P NON_SYNONYMOUS_CODING probably_damaging(0.961) deleterious(0.01) 
7 100187851 FBXO24 A C 65 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.462) deleterious(0) 
7 100192051 FBXO24 A C 266 D/A NON_SYNONYMOUS_CODING possibly_damaging(0.907) deleterious(0.03) 
19 40367831 FCGBP T G 4377 T/P NON_SYNONYMOUS_CODING benign(0.097) tolerated(0.21) 
19 40384149 FCGBP T G 3154 N/T NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.4) 
6 167417226 FGFR1OP G A 76 S/N NON_SYNONYMOUS_CODING benign(0.064) tolerated(0.41) 
6 167417227 FGFR1OP T A 76 S/R NON_SYNONYMOUS_CODING probably_damaging(0.972) tolerated(0.15) 
9 117995 FOXD4 G C 42 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
9 118001 FOXD4 T C 40 E/G NON_SYNONYMOUS_CODING benign(0) deleterious(0) 
4 48559517 FRYL G T 231 Q/K NON_SYNONYMOUS_CODING benign(0.042) deleterious(0.02) 
4 48559519 FRYL G T 230 P/Q NON_SYNONYMOUS_CODING probably_damaging(0.97) tolerated(0.05) 
4 48583513 FRYL C G 405 R/P NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.01) 
4 22737710 GBA3 C G 55 S/R NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.12) 
4 22694669 GBA3 G C 11 A/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0.01) 
14 39591707 GEMIN2 G C 160 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
14 39601192 GEMIN2 C T 222 L/F NON_SYNONYMOUS_CODING probably_damaging(0.958) deleterious(0.01) 
14 39601187 GEMIN2 C CT 220 . FRAMESHIFT_CODING . . 
1 231411911 GNPAT A C 595 E/D NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.19) 
1 231413267 GNPAT A C 613 K/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
5 89986671 GPR98 A C 2255 N/T NON_SYNONYMOUS_CODING benign(0.361) tolerated(0.57) 
5 89949754 GPR98 G A 1455 E/K NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 186094789 HMCN1 C A 4185 Q/K NON_SYNONYMOUS_CODING benign(0.059) tolerated(0.7) 
1 186062678 HMCN1 C A 3358 T/N NON_SYNONYMOUS_CODING possibly_damaging(0.909) tolerated(0.35) 
1 186052030 HMCN1 T G 2941 Y/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 22175151 HSPG2 T G 2574 L/F NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
1 22199879 HSPG2 T TG 116 . FRAMESHIFT_CODING . . 
4 3136225 HTT T G 864 V/G NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.12) 
4 3230343 HTT T G 2617 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 106573357 IGHV3-11 G T 76 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.62) 
14 106573358 IGHV3-11 T A 76 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106993935 IGHV3-48 A G 77 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106994010 IGHV3-48 C T 52 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
14 106993933 IGHV3-48 A T 78 Y/N NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.23) 
14 107113742 IGHV3-64 C T 118 R/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.18) 
14 107113745 IGHV3-64 G A 117 A/V NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.06) 
14 106478321 IGHV4-4 C T 46 G/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
14 106478298 IGHV4-4 T C 54 S/G NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.51) 
14 106478322 IGHV4-4 C A 46 G/C NON_SYNONYMOUS_CODING benign(0.096) deleterious(0) 
14 106478310 IGHV4-4 T C 50 S/G NON_SYNONYMOUS_CODING benign(0.1) tolerated(0.08) 
14 107034869 IGHV5-51 A C 71 Y/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
14 107034873 IGHV5-51 G C 69 I/M NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
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14 107034874 IGHV5-51 A C 69 I/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.41) 
1 18618361 IGSF21 T G 62 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
1 18691718 IGSF21 T G 181 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
7 50467818 IKZF1 C A 351 H/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.41) 
7 50455118 IKZF1 G C 222 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 105174274 INF2 T G 25 V/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.09) 
14 105180963 INF2 C T 1155 A/V NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
7 41729523 INHBA T C 336 N/D NON_SYNONYMOUS_CODING benign(0.074) deleterious(0.02) 
7 41729465 INHBA G C 355 P/R NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
3 4725969 ITPR1 G A 1159 G/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
3 4725973 ITPR1 T A 1160 N/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.94) 
3 4725976 ITPR1 C A 1161 N/K NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.94) 
3 124114087 KALRN A C 688 T/P NON_SYNONYMOUS_CODING benign(0.119) deleterious(0.03) 
3 124044867 KALRN C T 376 S/F NON_SYNONYMOUS_CODING possibly_damaging(0.893) deleterious(0.05) 
17 61611421 KCNH6 G A 284 D/N NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.08) 
17 61611569 KCNH6 A C 333 H/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.02) 
17 61613079 KCNH6 T G 384 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.2) 
3 183396927 KLHL24 AC A 553 . FRAMESHIFT_CODING . . 
3 183396938 KLHL24 G GA 556 . FRAMESHIFT_CODING . . 
3 183226121 KLHL6 T G 212 D/A NON_SYNONYMOUS_CODING benign(0) deleterious(0.01) 
3 183210456 KLHL6 T G 464 T/P NON_SYNONYMOUS_CODING benign(0.013) deleterious(0.02) 
4 88106903 KLHL8 T A 89 I/F NON_SYNONYMOUS_CODING benign(0.139) deleterious(0.02) 
4 88106900 KLHL8 G A 90 P/S NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.15) 
12 53044334 KRT2 G C 197 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
12 53044336 KRT2 A C 196 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 50750696 L2HGDH G C 199 A/G NON_SYNONYMOUS_CODING benign(0.325) deleterious(0.04) 
14 50750699 L2HGDH A C 198 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
6 129828682 LAMA2 G C 936 A/P NON_SYNONYMOUS_CODING benign(0.305) tolerated(0.25) 
6 129513846 LAMA2 T G 544 Y/D NON_SYNONYMOUS_CODING possibly_damaging(0.893) deleterious(0.01) 
18 21364082 LAMA3 A C 520 T/P NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.27) 
18 21519304 LAMA3 A C 2994 T/P NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.18) 
1 209796950 LAMB3 A C 753 V/G NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.04) 
1 209791293 LAMB3 T G 1004 T/P NON_SYNONYMOUS_CODING probably_damaging(0.954) deleterious(0.01) 
2 141259399 LRP1B A C 2841 C/G NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
2 141625828 LRP1B G A 1330 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
1 160783621 LY9 A C 217 D/A NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.22) 
1 160784275 LY9 A C 266 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 235914653 LYST A C 60 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.856) deleterious(0) 
1 235955172 LYST T G 1457 H/P NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 20198700 MACC1 G T 428 D/E NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.57) 
7 20198702 MACC1 C T 428 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.604) tolerated(0.18) 
1 39945661 MACF1 A C 284 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.564) tolerated(0.16) 
1 39934315 MACF1 T G 190 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.839) deleterious(0) 
1 117944954 MAN1A2 T A 150 I/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.96) 
1 117944964 MAN1A2 C A 153 N/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.96) 
15 43816035 MAP1A A C 788 Q/H NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
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15 43821989 MAP1A A C 2726 D/A NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
5 71494945 MAP1B C A 1921 Y/* STOP_GAINED . . 
5 71491052 MAP1B C A 641 Q/K NON_SYNONYMOUS_CODING benign(0.007) tolerated(1) 
5 71490953 MAP1B G A 608 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.792) tolerated(0.27) 
5 71490955 MAP1B C A 608 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.792) tolerated(0.67) 
21 47666659 MCM3AP A C 1478 S/A NON_SYNONYMOUS_CODING probably_damaging(0.973) deleterious(0) 
21 47665086 MCM3AP A C 1558 V/G NON_SYNONYMOUS_CODING probably_damaging(0.975) tolerated(0.63) 
15 41961151 MGA C G 20 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.3) 
15 42040862 MGA C A 1747 T/N NON_SYNONYMOUS_CODING possibly_damaging(0.812) deleterious(0) 
15 42000043 MGA A C 769 N/T NON_SYNONYMOUS_CODING possibly_damaging(0.911) deleterious(0) 
11 12315177 MICALCL A G 67 R/G NON_SYNONYMOUS_CODING benign(0.09) deleterious(0) 
11 12315180 MICALCL C G 68 R/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
10 129901721 MKI67 G T 2794 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.806) tolerated(0.13) 
10 129901067 MKI67 G C 3012 R/G NON_SYNONYMOUS_CODING probably_damaging(0.986) tolerated(0.38) 
7 151927025 MLL3 A G 987 Y/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932997 MLL3 C T 892 G/R NON_SYNONYMOUS_CODING probably_damaging(1) . 
11 19077079 MRGPRX2 G C 291 L/V NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.08) 
11 19077074 MRGPRX2 C G 292 Q/H NON_SYNONYMOUS_CODING benign(0.115) deleterious(0.01) 
7 100636338 MUC12 T C 832 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
7 100634922 MUC12 G A 360 A/T NON_SYNONYMOUS_CODING unknown(0) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9002636 MUC16 C T 35 V/I NON_SYNONYMOUS_CODING benign(0.051) tolerated(0.37) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 8961997 MUC16 C A 1101 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.448) deleterious(0) 
19 9002659 MUC16 C T 27 G/E NON_SYNONYMOUS_CODING possibly_damaging(0.582) tolerated(0.19) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
19 9002660 MUC16 C T 27 G/R NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.5) 
19 9059082 MUC16 C A 9455 S/I NON_SYNONYMOUS_CODING unknown(0) . 
19 9063517 MUC16 A G 7977 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195346803 MUC20 T G 369 S/A NON_SYNONYMOUS_CODING possibly_damaging(0.891) tolerated(0.14) 
3 195346337 MUC20 G C 213 W/C NON_SYNONYMOUS_CODING possibly_damaging(0.952) tolerated(0.06) 
3 195513846 MUC4 C G 1535 M/I NON_SYNONYMOUS_CODING benign(0.012) . 
3 195513847 MUC4 A G 1535 M/T NON_SYNONYMOUS_CODING benign(0.042) . 
3 195506549 MUC4 A G 3968 S/P NON_SYNONYMOUS_CODING benign(0.044) . 
3 195507226 MUC4 A G 3742 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195507673 MUC4 A G 3593 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508790 MUC4 T C 3221 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195505859 MUC4 T C 4198 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506099 MUC4 T C 4118 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506987 MUC4 T C 3822 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195508667 MUC4 T C 3262 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506582 MUC4 C T 3957 D/N NON_SYNONYMOUS_CODING benign(0.183) . 
3 195508789 MUC4 C T 3221 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195515017 MUC4 A G 1145 V/A NON_SYNONYMOUS_CODING benign(0.231) . 
3 195506569 MUC4 A G 3961 V/A NON_SYNONYMOUS_CODING benign(0.243) . 
3 195508787 MUC4 G T 3222 L/I NON_SYNONYMOUS_CODING benign(0.352) . 
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3 195510194 MUC4 G C 2753 L/V NON_SYNONYMOUS_CODING benign(0.352) . 
3 195510636 MUC4 C A 2605 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195508661 MUC4 A G 3264 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195508709 MUC4 A G 3248 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195506533 MUC4 C A 3973 S/I NON_SYNONYMOUS_CODING possibly_damaging(0.473) . 
3 195505849 MUC4 G A 4201 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507193 MUC4 G A 3753 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507385 MUC4 G A 3689 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507434 MUC4 C A 3673 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507446 MUC4 C T 3669 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508500 MUC4 G C 3317 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508668 MUC4 G C 3261 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195510649 MUC4 G A 2601 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506983 MUC4 G A 3823 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507443 MUC4 T G 3670 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507475 MUC4 G C 3659 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507827 MUC4 G A 3542 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195511525 MUC4 T C 2309 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511526 MUC4 C T 2309 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195507604 MUC4 C G 3616 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.811) . 
3 195506510 MUC4 G C 3981 H/D NON_SYNONYMOUS_CODING possibly_damaging(0.817) . 
3 195507445 MUC4 T A 3669 D/V NON_SYNONYMOUS_CODING possibly_damaging(0.862) . 
3 195507694 MUC4 A G 3586 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195508786 MUC4 A G 3222 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195506294 MUC4 T C 4053 N/D NON_SYNONYMOUS_CODING possibly_damaging(0.9) . 
3 195506522 MUC4 C A 3977 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.916) . 
3 195505870 MUC4 G A 4194 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195506990 MUC4 C G 3821 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195508670 MUC4 C G 3261 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195515414 MUC4 T C 1013 S/G NON_SYNONYMOUS_CODING possibly_damaging(0.943) . 
3 195506554 MUC4 G A 3966 A/V NON_SYNONYMOUS_CODING probably_damaging(0.959) . 
3 195515449 MUC4 A T 1001 V/E NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
3 195510910 MUC4 G T 2514 P/H NON_SYNONYMOUS_CODING probably_damaging(0.997) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510347 MUC4 T C 2702 T/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510373 MUC4 T C 2693 D/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510374 MUC4 C T 2693 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510396 MUC4 A C 2685 H/Q NON_SYNONYMOUS_CODING unknown(0) . 
3 195510415 MUC4 G T 2679 S/Y NON_SYNONYMOUS_CODING unknown(0) . 
3 195510430 MUC4 G T 2674 P/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510437 MUC4 G A 2672 P/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510466 MUC4 A G 2662 L/P NON_SYNONYMOUS_CODING unknown(0) . 
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3 195510515 MUC4 C T 2646 A/T NON_SYNONYMOUS_CODING unknown(0) . 
11 1263706 MUC5B T G 1866 F/V NON_SYNONYMOUS_CODING benign(0.014) . 
11 1263847 MUC5B A C 1913 T/P NON_SYNONYMOUS_CODING benign(0.049) . 
11 1262540 MUC5B C T 1477 T/M NON_SYNONYMOUS_CODING probably_damaging(0.985) . 
11 1269643 MUC5B A G 3845 R/G NON_SYNONYMOUS_CODING unknown(0) . 
11 1270876 MUC5B A C 4256 T/P NON_SYNONYMOUS_CODING unknown(0) . 
11 1283520 MUC5B A C 5468 D/A NON_SYNONYMOUS_CODING unknown(0) . 
11 1283527 MUC5B G C 5470 Q/H NON_SYNONYMOUS_CODING unknown(0) . 
11 1016957 MUC6 T G 1948 R/S NON_SYNONYMOUS_CODING benign(0.034) tolerated(0.84) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1016919 MUC6 C T 1961 R/K NON_SYNONYMOUS_CODING possibly_damaging(0.496) tolerated(0.33) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1017655 MUC6 G A 1716 P/S NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.14) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016559 MUC6 G C 2081 A/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.59) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1017596 MUC6 T G 1735 Q/H NON_SYNONYMOUS_CODING unknown(0) tolerated(0.18) 
11 1017604 MUC6 T G 1733 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.36) 
11 1018552 MUC6 G A 1417 P/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.73) 
11 1018559 MUC6 A C 1414 S/R NON_SYNONYMOUS_CODING unknown(0) tolerated(0.05) 
11 1018561 MUC6 T C 1414 S/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.07) 
11 1018566 MUC6 G C 1412 A/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.29) 
11 1019308 MUC6 T G 1333 T/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
11 1024039 MUC6 T C 1097 D/G NON_SYNONYMOUS_CODING unknown(0) deleterious(0.01) 
13 77673117 MYCBP2 T G 2686 K/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.46) 
13 77672809 MYCBP2 A G 2789 L/P NON_SYNONYMOUS_CODING benign(0.017) deleterious(0.03) 
13 77672228 MYCBP2 G T 2983 Q/K NON_SYNONYMOUS_CODING benign(0.021) tolerated(0.45) 
13 77745669 MYCBP2 G C 1880 R/G NON_SYNONYMOUS_CODING probably_damaging(0.98) deleterious(0.02) 
15 72192270 MYO9A A T 1057 S/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.63) 
15 72192271 MYO9A C T 1057 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.55) 
18 3129302 MYOM1 T G 908 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.1) 
18 3112368 MYOM1 G C 1116 R/G NON_SYNONYMOUS_CODING probably_damaging(0.997) deleterious(0.01) 
1 145367800 NBPF10 G A 586 D/N NON_SYNONYMOUS_CODING benign(0.009) deleterious(0.03) 
1 145304625 NBPF10 T G 445 W/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
1 145304635 NBPF10 C T 448 A/V NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
22 37260160 NCF4 A C 36 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.775) tolerated(0.37) 
22 37260158 NCF4 T C 35 F/S NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
22 37261010 NCF4 A C 56 Y/S NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 51579171 NCOA4 C G 10 S/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.16) 
10 51585072 NCOA4 G T 391 V/F NON_SYNONYMOUS_CODING possibly_damaging(0.785) deleterious(0.03) 
12 8242854 NECAP1 A T 87 D/V NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
12 8242857 NECAP1 C T 88 S/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
18 77208908 NFATC1 A C 505 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.39) 
18 77211052 NFATC1 T G 563 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
11 129756238 NFRKB G C 147 L/V NON_SYNONYMOUS_CODING benign(0.351) tolerated(0.97) 
11 129756228 NFRKB A T 150 I/N NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0) 
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3 25777564 NGLY1 G T 360 D/E NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
3 25773841 NGLY1 C A 465 W/L NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
3 25777566 NGLY1 C T 360 D/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
5 156895736 NIPAL4 C G 176 A/G NON_SYNONYMOUS_CODING benign(0.008) tolerated(0.17) 
5 156890324 NIPAL4 C G 120 R/G NON_SYNONYMOUS_CODING unknown(0) . 
10 103918982 NOLC1 G C 214 A/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.17) 
10 103918981 NOLC1 A AC 213-214 . FRAMESHIFT_CODING . . 
9 139413211 NOTCH1 T G 311 T/P NON_SYNONYMOUS_CODING benign(0.004) deleterious(0) 
9 139413097 NOTCH1 T G 349 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 44579029 NPC1L1 T G 323 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.45) 
7 44579031 NPC1L1 C G 322 G/A NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.85) 
9 134003052 NUP214 C T 63 P/S NON_SYNONYMOUS_CODING benign(0.02) tolerated(0.63) 
9 134003042 NUP214 G T 59 L/F NON_SYNONYMOUS_CODING benign(0.123) deleterious(0.01) 
11 3765778 NUP98 T G 457 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.909) deleterious(0.02) 
11 3752738 NUP98 C G 538 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.04) 
1 228430947 OBSCN C G 998 A/G NON_SYNONYMOUS_CODING benign(0.003) . 
1 228464168 OBSCN G C 2080 V/L NON_SYNONYMOUS_CODING probably_damaging(0.998) . 
11 78525384 ODZ4 T G 580 T/P NON_SYNONYMOUS_CODING benign(0.103) tolerated(0.29) 
11 78380763 ODZ4 G T 2209 D/E NON_SYNONYMOUS_CODING benign(0.119) tolerated(0.63) 
3 193332725 OPA1 C A 82 Y/* STOP_GAINED . . 
3 193386379 OPA1 A C 121 L/F NON_SYNONYMOUS_CODING unknown(0) . 
3 193386395 OPA1 G C 127 A/P NON_SYNONYMOUS_CODING unknown(0) . 
1 248436582 OR2T33 T C 179 T/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 248436638 OR2T33 A G 160 V/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.4) 
2 60995630 PAPOLG C A 47 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.7) 
2 60988881 PAPOLG T G 18 V/G NON_SYNONYMOUS_CODING benign(0.025) tolerated(0.09) 
7 82595154 PCLO A T 1256 I/K NON_SYNONYMOUS_CODING benign(0.009) . 
7 82578977 PCLO A G 3574 Y/H NON_SYNONYMOUS_CODING probably_damaging(0.998) . 
9 35095103 PIGO C G 154 A/P NON_SYNONYMOUS_CODING possibly_damaging(0.756) deleterious(0) 
9 35093527 PIGO T C 277 D/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
9 35090633 PIGO C CA 895 . FRAMESHIFT_CODING . . 
5 108698639 PJA2 T G 518 E/D NON_SYNONYMOUS_CODING probably_damaging(0.971) tolerated(0.66) 
5 108698646 PJA2 C T 516 G/E NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.27) 
6 51920399 PKHD1 C T 608 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.574) deleterious(0.03) 
6 51920465 PKHD1 A C 586 F/V NON_SYNONYMOUS_CODING possibly_damaging(0.903) deleterious(0.04) 
8 110463218 PKHD1L1 C A 2064 Q/K NON_SYNONYMOUS_CODING benign(0.023) tolerated(1) 
8 110455184 PKHD1L1 C T 1468 S/F NON_SYNONYMOUS_CODING probably_damaging(0.982) deleterious(0.01) 
8 144992368 PLEC A G 4011 L/P NON_SYNONYMOUS_CODING probably_damaging(1) . 
8 145049468 PLEC T G 24 S/R NON_SYNONYMOUS_CODING unknown(0) . 
1 208272311 PLXNA2 G C 537 C/W NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 208272313 PLXNA2 A C 537 C/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 74179763 PNMA1 A C 194 S/A NON_SYNONYMOUS_CODING benign(0.121) tolerated(0.17) 
14 74179765 PNMA1 A C 193 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 108155497 PNPLA8 G T 47 Q/K NON_SYNONYMOUS_CODING benign(0.032) tolerated(0.4) 
7 108155503 PNPLA8 A C 45 L/V NON_SYNONYMOUS_CODING benign(0.271) tolerated(0.17) 
12 81655761 PPFIA2 T G 1157 */C STOP_LOST . . 
313 
 
12 81741484 PPFIA2 C T 669 S/N NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
12 81769573 PPFIA2 A C 196 V/G ESSENTIAL_SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
16 68349938 PRMT7 A G 19 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.922) deleterious(0.04) 
16 68379609 PRMT7 T C 270 F/S NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
9 134366847 PRRC2B G C 94 Q/H NON_SYNONYMOUS_CODING benign(0.088) deleterious(0) 
9 134357909 PRRC2B A C 1712 D/A NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.02) 
9 134357908 PRRC2B G C 1712 D/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
3 184019670 PSMD2 A G 172 E/G NON_SYNONYMOUS_CODING benign(0.046) tolerated(0.1) 
3 184019400 PSMD2 G A 145 V/M NON_SYNONYMOUS_CODING possibly_damaging(0.915) tolerated(0.07) 
3 184024549 PSMD2 T G 654 V/G NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
10 27702786 PTCHD3 A C 132 W/G NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.36) 
10 27700857 PTCHD3 A C 364 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
12 70934671 PTPRB A C 1546 V/G NON_SYNONYMOUS_CODING benign(0.341) tolerated(0.2) 
12 71003065 PTPRB A G 37 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.909) deleterious(0.02) 
3 191179127 PYDC2 T C 59 F/S NON_SYNONYMOUS_CODING benign(0.29) deleterious(0) 
3 191179129 PYDC2 A C 60 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.817) tolerated(0.06) 
14 36140611 RALGAPA1 G A 1223 S/F NON_SYNONYMOUS_CODING benign(0.229) deleterious(0.01) 
14 36153095 RALGAPA1 C T 958 S/N NON_SYNONYMOUS_CODING probably_damaging(0.99) deleterious(0.03) 
13 49033835 RB1 G A 658 A/T NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
13 49033836 RB1 C A 658 A/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
12 114392983 RBM19 T G 292 T/P NON_SYNONYMOUS_CODING benign(0.021) tolerated(0.16) 
12 114356207 RBM19 G C 811 R/G NON_SYNONYMOUS_CODING benign(0.37) deleterious(0) 
9 3293246 RFX3 A C 188 L/V NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.11) 
9 3395524 RFX3 C T 22 S/N NON_SYNONYMOUS_CODING benign(0.026) deleterious(0.04) 
12 130892351 RIMBP2 G C 86 R/G NON_SYNONYMOUS_CODING benign(0.13) tolerated(0.41) 
12 130892349 RIMBP2 A C 10 V/G NON_SYNONYMOUS_CODING unknown(0) . 
1 25233788 RUNX3 G T 129 T/K NON_SYNONYMOUS_CODING benign(0.086) tolerated(0.06) 
1 25228963 RUNX3 T G 247 T/P NON_SYNONYMOUS_CODING benign(0.102) tolerated(0.21) 
7 4007044 SDK1 A C 508 K/N NON_SYNONYMOUS_CODING benign(0.245) tolerated(0.36) 
7 4259872 SDK1 C A 139 Q/K NON_SYNONYMOUS_CODING benign(0.253) tolerated(0.31) 
7 4247821 SDK1 A C 17 T/P NON_SYNONYMOUS_CODING probably_damaging(0.975) tolerated(0.11) 
4 119718894 SEC24D C T 330 A/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.87) 
4 119718897 SEC24D G T 329 Q/K NON_SYNONYMOUS_CODING benign(0.291) tolerated(0.09) 
1 53158524 SELRC1 A C 41 V/G NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.86) 
1 53158521 SELRC1 T C 42 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.951) deleterious(0.01) 
22 26773662 SEZ6L G C 978 R/P NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.21) 
22 26709766 SEZ6L T G 638 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
6 144416537 SF3B5 A C 33 V/G NON_SYNONYMOUS_CODING benign(0.103) deleterious(0.01) 
6 144416535 SF3B5 T C 34 N/D NON_SYNONYMOUS_CODING probably_damaging(0.997) deleterious(0.01) 
2 230914604 SLC16A14 C A 92 L/F NON_SYNONYMOUS_CODING benign(0.045) tolerated(0.31) 
2 230914600 SLC16A14 T A 94 I/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
6 74351582 SLC17A5 G T 119 Y/* STOP_GAINED . . 
6 74351580 SLC17A5 A T 120 I/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 108681800 SLC25A24 C A 358 A/S NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.79) 
1 108681808 SLC25A24 T C 355 D/G NON_SYNONYMOUS_CODING benign(0.023) tolerated(0.28) 
10 98770775 SLIT1 A G 1106 S/P NON_SYNONYMOUS_CODING benign(0.104) deleterious(0.04) 
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10 98778796 SLIT1 T G 939 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.707) tolerated(0.09) 
4 20598044 SLIT2 G T 1105 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.823) deleterious(0.03) 
4 20525686 SLIT2 G A 446 A/T NON_SYNONYMOUS_CODING probably_damaging(0.99) deleterious(0.01) 
7 127484411 SND1 G C 426 S/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.71) 
7 127343337 SND1 G C 267 S/T NON_SYNONYMOUS_CODING probably_damaging(0.989) tolerated(0.11) 
4 7735055 SORCS2 G C 867 A/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.28) 
4 7735058 SORCS2 G C 868 A/P NON_SYNONYMOUS_CODING possibly_damaging(0.848) tolerated(0.28) 
4 88416177 SPARCL1 C T 53 E/K NON_SYNONYMOUS_CODING benign(0.263) deleterious(0.02) 
4 88416171 SPARCL1 C T 55 E/K NON_SYNONYMOUS_CODING probably_damaging(0.991) tolerated(0.06) 
1 16258001 SPEN A C 1756 T/P NON_SYNONYMOUS_CODING benign(0.053) tolerated(0.41) 
1 16258610 SPEN C G 1959 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.536) tolerated(0.05) 
1 16203071 SPEN G A 260 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.1) 
1 16203072 SPEN C A 260 S/R NON_SYNONYMOUS_CODING possibly_damaging(0.903) tolerated(0.13) 
22 42276900 SREBF2 A C 648 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.34) 
22 42273997 SREBF2 T G 544 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.501) deleterious(0) 
22 42276902 SREBF2 G C 682 A/P NON_SYNONYMOUS_CODING unknown(0) . 
2 120003090 STEAP3 C A 6 D/E NON_SYNONYMOUS_CODING benign(0.427) tolerated(0.09) 
2 120003088 STEAP3 G A 6 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.513) tolerated(0.08) 
6 36489582 STK38 G A 107 Q/* STOP_GAINED . . 
6 36489585 STK38 C A 106 V/F NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
9 113169203 SVEP1 T G 2893 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.28) 
9 113265476 SVEP1 C G 442 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.927) tolerated(0.19) 
10 29779847 SVIL A C 1374 L/R NON_SYNONYMOUS_CODING possibly_damaging(0.952) deleterious(0) 
10 29813511 SVIL A G 826 S/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
6 152470619 SYNE1 C G 374 R/P NON_SYNONYMOUS_CODING benign(0.029) deleterious(0.02) 
6 152786454 SYNE1 C T 624 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.649) tolerated(0.27) 
7 35288322 TBX20 A C 171 V/G NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0) 
7 35288307 TBX20 T G 176 D/A NON_SYNONYMOUS_CODING probably_damaging(0.993) deleterious(0) 
7 35242076 TBX20 C T 437 R/H NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
8 56737244 TGS1 A C 848 R/S NON_SYNONYMOUS_CODING benign(0.021) deleterious(0.02) 
8 56708572 TGS1 T G 468 V/G NON_SYNONYMOUS_CODING benign(0.189) deleterious(0) 
16 426329 TMEM8A A C 151 V/G NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.56) 
16 422045 TMEM8A A G 560 F/S NON_SYNONYMOUS_CODING benign(0.282) tolerated(0.13) 
12 83251115 TMTC2 T G 137 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.926) deleterious(0) 
12 83251120 TMTC2 C G 139 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142008783 TRBV3-1 A G 86 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008785 TRBV3-1 A C 86 K/N NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.02) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142149029 TRBV5-5 T G 81 D/A NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.01) 
7 142149030 TRBV5-5 C G 81 D/H NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
7 142180566 TRBV6-5 A T 98 L/Q NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180567 TRBV6-5 G C 98 L/V NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
7 142180573 TRBV6-5 T C 96 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.12) 
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7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099581 TRBV7-8 A G 74 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
21 38498381 TTC3 T G 394 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.032) deleterious(0) 
21 38560797 TTC3 T G 1642 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
2 179634424 TTN C G 2916 A/P NON_SYNONYMOUS_CODING benign(0.02) . 
2 179472353 TTN T C 8748 K/E NON_SYNONYMOUS_CODING benign(0.099) . 
2 179419226 TTN A C 20676 I/M NON_SYNONYMOUS_CODING possibly_damaging(0.789) . 
2 179413028 TTN C A 22169 V/L NON_SYNONYMOUS_CODING possibly_damaging(0.891) . 
2 179468803 TTN T C 9264 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.936) . 
2 179595427 TTN A C 4701 S/A NON_SYNONYMOUS_CODING unknown(0) . 
2 179597615 TTN G C 4186 R/G NON_SYNONYMOUS_CODING unknown(0) . 
9 140137382 TUBB2C A C 238 T/P NON_SYNONYMOUS_CODING benign(0.081) . 
9 140137500 TUBB2C G C 277 G/A NON_SYNONYMOUS_CODING possibly_damaging(0.914) . 
1 19524272 UBR4 T G 262 N/T NON_SYNONYMOUS_CODING possibly_damaging(0.9) tolerated(0.27) 
1 19442066 UBR4 T G 45 D/A NON_SYNONYMOUS_CODING possibly_damaging(0.932) tolerated(0.26) 
1 19415470 UBR4 A C 402 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.004) deleterious(0.01) 
2 128896359 UGGT1 T G 551 V/G NON_SYNONYMOUS_CODING benign(0.052) deleterious(0) 
2 128945090 UGGT1 A G 91 D/G NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.34) 
1 216251520 USH2A T G 1828 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 215960138 USH2A T G 3421 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.832) deleterious(0.05) 
1 215960153 USH2A A C 3416 C/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
4 76708327 USO1 C A 325 T/N NON_SYNONYMOUS_CODING possibly_damaging(0.778) tolerated(0.08) 
4 76708333 USO1 T G 327 V/G NON_SYNONYMOUS_CODING probably_damaging(0.988) deleterious(0) 
12 62798066 USP15 G C 924 A/P NON_SYNONYMOUS_CODING benign(0.063) tolerated(0.05) 
12 62786861 USP15 C A 788 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.581) tolerated(0.28) 
2 61456113 USP34 G T 2254 T/N NON_SYNONYMOUS_CODING benign(0) . 
2 61575497 USP34 G T 446 A/E NON_SYNONYMOUS_CODING probably_damaging(0.98) . 
17 5036210 USP6 T G 67 I/M NON_SYNONYMOUS_CODING unknown(0) deleterious(0.04) 
17 5036211 USP6 C T 68 R/W NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
12 101685769 UTP20 G T 354 V/L NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.26) 
12 101764315 UTP20 C A 2221 Q/K NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 12317102 VPS13D T G 300 V/G NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.1) 
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1 12387776 VPS13D A C 2688 T/P NON_SYNONYMOUS_CODING benign(0.007) tolerated(0.26) 
7 38781702 VPS41 T A 714 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
7 38781705 VPS41 C A 713 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
12 118511659 VSIG10 ATGATCACCTCGGGCTGGG A 349-355 TQPEVII/I NON_SYNONYMOUS_CODING . . 
12 118519961 VSIG10 C T 212 R/Q NON_SYNONYMOUS_CODING probably_damaging(0.974) tolerated(0.41) 
2 98779398 VWA3B T G 208 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.485) tolerated(0.06) 
2 98736120 VWA3B C G 146 L/V NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.14) 
1 20671955 VWA5B1 A C 878 N/T NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.31) 
1 20678602 VWA5B1 C A 1031 S/R NON_SYNONYMOUS_CODING probably_damaging(0.976) deleterious(0.05) 
3 49051528 WDR6 T G 884 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.517) deleterious(0.01) 
3 49049503 WDR6 C G 209 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.649) deleterious(0.03) 
1 22446566 WNT4 C G 345 V/L NON_SYNONYMOUS_CODING possibly_damaging(0.798) deleterious(0.05) 
1 22446565 WNT4 A G 345 V/A NON_SYNONYMOUS_CODING probably_damaging(0.984) deleterious(0.02) 
16 69921959 WWP2 A C 241 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.36) 
16 69833118 WWP2 G C 87 S/T NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.03) 
3 39230842 XIRP1 T G 32 D/A NON_SYNONYMOUS_CODING benign(0.235) tolerated(0.21) 
3 39230866 XIRP1 A G 24 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.808) tolerated(0.08) 
3 39230843 XIRP1 C G 32 D/H NON_SYNONYMOUS_CODING probably_damaging(0.967) tolerated(0.07) 
16 87448068 ZCCHC14 T G 382 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.15) 
16 87448079 ZCCHC14 C G 378 R/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.13) 
20 39832697 ZHX3 T G 287 H/P NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
20 39831419 ZHX3 C G 713 S/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.68) 
7 148951025 ZNF212 G C 336 R/P NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.32) 
7 148950905 ZNF212 T G 296 V/G NON_SYNONYMOUS_CODING benign(0.159) deleterious(0.01) 
19 42584233 ZNF574 A G 582 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.615) deleterious(0) 
19 42583125 ZNF574 A C 213 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.819) tolerated(0.24) 
15 85326799 ZNF592 G A 298 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.3) 
15 85326800 ZNF592 T A 298 S/R NON_SYNONYMOUS_CODING benign(0.073) tolerated(0.11) 
1 227842961 ZNF678 G T 392 S/I NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.4) 
1 227843213 ZNF678 C T 476 T/I NON_SYNONYMOUS_CODING benign(0.102) tolerated(0.36) 
8 102213947 ZNF706 A T 8 I/N NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
8 102213962 ZNF706 C G 3 R/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
22 29445795 ZNRF3 C A 249 Y/* STOP_GAINED . . 
22 29383125 ZNRF3 T G 21 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
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CHD13: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
10 46321904 AGAP4 C T 260 R/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
22 16157622 ENSG00000206252 G C 106 P/R NON_SYNONYMOUS_CODING probably_damaging(0.989) . 
19 56283297 ENSG00000229292 G A 43 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.52) 
19 56284090 ENSG00000229292 G A 137 A/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.41) 
19 56283289 ENSG00000229292 A G 40 K/R NON_SYNONYMOUS_CODING benign(0.39) tolerated(0.51) 
1 146215113 ENSG00000232637 G A 84 H/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.05) 
10 47911590 FAM21B G A 193 G/D NON_SYNONYMOUS_CODING benign(0.282) tolerated(0.14) 
19 47259734 FKRP G C 343 E/Q NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 49388901 FRMPD2 C T 912 G/E NON_SYNONYMOUS_CODING benign(0.026) tolerated(0.06) 
16 30016636 INO80E T C 203 L/P NON_SYNONYMOUS_CODING probably_damaging(0.965) tolerated(0.15) 
19 50832152 KCNC3 T C 63 D/G NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
19 54725835 LILRB3 G C 175 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195510563 MUC4 G C 2630 P/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510565 MUC4 C T 2629 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510566 MUC4 T C 2629 S/G NON_SYNONYMOUS_CODING unknown(0) . 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 145359049 NBPF10 A G 2997 K/E NON_SYNONYMOUS_CODING benign(0.049) tolerated(1) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
18 14533105 POTEC G C 337 S/C NON_SYNONYMOUS_CODING probably_damaging(0.97) tolerated(0.19) 
2 130832358 POTEF T C 896 H/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 20010235 POTEM A G 393 V/A NON_SYNONYMOUS_CODING benign(0.006) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696022 PRAMEF19 A G 246 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 13696047 PRAMEF19 A T 237 D/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
1 13696054 PRAMEF19 G A 235 S/F NON_SYNONYMOUS_CODING benign(0) tolerated(0.69) 
1 13696090 PRAMEF19 T C 223 K/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.47) 
22 18901004 PRODH C T 166 R/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.6) 
2 108479432 RGPD4 G A 805 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.67) tolerated(0.2) 
7 72436652 TRIM74 A G 13 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
15 90320134 MESP2 AGGGCAGGGGCAG A 183-186 GQGQ/- NON_SYNONYMOUS_CODING . . 
17 46115072 COPZ2 C CG 22 . FRAMESHIFT_CODING . . 
17 46115084 COPZ2 T TGG 18 . FRAMESHIFT_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
3 133969437 RYK A AG 19-20 . SPLICE_SITE:FRAMESHIFT_CODING . . 
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CHD13: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97845632 ANKRD36 T C 566 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.23) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97845616 ANKRD36 G T 561 D/Y NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
12 101368637 ANO4 A C 191 Y/S NON_SYNONYMOUS_CODING probably_damaging(0.983) tolerated(0.39) 
12 101368625 ANO4 G A 187 R/K SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
22 39498015 APOBEC3H C G 171 R/G NON_SYNONYMOUS_CODING benign(0.057) deleterious(0.01) 
22 39498005 APOBEC3H T A 167 D/E NON_SYNONYMOUS_CODING benign(0.18) tolerated(0.35) 
11 64666179 ATG2A A G 1338 S/P NON_SYNONYMOUS_CODING benign(0.403) deleterious(0.02) 
11 64666182 ATG2A C G 1337 A/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
5 137503739 BRD8 G A 224 S/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
5 137503737 BRD8 C A 225 G/C NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
12 112622338 C12orf51 T G 3056 T/P NON_SYNONYMOUS_CODING benign(0.187) . 
12 112688167 C12orf51 A C 822 V/G NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
1 40535481 CAP1 T C 310 S/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
1 40535490 CAP1 C G 313 R/G NON_SYNONYMOUS_CODING benign(0.048) tolerated(0.34) 
19 14507228 CD97 A C 141 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.28) 
19 14507213 CD97 A C 136 T/P NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.01) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
17 45214528 CDC27 A T 635 Y/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
8 68062165 CSPP1 G A 703 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.64) 
8 68062160 CSPP1 T A 701 N/K NON_SYNONYMOUS_CODING benign(0.153) tolerated(0.98) 
15 51766636 DMXL2 G A 1736 A/V NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 51766637 DMXL2 C A 1736 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.57) 
10 47769356 ENSG00000215033 C A 59 D/E NON_SYNONYMOUS_CODING unknown(0) . 
10 47769358 ENSG00000215033 G A 60 G/D NON_SYNONYMOUS_CODING unknown(0) . 
9 46386995 ENSG00000237198 C A 3 R/M NON_SYNONYMOUS_CODING benign(0.013) tolerated(0.36) 
9 46386902 ENSG00000237198 G A 34 T/I NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
9 46386956 ENSG00000237198 C G 16 R/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
9 46386806 ENSG00000237198 C T 66 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(0.75) 
12 132445256 EP400 A C 31 H/P NON_SYNONYMOUS_CODING unknown(0) . 
12 132445273 EP400 T C 37 S/P NON_SYNONYMOUS_CODING unknown(0) . 
8 12285102 FAM86B2 T C 91 E/G NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
8 12285103 FAM86B2 C T 91 E/K NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
4 187518120 FAT1 T C 4194 I/V NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.34) 
4 187540958 FAT1 G A 2263 T/M NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
20 29628328 FRG1B C G 110 I/M NON_SYNONYMOUS_CODING benign(0.191) deleterious(0.03) 
319 
 
20 29623254 FRG1B G A 24 D/N SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.607) tolerated(0.6) 
10 135440123 FRG2B C T 42 E/K NON_SYNONYMOUS_CODING benign(0.009) tolerated(0.33) 
10 135440159 FRG2B T A 30 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.45) 
1 37319269 GRIK3 G A 387 R/W NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 37319270 GRIK3 C A 386 L/F NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.75) 
6 32489937 HLA-DRB5 G A 39 Q/* STOP_GAINED . . 
6 32489935 HLA-DRB5 C G 39 Q/H NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.12) 
6 32489852 HLA-DRB5 A G 67 L/S NON_SYNONYMOUS_CODING possibly_damaging(0.558) deleterious(0) 
14 106471410 IGHV1-3 T C 63 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106471515 IGHV1-3 C A 28 A/S NON_SYNONYMOUS_CODING probably_damaging(0.975) tolerated(0.17) 
14 106573354 IGHV3-11 A G 77 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573357 IGHV3-11 G T 76 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.62) 
14 106573358 IGHV3-11 T A 76 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573378 IGHV3-11 T G 69 Y/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.39) 
14 106573418 IGHV3-11 T C 56 I/V NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573423 IGHV3-11 C T 54 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.65) 
14 106573352 IGHV3-11 A T 78 Y/N NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.23) 
14 107034847 IGHV5-51 C T 78 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.37) 
14 107034854 IGHV5-51 C A 76 D/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
14 107034846 IGHV5-51 T G 78 R/S NON_SYNONYMOUS_CODING benign(0.136) tolerated(0.44) 
17 39346592 KRTAP9-1 ACCT A 152-153 TC/S NON_SYNONYMOUS_CODING . . 
17 39346433 KRTAP9-1 A C 99 T/P SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.08) 
1 152777625 LCE1C A C 110 S/R NON_SYNONYMOUS_CODING unknown(0) . 
1 152777627 LCE1C T C 110 S/G NON_SYNONYMOUS_CODING unknown(0) . 
12 122685179 LRRC43 C A 402 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.92) 
12 122685176 LRRC43 G A 401 R/K NON_SYNONYMOUS_CODING benign(0.005) tolerated(1) 
12 122685163 LRRC43 A G 397 K/E NON_SYNONYMOUS_CODING probably_damaging(0.99) tolerated(0.89) 
12 122685164 LRRC43 A G 397 K/R NON_SYNONYMOUS_CODING probably_damaging(0.99) tolerated(0.23) 
7 151927025 MLL3 A G 987 Y/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932997 MLL3 C T 892 G/R NON_SYNONYMOUS_CODING probably_damaging(1) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9002636 MUC16 C T 35 V/I NON_SYNONYMOUS_CODING benign(0.051) tolerated(0.37) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 9002659 MUC16 C T 27 G/E NON_SYNONYMOUS_CODING possibly_damaging(0.582) tolerated(0.19) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
19 9002660 MUC16 C T 27 G/R NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.5) 
3 195510653 MUC4 A C 2600 S/A NON_SYNONYMOUS_CODING benign(0.035) . 
3 195506549 MUC4 A G 3968 S/P NON_SYNONYMOUS_CODING benign(0.044) . 
3 195508796 MUC4 C G 3219 V/L NON_SYNONYMOUS_CODING benign(0.095) . 
3 195510228 MUC4 C G 2741 E/D NON_SYNONYMOUS_CODING benign(0.182) . 
3 195509212 MUC4 G A 3080 S/L NON_SYNONYMOUS_CODING benign(0.204) . 
3 195506569 MUC4 A G 3961 V/A NON_SYNONYMOUS_CODING benign(0.243) . 
3 195510649 MUC4 G A 2601 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195511076 MUC4 T A 2459 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.609) . 
3 195511102 MUC4 G A 2450 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
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3 195506542 MUC4 G T 3970 P/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
3 195510347 MUC4 T C 2702 T/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510509 MUC4 A C 2648 S/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510601 MUC4 A G 2617 V/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510610 MUC4 A G 2614 L/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510611 MUC4 G T 2614 L/I NON_SYNONYMOUS_CODING unknown(0) . 
3 195510613 MUC4 C T 2613 S/N NON_SYNONYMOUS_CODING unknown(0) . 
11 1018095 MUC6 G A 1569 P/L NON_SYNONYMOUS_CODING benign(0.014) deleterious(0.01) 
11 1016957 MUC6 T G 1948 R/S NON_SYNONYMOUS_CODING benign(0.034) tolerated(0.84) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1017307 MUC6 G A 1832 P/S NON_SYNONYMOUS_CODING benign(0.34) tolerated(0.21) 
11 1016919 MUC6 C T 1961 R/K NON_SYNONYMOUS_CODING possibly_damaging(0.496) tolerated(0.33) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1016583 MUC6 T G 2073 Q/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0.03) 
11 1018207 MUC6 T C 1532 T/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.28) 
11 1018552 MUC6 G A 1417 P/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.73) 
11 1018555 MUC6 C T 1416 V/I NON_SYNONYMOUS_CODING unknown(0) tolerated(0.39) 
9 139413211 NOTCH1 T G 311 T/P NON_SYNONYMOUS_CODING benign(0.004) deleterious(0) 
9 139417464 NOTCH1 T G 194 T/P NON_SYNONYMOUS_CODING benign(0.045) tolerated(0.07) 
9 139413097 NOTCH1 T G 349 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 228430947 OBSCN C G 998 A/G NON_SYNONYMOUS_CODING benign(0.003) . 
1 228434292 OBSCN C G 1274 A/G NON_SYNONYMOUS_CODING benign(0.006) . 
1 248436582 OR2T33 T C 179 T/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 248436638 OR2T33 A G 160 V/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.4) 
6 106546559 PRDM1 A G 4 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.878) . 
6 106546576 PRDM1 A C 10 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.901) deleterious(0) 
8 48817516 PRKDC C G 985 E/D NON_SYNONYMOUS_CODING probably_damaging(0.976) tolerated(0.13) 
8 48732067 PRKDC T A 3113 Y/F NON_SYNONYMOUS_CODING probably_damaging(0.992) tolerated(0.18) 
9 33794812 PRSS3 G T 8 G/V NON_SYNONYMOUS_CODING benign(0) deleterious(0) 
9 33798075 PRSS3 T C 150 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33798574 PRSS3 G A 182 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 85571228 RETSAT G C 265 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.43) 
2 85571225 RETSAT T C 266 E/G NON_SYNONYMOUS_CODING benign(0.048) tolerated(0.28) 
2 87205020 RGPD1 G T 810 R/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 87204998 RGPD1 G A 803 A/T NON_SYNONYMOUS_CODING benign(0.15) tolerated(0.19) 
2 87205031 RGPD1 T C 814 C/R NON_SYNONYMOUS_CODING possibly_damaging(0.85) tolerated(0.78) 
18 76752544 SALL3 G T 185 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.14) 
18 76752545 SALL3 C T 185 A/V NON_SYNONYMOUS_CODING unknown(0) tolerated(0.06) 
12 109017672 SELPLG G C 154 P/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.4) 
12 109017674 SELPLG A G 153 V/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.94) 
5 131705926 SLC22A5 A C 88 T/P NON_SYNONYMOUS_CODING benign(0.241) tolerated(0.16) 
5 131705923 SLC22A5 G C 87 A/P NON_SYNONYMOUS_CODING benign(0.388) tolerated(0.12) 
1 16262465 SPEN A C 3244 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.05) 
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1 16262471 SPEN A C 3246 T/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0.02) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142008783 TRBV3-1 A G 86 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008675 TRBV3-1 A G 50 T/A NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
7 142008785 TRBV3-1 A C 86 K/N NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.02) 
7 142008718 TRBV3-1 T C 64 I/T NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
7 142008672 TRBV3-1 G A 49 D/N NON_SYNONYMOUS_CODING benign(0.006) tolerated(0.61) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142168414 TRBV5-4 G C 103 D/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142168466 TRBV5-4 A C 86 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099581 TRBV7-8 A G 74 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
7 142099533 TRBV7-8 T C 90 E/G NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142099537 TRBV7-8 G T 89 P/T NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.39) 
17 5036210 USP6 T G 67 I/M NON_SYNONYMOUS_CODING unknown(0) deleterious(0.04) 
17 5036211 USP6 C T 68 R/W NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
6 33423203 ZBTB9 G C 109 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.936) tolerated(0.38) 
6 33423200 ZBTB9 T C 108 L/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
19 53269628 ZNF600 T A 461 K/* STOP_GAINED . . 
19 53269621 ZNF600 A G 463 I/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.29) 
19 53269622 ZNF600 T A 463 I/F NON_SYNONYMOUS_CODING benign(0.204) deleterious(0.01) 
19 53269623 ZNF600 T C 462 I/M NON_SYNONYMOUS_CODING benign(0.381) deleterious(0.01) 
19 53269627 ZNF600 T A 461 K/M NON_SYNONYMOUS_CODING probably_damaging(0.96) tolerated(0.06) 
19 52887918 ZNF880 A G 362 N/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 52887929 ZNF880 C T 366 H/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 52887924 ZNF880 A T 364 N/I NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.24) 
19 52887930 ZNF880 A G 366 H/R NON_SYNONYMOUS_CODING benign(0.01) tolerated(0.48) 
19 52887923 ZNF880 A C 364 N/H NON_SYNONYMOUS_CODING benign(0.012) tolerated(0.19) 
19 52887926 ZNF880 G C 365 A/P NON_SYNONYMOUS_CODING benign(0.303) deleterious(0.01) 
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CHD16: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
10 46321880 AGAP4 C T 268 R/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 46321904 AGAP4 C T 260 R/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
10 51748584 AGAP6 A G 37 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.72) 
10 51464656 AGAP7 G C 600 D/E NON_SYNONYMOUS_CODING probably_damaging(0.995) tolerated(0.06) 
10 51465650 AGAP7 C T 269 R/Q NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.03) 
14 105415361 AHNAK2 T C 2143 N/D NON_SYNONYMOUS_CODING benign(0.004) tolerated(1) 
14 105417646 AHNAK2 G A 1381 P/L NON_SYNONYMOUS_CODING probably_damaging(0.99) deleterious(0.02) 
1 22315762 CELA3B C A 268 A/E NON_SYNONYMOUS_CODING benign(0.203) tolerated(0.09) 
10 89124859 FAM22D G A 473 G/S NON_SYNONYMOUS_CODING benign(0.183) tolerated(0.22) 
9 97080827 FAM22F C G 565 G/R NON_SYNONYMOUS_CODING benign(0.424) tolerated(0.07) 
8 12285064 FAM86B2 A G 104 S/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
8 12285132 FAM86B2 C G 81 C/S NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 31324931 HLA-B A C 3 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195510610 MUC4 A G 2614 L/P NON_SYNONYMOUS_CODING unknown(0) . 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 102590845 NR4A3 A C 185 D/A NON_SYNONYMOUS_CODING benign(0.381) tolerated(0.31) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 130832358 POTEF T C 896 H/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696022 PRAMEF19 A G 246 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 13696047 PRAMEF19 A T 237 D/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
1 13696054 PRAMEF19 G A 235 S/F NON_SYNONYMOUS_CODING benign(0) tolerated(0.69) 
2 108479432 RGPD4 G A 805 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.67) tolerated(0.2) 
7 72436652 TRIM74 A G 13 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
7 36552787 AOAH A AG 639 . SPLICE_SITE:FRAMESHIFT_CODING . . 
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CHD16: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
17 35631165 ACACA A T 214 N/K NON_SYNONYMOUS_CODING benign(0.016) tolerated(0.94) 
17 35445961 ACACA G T 976 Q/K NON_SYNONYMOUS_CODING benign(0.408) tolerated(0.24) 
17 35548174 ACACA G T 198 L/I NON_SYNONYMOUS_CODING possibly_damaging(0.919) tolerated(0.23) 
17 35445967 ACACA C T 974 E/K NON_SYNONYMOUS_CODING probably_damaging(0.973) deleterious(0) 
14 23559259 ACIN1 G A 181 S/F NON_SYNONYMOUS_CODING probably_damaging(0.958) deleterious(0) 
14 23531731 ACIN1 A C 1020 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.988) deleterious(0) 
10 4879755 AKR1E2 C A 188 F/L NON_SYNONYMOUS_CODING benign(0.055) deleterious(0.03) 
10 4875551 AKR1E2 A C 73 T/P NON_SYNONYMOUS_CODING benign(0.426) deleterious(0) 
2 29543655 ALK A C 503 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.496) deleterious(0.05) 
2 29416173 ALK C T 1594 E/K NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.01) 
4 114280246 ANK2 G A 3458 R/K NON_SYNONYMOUS_CODING probably_damaging(0.987) . 
4 114275541 ANK2 G A 1890 E/K NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
4 114275548 ANK2 A C 1892 H/P NON_SYNONYMOUS_CODING probably_damaging(0.996) . 
10 61836157 ANK3 G T 1494 Y/* STOP_GAINED . . 
10 61829520 ANK3 C G 3707 A/P NON_SYNONYMOUS_CODING probably_damaging(0.962) . 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97845632 ANKRD36 T C 566 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.23) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
22 39498015 APOBEC3H C G 171 R/G NON_SYNONYMOUS_CODING benign(0.057) deleterious(0.01) 
22 39498005 APOBEC3H T A 167 D/E NON_SYNONYMOUS_CODING benign(0.18) tolerated(0.35) 
1 155311840 ASH1L C A 2788 D/Y NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 155322556 ASH1L C G 2441 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 1423284 ATAD3B A G 419 K/R NON_SYNONYMOUS_CODING probably_damaging(0.966) tolerated(0.25) 
1 1423286 ATAD3B C G 420 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.03) 
1 1392550 ATAD3C A G 244 K/R NON_SYNONYMOUS_CODING benign(0.184) tolerated(0.23) 
1 1392552 ATAD3C C G 245 R/G NON_SYNONYMOUS_CODING probably_damaging(0.99) deleterious(0) 
11 64666179 ATG2A A G 1338 S/P NON_SYNONYMOUS_CODING benign(0.403) deleterious(0.02) 
11 64666182 ATG2A C G 1337 A/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
11 63426568 ATL3 G C 120 A/G NON_SYNONYMOUS_CODING probably_damaging(0.988) deleterious(0.01) 
11 63410966 ATL3 A C 220 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.065) deleterious(0.02) 
11 108175544 ATM C G 1880 T/R NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.03) 
11 108114752 ATM T A 190 I/K NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.03) 
11 108114755 ATM T A 191 I/N NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
3 113524266 ATP6V1A G C 552 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.902) tolerated(0.09) 
3 113508633 ATP6V1A G T 312 V/L NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
20 3565431 ATRN C A 956 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.72) 
20 3565356 ATRN T G 931 C/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
21 30969925 BACH1 A G 184 M/V NON_SYNONYMOUS_CODING unknown(0) deleterious(0.01) 
324 
 
21 30969926 BACH1 T G 184 M/R NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
6 70048890 BAI3 A C 55 T/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.03) 
6 69758083 BAI3 G A 705 S/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
5 137503739 BRD8 G A 224 S/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
5 137503737 BRD8 C A 225 G/C NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
3 9785283 BRPF1 T G 772 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.916) deleterious(0.01) 
3 9786696 BRPF1 A C 969 L/F NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.09) 
3 49689227 BSN C A 746 S/R NON_SYNONYMOUS_CODING benign(0.009) . 
3 49699596 BSN A G 3440 S/G NON_SYNONYMOUS_CODING unknown(0) . 
12 112688161 C12orf51 G C 824 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.806) . 
12 112650430 C12orf51 T C 242 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.875) tolerated(0.17) 
12 112688167 C12orf51 A C 822 V/G NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
12 112688164 C12orf51 T C 823 E/G NON_SYNONYMOUS_CODING probably_damaging(0.98) . 
1 172414269 C1orf105 C A 26 N/K NON_SYNONYMOUS_CODING benign(0.081) deleterious(0) 
1 172414265 C1orf105 T A 25 V/E NON_SYNONYMOUS_CODING benign(0.106) deleterious(0.01) 
11 73789554 C2CD3 C G 211 E/D NON_SYNONYMOUS_CODING possibly_damaging(0.485) tolerated(0.52) 
11 73760510 C2CD3 A C 553 Y/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
3 126915976 C3orf56 T C 150 S/P NON_SYNONYMOUS_CODING benign(0.278) . 
3 126915973 C3orf56 A C 149 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.449) . 
4 100434303 C4orf17 G A 22 R/K NON_SYNONYMOUS_CODING possibly_damaging(0.942) tolerated(0.25) 
4 100434307 C4orf17 T A 23 N/K NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
1 9011491 CA6 C G 90 A/G NON_SYNONYMOUS_CODING benign(0.424) deleterious(0.03) 
1 9030968 CA6 A C 258 T/P NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.15) 
3 53839025 CACNA1D C A 1887 Y/* STOP_GAINED . . 
3 53700459 CACNA1D T G 24 V/G NON_SYNONYMOUS_CODING benign(0.013) tolerated(0.2) 
3 53756421 CACNA1D T G 243 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 77808570 CBX4 A G 291 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.727) deleterious(0.04) 
17 77808572 CBX4 C G 290 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.14) 
13 37012869 CCNA1 A G 252 E/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
13 37012872 CCNA1 T G 253 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
20 34082403 CEP250 T G 973 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.805) deleterious(0) 
20 34090351 CEP250 G C 1329 R/P NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.14) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
1 6185909 CHD5 T C 771 D/G NON_SYNONYMOUS_CODING benign(0.009) deleterious(0.03) 
1 6185908 CHD5 A C 771 D/E NON_SYNONYMOUS_CODING benign(0.024) tolerated(0.27) 
19 42795827 CIC G C 939 G/A NON_SYNONYMOUS_CODING benign(0.106) tolerated(0.44) 
19 42795826 CIC G C 939 G/R NON_SYNONYMOUS_CODING possibly_damaging(0.765) deleterious(0.03) 
16 74446721 CLEC18B C G 165 S/T NON_SYNONYMOUS_CODING benign(0.08) deleterious(0.04) 
16 74446719 CLEC18B T G 166 T/P NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.03) 
19 7833803 CLEC4M A G 310 N/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
19 7830154 CLEC4M G A 72 V/M SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
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17 71193206 COG1 A C 243 N/T NON_SYNONYMOUS_CODING benign(0.011) tolerated(1) 
17 71192877 COG1 G C 183 A/P NON_SYNONYMOUS_CODING probably_damaging(0.98) tolerated(0.1) 
6 56044835 COL21A1 C A 61 V/F NON_SYNONYMOUS_CODING possibly_damaging(0.775) deleterious(0.02) 
6 56044517 COL21A1 C G 167 A/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
10 126678128 CTBP2 T A 433 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
10 126678177 CTBP2 G T 416 N/K NON_SYNONYMOUS_CODING benign(0.01) tolerated(0.46) 
6 43013806 CUL7 C T 979 S/N NON_SYNONYMOUS_CODING benign(0.014) deleterious(0.01) 
6 43006603 CUL7 G T 1557 L/M NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
11 6645186 DCHS1 G C 2574 A/G NON_SYNONYMOUS_CODING probably_damaging(0.984) tolerated(0.17) 
11 6661865 DCHS1 A C 327 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.11) 
14 94517736 DDX24 T G 751 H/P NON_SYNONYMOUS_CODING benign(0.35) tolerated(0.2) 
14 94517728 DDX24 A G 754 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.746) deleterious(0.01) 
14 94521529 DDX24 A C 621 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
13 42734171 DGKH G T 116 E/* STOP_GAINED . . 
13 42742929 DGKH C G 312 R/G NON_SYNONYMOUS_CODING probably_damaging(0.977) deleterious(0.01) 
3 38151765 DLEC1 A C 1146 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
3 38157998 DLEC1 T G 1304 V/G NON_SYNONYMOUS_CODING probably_damaging(0.989) deleterious(0) 
15 51766636 DMXL2 G A 1736 A/V NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 51766637 DMXL2 C A 1736 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.57) 
5 13866368 DNAH5 C A 1359 L/F NON_SYNONYMOUS_CODING benign(0.407) deleterious(0.01) 
5 13754379 DNAH5 C A 3496 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
6 38816506 DNAH8 G C 1493 V/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.86) 
6 38917321 DNAH8 A C 3858 T/P NON_SYNONYMOUS_CODING benign(0.023) tolerated(0.38) 
12 56221271 DNAJC14 A C 391 V/G NON_SYNONYMOUS_CODING probably_damaging(0.963) deleterious(0) 
12 56221154 DNAJC14 C G 430 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
8 25216495 DOCK5 G T 956 C/F NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.04) 
8 25216525 DOCK5 A C 966 D/A NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.36) 
21 41648091 DSCAM G T 515 Y/* STOP_GAINED . . 
21 41514605 DSCAM G T 848 Q/K NON_SYNONYMOUS_CODING benign(0.042) tolerated(0.91) 
13 41515337 ELF1 T G 326 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.08) 
13 41556183 ELF1 G C 3 A/G NON_SYNONYMOUS_CODING benign(0.046) . 
10 93577 ENSG00000173876 T A 180 K/M NON_SYNONYMOUS_CODING benign(0.366) deleterious(0) 
10 93576 ENSG00000173876 C A 180 K/N NON_SYNONYMOUS_CODING possibly_damaging(0.479) deleterious(0.01) 
19 56283297 ENSG00000229292 G A 43 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.52) 
19 56284090 ENSG00000229292 G A 137 A/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.41) 
19 56283289 ENSG00000229292 A G 40 K/R NON_SYNONYMOUS_CODING benign(0.39) tolerated(0.51) 
2 46609200 EPAS1 C A 753 D/E NON_SYNONYMOUS_CODING benign(0.003) tolerated(1) 
2 46609198 EPAS1 G A 753 D/N NON_SYNONYMOUS_CODING benign(0.418) tolerated(0.07) 
7 143096891 EPHA1 T C 230 T/A NON_SYNONYMOUS_CODING benign(0.124) tolerated(0.15) 
7 143096809 EPHA1 A C 257 V/G NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0) 
1 38227650 EPHA10 T C 93 I/V NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.21) 
1 38227136 EPHA10 A C 264 V/G NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0) 
4 66467416 EPHA5 G C 285 P/A NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.03) 
4 66467418 EPHA5 A C 284 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
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6 93967945 EPHA7 G A 661 A/V NON_SYNONYMOUS_CODING benign(0.012) tolerated(0.49) 
6 93967943 EPHA7 C A 662 V/L NON_SYNONYMOUS_CODING probably_damaging(0.994) deleterious(0) 
1 6504703 ESPN T C 385 S/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
1 6488413 ESPN C T 141 P/L NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
3 185797863 ETV5 G T 131 F/L NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.1) 
3 185802064 ETV5 G A 80 L/F NON_SYNONYMOUS_CODING benign(0.01) tolerated(0.51) 
16 74761211 FA2H T G 146 H/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
16 74761247 FA2H A C 134 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
6 71187018 FAM135A A C 131 T/P NON_SYNONYMOUS_CODING benign(0.013) deleterious(0) 
6 71187020 FAM135A A C 133 H/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
15 41043735 FAM82A2 C G 138 R/P NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.15) 
15 41029923 FAM82A2 A C 376 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
2 207651481 FASTKD2 T A 484 S/R NON_SYNONYMOUS_CODING benign(0.291) deleterious(0.05) 
2 207651480 FASTKD2 G A 484 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.712) tolerated(0.34) 
7 100187851 FBXO24 A C 65 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.462) deleterious(0) 
7 100192051 FBXO24 A C 266 D/A NON_SYNONYMOUS_CODING possibly_damaging(0.907) deleterious(0.03) 
3 121340505 FBXO40 T C 77 S/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
3 121340335 FBXO40 A C 20 N/T NON_SYNONYMOUS_CODING benign(0.052) tolerated(0.06) 
9 117371 FOXD4 C G 250 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 117995 FOXD4 G C 42 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
11 126146290 FOXRED1 T G 311 Y/D SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.804) deleterious(0.01) 
11 126146291 FOXRED1 A G 311 Y/C SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.938) deleterious(0) 
10 135440122 FRG2B T C 42 E/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
10 135440123 FRG2B C T 42 E/K NON_SYNONYMOUS_CODING benign(0.009) tolerated(0.33) 
10 135440159 FRG2B T A 30 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.45) 
17 7507359 FXR2 A C 90 W/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 7507352 FXR2 G GC 92 . FRAMESHIFT_CODING . . 
14 39591707 GEMIN2 G C 160 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
14 39601192 GEMIN2 C T 222 L/F NON_SYNONYMOUS_CODING probably_damaging(0.958) deleterious(0.01) 
14 39601187 GEMIN2 C CT 220 . FRAMESHIFT_CODING . . 
1 231411911 GNPAT A C 595 E/D NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.19) 
1 231413267 GNPAT A C 613 K/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
5 89986671 GPR98 A C 2255 N/T NON_SYNONYMOUS_CODING benign(0.361) tolerated(0.57) 
5 89949754 GPR98 G A 1455 E/K NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
5 176868780 GRK6 A C 574 T/P NON_SYNONYMOUS_CODING benign(0.006) deleterious(0.04) 
5 176863218 GRK6 T G 401 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
6 43589395 GTPBP2 G T 231 Q/K NON_SYNONYMOUS_CODING benign(0.143) tolerated(0.29) 
6 43589397 GTPBP2 A T 230 V/E NON_SYNONYMOUS_CODING possibly_damaging(0.88) deleterious(0) 
7 106836338 HBP1 A C 376 Q/P NON_SYNONYMOUS_CODING probably_damaging(0.963) deleterious(0.02) 
7 106836335 HBP1 G C 375 R/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
2 37215874 HEATR5B T G 43 R/S NON_SYNONYMOUS_CODING probably_damaging(0.982) tolerated(0.18) 
2 37215885 HEATR5B C T 40 E/K NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.15) 
15 28566562 HERC2 G C 6 F/L NON_SYNONYMOUS_CODING possibly_damaging(0.794) tolerated(0.37) 
15 28501298 HERC2 A C 895 S/A NON_SYNONYMOUS_CODING possibly_damaging(0.812) deleterious(0.03) 
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15 28566548 HERC2 T C 11 Q/R NON_SYNONYMOUS_CODING possibly_damaging(0.916) tolerated(0.79) 
6 32548544 HLA-DRB1 T G 248 I/L NON_SYNONYMOUS_CODING benign(0) deleterious(0) 
6 32557449 HLA-DRB1 G A 24 S/F NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.06) 
6 32549357 HLA-DRB1 G A 210 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.481) deleterious(0) 
8 28908545 HMBOX1 C G 402 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.537) tolerated(0.57) 
8 28866621 HMBOX1 T G 207 L/V NON_SYNONYMOUS_CODING possibly_damaging(0.653) tolerated(0.08) 
1 186094789 HMCN1 C A 4185 Q/K NON_SYNONYMOUS_CODING benign(0.059) tolerated(0.7) 
1 186062678 HMCN1 C A 3358 T/N NON_SYNONYMOUS_CODING possibly_damaging(0.909) tolerated(0.35) 
1 186052030 HMCN1 T G 2941 Y/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 23745525 HOMEZ T G 306 K/N NON_SYNONYMOUS_CODING benign(0.406) deleterious(0.02) 
14 23745520 HOMEZ A G 308 L/P NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.02) 
4 3109121 HTT G T 240 G/C NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
4 3136225 HTT T G 864 V/G NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.12) 
4 3230343 HTT T G 2617 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 18618361 IGSF21 T G 62 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
1 18691718 IGSF21 T G 181 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
7 50467818 IKZF1 C A 351 H/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.41) 
7 50455118 IKZF1 G C 222 R/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 105180962 INF2 G T 1155 A/S NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
14 105180963 INF2 C T 1155 A/V NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
7 41729523 INHBA T C 336 N/D NON_SYNONYMOUS_CODING benign(0.074) deleterious(0.02) 
7 41729465 INHBA G C 355 P/R NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
3 4725969 ITPR1 G A 1159 G/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
3 4725973 ITPR1 T A 1160 N/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.94) 
3 4725976 ITPR1 C A 1161 N/K NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.94) 
14 58934505 KIAA0586 C A 629 S/R NON_SYNONYMOUS_CODING benign(0.128) tolerated(0.16) 
14 58954767 KIAA0586 A C 1016 D/A NON_SYNONYMOUS_CODING possibly_damaging(0.902) deleterious(0.02) 
17 44109576 KIAA1267 C A 270 S/I NON_SYNONYMOUS_CODING possibly_damaging(0.527) deleterious(0.03) 
17 44109607 KIAA1267 T G 260 T/P NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
17 39346592 KRTAP9-1 ACCT A 152-153 TC/S NON_SYNONYMOUS_CODING . . 
17 39346433 KRTAP9-1 A C 99 T/P SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.08) 
13 76287349 LMO7 A T 86 D/V NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.01) 
13 76287354 LMO7 C G 88 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
4 151236754 LRBA T G 2551 D/A NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.3) 
4 151837565 LRBA G T 294 F/L NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.19) 
2 141259399 LRP1B A C 2841 C/G NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
2 141625828 LRP1B G A 1330 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
1 53746346 LRP8 T G 137 T/P NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.25) 
1 53724069 LRP8 A G 264 S/P NON_SYNONYMOUS_CODING probably_damaging(0.966) deleterious(0.01) 
11 65315445 LTBP3 A G 598 S/P NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.1) 
11 65310596 LTBP3 A C 859 V/G NON_SYNONYMOUS_CODING probably_damaging(0.985) tolerated(0.39) 
1 160783621 LY9 A C 217 D/A NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.22) 
1 160784275 LY9 A C 266 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 235914653 LYST A C 60 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.856) deleterious(0) 
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1 235955172 LYST T G 1457 H/P NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 20198700 MACC1 G T 428 D/E NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.57) 
7 20198702 MACC1 C T 428 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.604) tolerated(0.18) 
1 39945661 MACF1 A C 284 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.564) tolerated(0.16) 
1 39934315 MACF1 T G 190 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.839) deleterious(0) 
1 117944954 MAN1A2 T A 150 I/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.96) 
1 117944964 MAN1A2 C A 153 N/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.96) 
5 71491052 MAP1B C A 641 Q/K NON_SYNONYMOUS_CODING benign(0.007) tolerated(1) 
5 71490953 MAP1B G A 608 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.792) tolerated(0.27) 
5 71490955 MAP1B C A 608 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.792) tolerated(0.67) 
5 71490718 MAP1B G C 529 K/N NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
19 45783923 MARK4 A C 403 T/P NON_SYNONYMOUS_CODING benign(0.003) tolerated(1) 
19 45805775 MARK4 G C 16 R/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0.01) 
15 41961151 MGA C G 20 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.3) 
15 42040862 MGA C A 1747 T/N NON_SYNONYMOUS_CODING possibly_damaging(0.812) deleterious(0) 
15 42000043 MGA A C 769 N/T NON_SYNONYMOUS_CODING possibly_damaging(0.911) deleterious(0) 
11 12315177 MICALCL A G 67 R/G NON_SYNONYMOUS_CODING benign(0.09) deleterious(0) 
11 12315180 MICALCL C G 68 R/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
10 129901721 MKI67 G T 2794 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.806) tolerated(0.13) 
10 129901067 MKI67 G C 3012 R/G NON_SYNONYMOUS_CODING probably_damaging(0.986) tolerated(0.38) 
7 151932961 MLL3 G A 904 R/* STOP_GAINED . . 
7 151927025 MLL3 A G 987 Y/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932997 MLL3 C T 892 G/R NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 100636383 MUC12 G A 847 V/I NON_SYNONYMOUS_CODING possibly_damaging(0.871) . 
7 100645731 MUC12 G A 3963 E/K NON_SYNONYMOUS_CODING possibly_damaging(0.952) . 
7 100634922 MUC12 G A 360 A/T NON_SYNONYMOUS_CODING unknown(0) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9002636 MUC16 C T 35 V/I NON_SYNONYMOUS_CODING benign(0.051) tolerated(0.37) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 8961997 MUC16 C A 1101 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.448) deleterious(0) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
19 9002660 MUC16 C T 27 G/R NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.5) 
19 9059082 MUC16 C A 9455 S/I NON_SYNONYMOUS_CODING unknown(0) . 
19 9063517 MUC16 A G 7977 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195513846 MUC4 C G 1535 M/I NON_SYNONYMOUS_CODING benign(0.012) . 
3 195513847 MUC4 A G 1535 M/T NON_SYNONYMOUS_CODING benign(0.042) . 
3 195507226 MUC4 A G 3742 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195505859 MUC4 T C 4198 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195510228 MUC4 C G 2741 E/D NON_SYNONYMOUS_CODING benign(0.182) . 
3 195507228 MUC4 G C 3741 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195508716 MUC4 A C 3245 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195515017 MUC4 A G 1145 V/A NON_SYNONYMOUS_CODING benign(0.231) . 
3 195510194 MUC4 G C 2753 L/V NON_SYNONYMOUS_CODING benign(0.352) . 
3 195508709 MUC4 A G 3248 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
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3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507193 MUC4 G A 3753 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507385 MUC4 G A 3689 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507446 MUC4 C T 3669 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508500 MUC4 G C 3317 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195510649 MUC4 G A 2601 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506983 MUC4 G A 3823 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507443 MUC4 T G 3670 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507827 MUC4 G A 3542 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195511285 MUC4 T C 2389 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511286 MUC4 C T 2389 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511525 MUC4 T C 2309 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511526 MUC4 C T 2309 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195507445 MUC4 T A 3669 D/V NON_SYNONYMOUS_CODING possibly_damaging(0.862) . 
3 195507461 MUC4 G A 3664 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.864) . 
3 195507694 MUC4 A G 3586 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195505870 MUC4 G A 4194 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195515449 MUC4 A T 1001 V/E NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510373 MUC4 T C 2693 D/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510374 MUC4 C T 2693 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510396 MUC4 A C 2685 H/Q NON_SYNONYMOUS_CODING unknown(0) . 
3 195510415 MUC4 G T 2679 S/Y NON_SYNONYMOUS_CODING unknown(0) . 
3 195510466 MUC4 A G 2662 L/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510492 MUC4 C G 2653 Q/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510601 MUC4 A G 2617 V/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510611 MUC4 G T 2614 L/I NON_SYNONYMOUS_CODING unknown(0) . 
3 195510613 MUC4 C T 2613 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510614 MUC4 T C 2613 S/G NON_SYNONYMOUS_CODING unknown(0) . 
11 1263706 MUC5B T G 1866 F/V NON_SYNONYMOUS_CODING benign(0.014) . 
11 1263847 MUC5B A C 1913 T/P NON_SYNONYMOUS_CODING benign(0.049) . 
11 1283520 MUC5B A C 5468 D/A NON_SYNONYMOUS_CODING unknown(0) . 
11 1283527 MUC5B G C 5470 Q/H NON_SYNONYMOUS_CODING unknown(0) . 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1017307 MUC6 G A 1832 P/S NON_SYNONYMOUS_CODING benign(0.34) tolerated(0.21) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016559 MUC6 G C 2081 A/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.59) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1017604 MUC6 T G 1733 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.36) 
11 1018552 MUC6 G A 1417 P/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.73) 
11 1018561 MUC6 T C 1414 S/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.07) 
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13 77673117 MYCBP2 T G 2686 K/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.46) 
13 77672809 MYCBP2 A G 2789 L/P NON_SYNONYMOUS_CODING benign(0.017) deleterious(0.03) 
13 77672228 MYCBP2 G T 2983 Q/K NON_SYNONYMOUS_CODING benign(0.021) tolerated(0.45) 
15 72192270 MYO9A A T 1057 S/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.63) 
15 72192271 MYO9A C T 1057 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.55) 
18 3129302 MYOM1 T G 908 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.1) 
18 3112368 MYOM1 G C 1116 R/G NON_SYNONYMOUS_CODING probably_damaging(0.997) deleterious(0.01) 
18 3174178 MYOM1 G A 351 R/W NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
1 145367800 NBPF10 G A 586 D/N NON_SYNONYMOUS_CODING benign(0.009) deleterious(0.03) 
1 145302775 NBPF10 T G 330 Y/D NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
1 145304625 NBPF10 T G 445 W/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
1 145304635 NBPF10 C T 448 A/V NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
22 37260160 NCF4 A C 36 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.775) tolerated(0.37) 
22 37260158 NCF4 T C 35 F/S NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
12 8242854 NECAP1 A T 87 D/V NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
12 8242857 NECAP1 C T 88 S/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
18 77208908 NFATC1 A C 505 T/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.39) 
18 77211052 NFATC1 T G 563 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
11 129756238 NFRKB G C 147 L/V NON_SYNONYMOUS_CODING benign(0.351) tolerated(0.97) 
11 129739483 NFRKB G A 1171 S/F NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0.01) 
3 25777564 NGLY1 G T 360 D/E NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
3 25773841 NGLY1 C A 465 W/L NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
5 156895736 NIPAL4 C G 176 A/G NON_SYNONYMOUS_CODING benign(0.008) tolerated(0.17) 
5 156890324 NIPAL4 C G 120 R/G NON_SYNONYMOUS_CODING unknown(0) . 
3 48337624 NME6 A C 73 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
3 48340012 NME6 T C 7 S/G SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.053) tolerated(0.29) 
9 139413211 NOTCH1 T G 311 T/P NON_SYNONYMOUS_CODING benign(0.004) deleterious(0) 
9 139413097 NOTCH1 T G 349 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
16 15224274 NPIPP1 A G 143 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.911) deleterious(0.01) 
16 15222129 NPIPP1 G A 319 P/S NON_SYNONYMOUS_CODING unknown(0) . 
3 193332725 OPA1 C A 82 Y/* STOP_GAINED . . 
3 193386395 OPA1 G C 127 A/P NON_SYNONYMOUS_CODING unknown(0) . 
4 146063400 OTUD4 T G 590 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.915) deleterious(0.02) 
4 146063397 OTUD4 T TG 591 . FRAMESHIFT_CODING . . 
2 60995630 PAPOLG C A 47 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.7) 
2 60988881 PAPOLG T G 18 V/G NON_SYNONYMOUS_CODING benign(0.025) tolerated(0.09) 
16 66919665 PDP2 C G 493 A/G NON_SYNONYMOUS_CODING benign(0.211) deleterious(0.04) 
16 66918831 PDP2 A G 215 E/G NON_SYNONYMOUS_CODING probably_damaging(0.994) deleterious(0.01) 
5 108698639 PJA2 T G 518 E/D NON_SYNONYMOUS_CODING probably_damaging(0.971) tolerated(0.66) 
5 108698646 PJA2 C T 516 G/E NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.27) 
6 51920399 PKHD1 C T 608 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.574) deleterious(0.03) 
6 51920465 PKHD1 A C 586 F/V NON_SYNONYMOUS_CODING possibly_damaging(0.903) deleterious(0.04) 
8 110463218 PKHD1L1 C A 2064 Q/K NON_SYNONYMOUS_CODING benign(0.023) tolerated(1) 
8 110455184 PKHD1L1 C T 1468 S/F NON_SYNONYMOUS_CODING probably_damaging(0.982) deleterious(0.01) 
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8 110523026 PKHD1L1 T G 734 C/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.02) 
12 19475590 PLEKHA5 C G 47 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
12 19459391 PLEKHA5 C A 635 T/N NON_SYNONYMOUS_CODING unknown(0) . 
1 208252715 PLXNA2 A C 826 C/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 208272313 PLXNA2 A C 537 C/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
14 74179763 PNMA1 A C 194 S/A NON_SYNONYMOUS_CODING benign(0.121) tolerated(0.17) 
14 74179765 PNMA1 A C 193 V/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
7 108155497 PNPLA8 G T 47 Q/K NON_SYNONYMOUS_CODING benign(0.032) tolerated(0.4) 
7 108155503 PNPLA8 A C 45 L/V NON_SYNONYMOUS_CODING benign(0.271) tolerated(0.17) 
15 89862549 POLG A C 1005 V/G NON_SYNONYMOUS_CODING probably_damaging(0.991) tolerated(0.34) 
15 89864175 POLG T G 935 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
2 86272763 POLR1A A C 955 F/V NON_SYNONYMOUS_CODING probably_damaging(0.997) deleterious(0) 
2 86272426 POLR1A T G 982 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
12 81741484 PPFIA2 C T 669 S/N NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
12 81769573 PPFIA2 A C 196 V/G ESSENTIAL_SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
9 134366847 PRRC2B G C 94 Q/H NON_SYNONYMOUS_CODING benign(0.088) deleterious(0) 
9 134357909 PRRC2B A C 1712 D/A NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.02) 
9 134357908 PRRC2B G C 1712 D/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
3 184019670 PSMD2 A G 172 E/G NON_SYNONYMOUS_CODING benign(0.046) tolerated(0.1) 
3 184019400 PSMD2 G A 145 V/M NON_SYNONYMOUS_CODING possibly_damaging(0.915) tolerated(0.07) 
3 184024549 PSMD2 T G 654 V/G NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
10 27702786 PTCHD3 A C 132 W/G NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.36) 
10 27700857 PTCHD3 A C 364 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
12 70934671 PTPRB A C 1546 V/G NON_SYNONYMOUS_CODING benign(0.341) tolerated(0.2) 
12 71003065 PTPRB A G 37 S/P NON_SYNONYMOUS_CODING possibly_damaging(0.909) deleterious(0.02) 
3 191179127 PYDC2 T C 59 F/S NON_SYNONYMOUS_CODING benign(0.29) deleterious(0) 
3 191179129 PYDC2 A C 60 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.817) tolerated(0.06) 
13 49033835 RB1 G A 658 A/T NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
13 49033836 RB1 C A 658 A/D NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
9 3293246 RFX3 A C 188 L/V NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.11) 
9 3395524 RFX3 C T 22 S/N NON_SYNONYMOUS_CODING benign(0.026) deleterious(0.04) 
2 87205020 RGPD1 G T 810 R/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
2 87205031 RGPD1 T C 814 C/R NON_SYNONYMOUS_CODING possibly_damaging(0.85) tolerated(0.78) 
12 130892351 RIMBP2 G C 86 R/G NON_SYNONYMOUS_CODING benign(0.13) tolerated(0.41) 
12 130892349 RIMBP2 A C 10 V/G NON_SYNONYMOUS_CODING unknown(0) . 
7 4259872 SDK1 C A 139 Q/K NON_SYNONYMOUS_CODING benign(0.253) tolerated(0.31) 
7 4247821 SDK1 A C 17 T/P NON_SYNONYMOUS_CODING probably_damaging(0.975) tolerated(0.11) 
22 26773659 SEZ6L T C 977 L/P NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0) 
22 26773662 SEZ6L G C 978 R/P NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.21) 
22 26709766 SEZ6L T G 638 V/G NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
6 74351582 SLC17A5 G T 119 Y/* STOP_GAINED . . 
6 74351580 SLC17A5 A T 120 I/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 79249833 SLC38A10 A C 283 V/G NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
17 79254419 SLC38A10 C G 206 A/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
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4 20598044 SLIT2 G T 1105 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.823) deleterious(0.03) 
4 20525686 SLIT2 G A 446 A/T NON_SYNONYMOUS_CODING probably_damaging(0.99) deleterious(0.01) 
4 20525687 SLIT2 C A 446 A/E NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
4 88416177 SPARCL1 C T 53 E/K NON_SYNONYMOUS_CODING benign(0.263) deleterious(0.02) 
4 88416183 SPARCL1 C T 51 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) deleterious(0.01) 
4 88416171 SPARCL1 C T 55 E/K NON_SYNONYMOUS_CODING probably_damaging(0.991) tolerated(0.06) 
1 16258610 SPEN C G 1959 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.536) tolerated(0.05) 
1 16203071 SPEN G A 260 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.1) 
1 16203072 SPEN C A 260 S/R NON_SYNONYMOUS_CODING possibly_damaging(0.903) tolerated(0.13) 
6 36489582 STK38 G A 107 Q/* STOP_GAINED . . 
6 36489585 STK38 C A 106 V/F NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
22 24584027 SUSD2 C A 755 Y/* STOP_GAINED . . 
22 24579157 SUSD2 G T 70 G/V NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
6 152665230 SYNE1 C T 4000 E/K NON_SYNONYMOUS_CODING benign(0.42) . 
6 152786454 SYNE1 C T 624 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.649) tolerated(0.27) 
7 35288322 TBX20 A C 171 V/G NON_SYNONYMOUS_CODING probably_damaging(0.991) deleterious(0) 
7 35288307 TBX20 T G 176 D/A NON_SYNONYMOUS_CODING probably_damaging(0.993) deleterious(0) 
1 152084213 TCHH C G 494 E/Q NON_SYNONYMOUS_CODING unknown(0) . 
1 152084216 TCHH C G 493 E/Q NON_SYNONYMOUS_CODING unknown(0) . 
8 56737244 TGS1 A C 848 R/S NON_SYNONYMOUS_CODING benign(0.021) deleterious(0.02) 
8 56708572 TGS1 T G 468 V/G NON_SYNONYMOUS_CODING benign(0.189) deleterious(0) 
4 113199252 TIFA A T 107 N/K NON_SYNONYMOUS_CODING possibly_damaging(0.586) tolerated(0.22) 
4 113199244 TIFA T G 110 D/A NON_SYNONYMOUS_CODING possibly_damaging(0.907) tolerated(0.1) 
17 32956084 TMEM132E T C 310 F/S NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.5) 
17 32956086 TMEM132E A C 311 T/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.03) 
16 426329 TMEM8A A C 151 V/G NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.56) 
16 422045 TMEM8A A G 560 F/S NON_SYNONYMOUS_CODING benign(0.282) tolerated(0.13) 
12 83251115 TMTC2 T G 137 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.926) deleterious(0) 
12 83251120 TMTC2 C G 139 R/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 26671484 TNFAIP1 C A 166 T/K NON_SYNONYMOUS_CODING possibly_damaging(0.917) deleterious(0) 
17 26666686 TNFAIP1 A C 47 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.952) deleterious(0.01) 
1 12198361 TNFRSF8 A C 359 T/P NON_SYNONYMOUS_CODING benign(0.004) deleterious(0) 
1 12144552 TNFRSF8 A C 32 N/T NON_SYNONYMOUS_CODING benign(0.025) tolerated(0.61) 
16 1279714 TPSB2 A G 29 V/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.33) 
16 1279732 TPSB2 C A 23 G/V NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.17) 
6 52369436 TRAM2 A G 331 V/A NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.83) 
6 52370454 TRAM2 C G 273 R/P NON_SYNONYMOUS_CODING probably_damaging(0.999) tolerated(0.19) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142008645 TRBV3-1 A C 40 I/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008750 TRBV3-1 A T 75 I/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
7 142008783 TRBV3-1 A G 86 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008675 TRBV3-1 A G 50 T/A NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
7 142008727 TRBV3-1 G T 67 S/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.4) 
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7 142008785 TRBV3-1 A C 86 K/N NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.02) 
7 142008718 TRBV3-1 T C 64 I/T NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
7 142008672 TRBV3-1 G A 49 D/N NON_SYNONYMOUS_CODING benign(0.006) tolerated(0.61) 
7 142008745 TRBV3-1 T C 73 L/P NON_SYNONYMOUS_CODING probably_damaging(0.993) tolerated(0.27) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142045677 TRBV4-2 A AG 69 . FRAMESHIFT_CODING . . 
7 142180566 TRBV6-5 A T 98 L/Q NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180567 TRBV6-5 G C 98 L/V NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
7 142180573 TRBV6-5 T C 96 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.12) 
7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099581 TRBV7-8 A G 74 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
7 142099533 TRBV7-8 T C 90 E/G NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142099537 TRBV7-8 G T 89 P/T NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.39) 
21 38498381 TTC3 T G 394 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.032) deleterious(0) 
21 38560797 TTC3 T G 1642 V/G SPLICE_SITE:NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
2 179472353 TTN T C 8748 K/E NON_SYNONYMOUS_CODING benign(0.099) . 
2 179419226 TTN A C 20676 I/M NON_SYNONYMOUS_CODING possibly_damaging(0.789) . 
2 179413028 TTN C A 22169 V/L NON_SYNONYMOUS_CODING possibly_damaging(0.891) . 
2 179468803 TTN T C 9264 E/G NON_SYNONYMOUS_CODING possibly_damaging(0.936) . 
2 179592426 TTN A C 5383 S/A NON_SYNONYMOUS_CODING unknown(0) . 
2 179595427 TTN A C 4701 S/A NON_SYNONYMOUS_CODING unknown(0) . 
2 179597615 TTN G C 4186 R/G NON_SYNONYMOUS_CODING unknown(0) . 
10 60121265 UBE2D1 G A 33 W/* STOP_GAINED . . 
10 60121266 UBE2D1 C A 34 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.836) deleterious(0.04) 
1 19524272 UBR4 T G 262 N/T NON_SYNONYMOUS_CODING possibly_damaging(0.9) tolerated(0.27) 
1 19442066 UBR4 T G 45 D/A NON_SYNONYMOUS_CODING possibly_damaging(0.932) tolerated(0.26) 
2 128896359 UGGT1 T G 551 V/G NON_SYNONYMOUS_CODING benign(0.052) deleterious(0) 
2 128945090 UGGT1 A G 91 D/G NON_SYNONYMOUS_CODING probably_damaging(0.996) tolerated(0.34) 
1 216251520 USH2A T G 1828 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
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1 215960138 USH2A T G 3421 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.832) deleterious(0.05) 
1 215960151 USH2A A C 3416 C/W NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
1 215960153 USH2A A C 3416 C/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
12 62798066 USP15 G C 924 A/P NON_SYNONYMOUS_CODING benign(0.063) tolerated(0.05) 
12 62786861 USP15 C A 788 Q/K NON_SYNONYMOUS_CODING possibly_damaging(0.581) tolerated(0.28) 
17 5036210 USP6 T G 67 I/M NON_SYNONYMOUS_CODING unknown(0) deleterious(0.04) 
17 5036211 USP6 C T 68 R/W NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
12 101685769 UTP20 G T 354 V/L NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.26) 
12 101764315 UTP20 C A 2221 Q/K NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
2 98779398 VWA3B T G 208 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.485) tolerated(0.06) 
2 98853082 VWA3B G T 854 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
1 20671955 VWA5B1 A C 878 N/T NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.31) 
1 20678602 VWA5B1 C A 1031 S/R NON_SYNONYMOUS_CODING probably_damaging(0.976) deleterious(0.05) 
15 85191135 WDR73 A C 113 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.948) deleterious(0) 
15 85197480 WDR73 A C 9 V/G NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.01) 
4 6296897 WFS1 A C 281 D/A NON_SYNONYMOUS_CODING benign(0.019) tolerated(0.08) 
4 6303810 WFS1 A C 141 H/P NON_SYNONYMOUS_CODING possibly_damaging(0.625) tolerated(0.1) 
16 87448068 ZCCHC14 T G 382 T/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.15) 
16 87448079 ZCCHC14 C G 378 R/P NON_SYNONYMOUS_CODING unknown(0) tolerated(0.13) 
8 77761278 ZFHX4 A C 1142 T/P NON_SYNONYMOUS_CODING benign(0.189) . 
8 77765378 ZFHX4 A C 2029 D/A NON_SYNONYMOUS_CODING probably_damaging(0.978) . 
5 121488461 ZNF474 A C 259 H/P NON_SYNONYMOUS_CODING benign(0.144) deleterious(0.02) 
5 121488458 ZNF474 T C 258 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.924) tolerated(0.29) 
15 85326799 ZNF592 G A 298 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.3) 
15 85326800 ZNF592 T A 298 S/R NON_SYNONYMOUS_CODING benign(0.073) tolerated(0.11) 
8 102213947 ZNF706 A T 8 I/N NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
8 102213962 ZNF706 C G 3 R/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
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CHD20: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
2 241631603 AQP12A C T 79 S/L NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.26) 
19 43860251 CD177 G A 204 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 43860255 CD177 T G 205 M/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.38) 
16 29395010 ENSG00000254206 G T 415 P/T NON_SYNONYMOUS_CODING probably_damaging(0.992) tolerated(0.07) 
15 82637079 GOLGA6L10 C T 336 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 31324931 HLA-B A C 3 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 54725835 LILRB3 G C 175 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
17 44408066 LRRC37A C A 1141 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.11) 
7 100636446 MUC12 G A 868 D/N NON_SYNONYMOUS_CODING unknown(0) . 
7 100636447 MUC12 A G 868 D/G NON_SYNONYMOUS_CODING unknown(0) . 
7 100636459 MUC12 C T 872 T/M NON_SYNONYMOUS_CODING unknown(0) . 
7 100636467 MUC12 C G 875 L/V NON_SYNONYMOUS_CODING unknown(0) . 
7 100639147 MUC12 A G 1768 E/G NON_SYNONYMOUS_CODING unknown(0) . 
7 100639177 MUC12 C T 1778 S/L NON_SYNONYMOUS_CODING unknown(0) . 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195510389 MUC4 A G 2688 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510526 MUC4 A G 2642 L/P NON_SYNONYMOUS_CODING unknown(0) . 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 145359049 NBPF10 A G 2997 K/E NON_SYNONYMOUS_CODING benign(0.049) tolerated(1) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696090 PRAMEF19 T C 223 K/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.47) 
22 18901004 PRODH C T 166 R/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.6) 
7 72436652 TRIM74 A G 13 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
18 30352057 ENSG00000228835 GCGCCGGCC G 119-121 . FRAMESHIFT_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
18 44549025 TCEB3CL T TGC 425 . FRAMESHIFT_CODING . . 
3 133969437 RYK A AG 19-20 . SPLICE_SITE:FRAMESHIFT_CODING . . 
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CHD20: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
5 434045 AHRR C G 401 T/R NON_SYNONYMOUS_CODING benign(0.284) deleterious(0) 
5 433020 AHRR G A 361 R/Q NON_SYNONYMOUS_CODING possibly_damaging(0.883) deleterious(0.04) 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97845632 ANKRD36 T C 566 I/T NON_SYNONYMOUS_CODING possibly_damaging(0.767) tolerated(0.23) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
2 97833340 ANKRD36 A G 520 T/A SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.741) tolerated(1) 
20 18433273 C20orf12 T G 179 T/P NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.15) 
20 18433277 C20orf12 T G 25 H/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
17 20243114 CCDC144C G T 304 V/F NON_SYNONYMOUS_CODING benign(0.127) deleterious(0) 
17 20243376 CCDC144C A G 391 K/R NON_SYNONYMOUS_CODING benign(0.29) deleterious(0) 
17 20269243 CCDC144C A G 901 Q/R NON_SYNONYMOUS_CODING benign(0.378) tolerated(0.37) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
8 68062165 CSPP1 G A 703 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.64) 
8 68062160 CSPP1 T A 701 N/K NON_SYNONYMOUS_CODING benign(0.153) tolerated(0.98) 
6 132030560 CTAGE9 G A 533 T/M NON_SYNONYMOUS_CODING benign(0.062) tolerated(0.07) 
6 132030966 CTAGE9 G C 398 L/V NON_SYNONYMOUS_CODING probably_damaging(0.973) deleterious(0.01) 
16 15457629 ENSG00000183793 T A 314 T/S NON_SYNONYMOUS_CODING benign(0.158) tolerated(0.82) 
16 15457628 ENSG00000183793 G T 314 T/N NON_SYNONYMOUS_CODING benign(0.348) tolerated(0.39) 
19 56283297 ENSG00000229292 G A 43 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.52) 
19 56284090 ENSG00000229292 G A 137 A/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.41) 
9 46386995 ENSG00000237198 C A 3 R/M NON_SYNONYMOUS_CODING benign(0.013) tolerated(0.36) 
9 46386902 ENSG00000237198 G A 34 T/I NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
9 46386956 ENSG00000237198 C G 16 R/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
9 46386785 ENSG00000237198 G C 73 T/R NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
9 46386806 ENSG00000237198 C T 66 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(0.75) 
18 11619510 ENSG00000257513 A C 351 */E STOP_LOST . . 
18 11619549 ENSG00000257513 T G 338 K/Q NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.03) 
10 88988115 FAM22A G A 160 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
10 88992687 FAM22A C T 37 P/L NON_SYNONYMOUS_CODING probably_damaging(0.967) deleterious(0) 
20 29628328 FRG1B C G 110 I/M NON_SYNONYMOUS_CODING benign(0.191) deleterious(0.03) 
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20 29632672 FRG1B C T 163 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
10 135440122 FRG2B T C 42 E/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
10 135440123 FRG2B C T 42 E/K NON_SYNONYMOUS_CODING benign(0.009) tolerated(0.33) 
10 135440203 FRG2B A T 15 I/N NON_SYNONYMOUS_CODING benign(0.097) deleterious(0.02) 
10 135440159 FRG2B T A 30 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.94) tolerated(0.45) 
10 135440108 FRG2B C T 47 A/T NON_SYNONYMOUS_CODING probably_damaging(0.997) tolerated(0.31) 
15 23264768 GOLGA8IP A G 458 S/G NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.85) 
15 23262005 GOLGA8IP G A 373 V/I NON_SYNONYMOUS_CODING benign(0.188) tolerated(0.18) 
6 31324036 HLA-B T A 177 E/V NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 31324547 HLA-B G C 88 N/K NON_SYNONYMOUS_CODING benign(0.192) deleterious(0.02) 
9 35906556 HRCT1 A C 91 H/P NON_SYNONYMOUS_CODING unknown(0) . 
9 35906559 HRCT1 A C 92 H/P NON_SYNONYMOUS_CODING unknown(0) . 
14 106573354 IGHV3-11 A G 77 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573357 IGHV3-11 G T 76 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.62) 
14 106573358 IGHV3-11 T A 76 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106573352 IGHV3-11 A T 78 Y/N NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.23) 
14 106993935 IGHV3-48 A G 77 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
14 106994010 IGHV3-48 C T 52 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
14 107113742 IGHV3-64 C T 118 R/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.18) 
14 107113745 IGHV3-64 G A 117 A/V NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.06) 
14 107114170 IGHV3-64 A G 10 F/L NON_SYNONYMOUS_CODING benign(0.012) tolerated(0.06) 
14 107034847 IGHV5-51 C T 78 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.37) 
14 107034854 IGHV5-51 C A 76 D/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
14 107034869 IGHV5-51 A C 71 Y/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.32) 
14 107034873 IGHV5-51 G C 69 I/M NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
14 107034874 IGHV5-51 A C 69 I/S NON_SYNONYMOUS_CODING benign(0) tolerated(0.41) 
14 107034846 IGHV5-51 T G 78 R/S NON_SYNONYMOUS_CODING benign(0.136) tolerated(0.44) 
7 151927025 MLL3 A G 987 Y/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932991 MLL3 G A 894 R/W NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932997 MLL3 C T 892 G/R NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 100645731 MUC12 G A 3963 E/K NON_SYNONYMOUS_CODING possibly_damaging(0.952) . 
7 100637073 MUC12 C T 1077 R/C NON_SYNONYMOUS_CODING unknown(0) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 9002659 MUC16 C T 27 G/E NON_SYNONYMOUS_CODING possibly_damaging(0.582) tolerated(0.19) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
19 9002660 MUC16 C T 27 G/R NON_SYNONYMOUS_CODING probably_damaging(0.998) tolerated(0.5) 
3 195507053 MUC4 A C 3800 S/A NON_SYNONYMOUS_CODING benign(0.035) . 
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3 195513847 MUC4 A G 1535 M/T NON_SYNONYMOUS_CODING benign(0.042) . 
3 195506549 MUC4 A G 3968 S/P NON_SYNONYMOUS_CODING benign(0.044) . 
3 195507226 MUC4 A G 3742 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506099 MUC4 T C 4118 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195510228 MUC4 C G 2741 E/D NON_SYNONYMOUS_CODING benign(0.182) . 
3 195505836 MUC4 G C 4205 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195509212 MUC4 G A 3080 S/L NON_SYNONYMOUS_CODING benign(0.204) . 
3 195515017 MUC4 A G 1145 V/A NON_SYNONYMOUS_CODING benign(0.231) . 
3 195506569 MUC4 A G 3961 V/A NON_SYNONYMOUS_CODING benign(0.243) . 
3 195506293 MUC4 T C 4053 N/S NON_SYNONYMOUS_CODING benign(0.258) . 
3 195510194 MUC4 G C 2753 L/V NON_SYNONYMOUS_CODING benign(0.352) . 
3 195508661 MUC4 A G 3264 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195506533 MUC4 C A 3973 S/I NON_SYNONYMOUS_CODING possibly_damaging(0.473) . 
3 195506746 MUC4 G A 3902 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507193 MUC4 G A 3753 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507385 MUC4 G A 3689 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507494 MUC4 C T 3653 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507948 MUC4 G T 3501 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195510649 MUC4 G A 2601 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506983 MUC4 G A 3823 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507475 MUC4 G C 3659 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507827 MUC4 G A 3542 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195511076 MUC4 T A 2459 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.609) . 
3 195511525 MUC4 T C 2309 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511526 MUC4 C T 2309 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195506501 MUC4 G A 3984 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.768) . 
3 195507604 MUC4 C G 3616 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.811) . 
3 195507461 MUC4 G A 3664 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.864) . 
3 195507694 MUC4 A G 3586 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195506294 MUC4 T C 4053 N/D NON_SYNONYMOUS_CODING possibly_damaging(0.9) . 
3 195513622 MUC4 G C 1610 S/C NON_SYNONYMOUS_CODING possibly_damaging(0.909) . 
3 195506291 MUC4 C T 4054 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.922) . 
3 195506752 MUC4 C T 3900 R/H NON_SYNONYMOUS_CODING possibly_damaging(0.924) . 
3 195506990 MUC4 C G 3821 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195511102 MUC4 G A 2450 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195514948 MUC4 G A 1168 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
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3 195506302 MUC4 G T 4050 P/H NON_SYNONYMOUS_CODING probably_damaging(0.998) . 
3 195506542 MUC4 G T 3970 P/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510347 MUC4 T C 2702 T/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510373 MUC4 T C 2693 D/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510374 MUC4 C T 2693 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510415 MUC4 G T 2679 S/Y NON_SYNONYMOUS_CODING unknown(0) . 
3 195510505 MUC4 G A 2649 A/V NON_SYNONYMOUS_CODING unknown(0) . 
3 195510509 MUC4 A C 2648 S/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510515 MUC4 C T 2646 A/T NON_SYNONYMOUS_CODING unknown(0) . 
3 195510518 MUC4 C T 2645 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510553 MUC4 G A 2633 A/V NON_SYNONYMOUS_CODING unknown(0) . 
3 195510565 MUC4 C T 2629 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510610 MUC4 A G 2614 L/P NON_SYNONYMOUS_CODING unknown(0) . 
11 1018095 MUC6 G A 1569 P/L NON_SYNONYMOUS_CODING benign(0.014) deleterious(0.01) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1018552 MUC6 G A 1417 P/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.73) 
17 16097792 NCOR1 T C 31 N/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
17 16097786 NCOR1 C T 33 R/H NON_SYNONYMOUS_CODING possibly_damaging(0.806) tolerated(0.66) 
11 78383335 ODZ4 C T 1846 V/I NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.2) 
11 78413365 ODZ4 T G 1431 Q/H NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0.01) 
1 248436582 OR2T33 T C 179 T/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 248436638 OR2T33 A G 160 V/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.4) 
19 4511376 PLIN4 C A 852 G/C NON_SYNONYMOUS_CODING benign(0) tolerated(0.14) 
19 4511379 PLIN4 G C 851 L/V NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33795579 PRSS3 C T 3 P/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.73) 
9 33795581 PRSS3 T C 4 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33795593 PRSS3 G A 8 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
9 33798075 PRSS3 T C 150 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
12 11183406 TAS2R31 C T 177 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.42) 
12 11183475 TAS2R31 G A 154 R/W NON_SYNONYMOUS_CODING benign(0) tolerated(0.87) 
12 11183496 TAS2R31 T C 147 I/V NON_SYNONYMOUS_CODING benign(0) tolerated(0.47) 
12 11183793 TAS2R31 G C 48 L/V NON_SYNONYMOUS_CODING benign(0.162) tolerated(0.06) 
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7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142149029 TRBV5-5 T G 81 D/A NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.01) 
7 142149030 TRBV5-5 C G 81 D/H NON_SYNONYMOUS_CODING benign(0.002) deleterious(0.01) 
7 142180566 TRBV6-5 A T 98 L/Q NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180573 TRBV6-5 T C 96 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.12) 
7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142247271 TRBV7-3 G A 62 P/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142247380 TRBV7-3 T A 26 T/S NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.87) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
7 142099533 TRBV7-8 T C 90 E/G NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
2 179465893 TTN G A 9640 P/S NON_SYNONYMOUS_CODING benign(0.014) . 
2 179641088 TTN G C 1789 Q/E NON_SYNONYMOUS_CODING benign(0.014) . 
2 179634421 TTN T G 2917 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.539) . 
8 11995122 USP17L2 T C 383 E/G NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.2) 
8 11995939 USP17L2 G A 111 R/W NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.01) 
19 21948513 ZNF100 G A 27 Q/* STOP_GAINED . . 
19 21948524 ZNF100 C T 23 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.89) 
19 21948511 ZNF100 C G 27 Q/H NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.58) 
 
341 
 
CHD22: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
7 150783917 AGAP3 T G 30 L/R NON_SYNONYMOUS_CODING unknown(0) tolerated(0.06) 
7 150783920 AGAP3 T G 31 V/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.74) 
7 150783922 AGAP3 T G 32 C/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.42) 
10 46321904 AGAP4 C T 260 R/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
19 43860251 CD177 G A 204 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 66553727 ENSG00000170161 T C 60 V/A NON_SYNONYMOUS_CODING benign(0) . 
10 47911590 FAM21B G A 193 G/D NON_SYNONYMOUS_CODING benign(0.282) tolerated(0.14) 
8 12285102 FAM86B2 T C 91 E/G NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
8 12285103 FAM86B2 C T 91 E/K NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
15 82637079 GOLGA6L10 C T 336 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 34673973 GOLGA8A C T 513 R/Q NON_SYNONYMOUS_CODING benign(0.003) tolerated(1) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 32549357 HLA-DRB1 G A 210 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.481) deleterious(0) 
1 22215199 HSPG2 G C 6 P/R NON_SYNONYMOUS_CODING unknown(0) . 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195514768 MUC4 T C 1228 D/G NON_SYNONYMOUS_CODING benign(0.144) . 
3 195507494 MUC4 C T 3653 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195514733 MUC4 C A 1240 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.533) . 
3 195514948 MUC4 G A 1168 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510389 MUC4 A G 2688 S/P NON_SYNONYMOUS_CODING unknown(0) . 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248802469 OR2T35 C T 31 V/I NON_SYNONYMOUS_CODING benign(0) tolerated(0.2) 
2 131245713 POTEI C G 434 S/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
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2 131221622 POTEI C T 665 M/I NON_SYNONYMOUS_CODING possibly_damaging(0.539) deleterious(0) 
14 20010235 POTEM A G 393 V/A NON_SYNONYMOUS_CODING benign(0.006) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696022 PRAMEF19 A G 246 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 13696047 PRAMEF19 A T 237 D/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
1 13696054 PRAMEF19 G A 235 S/F NON_SYNONYMOUS_CODING benign(0) tolerated(0.69) 
1 13696090 PRAMEF19 T C 223 K/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.47) 
22 18901004 PRODH C T 166 R/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.6) 
7 72436652 TRIM74 A G 13 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.29) 
1 117122285 IGSF3 G GTCC 1041 D/ED NON_SYNONYMOUS_CODING . . 
15 90320134 MESP2 AGGGCAGGGGCAG A 183-186 GQGQ/- NON_SYNONYMOUS_CODING . . 
3 12046123 SYN2 AAGC A 33-34 QA/Q NON_SYNONYMOUS_CODING . . 
20 60640305 TAF4 TGCCAGG T 186-187 PG/- NON_SYNONYMOUS_CODING . . 
17 46115072 COPZ2 C CG 22 . FRAMESHIFT_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
17 46115122 COPZ2 A AG 05-Jun . SPLICE_SITE:FRAMESHIFT_CODING . . 
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CHD22: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
12 101368637 ANO4 A C 191 Y/S NON_SYNONYMOUS_CODING probably_damaging(0.983) tolerated(0.39) 
12 101368625 ANO4 G A 187 R/K SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
22 39498015 APOBEC3H C G 171 R/G NON_SYNONYMOUS_CODING benign(0.057) deleterious(0.01) 
22 39498005 APOBEC3H T A 167 D/E NON_SYNONYMOUS_CODING benign(0.18) tolerated(0.35) 
5 137503739 BRD8 G A 224 S/F NON_SYNONYMOUS_CODING probably_damaging(0.996) deleterious(0.01) 
5 137503737 BRD8 C A 225 G/C NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.06) 
17 56386386 BZRAP1 G T 1416 P/Q NON_SYNONYMOUS_CODING possibly_damaging(0.948) deleterious(0) 
17 56386402 BZRAP1 A G 1411 S/P NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
12 112622338 C12orf51 T G 3056 T/P NON_SYNONYMOUS_CODING benign(0.187) . 
12 112688167 C12orf51 A C 822 V/G NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
20 18433273 C20orf12 T G 179 T/P NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.15) 
20 18433277 C20orf12 T G 25 H/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
12 121093651 CABP1 TGTGC T 13-14 . FRAMESHIFT_CODING . . 
12 121093653 CABP1 TGC T 14 . FRAMESHIFT_CODING . . 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
2 9599739 CPSF3 T A 593 I/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.51) 
2 9599742 CPSF3 G A 594 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.93) 
10 126678128 CTBP2 T A 433 T/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
10 126678177 CTBP2 G T 416 N/K NON_SYNONYMOUS_CODING benign(0.01) tolerated(0.46) 
15 51766636 DMXL2 G A 1736 A/V NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
15 51766637 DMXL2 C A 1736 A/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.57) 
16 15457629 ENSG00000183793 T A 314 T/S NON_SYNONYMOUS_CODING benign(0.158) tolerated(0.82) 
16 15457628 ENSG00000183793 G T 314 T/N NON_SYNONYMOUS_CODING benign(0.348) tolerated(0.39) 
2 131985945 ENSG00000188219 A G 349 H/R NON_SYNONYMOUS_CODING benign(0.429) tolerated(0.2) 
2 132021023 ENSG00000188219 G A 665 M/I NON_SYNONYMOUS_CODING possibly_damaging(0.539) deleterious(0) 
12 132445256 EP400 A C 31 H/P NON_SYNONYMOUS_CODING unknown(0) . 
12 132445261 EP400 A C 33 N/H NON_SYNONYMOUS_CODING unknown(0) . 
12 132445273 EP400 T C 37 S/P NON_SYNONYMOUS_CODING unknown(0) . 
2 97757290 FAHD2B C T 52 V/I NON_SYNONYMOUS_CODING benign(0.004) tolerated(1) 
2 97757296 FAHD2B C T 50 G/R NON_SYNONYMOUS_CODING probably_damaging(0.989) tolerated(0.21) 
8 12042969 FAM86B1 G A 42 R/W NON_SYNONYMOUS_CODING benign(0.016) deleterious(0.03) 
8 12042783 FAM86B1 A G 104 S/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
8 12042851 FAM86B1 C G 81 C/S NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
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15 84909434 GOLGA6L4 G A 119 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(0.5) 
15 84908750 GOLGA6L4 T A 27 L/Q SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.23) 
6 31324036 HLA-B T A 177 E/V NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 31324931 HLA-B A C 3 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
6 32548544 HLA-DRB1 T G 248 I/L NON_SYNONYMOUS_CODING benign(0) deleterious(0) 
6 32549402 HLA-DRB1 C T 195 R/Q NON_SYNONYMOUS_CODING benign(0.002) tolerated(1) 
6 32549582 HLA-DRB1 G T 135 T/N NON_SYNONYMOUS_CODING benign(0.374) deleterious(0) 
6 32497985 HLA-DRB5 A G 6 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.512) deleterious(0) 
6 32489852 HLA-DRB5 A G 67 L/S NON_SYNONYMOUS_CODING possibly_damaging(0.558) deleterious(0) 
17 39346592 KRTAP9-1 ACCT A 152-153 TC/S NON_SYNONYMOUS_CODING . . 
17 39346433 KRTAP9-1 A C 99 T/P SPLICE_SITE:NON_SYNONYMOUS_CODING unknown(0) tolerated(0.08) 
11 12183916 MICAL2 C T 72 R/C NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
11 12225829 MICAL2 G T 99 L/F NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.03) 
11 12315350 MICALCL C G 124 I/M NON_SYNONYMOUS_CODING possibly_damaging(0.519) tolerated(0.07) 
11 12315162 MICALCL A C 62 T/P NON_SYNONYMOUS_CODING probably_damaging(0.988) deleterious(0) 
7 100634922 MUC12 G A 360 A/T NON_SYNONYMOUS_CODING unknown(0) . 
7 100636446 MUC12 G A 868 D/N NON_SYNONYMOUS_CODING unknown(0) . 
7 100636447 MUC12 A G 868 D/G NON_SYNONYMOUS_CODING unknown(0) . 
7 100636459 MUC12 C T 872 T/M NON_SYNONYMOUS_CODING unknown(0) . 
7 100639147 MUC12 A G 1768 E/G NON_SYNONYMOUS_CODING unknown(0) . 
7 100642455 MUC12 G A 2871 A/T NON_SYNONYMOUS_CODING unknown(0) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9005721 MUC16 C G 69 D/H NON_SYNONYMOUS_CODING benign(0.02) tolerated(0.14) 
19 9002636 MUC16 C T 35 V/I NON_SYNONYMOUS_CODING benign(0.051) tolerated(0.37) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 9005697 MUC16 C T 77 A/T NON_SYNONYMOUS_CODING benign(0.138) tolerated(0.19) 
19 9005706 MUC16 T C 74 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.847) tolerated(0.65) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
3 195513846 MUC4 C G 1535 M/I NON_SYNONYMOUS_CODING benign(0.012) . 
3 195506387 MUC4 G T 4022 P/T NON_SYNONYMOUS_CODING benign(0.025) . 
3 195513847 MUC4 A G 1535 M/T NON_SYNONYMOUS_CODING benign(0.042) . 
3 195506549 MUC4 A G 3968 S/P NON_SYNONYMOUS_CODING benign(0.044) . 
3 195506590 MUC4 G A 3954 P/L NON_SYNONYMOUS_CODING benign(0.057) . 
3 195505910 MUC4 T C 4181 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195505945 MUC4 A G 4169 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506137 MUC4 A G 4105 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506150 MUC4 T C 4101 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506215 MUC4 C G 4079 S/T NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508022 MUC4 T C 3477 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508343 MUC4 A T 3370 S/T NON_SYNONYMOUS_CODING benign(0.095) . 
3 195506364 MUC4 G C 4029 H/Q NON_SYNONYMOUS_CODING benign(0.118) . 
3 195506473 MUC4 A G 3993 V/A NON_SYNONYMOUS_CODING benign(0.137) . 
3 195505859 MUC4 T C 4198 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506099 MUC4 T C 4118 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
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3 195506723 MUC4 T C 3910 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506987 MUC4 T C 3822 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195508667 MUC4 T C 3262 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195506582 MUC4 C T 3957 D/N NON_SYNONYMOUS_CODING benign(0.183) . 
3 195505836 MUC4 G C 4205 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195505909 MUC4 C T 4181 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195506149 MUC4 C T 4101 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195507228 MUC4 G C 3741 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195508716 MUC4 A C 3245 H/Q NON_SYNONYMOUS_CODING benign(0.204) . 
3 195508789 MUC4 C T 3221 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195515017 MUC4 A G 1145 V/A NON_SYNONYMOUS_CODING benign(0.231) . 
3 195506569 MUC4 A G 3961 V/A NON_SYNONYMOUS_CODING benign(0.243) . 
3 195507428 MUC4 T A 3675 T/S NON_SYNONYMOUS_CODING benign(0.352) . 
3 195508787 MUC4 G T 3222 L/I NON_SYNONYMOUS_CODING benign(0.352) . 
3 195510194 MUC4 G C 2753 L/V NON_SYNONYMOUS_CODING benign(0.352) . 
3 195506076 MUC4 C G 4125 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195510636 MUC4 C G 2605 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195508661 MUC4 A G 3264 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195508709 MUC4 A G 3248 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195506533 MUC4 C A 3973 S/I NON_SYNONYMOUS_CODING possibly_damaging(0.473) . 
3 195505897 MUC4 G A 4185 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506650 MUC4 G A 3934 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506704 MUC4 T C 3916 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506746 MUC4 G A 3902 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506963 MUC4 C T 3830 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507155 MUC4 C T 3766 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507193 MUC4 G A 3753 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507385 MUC4 G A 3689 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507434 MUC4 C A 3673 A/S NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507446 MUC4 C T 3669 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508009 MUC4 G A 3481 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508070 MUC4 C T 3461 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508500 MUC4 G C 3317 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508502 MUC4 C T 3317 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508668 MUC4 G C 3261 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195505906 MUC4 G A 4182 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195506147 MUC4 G A 4102 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195506213 MUC4 T G 4080 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195506983 MUC4 G A 3823 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507379 MUC4 G C 3691 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507443 MUC4 T G 3670 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507475 MUC4 G C 3659 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507827 MUC4 G A 3542 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
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3 195508678 MUC4 G T 3258 S/Y NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195511412 MUC4 T A 2347 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.609) . 
3 195508127 MUC4 G C 3442 P/A NON_SYNONYMOUS_CODING possibly_damaging(0.692) . 
3 195506602 MUC4 G C 3950 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.717) . 
3 195511285 MUC4 T C 2389 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511286 MUC4 C T 2389 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511525 MUC4 T C 2309 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511526 MUC4 C T 2309 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195506501 MUC4 G A 3984 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.768) . 
3 195506282 MUC4 A C 4057 L/V NON_SYNONYMOUS_CODING possibly_damaging(0.806) . 
3 195507412 MUC4 C G 3680 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.811) . 
3 195507604 MUC4 C G 3616 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.811) . 
3 195507445 MUC4 T A 3669 D/V NON_SYNONYMOUS_CODING possibly_damaging(0.862) . 
3 195506146 MUC4 A G 4102 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195507694 MUC4 A G 3586 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195508510 MUC4 A G 3314 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195508786 MUC4 A G 3222 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195506341 MUC4 C T 4037 S/N NON_SYNONYMOUS_CODING possibly_damaging(0.893) . 
3 195506342 MUC4 T C 4037 S/G NON_SYNONYMOUS_CODING possibly_damaging(0.893) . 
3 195506626 MUC4 G A 3942 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.893) . 
3 195505870 MUC4 G A 4194 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195506914 MUC4 G A 3846 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195508018 MUC4 G A 3478 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195506990 MUC4 C G 3821 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195507422 MUC4 C G 3677 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195508238 MUC4 C G 3405 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195508670 MUC4 C G 3261 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195515414 MUC4 T C 1013 S/G NON_SYNONYMOUS_CODING possibly_damaging(0.943) . 
3 195506554 MUC4 G A 3966 A/V NON_SYNONYMOUS_CODING probably_damaging(0.959) . 
3 195508228 MUC4 G C 3408 P/R NON_SYNONYMOUS_CODING probably_damaging(0.968) . 
3 195515008 MUC4 C G 1148 G/A NON_SYNONYMOUS_CODING probably_damaging(0.972) . 
3 195513826 MUC4 G A 1542 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195514825 MUC4 G A 1209 A/V NON_SYNONYMOUS_CODING probably_damaging(0.978) . 
3 195515449 MUC4 A T 1001 V/E NON_SYNONYMOUS_CODING probably_damaging(0.979) . 
3 195515435 MUC4 C T 1006 A/T NON_SYNONYMOUS_CODING probably_damaging(0.985) . 
3 195506734 MUC4 G T 3906 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
3 195515134 MUC4 G T 1106 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
3 195508336 MUC4 C T 3372 G/D NON_SYNONYMOUS_CODING probably_damaging(0.994) . 
3 195510910 MUC4 G T 2514 P/H NON_SYNONYMOUS_CODING probably_damaging(0.997) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510347 MUC4 T C 2702 T/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510396 MUC4 A C 2685 H/Q NON_SYNONYMOUS_CODING unknown(0) . 
3 195510415 MUC4 G T 2679 S/Y NON_SYNONYMOUS_CODING unknown(0) . 
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3 195510526 MUC4 A G 2642 L/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510611 MUC4 G T 2614 L/I NON_SYNONYMOUS_CODING unknown(0) . 
3 195510613 MUC4 C T 2613 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510614 MUC4 T C 2613 S/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195538657 MUC4 CA C 11 . FRAMESHIFT_CODING . . 
3 195505742 MUC4 G C 963 H/D SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.662) tolerated(0.09) 
11 1264346 MUC5B C A 2079 T/K NON_SYNONYMOUS_CODING benign(0.29) . 
11 1265107 MUC5B C T 2333 P/S NON_SYNONYMOUS_CODING benign(0.409) . 
11 1264717 MUC5B C T 2203 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.662) . 
11 1269557 MUC5B C T 3816 T/M NON_SYNONYMOUS_CODING unknown(0) . 
11 1269707 MUC5B C T 3866 P/L NON_SYNONYMOUS_CODING unknown(0) . 
11 1270647 MUC5B G C 4179 Q/H NON_SYNONYMOUS_CODING unknown(0) . 
11 1017744 MUC6 T C 1686 N/S NON_SYNONYMOUS_CODING benign(0.014) tolerated(0.97) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1017307 MUC6 G A 1832 P/S NON_SYNONYMOUS_CODING benign(0.34) tolerated(0.21) 
11 1016919 MUC6 C T 1961 R/K NON_SYNONYMOUS_CODING possibly_damaging(0.496) tolerated(0.33) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1018207 MUC6 T C 1532 T/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.28) 
11 1018552 MUC6 G A 1417 P/S NON_SYNONYMOUS_CODING unknown(0) tolerated(0.73) 
1 145367800 NBPF10 G A 586 D/N NON_SYNONYMOUS_CODING benign(0.009) deleterious(0.03) 
1 145359049 NBPF10 A G 2997 K/E NON_SYNONYMOUS_CODING benign(0.049) tolerated(1) 
1 145302775 NBPF10 T G 330 Y/D NON_SYNONYMOUS_CODING unknown(0) tolerated(1) 
2 152436012 NEB T G 5515 K/T NON_SYNONYMOUS_CODING possibly_damaging(0.462) . 
2 152448640 NEB T C 4912 N/D NON_SYNONYMOUS_CODING unknown(0) . 
1 228430947 OBSCN C G 998 A/G NON_SYNONYMOUS_CODING benign(0.003) . 
1 228434292 OBSCN C G 1274 A/G NON_SYNONYMOUS_CODING benign(0.006) . 
1 248722611 OR2T29 C G 61 S/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248722624 OR2T29 C T 57 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
1 248722621 OR2T29 G A 58 H/Y NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.03) 
1 248436582 OR2T33 T C 179 T/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 248436638 OR2T33 A G 160 V/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.4) 
1 248737293 OR2T34 G A 256 L/F NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248737230 OR2T34 T C 277 M/V NON_SYNONYMOUS_CODING benign(0.018) deleterious(0.01) 
9 33795581 PRSS3 T C 4 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33795593 PRSS3 G A 8 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
9 33798075 PRSS3 T C 150 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
9 33798574 PRSS3 G A 182 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 14104595 RFX1 C G 21 A/P NON_SYNONYMOUS_CODING unknown(0) . 
19 14104610 RFX1 A G 16 S/P NON_SYNONYMOUS_CODING unknown(0) . 
19 14104590 RFX1 C CG 22 . FRAMESHIFT_CODING . . 
19 50154276 SCAF1 A C 210 T/P NON_SYNONYMOUS_CODING unknown(0) . 
19 50154285 SCAF1 G C 213 A/P NON_SYNONYMOUS_CODING unknown(0) . 
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19 51920115 SIGLEC10 C T 171 E/K NON_SYNONYMOUS_CODING benign(0.124) tolerated(0.42) 
19 51920112 SIGLEC10 C T 172 E/K NON_SYNONYMOUS_CODING benign(0.16) tolerated(0.77) 
18 11610570 SLC35G4 C T 287 R/W NON_SYNONYMOUS_CODING benign(0) tolerated(0.19) 
18 11610580 SLC35G4 T G 290 I/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 49132198 SPHK2 A C 351 Y/S NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
19 49132201 SPHK2 T C 352 L/P NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
12 11244027 TAS2R43 T C 268 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
12 11244036 TAS2R43 T G 265 K/Q NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
12 11244015 TAS2R43 G A 272 P/S NON_SYNONYMOUS_CODING benign(0.113) deleterious(0.04) 
12 11244017 TAS2R43 T C 271 Y/C NON_SYNONYMOUS_CODING benign(0.256) deleterious(0.04) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142008783 TRBV3-1 A G 86 K/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142008785 TRBV3-1 A C 86 K/N NON_SYNONYMOUS_CODING benign(0.001) deleterious(0.02) 
7 142045680 TRBV4-2 T C 70 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.67) 
7 142045693 TRBV4-2 C T 74 T/I NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142168414 TRBV5-4 G C 103 D/E NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142168466 TRBV5-4 A C 86 L/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.24) 
7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099581 TRBV7-8 A G 74 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
7 142099533 TRBV7-8 T C 90 E/G NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.36) 
7 142099537 TRBV7-8 G T 89 P/T NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.39) 
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CHD23: Homozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
10 46321904 AGAP4 C T 260 R/H NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.02) 
9 67968476 ANKRD20A1 C T 679 R/C NON_SYNONYMOUS_CODING benign(0.382) deleterious(0) 
16 4748050 ANKS3 C T 580 E/K NON_SYNONYMOUS_CODING possibly_damaging(0.937) deleterious(0) 
9 66553727 ENSG00000170161 T C 60 V/A NON_SYNONYMOUS_CODING benign(0) . 
4 9237400 ENSG00000223569 G C 430 Q/H NON_SYNONYMOUS_CODING benign(0.114) tolerated(0.27) 
4 9221944 ENSG00000227551 T C 23 S/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
4 9222968 ENSG00000227551 G C 364 S/T NON_SYNONYMOUS_CODING possibly_damaging(0.598) tolerated(0.13) 
4 9337474 ENSG00000229579 G C 364 S/T NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.13) 
4 9351709 ENSG00000231051 G C 364 S/T NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.13) 
4 9213672 ENSG00000231396 G C 430 Q/H NON_SYNONYMOUS_CODING benign(0.095) tolerated(0.28) 
4 9356454 ENSG00000231637 G C 364 S/T NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.13) 
4 9212449 ENSG00000232399 T C 23 S/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.15) 
4 9227712 ENSG00000232399 G C 364 S/T NON_SYNONYMOUS_CODING possibly_damaging(0.935) tolerated(0.12) 
1 146215113 ENSG00000232637 G A 84 H/Y NON_SYNONYMOUS_CODING benign(0) tolerated(0.05) 
4 9218420 ENSG00000233136 G C 430 Q/H NON_SYNONYMOUS_CODING benign(0.154) tolerated(0.29) 
4 9217197 ENSG00000233136 T C 23 S/P NON_SYNONYMOUS_CODING probably_damaging(0.992) tolerated(0.18) 
4 9346964 ENSG00000235780 G C 364 S/T NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.13) 
4 9256393 ENSG00000248920 G C 430 Q/H NON_SYNONYMOUS_CODING benign(0.154) tolerated(0.28) 
4 9256194 ENSG00000248920 G C 364 S/T NON_SYNONYMOUS_CODING possibly_damaging(0.935) tolerated(0.13) 
4 9270435 ENSG00000248933 G C 364 S/T NON_SYNONYMOUS_CODING possibly_damaging(0.935) tolerated(0.14) 
4 9270634 ENSG00000248933 G C 430 Q/H NON_SYNONYMOUS_CODING probably_damaging(0.961) tolerated(0.29) 
4 9246894 ENSG00000249104 G C 430 Q/H NON_SYNONYMOUS_CODING benign(0.154) tolerated(0.27) 
4 9246695 ENSG00000249104 G C 364 S/T NON_SYNONYMOUS_CODING possibly_damaging(0.935) tolerated(0.13) 
4 9264664 ENSG00000249811 T C 23 S/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
4 9265688 ENSG00000249811 G C 364 S/T NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.13) 
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4 9260940 ENSG00000250745 G C 364 S/T NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.14) 
4 9250422 ENSG00000250844 T C 23 S/P NON_SYNONYMOUS_CODING probably_damaging(0.992) tolerated(0.16) 
19 40382736 FCGBP A T 3384 S/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.24) 
7 74212311 GTF2IRD2 G T 61 H/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
19 54725156 LILRB3 T C 252 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
17 44408066 LRRC37A C A 1141 F/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.11) 
7 100636446 MUC12 G A 868 D/N NON_SYNONYMOUS_CODING unknown(0) . 
7 100636447 MUC12 A G 868 D/G NON_SYNONYMOUS_CODING unknown(0) . 
7 100636459 MUC12 C T 872 T/M NON_SYNONYMOUS_CODING unknown(0) . 
7 100636467 MUC12 C G 875 L/V NON_SYNONYMOUS_CODING unknown(0) . 
7 100639147 MUC12 A G 1768 E/G NON_SYNONYMOUS_CODING unknown(0) . 
7 100639177 MUC12 C T 1778 S/L NON_SYNONYMOUS_CODING unknown(0) . 
3 195512186 MUC4 T C 2089 I/V NON_SYNONYMOUS_CODING benign(0.028) . 
3 195506473 MUC4 A G 3993 V/A NON_SYNONYMOUS_CODING benign(0.137) . 
1 145327548 NBPF10 A G 1369 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 248737259 OR2T34 C G 267 R/P NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13695685 PRAMEF19 G A 358 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
1 13695787 PRAMEF19 C G 324 G/A NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
1 13696022 PRAMEF19 A G 246 W/R NON_SYNONYMOUS_CODING benign(0) tolerated(0.25) 
1 13696090 PRAMEF19 T C 223 K/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.47) 
2 113145814 RGPD8 C T 1570 G/R NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
4 9342219 USP17L5 G C 364 S/T NON_SYNONYMOUS_CODING probably_damaging(0.969) tolerated(0.13) 
15 30665280 CHRFAM7A TCA T 76 . FRAMESHIFT_CODING . . 
18 30352057 ENSG00000228835 GCGCCGGCC G 119-121 . FRAMESHIFT_CODING . . 
21 43298954 PRDM15 C CG 88 . FRAMESHIFT_CODING . . 
3 133969437 RYK A AG 19-20 . SPLICE_SITE:FRAMESHIFT_CODING . . 
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CHD23: Compound heterozygous variants 
 
CHR ID 
NUCLEOTIDE 
POSITION 
GENE 
NAME 
REF 
SEQUENCE 
ALTERNATE 
SEQUENCE 
AMINO ACID 
NO. 
RESIDUE 
CHANGE 
FUNCTION OF VARIANT POLYPHEN SIFT 
10 51464656 AGAP7 G C 600 D/E NON_SYNONYMOUS_CODING probably_damaging(0.995) tolerated(0.06) 
10 51465650 AGAP7 C T 269 R/Q NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0.03) 
11 111741081 ALG9 G T 281 N/K NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.05) 
11 111741090 ALG9 T A 278 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.68) tolerated(0.22) 
2 97808524 ANKRD36 A G 285 I/V NON_SYNONYMOUS_CODING benign(0.296) tolerated(1) 
2 97808515 ANKRD36 G A 282 E/K NON_SYNONYMOUS_CODING probably_damaging(0.959) tolerated(1) 
2 97808510 ANKRD36 G A 280 G/D NON_SYNONYMOUS_CODING probably_damaging(1) tolerated(0.85) 
12 101368637 ANO4 A C 191 Y/S NON_SYNONYMOUS_CODING probably_damaging(0.983) tolerated(0.39) 
12 101368625 ANO4 G A 187 R/K SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
17 56386386 BZRAP1 G T 1416 P/Q NON_SYNONYMOUS_CODING possibly_damaging(0.948) deleterious(0) 
17 56386402 BZRAP1 A G 1411 S/P NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0) 
3 54420749 CACNA2D3 T G 110 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.887) deleterious(0) 
3 54420752 CACNA2D3 A G 111 E/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0.01) 
17 45234417 CDC27 A G 235 I/T NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.19) 
17 45234303 CDC27 G C 273 A/G NON_SYNONYMOUS_CODING possibly_damaging(0.783) tolerated(0.07) 
17 45214528 CDC27 A T 635 Y/N NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
17 7788343 CHD3 C CCCG 73-74 -/P NON_SYNONYMOUS_CODING . . 
17 7796794 CHD3 A C 293 I/L NON_SYNONYMOUS_CODING benign(0) . 
17 7796803 CHD3 T C 296 S/P NON_SYNONYMOUS_CODING benign(0.001) . 
17 7796819 CHD3 T C 301 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.88) . 
19 42795827 CIC G C 939 G/A NON_SYNONYMOUS_CODING benign(0.106) tolerated(0.44) 
19 42795811 CIC C G 934 R/G NON_SYNONYMOUS_CODING possibly_damaging(0.717) deleterious(0.01) 
2 9599739 CPSF3 T A 593 I/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.51) 
2 9599742 CPSF3 G A 594 R/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.93) 
8 68062165 CSPP1 G A 703 S/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.64) 
8 68062160 CSPP1 T A 701 N/K NON_SYNONYMOUS_CODING benign(0.153) tolerated(0.98) 
5 13886235 DNAH5 G A 861 L/F NON_SYNONYMOUS_CODING benign(0.004) tolerated(0.7) 
5 13830760 DNAH5 C T 2003 V/I NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
19 18583686 ELL C A 12 V/F NON_SYNONYMOUS_CODING possibly_damaging(0.681) . 
19 18583688 ELL G A 11 S/F NON_SYNONYMOUS_CODING possibly_damaging(0.819) . 
19 18583691 ELL T A 10 D/V SPLICE_SITE:NON_SYNONYMOUS_CODING possibly_damaging(0.948) . 
2 96519492 ENSG00000174501 C T 732 D/N NON_SYNONYMOUS_CODING probably_damaging(0.978) tolerated(0.06) 
2 96610395 ENSG00000174501 C CA 490-491 . FRAMESHIFT_CODING . . 
16 15457629 ENSG00000183793 T A 314 T/S NON_SYNONYMOUS_CODING benign(0.158) tolerated(0.82) 
16 15457628 ENSG00000183793 G T 314 T/N NON_SYNONYMOUS_CODING benign(0.348) tolerated(0.39) 
9 46386995 ENSG00000237198 C A 3 R/M NON_SYNONYMOUS_CODING benign(0.013) tolerated(0.36) 
9 46386956 ENSG00000237198 C G 16 R/P NON_SYNONYMOUS_CODING probably_damaging(0.998) deleterious(0) 
9 46386806 ENSG00000237198 C T 66 R/Q NON_SYNONYMOUS_CODING unknown(0) tolerated(0.75) 
15 32693591 ENSG00000249931 T G 45 K/T NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
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15 32693595 ENSG00000249931 C G 44 E/Q NON_SYNONYMOUS_CODING benign(0.006) tolerated(0.07) 
14 104040459 ENSG00000256500 A T 126 I/F NON_SYNONYMOUS_CODING benign(0.423) deleterious(0) 
14 104040450 ENSG00000256500 G A 123 E/K NON_SYNONYMOUS_CODING possibly_damaging(0.609) deleterious(0) 
3 13679670 FBLN2 T G 110 */G STOP_LOST . . 
3 13679659 FBLN2 T G 106 V/G NON_SYNONYMOUS_CODING possibly_damaging(0.811) deleterious(0) 
1 240370946 FMN2 C T 945 P/L NON_SYNONYMOUS_CODING unknown(0) tolerated(0.26) 
1 240371426 FMN2 T C 1105 V/A NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
20 29625928 FRG1B G A 58 V/I NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.17) 
20 29625947 FRG1B T C 64 I/T NON_SYNONYMOUS_CODING benign(0.017) deleterious(0) 
20 29628328 FRG1B C G 110 I/M NON_SYNONYMOUS_CODING benign(0.191) deleterious(0.03) 
7 150327209 GIMAP6 G T 8 Q/K NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
7 150327226 GIMAP6 T C 2 E/G NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
2 90249273 IGKV1D-43 C G 77 Q/E NON_SYNONYMOUS_CODING benign(0) tolerated(0.68) 
2 90249269 IGKV1D-43 T A 75 S/R NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.23) 
17 38975147 KRT10 G T 547 S/Y NON_SYNONYMOUS_CODING unknown(0) . 
17 38975149 KRT10 G T 546 S/R NON_SYNONYMOUS_CODING unknown(0) . 
17 38975151 KRT10 T C 546 S/G NON_SYNONYMOUS_CODING unknown(0) . 
12 122685179 LRRC43 C A 402 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(0.92) 
12 122685176 LRRC43 G A 401 R/K NON_SYNONYMOUS_CODING benign(0.005) tolerated(1) 
12 122685163 LRRC43 A G 397 K/E NON_SYNONYMOUS_CODING probably_damaging(0.99) tolerated(0.89) 
12 122685164 LRRC43 A G 397 K/R NON_SYNONYMOUS_CODING probably_damaging(0.99) tolerated(0.23) 
7 151927025 MLL3 A G 987 Y/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 151932997 MLL3 C T 892 G/R NON_SYNONYMOUS_CODING probably_damaging(1) . 
7 100634922 MUC12 G A 360 A/T NON_SYNONYMOUS_CODING unknown(0) . 
7 100638484 MUC12 A T 1547 K/I NON_SYNONYMOUS_CODING unknown(0) . 
19 9002623 MUC16 C T 39 R/H NON_SYNONYMOUS_CODING benign(0.011) tolerated(0.24) 
19 9002636 MUC16 C T 35 V/I NON_SYNONYMOUS_CODING benign(0.051) tolerated(0.37) 
19 9002612 MUC16 T G 43 K/Q NON_SYNONYMOUS_CODING benign(0.055) tolerated(0.23) 
19 9002597 MUC16 C T 48 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.866) deleterious(0) 
3 195507053 MUC4 A C 3800 S/A NON_SYNONYMOUS_CODING benign(0.035) . 
3 195513847 MUC4 A G 1535 M/T NON_SYNONYMOUS_CODING benign(0.042) . 
3 195506549 MUC4 A G 3968 S/P NON_SYNONYMOUS_CODING benign(0.044) . 
3 195507226 MUC4 A G 3742 V/A NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508790 MUC4 T C 3221 S/G NON_SYNONYMOUS_CODING benign(0.095) . 
3 195508796 MUC4 C G 3219 V/L NON_SYNONYMOUS_CODING benign(0.095) . 
3 195514768 MUC4 T C 1228 D/G NON_SYNONYMOUS_CODING benign(0.144) . 
3 195506099 MUC4 T C 4118 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195508667 MUC4 T C 3262 T/A NON_SYNONYMOUS_CODING benign(0.182) . 
3 195508789 MUC4 C T 3221 S/N NON_SYNONYMOUS_CODING benign(0.204) . 
3 195509212 MUC4 G A 3080 S/L NON_SYNONYMOUS_CODING benign(0.204) . 
3 195515017 MUC4 A G 1145 V/A NON_SYNONYMOUS_CODING benign(0.231) . 
3 195506569 MUC4 A G 3961 V/A NON_SYNONYMOUS_CODING benign(0.243) . 
3 195506293 MUC4 T C 4053 N/S NON_SYNONYMOUS_CODING benign(0.258) . 
3 195508787 MUC4 G T 3222 L/I NON_SYNONYMOUS_CODING benign(0.352) . 
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3 195510194 MUC4 G C 2753 L/V NON_SYNONYMOUS_CODING benign(0.352) . 
3 195510636 MUC4 C G 2605 Q/H NON_SYNONYMOUS_CODING benign(0.391) . 
3 195508661 MUC4 A G 3264 S/P NON_SYNONYMOUS_CODING benign(0.421) . 
3 195506533 MUC4 C A 3973 S/I NON_SYNONYMOUS_CODING possibly_damaging(0.473) . 
3 195507062 MUC4 C T 3797 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507385 MUC4 G A 3689 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507446 MUC4 C T 3669 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195507494 MUC4 C T 3653 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508500 MUC4 G C 3317 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195508668 MUC4 G C 3261 D/E NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195510649 MUC4 G A 2601 A/V NON_SYNONYMOUS_CODING possibly_damaging(0.509) . 
3 195506983 MUC4 G A 3823 T/I NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507443 MUC4 T G 3670 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507475 MUC4 G C 3659 T/R NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195507827 MUC4 G A 3542 L/F NON_SYNONYMOUS_CODING possibly_damaging(0.607) . 
3 195511076 MUC4 T A 2459 T/S NON_SYNONYMOUS_CODING possibly_damaging(0.609) . 
3 195511525 MUC4 T C 2309 D/G NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195511526 MUC4 C T 2309 D/N NON_SYNONYMOUS_CODING possibly_damaging(0.748) . 
3 195506501 MUC4 G A 3984 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.768) . 
3 195506282 MUC4 A C 4057 L/V NON_SYNONYMOUS_CODING possibly_damaging(0.806) . 
3 195507604 MUC4 C G 3616 R/P NON_SYNONYMOUS_CODING possibly_damaging(0.811) . 
3 195506510 MUC4 G C 3981 H/D NON_SYNONYMOUS_CODING possibly_damaging(0.817) . 
3 195507445 MUC4 T A 3669 D/V NON_SYNONYMOUS_CODING possibly_damaging(0.862) . 
3 195507461 MUC4 G A 3664 P/S NON_SYNONYMOUS_CODING possibly_damaging(0.864) . 
3 195507694 MUC4 A G 3586 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195508786 MUC4 A G 3222 L/P NON_SYNONYMOUS_CODING possibly_damaging(0.881) . 
3 195506291 MUC4 C T 4054 A/T NON_SYNONYMOUS_CODING possibly_damaging(0.922) . 
3 195506914 MUC4 G A 3846 P/L NON_SYNONYMOUS_CODING possibly_damaging(0.931) . 
3 195506990 MUC4 C G 3821 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195508670 MUC4 C G 3261 D/H NON_SYNONYMOUS_CODING possibly_damaging(0.934) . 
3 195511102 MUC4 G A 2450 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195514948 MUC4 G A 1168 P/L NON_SYNONYMOUS_CODING probably_damaging(0.975) . 
3 195510622 MUC4 G T 2610 P/H NON_SYNONYMOUS_CODING probably_damaging(0.991) . 
3 195506302 MUC4 G T 4050 P/H NON_SYNONYMOUS_CODING probably_damaging(0.998) . 
3 195506542 MUC4 G T 3970 P/H NON_SYNONYMOUS_CODING probably_damaging(1) . 
3 195510310 MUC4 T G 2714 Y/S NON_SYNONYMOUS_CODING unknown(0) . 
3 195510341 MUC4 A G 2704 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510347 MUC4 T C 2702 T/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510350 MUC4 C G 2701 D/H NON_SYNONYMOUS_CODING unknown(0) . 
3 195510373 MUC4 T C 2693 D/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510374 MUC4 C T 2693 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510389 MUC4 A G 2688 S/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510396 MUC4 A C 2685 H/Q NON_SYNONYMOUS_CODING unknown(0) . 
3 195510492 MUC4 C G 2653 Q/H NON_SYNONYMOUS_CODING unknown(0) . 
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3 195510509 MUC4 A C 2648 S/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510518 MUC4 C T 2645 D/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510563 MUC4 G C 2630 P/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510565 MUC4 C T 2629 S/N NON_SYNONYMOUS_CODING unknown(0) . 
3 195510566 MUC4 T C 2629 S/G NON_SYNONYMOUS_CODING unknown(0) . 
3 195510601 MUC4 A G 2617 V/A NON_SYNONYMOUS_CODING unknown(0) . 
3 195510610 MUC4 A G 2614 L/P NON_SYNONYMOUS_CODING unknown(0) . 
3 195510611 MUC4 G T 2614 L/I NON_SYNONYMOUS_CODING unknown(0) . 
3 195510613 MUC4 C T 2613 S/N NON_SYNONYMOUS_CODING unknown(0) . 
11 1016957 MUC6 T G 1948 R/S NON_SYNONYMOUS_CODING benign(0.034) tolerated(0.84) 
11 1017466 MUC6 T C 1779 R/G NON_SYNONYMOUS_CODING benign(0.142) tolerated(0.57) 
11 1017307 MUC6 G A 1832 P/S NON_SYNONYMOUS_CODING benign(0.34) tolerated(0.21) 
11 1016733 MUC6 G T 2023 T/K NON_SYNONYMOUS_CODING probably_damaging(0.976) tolerated(0.24) 
11 1018042 MUC6 A G 1587 S/P NON_SYNONYMOUS_CODING probably_damaging(0.979) deleterious(0.01) 
11 1016554 MUC6 C T 2083 A/T NON_SYNONYMOUS_CODING unknown(0) tolerated(0.6) 
11 1016559 MUC6 G C 2081 A/G NON_SYNONYMOUS_CODING unknown(0) tolerated(0.59) 
11 1016565 MUC6 C T 2079 S/N NON_SYNONYMOUS_CODING unknown(0) tolerated(0.09) 
11 1016583 MUC6 T G 2073 Q/P NON_SYNONYMOUS_CODING unknown(0) deleterious(0.03) 
16 74425734 NPIPL2 T C 363 V/A NON_SYNONYMOUS_CODING benign(0.012) tolerated(0.66) 
16 74425727 NPIPL2 T C 361 W/R NON_SYNONYMOUS_CODING possibly_damaging(0.919) tolerated(0.08) 
12 5603600 NTF3 C G 74 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
12 5603598 NTF3 A G 73 E/G NON_SYNONYMOUS_CODING benign(0.261) deleterious(0.01) 
11 45957282 PHF21A C T 39 E/K NON_SYNONYMOUS_CODING probably_damaging(0.992) deleterious(0.01) 
11 45957279 PHF21A C T 40 E/K NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
11 45957285 PHF21A C T 38 E/K NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
12 106820987 POLR3B C T 314 L/F NON_SYNONYMOUS_CODING benign(0.088) deleterious(0) 
12 106820975 POLR3B C T 310 L/F SPLICE_SITE:NON_SYNONYMOUS_CODING benign(0.102) deleterious(0) 
18 14542791 POTEC C T 119 A/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.41) 
18 14533105 POTEC G C 337 S/C NON_SYNONYMOUS_CODING probably_damaging(0.97) tolerated(0.19) 
22 18901004 PRODH C T 166 R/Q NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.6) 
22 18905964 PRODH C T 76 R/H NON_SYNONYMOUS_CODING possibly_damaging(0.726) tolerated(0.14) 
2 85571228 RETSAT G C 265 A/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.43) 
2 85571225 RETSAT T C 266 E/G NON_SYNONYMOUS_CODING benign(0.048) tolerated(0.28) 
19 14104595 RFX1 C G 21 A/P NON_SYNONYMOUS_CODING unknown(0) . 
19 14104610 RFX1 A G 16 S/P NON_SYNONYMOUS_CODING unknown(0) . 
6 108197860 SEC63 G T 648 Q/K NON_SYNONYMOUS_CODING probably_damaging(0.987) tolerated(0.15) 
6 108197851 SEC63 A C 651 W/G NON_SYNONYMOUS_CODING probably_damaging(1) deleterious(0) 
8 145095684 SPATC1 A C 328 T/P NON_SYNONYMOUS_CODING benign(0.102) tolerated(0.27) 
8 145095681 SPATC1 A C 327 T/P NON_SYNONYMOUS_CODING probably_damaging(0.995) deleterious(0.03) 
1 234601448 TARBP1 T A 419 I/F NON_SYNONYMOUS_CODING benign(0.07) tolerated(0.26) 
1 234601451 TARBP1 T A 418 I/F NON_SYNONYMOUS_CODING possibly_damaging(0.915) tolerated(0.09) 
7 142498738 TRBC2 C G 5 N/K NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.34) 
7 142498735 TRBC2 A C 4 K/N NON_SYNONYMOUS_CODING benign(0.111) tolerated(0.08) 
7 142223959 TRBV11-1 C T 70 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
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7 142224021 TRBV11-1 G T 49 A/D NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.63) 
7 142223962 TRBV11-1 G C 69 Q/E NON_SYNONYMOUS_CODING benign(0.009) tolerated(0.25) 
7 142223964 TRBV11-1 A T 68 F/Y NON_SYNONYMOUS_CODING benign(0.014) tolerated(0.2) 
7 142224003 TRBV11-1 C A 55 R/L NON_SYNONYMOUS_CODING benign(0.428) tolerated(0.05) 
7 142180567 TRBV6-5 G C 98 L/V NON_SYNONYMOUS_CODING benign(0) tolerated(0.06) 
7 142180573 TRBV6-5 T C 96 R/G NON_SYNONYMOUS_CODING benign(0) tolerated(0.12) 
7 142180585 TRBV6-5 C T 92 D/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.79) 
7 142180590 TRBV6-5 G T 90 T/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180593 TRBV6-5 G T 89 T/N NON_SYNONYMOUS_CODING benign(0) tolerated(0.44) 
7 142180596 TRBV6-5 G A 88 S/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.31) 
7 142180618 TRBV6-5 T C 81 N/D NON_SYNONYMOUS_CODING benign(0) tolerated(0.78) 
7 142180633 TRBV6-5 G T 76 Q/K NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180635 TRBV6-5 T G 75 D/A NON_SYNONYMOUS_CODING benign(0) tolerated(0.22) 
7 142180641 TRBV6-5 A G 73 I/T NON_SYNONYMOUS_CODING benign(0) tolerated(0.91) 
7 142180704 TRBV6-5 G T 52 S/Y NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142180737 TRBV6-5 T A 41 Q/L NON_SYNONYMOUS_CODING benign(0) tolerated(0.16) 
7 142180578 TRBV6-5 G A 94 P/L NON_SYNONYMOUS_CODING benign(0.002) tolerated(0.17) 
7 142180588 TRBV6-5 C G 91 E/Q NON_SYNONYMOUS_CODING benign(0.005) tolerated(0.2) 
7 142180647 TRBV6-5 G T 71 A/D NON_SYNONYMOUS_CODING benign(0.08) tolerated(0.18) 
7 142099548 TRBV7-8 A G 85 F/S NON_SYNONYMOUS_CODING benign(0) tolerated(1) 
7 142099581 TRBV7-8 A G 74 L/P NON_SYNONYMOUS_CODING benign(0) tolerated(0.35) 
7 142099512 TRBV7-8 T G 97 K/T NON_SYNONYMOUS_CODING benign(0.001) tolerated(0.14) 
7 142099537 TRBV7-8 G T 89 P/T NON_SYNONYMOUS_CODING benign(0.003) tolerated(0.39) 
2 179544685 TTN C CTCT 9928 E/EE NON_SYNONYMOUS_CODING . . 
2 179634421 TTN T G 2917 T/P NON_SYNONYMOUS_CODING possibly_damaging(0.539) . 
2 179483108 TTN C T 6753 V/I NON_SYNONYMOUS_CODING possibly_damaging(0.737) . 
2 179507024 TTN C A 4435 V/F NON_SYNONYMOUS_CODING possibly_damaging(0.741) . 
2 179400061 TTN G A 24693 R/W NON_SYNONYMOUS_CODING probably_damaging(1) . 
17 5036210 USP6 T G 67 I/M NON_SYNONYMOUS_CODING unknown(0) deleterious(0.04) 
17 5036211 USP6 C T 68 R/W NON_SYNONYMOUS_CODING unknown(0) deleterious(0) 
19 21992147 ZNF43 G T 230 T/K NON_SYNONYMOUS_CODING benign(0.001) tolerated(1) 
19 21992138 ZNF43 T A 233 E/V NON_SYNONYMOUS_CODING probably_damaging(0.966) deleterious(0.04) 
19 21991497 ZNF43 G T 447 H/N NON_SYNONYMOUS_CODING probably_damaging(0.999) deleterious(0) 
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APPENDIX H: Analysis of whole exome sequencing data from WTSI: Across the familial CHD cohort 
 
Table 1: List of genes with functional homozygous variants in > 1 consanguineous families (i.e CHD1 and CHD4) 
 
 
 
 
 
 
 
Table 2: List of genes with functional homozygous variants in > 1 consanguineous or non-consanguineous family 
 
AGAP4 ENSG00000228835 HLA-B NBPF10 POTEI 
AGAP6 ENSG00000232637 KCNC3 NBPF12 POTEM 
AGAP7 FAM21B LILRB3 NBPF14 PRAMEF19 
CD177 FAM22D LRRC37A NBPF16 PRAMEF3 
CELA3B FAM22F MBD3L2 NR4A3 PRDM15 
COPZ2 FAM86B2 MESP2 OR2T34 PRODH 
ENSG00000170161 GOLGA6L10 MUC12 OR2T35 RGPD4 
ENSG00000215749 GTF2IRD2 MUC4 POTEF RYK 
    TRIM74 
 
 
ENSG00000228835 MBD3L2 NBPF14 POTEM 
ENSG00000232637 MESP2 NBPF16 PRAMEF19 
GTF2IRD2 MUC4 OR2T34 PRDM15 
HLA-B NBPF10 POTEF PRODH 
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Table 3: List of genes with functional compound heterozygous variants  
in >1 non-consanguineous family (i.e. CHD5, 6, 13, 16, 20, 22, and 23) 
 
AGAP7 CPSF3 GRIK3 MYOM1 SELPLG 
ACACA CSPP1 HLA-B NBPF10 SEZ6L 
AKR1E2 CTBP2 
HLA-
DRB1 
NCF4 SLC17A5 
ANKRD36 CUL7 
HLA-
DRB5 
NECAP1 SLIT2 
ANO4 DCHS1 HMCN1 NFATC1 SPARCL1 
APOBEC3H DDX24 HTT NFRKB SPEN 
ASH1L DGKH IGHV3-11 NGLY1 STK38 
ATAD3B DLEC1 IGHV3-48 NIPAL4 SYNE1 
ATAD3C DMXL2 IGHV3-64 NOTCH1 TBX20 
ATG2A DNAH5 IGHV5-51 OBSCN TGS1 
ATL3 DNAH8 IGSF21 ODZ4 TMEM8A 
ATM DNAJC14 IKZF1 OPA1 TMTC2 
ATP6V1A DOCK5 INF2 OR2T33 TRBC2 
ATRN DSCAM INHBA PAPOLG TRBV3-1 
BACH1 ELF1 ITPR1 PJA2 TRBV4-2 
BAI3 ENSG00000183793 KRTAP9-1 PKHD1 TRBV5-4 
BRD8 ENSG00000229292 LRP1B PKHD1L1 TRBV5-5 
BRPF1 ENSG00000237198 LRRC43 PLIN4 TRBV6-5 
BZRAP1 ENSG00000257513 LY9 PLXNA2 TRBV7-8 
C12orf51 EP400 LYST PNMA1 TTC3 
C20orf12 EPHA10 MACC1 PNPLA8 TTN 
C2CD3 EPHA5 MACF1 PPFIA2 UBR4 
C3orf56 ESPN MAN1A2 PRRC2B UGGT1 
C4orf17 FA2H MAP1B PRSS3 USH2A 
CACNA1D FAM135A MGA PSMD2 USP15 
CAP1 FAM82A2 MICALCL PTCHD3 USP6 
CBX4 FASTKD2 MKI67 PTPRB UTP20 
CCNA1 FBLN2 MLL3 PYDC2 VWA3B 
CD97 FBXO24 MUC12 RB1 VWA5B1 
CDC27 FOXD4 MUC16 RETSAT ZCCHC14 
CEP250 FRG1B MUC4 RFX1 ZNF592 
CHD3 FRG2B MUC5B RFX3 ZNF706 
CHD5 GEMIN2 MUC6 RGPD1  
CIC GNPAT MYCBP2 RIMBP2  
CLEC18B GPR98 MYO9A SDK1  
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Table 4: List of genes with functional homozygous or compound 
heterozygous variants in > 1 consanguineous or non-consanguineous 
family 
 
ACACA CCNA1 ENSG00000215749 HLA-B 
AGAP4 CD177 ENSG00000228835 HLA-DRB1 
AGAP6 CD97 ENSG00000229292 HLA-DRB5 
AGAP7 CDC27 ENSG00000232637 HMCN1 
AHNAK2 CELA3B ENSG00000237198 HSPG2 
AKR1E2 CEP250 ENSG00000249931 HTT 
ANK2 CHD3 ENSG00000257513 IGHV3-11 
ANKRD32 CHD5 EP400 IGHV3-48 
ANKRD36 CIC EPHA10 IGHV3-64 
ANO4 CLEC18B EPHA2 IGHV5-51 
APOBEC3H CLIP1 EPHA5 IGSF21 
ASH1L CLTCL1 ESPN IGSF3 
ATAD3B CNTNAP2 FA2H IKZF1 
ATAD3C COL21A1 FAM135A INF2 
ATF7IP COPZ2 FAM21B INHBA 
ATG2A CPSF3 FAM22D ITPR1 
ATL3 CSPP1 FAM22F KCNC3 
ATM CTAGE9 FAM82A2 KRTAP9-1 
ATP6V1A CTBP2 FAM86B2 LAMB3 
ATRN CUL7 FASTKD2 LCE1C 
BACH1 DCHS1 FAT3 LILRB3 
BAI3 DDX24 FBLN2 LMO7 
BCL9 DGKH FBXO24 LRBA 
BRD8 DLEC1 FCGBP LRP1B 
BRPF1 DMXL2 FOXD4 LRRC37A 
BZRAP1 DNAH5 FRG1B LRRC37A3 
C12orf51 DNAH8 FRG2B LRRC43 
C20orf12 DNAJC14 FRYL LY9 
C2CD3 DOCK5 GEMIN2 LYST 
C3orf56 DSCAM GNPAT MACC1 
C4orf17 ELF1 GOLGA6L10 MACF1 
CACNA1D ENSG00000170161 GOLGA8A MAN1A2 
CAP1 ENSG00000174501 GPR98 MAP1B 
CBX4 ENSG00000183793 GRIK3 MBD3L2 
CCDC108 ENSG00000188219 GTF2IRD2 MEGF9 
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MESP2 ODZ4 PSMD2 TRBC2 
MGA OPA1 PTCHD3 TRBV3-1 
MICAL2 OR2T33 PTPRB TRBV4-2 
MICALCL OR2T34 PYDC2 TRBV5-4 
MKI67 OR2T35 RB1 TRBV5-5 
MLL3 PAPOLG RETSAT TRBV6-5 
MUC12 PDK4 RFX1 TRBV7-3 
MUC16 PJA2 RFX3 TRBV7-8 
MUC4 PKHD1 RGPD1 TRIM74 
MUC5B PKHD1L1 RGPD4 TTC3 
MUC6 PLIN4 RIMBP2 TTN 
MYCBP2 PLXNA2 RYK UBR4 
MYO9A PNMA1 SDK1 UGGT1 
MYOM1 PNPLA8 SELPLG UTP20 
NBPF10 POLR3B SEZ6L USH2A 
NBPF12 POTEC SIGLEC10 USP15 
NBPF14 POTEF SLC17A5 USP49 
NBPF16 POTEI SLIT2 USP6 
NCF4 POTEM SPARCL1 VWA3B 
NECAP1 PPFIA2 SPEN VWA5B1 
NFATC1 PRAMEF19 STK38 ZBTB9 
NFRKB PRAMEF3 SYNE1 ZCCHC14 
NGLY1 PRDM1 TBX20 ZNF592 
NIPAL4 PRDM15 TCHH ZNF706 
NOTCH1 PRODH TGS1 ZNF880 
NR4A3 PRRC2B TMEM8A  
OBSCN PRSS3 TMTC2  
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